<SEC-DOCUMENT>0001554757-12-000408.txt : 20121119
<SEC-HEADER>0001554757-12-000408.hdr.sgml : 20121119
<ACCEPTANCE-DATETIME>20121119154326
ACCESSION NUMBER:		0001554757-12-000408
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20120930
FILED AS OF DATE:		20121119
DATE AS OF CHANGE:		20121119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TAPIMMUNE INC
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27239
		FILM NUMBER:		121214527

	BUSINESS ADDRESS:	
		STREET 1:		UNIT 2 - 3590 WEST 41ST AVENUE
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6N 3E6
		BUSINESS PHONE:		604-264-8274

	MAIL ADDRESS:	
		STREET 1:		UNIT 2 - 3590 WEST 41ST AVENUE
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6N 3E6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EDUVERSE COM
		DATE OF NAME CHANGE:	19990827
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tapimmune10q.htm
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: a-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">FORM 10-Q</font></font><br>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td width="3%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline;" face="Wingdings">x</font></font></td>
<td width="97%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">September 30, 2012</font></font></td>
</tr><tr>
<td width="3%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="97%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="3%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></td>
<td width="97%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number: <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">000-27239</font></font><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">TAPIMMUNE INC.</font></font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Name of registrant in its charter)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NEVADA</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">88-0277072</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State or other jurisdiction of incorporation or organization)</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(I.R.S. Employer Identification No.)</font></div>
</td>
</tr><tr>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1551 Eastlake Avenue East, Suite 100 </font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Seattle, Washington</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">98102</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Address of principal executive offices)</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Zip Code)</font></div>
</td>
</tr><tr>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(206) 504 7279</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Issuer's telephone number)</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;&#160;No&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;No&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definition of &#8220;accelerated filer&#8221;, &#8220;large accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act (check one):</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline;" face="Wingdings">o </font>Large accelerated filer&#160;&#160;&#160;</font></td>
<td width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline;" face="Wingdings">o </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accelerated filer</font></font></td>
</tr><tr>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
</tr><tr>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline;" face="Wingdings">o </font>Non-accelerated filer (Do not check&#160;if smaller reporting company)&#160;</font></td>
<td width="2%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="48%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline;" face="Wingdings">x <font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Smaller reporting company</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;No&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of November 19, 2012, the Company had 73,861,754 shares of common stock issued and outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART I &#8211; FINANCIAL INFORMATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="TEXT-DECORATION: underline">Item 1.</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financial Statements</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td align="left" valign="top" width="94%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Description</font></font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Page</font></font></div>
</td>
</tr><tr>
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Balance Sheets as of September 30, 2012 (Unaudited) and December 31, 2011</font></div>
</td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2012 and 2011 and for the Period from July 27, 1999 (Date of Inception) to September 30, 2012 (Unaudited)</font></div>
</td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2012 and 2011 and for the Period from July 27, 1999 (Date of Inception) to September 30, 2012 (Unaudited)</font></div>
</td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to the Consolidated Financial Statements (Unaudited)</font></div>
</td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="94%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">TAPIMMUNE INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(A Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CONSOLIDATED BALANCE SHEETS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td colspan="7" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ASSETS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current Assets</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,727</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250,234</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Due from government agency</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,099</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,060</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Prepaid expenses and deposits (Note 7)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22,504</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,627</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Deferred financing costs (Note 5)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,641</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,971</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">307,921</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Deferred financing costs (Note 5)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,768</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,291</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,739</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">340,212</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td colspan="7" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current Liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Accounts payable and accrued liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,327,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">794,291</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Research agreement obligations (Note 3)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">365,970</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">259,752</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Derivative liability &#8211; warrants (Note 4)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Derivative liability &#8211; conversion option (Note 4)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Convertible notes payable (Note 5)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,184,351</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">998,790</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Loans payable (Note 6)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Promissory note (Note 7)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">167,942</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Due to related parties (Note 8)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">281,475</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">322,905</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,428,280</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,800,572</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders&#8217; Deficit</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Capital stock (Note 9)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Common stock, $0.001 par value, 150,000,000 shares authorized 73,861,754 shares issued and outstanding (2011 &#8211; 52,073,460)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">73,864</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,072</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Additional paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43,220,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,943,374</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Shares and warrants to be issued</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">242,062</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">362,906</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Deferred compensation (Note 9)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(35,968</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Deficit accumulated during the development stage</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(47,840,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(43,722,216</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Accumulated other comprehensive loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(63,082</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(60,528</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,367,541</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,460,360</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,739</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">340,212</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">COMMITMENTS AND CONTINGENCIES</font> (Notes 1, 3, 5 and 11)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these consolidated financial statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">TAPIMMUNE INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(A DEVELOPMENT STAGE COMPANY)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(UNAUDITED)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-TOP: black 1.5pt solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-TOP: black 1.5pt solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 1999</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(inception) to</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expenses</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Consulting fees</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">57,260</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43,750</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">119,790</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">119,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,158,477</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Consulting fees &#8211; stock-based (Note 9)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">109,728</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">307,734</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,283,561</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">692,253</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,005,914</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Depreciation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">213,227</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">268,286</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,875</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">880,353</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">66,012</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,797,589</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Interest and finance charges (Note 4)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">214,811</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">103,740</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">411,783</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">558,577</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,242,796</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Management fees (Note 8)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">125,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">186,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,897,154</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Management fees &#8211; stock-based</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(Notes 8 and 9)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,334</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29,563</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">146,960</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">360,260</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,471,749</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Professional fees</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,757</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36,173</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">208,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">317,130</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,135,438</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Research and development (Note 8)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">297,996</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">432,289</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">406,944</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,343,454</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Research and development&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211; stock-based</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">612,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">796,737</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">904,931</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,608,702</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,706,726</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,877,798</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Loss Before Other Items</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(796,737</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(904,931</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,608,702</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,706,726</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(39,877,798</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Items</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Foreign exchange (loss) gain</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,193</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,654</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,304 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(293</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Changes in fair value of derivative&#160;liabilities (Note 4)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">121,385</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">544,576</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(277,118</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,619,716</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Loss on debt financing</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(85,550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(85,550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,354,263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Gain (loss) on settlement of debt (Note 9)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,688</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(482,474</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,602,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Gain on extinguishment of derivative&#160;&#160;liabilities -&#160;warrants (Note 4)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,088,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">290,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Interest income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Loss on disposal of assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,399</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Loss for the Period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(768,095</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(844,277</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,118,684</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,378,036</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(47,840,900</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -3.6pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and Diluted Net Loss </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">per Share</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.01</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.02</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.07</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.05</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average Number of </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Shares Outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">73,128,058</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,213,710</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,560,295</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,845,195</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these consolidated financial statements.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">TAPIMMUNE INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(A DEVELOPMENT STAGE COMPANY)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(UNAUDITED)</font></div>

<div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period from</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 1999</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(inception) to</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="12" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM OPERATING ACTIVITIES</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,118,684</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,378,036</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(47,840,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net loss to</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">net cash from operating activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Depreciation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">213,228</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Non-cash loss on debt financing</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">85,550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,354,263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Changes in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(544,576</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">277,118</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,619,716</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Loss (gain) on settlement of debt</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(28,688</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">482,474</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,602,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Gain on extinguishment of derivative liabilities -&#160;warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,088,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(290,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Loss on disposal of assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,399</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Non-cash interest and financing charges</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">558,577</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,468,499</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Stock based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,430,521</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,052,513</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,105,913</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Changes in operating assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Due from government agency</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,077</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Prepaid expenses and deposits</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,123</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(46,504</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Deferred financing costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,118</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54,974</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,160</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Accounts payable and accrued liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">919,884</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">85,019</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,501,360</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Research agreement obligations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">106,218</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">79,207</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">584,101</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET CASH USED IN&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OPERATING ACTIVITIES</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,116,770</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(876,729</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(15,971,200</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="12" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM FINANCING ACTIVITIES</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of shares, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">455,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">194,750</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,760,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Convertible notes, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">206,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">724,535</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,727,906</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from promissory notes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,942</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,942</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from loans payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">446,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes and loans payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">919,845</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Advances from (to) related parties</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">120,321</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(31,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,707,912</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock subscriptions</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">140,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET CASH PROVIDED BY&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FINANCING ACTIVITIES</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">870,263</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">887,985</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,770,180&nbsp;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="12" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM INVESTING ACTIVITIES</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchase of furniture and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(218,626</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash acquired on reverse acquisition</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">423,373</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET CASH PROVIDED BY </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INVESTING ACTIVITIES</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">204,747</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INCREASE (DECREASE) IN CASH</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(246,507</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,256</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,727</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH, BEGINNING OF PERIOD</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250,234</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,516</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH, END OF PERIOD</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,727</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34,772</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,727</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Supplemental cash flow information and non-cash investing and financing activities:</font> (Note 10)</font></div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these consolidated financial statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">TAPIMMUNE INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(A DEVELOPMENT STAGE COMPANY)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">SEPTEMBER 30, 2012 (UNAUDITED)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 1:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">NATURE OF OPERATIONS</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TapImmune Inc. (the &#8220;Company&#8221;), a Nevada corporation incorporated in 1992, is a development stage company which was formed for the purpose of building a biotechnology business specializing in the discovery and development of immunotherapeutics aimed at the treatment of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since inception, the Company has been party to various Collaborative Research Agreements (&#8220;CRA&#8221;) working with universities to carry out development of the licensed technology and providing TapImmune the option to acquire the rights to commercialize any additional technologies developed within the CRA. The lead product candidate, now wholly owned and with no ongoing license or royalty, resulting from these license agreements is an immunotherapy vaccine, on which the Company has been completing pre-clinical work in anticipation of clinical trials. Specifically, the Company has obtained and expanded on three U.S. and international patents, tested various viral vectors, licensed a viral vector and is working towards production of a clinical grade vaccine. The Company plans to continue development of the lead product vaccine through to clinical trials in both oncology and infectious diseases alone or in partnership with other vaccine developers.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at September 30, 2012, the Company had a working capital deficiency of $3,315,751 (excluding derivative liabilities recorded as current liabilities) and has incurred significant losses since inception. Further losses are anticipated in the development stage raising substantial doubt as to the Company&#8217;s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on raising additional capital to fund ongoing research and development, maintenance and protection of patents, accommodation from certain debt obligations and ultimately on generating future profitable operations. Planned expenditures relating to future clinical trials of the Company&#8217;s immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing research and development as well as working capital requirements. The Company&#8217;s future capital requirements will depend on many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs of commercialization activities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management is addressing going concern remediation through seeking new sources of capital, restructuring and retiring debt through conversion to equity and debt settlement arrangements with creditors, cost reduction programs and seeking possible joint venture participation. Management&#8217;s plans are intended to return the Company to financial stability and improve continuing operations. The Company is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet immediate working capital requirements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional funding was raised through equity and debt placements in 2011 and the first nine months of 2012, and management intends to continue restructuring outstanding debt and equity instruments. Additional capital is required currently to expand programs including pre-clinical work and to establish future manufacturing contracts necessary for clinical trials for the lead TAP (Transporters of Antigen Processing) vaccine and infectious disease adjuvant technology. Strategic partnerships will be needed to continue the product development portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company over the next twelve months.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There is no certainty that the Company will be able to arrange sufficient funding to satisfy current debt obligations or to continue development of products to marketability.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 2:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basis of Presentation</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the opinion of management, the accompanying balance sheets and related statements of operations and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. Examples include: valuation of the derivative liabilities and stock-based compensation. Actual results and outcomes may differ from management&#8217;s estimates and assumptions.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interim results are not necessarily indicative of results for a full year. The information included in this quarterly report on Form 10-Q should be read in conjunction with information included in the Company&#8217;s annual report on Form 10-K filed on April 16, 2012, with the U.S. Securities and Exchange Commission.</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 3:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">RESEARCH AGREEMENTS</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Crucell Holland B.V. (&#8220;Crucell&#8221;) &#8211; Research License and Option Agreement</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective August 7, 2003, Crucell and the Company&#8217;s subsidiary GeneMax Pharmaceuticals, Inc. (&#8220;GPI&#8221;) entered into a five-year research license and option agreement whereby Crucell granted to GPI a non-exclusive worldwide license for the research use of its adenovirus technology. The Company was required to make certain payments over the five-year term totaling Euro &#8364;450,000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At December 31, 2008, $243,598 (&#8364;172,801) was owing to Crucell under this agreement. During the year ended December 31, 2009, management negotiated a settlement of the outstanding balance requiring a &#8364;17,000 cash payment (paid) and the issuance of 265,000 shares of the Company&#8217;s common stock (refer to Note 9).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, retroactively effective August 7, 2008, the Company negotiated an amended license agreement for the use of Crucell&#8217;s adenovirus technology. The Company is required to make annual license payments on the anniversary of the effective date for the three year term equal to &#8364;75,000 per annum. As at September 30, 2012, the Company had accrued $365,970 (&#8364;284,578) under the amended agreement, inclusive of interest on outstanding amounts. The Company is currently delinquent on making its first annual license payment under the amended license agreement. Crucell has the right to cancel the agreement however, to date, the Company has not received any notice terminating the license agreement. Management plans to negotiate an amended payment structure with Crucell that, if successful, would allow the Company to maintain the license agreement in good standing. However, there is no certainty that the license agreement will be maintained or that management will successfully negotiate new terms.</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 4:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">DERIVATIVE WARRANT LIABILITY AND FAIR VALUE</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has evaluated the application ASC 480-10 <font style="DISPLAY: inline; FONT-STYLE: italic">Distinguishing liabilities from equity</font>, ASC 815-40 <font style="DISPLAY: inline; FONT-STYLE: italic">Contracts in an Entity&#8217;s Own Equity</font> and ASC 718-10 <font style="DISPLAY: inline; FONT-STYLE: italic">Compensation &#8211; Stock Compensation</font> to the issued and outstanding warrants to purchase common stock that were issued with the convertible notes, private placements, consulting agreements, and various debt settlements during 2009 through 2012. Based on the guidance, management concluded these instruments are required to be accounted for as derivatives either due to a ratchet down protection feature available on the exercise price (Note 5) or a holder&#8217;s right to put the warrants back to the Company for cash under certain conditions or a conversion option feature with conversion into variable number of shares. Under ASC 815-40-25, the Company records the fair value of these warrants and conversion options (derivatives) on its balance sheet, at fair value, with changes in the values reflected in the statements of operations as &#8220;Changes in fair value of derivative liabilities&#8221;. The fair value of the share purchase warrants are recorded on the balance sheet under &#8216;Derivative liability &#8211; warrants&#8217; and the fair value of the conversion options are recorded on the balance sheet under &#8216;Derivative liability &#8211; conversion option&#8217;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820-10 describes three levels of inputs that may be used to measure fair value: Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities; Level 2 &#8211; Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company&#8217;s Level 3 liabilities consist of the derivative liabilities associated with the warrants issued with the convertible notes during the year ended December 31, 2011. At September 30, 2012, all of the Company&#8217;s derivative liabilities were categorized as Level 3 fair value liabilities. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Level 3 Valuation Techniques</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Financial liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 financial liabilities consist of the notes and warrants for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Determining fair value of share purchase warrants, given the Company&#8217;s stage of development and financial position, is highly subjective and identifying appropriate measurement criteria and models is subject to uncertainty. There are several generally accepted pricing models for warrants and options and derivative provisions. The Company has chosen to value the warrants and conversion option on the notes that contain ratchet down provisions using the Binomial model under the following assumptions:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="7" valign="top" width="39%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2011</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="7" valign="top" width="39%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2012</font></div>
</td>
</tr><tr>
<td valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected Life (Years)</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free Rate</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend yield</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected Life (Years)</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free Rate</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend yield</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="21%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Share purchase warrants</font></div>
</td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.09 to 4.80</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.12% to 0.83%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">199%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.33 to 4.03</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.10% to 0.62%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">199%</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="7" valign="top" width="39%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">At Initial Recognition</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="7" valign="top" width="39%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2012</font></div>
</td>
</tr><tr>
<td valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected Life (Years)</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free Rate</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend yield</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected Life (Years)</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free Rate</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend yield</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="21%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Conversion Option</font></div>
</td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.25 to 1.04</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.11% to 0.20%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">138.31% to 141.43%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.11 to 1.00</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.06% to 0.17%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00%</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">138.31% to 141.21%</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management&#8217;s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability &#8211; warrants:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" width="39%" style="BORDER-TOP: black 2px solid; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-TOP: black 2px solid; PADDING-BOTTOM: 2px; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="14" valign="bottom" width="59%" style="BORDER-TOP: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;As of September 30, 2012</font></font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="39%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="14" valign="bottom" width="59%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value Measurements</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="39%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Carrying Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 2</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 3</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability - warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871,858</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability &#8211; conversion option</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="39%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,072,558</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,072,558</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,072,558</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" width="39%" style="BORDER-TOP: black 2px solid; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="14" valign="bottom" width="59%" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">As of December 31, 2011</font></font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="39%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="14" valign="bottom" width="59%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value Measurements Using</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="39%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Carrying Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 2</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 3</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability - warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="39%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The table below provides a summary of the changes in fair value, including net transfers, in and/or out, of financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2012 and the year ended December 31, 2011:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" width="61%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="11" valign="bottom" width="38%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value Measurements Using Level 3 Inputs</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="61%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability - warrants</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability &#8211; conversion option</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance,&#160;&#160;December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,819,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">175,389</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,994,901</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additions during the year</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,587,275</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,587,275</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total unrealized (gains) or losses included in net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(631,631</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(37,079</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(668,710</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Debt settlement</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,457,322</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(138,310</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,595,632</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="61%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Transfers in and/or out of Level 3</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additions during the year</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">299,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total unrealized (gains) or losses included in net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(445,976</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(98,600</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(544,576</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Debt settlement</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="61%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Transfers in and/or out of Level 3</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="61%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, September 30, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871,858</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,700</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,072,558</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The fair value of the warrants and conversion options is determined using a Binomial option pricing model. The valuation of warrants and conversion options is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. Ultimately, the Company may incur amounts to settle the warrants at a cash settlement value that is significantly different than the carrying value of the liability in the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants and conversion options liability are recognized as a component of other income (expense) in the statement of operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The net cash settlement value at the time of any future Fundamental Transaction will depend upon the value of the following inputs at that time: the consideration value per share of the Company&#8217;s common stock, the volatility of the Company&#8217;s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U.S. Treasury security yields, and the Company&#8217;s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 5:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">CONVERTIBLE NOTES PAYABLE</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following is a summary of debt instrument transactions that are relevant to the current period:</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Face Value</font></div>
</td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Principal Repayment</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unamortized</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Note</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Discount</font></div>
</td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">February 2011 Secured Convertible Notes</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Senior Secured Notes, due February 24, 2014</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,184,694</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">225,800</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">958,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 2011 Secured Convertible Notes</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Senior Secured Notes, due April 4, 2014</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">215,000</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,786</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">163,214</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 2011 Secured Convertible Note</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Senior Secured Notes, due June 6, 2014</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,000</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,650</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,350</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 8, 2012 Convertible Note</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Note due August 8, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">111,430</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">95,250</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,180</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 12, 2012 Convertible Note</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Note due November 12, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,500</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,658</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,842</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 20, 2012 Convertible Note</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Note due August 20, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,000</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,757</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,245</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 2012 Convertible Note</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Note due October 1, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">82,500</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">79,874</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,626</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,671,124</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">486,773</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,184,351</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">February 2011 Secured Convertible Notes</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 24, 2011, the Company entered into a securities purchase agreement with accredited investors to place Senior Secured Convertible Notes (the &#8220;February 2011 Notes&#8221;) with a maturity date of three years after the issuance thereof in the aggregate principal amount of $1,184,694. Consideration under the notes consisted of $944,694 in cash proceeds, including accrued interest, and $240,000 was subscribed for by two of the holders of outstanding and demandable 2010 secured convertible notes (the &#8220;2010 Notes&#8221;). The holders of the 2010 Notes returned their Series A, Series B and Series C warrants to the Company for cancellation. In connection with the issuance of the February 2011 Notes, the Company entered into a 2011 Security Agreement with the note holders securing the February 2011 Notes with all of the Company&#8217;s assets. One year after the issuance of the February 2011 Notes, the note holders have the option to convert a portion or all of the outstanding balance of the February 2011 Notes including any accrued interest into shares of the Company&#8217;s common stock at a conversion rate of $0.15 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The February 2011 Notes bear interest at the rate of 10% per annum except in case of default, in which case they bear interest at the rate of 20% per annum. The interest is due on the February 2011 Notes at the end of each three month period, starting three months from their issuance. One year after the issuance of the February 2011 Notes, the Company may elect to prepay a portion of the principal. If the Company makes such an election, the holders may elect to receive such prepayment in cash or in shares of the Company&#8217;s common stock, at a conversion rate of $0.15 per share, or in a combination thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company paid a finders&#8217; fee of $41,500. The finder&#8217;s fee was accounted for as deferred financing costs, and is being amortized over the term of the notes. At September 30, 2012, $18,495 of the $20,768 in deferred financing costs relates to the February 2011 Notes which remains unamortized, and is presented in long-term assets on the Company&#8217;s Balance Sheet.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the issuance of the February 2011 Notes, the Company issued 2,369,388 warrants, exercisable into common stock at $0.25 with five year terms. The Company may force the exercise of the warrants at any time that the average volume weighted average price of the Company&#8217;s common stock over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&#8217;s common stock sold over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of the shares underlying the warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">After reviewing a Fundamental Transaction clause contained in the warrants, the Company allocated the net proceeds to the warrants based on the calculated fair value at the date of issuance. The fair value of the warrants was recorded at $483,355 and recognized as derivative liabilities and the debt was recorded at $701,339. The fair value of the warrants was calculated using the Binomial option pricing model under the following assumptions: estimated life of five years, risk free rate of 2.06%, dividend yield of 0% and volatility of 199%. The debt discount is being accreted over the three year term of the February 2011 Notes using the effective interest rate method.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2012, accretion of the debt discount of $120,839 was recorded for the February 2011 Notes.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">April 2011 Secured Convertible Notes</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 4, 2011, the Company entered into a securities purchase agreement with accredited investors to place Senior Secured Convertible Notes (the &#8220;April 2011 Notes&#8221;) with a maturity date of three years after the issuance thereof in the aggregate principal amount of $215,000. Consideration under the notes consisted of $190,000 in cash proceeds, and $25,000 was subscribed for by a holder of 2010 Notes in exchange for the extinguishment of the Series A, Series B and Series C warrants related to the 2010 Notes. In connection with the issuance of the April 2011 Notes, the Company entered into a 2011 Security Agreement with the note holders securing the April 2011 Notes with a secondary security interest in all of the Company&#8217;s assets. One year after the issuance of the April 2011 Notes, the note holders have the option to convert a portion or all of the outstanding balance of the April 2011 Notes including any accrued interest into shares of the Company&#8217;s common stock at a conversion rate of $0.15 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The April 2011 Notes bear interest at the rate of 10% per annum except in case of default, in which case they bear interest at the rate of 20% per annum. The interest is due on the April 2011 Notes at the end of each three month period, starting three months from their issuance. One year after the issuance of the April 2011 Notes, the Company may elect to prepay a portion of the principal. If the Company makes such an election, the holders may elect to receive such prepayment in cash or in shares of the Company&#8217;s common stock, at a conversion rate of $0.15 per share, or in a combination thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company paid a finders&#8217; fee of $4,550. The finder&#8217;s fee was accounted for as deferred financing costs, and is being amortized over the term of the notes. At September 30, 2012, $2,273 of the $20,768 in deferred financing costs relates to the April 2011 Notes which remains unamortized, and is presented in long-term assets on the Company&#8217;s Balance Sheet.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the issuance of the April 2011 Notes, the Company issued 430,000 warrants, exercisable into common stock at $0.25 with 2 year terms. The Company may force the exercise of the warrants at any time that the average volume weighted average price of the Company&#8217;s common stock over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&#8217;s common stock sold over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of the shares underlying the warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has allocated the net proceeds to the warrants based on the calculated fair value. The fair value of the warrants was recorded at $130,720 and recognized as derivative liabilities and the debt was recorded at $84,280. The fair value of the warrants was calculated using the Binomial option pricing model under the following assumptions: estimated life of two years, risk free rate of 0.77%, dividend yield of 0% and volatility of 199%. The debt discount is being accreted over the three year term of the April 2011 Notes using the effective interest rate method.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2012, accretion of the debt discount of $25,752 was recorded for the April 2011 Notes.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">June 2011 Secured Convertible Note</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 6, 2011, the Company entered into a securities purchase agreement with accredited investors to place Senior Secured Convertible Note (the &#8220;June 2011 Note&#8221;) with a maturity date of three years after the issuance thereof in the aggregate principal amount of $30,000. In connection with the issuance of the June 2011 Note, the Company entered into a 2011 Security Agreement with the note holder securing the June 2011 Note with a secondary security interest in all of the Company&#8217;s assets. One year after the issuance of the June 2011 Note, the note holder has the option to convert a portion or all of the outstanding balance of the June 2011 Note including any accrued interest into shares of the Company&#8217;s common stock at a conversion rate of $0.15 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The June 2011 Note bears interest at the rate of 10% per annum except in case of default, in which case it bears interest at the rate of 20% per annum. The interest is due on the June 2011 Note at the end of each three month period, starting three months from its issuance. One year after the issuance of the June 2011 Note, the Company may elect to prepay a portion of the principal. If the Company makes such an election, the holders may elect to receive such prepayment in cash or in shares of the Company&#8217;s common stock, at a conversion rate of $0.15 per share, or in a combination thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the issuance of the June 2011 Note, the Company issued 60,000 warrants, exercisable into common stock at $0.25 with two year terms. The Company may force the exercise of the warrants at any time that the average volume weighted average price of the Company&#8217;s common stock over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&#8217;s common stock sold over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of the shares underlying the warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has allocated the net proceeds to the warrants based on the calculated fair value. The fair value of the warrants was recorded at $8,280 and recognized as derivative liabilities and the debt was recorded at $21,720. The fair value of the warrants was calculated using the Binomial option pricing model under the following assumptions: estimated life of two years, risk free rate of 0.43%, dividend yield of 0% and volatility of 199%. The debt discount is being accreted over the three year term of the June 2011 Note using the effective interest rate method.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2012, accretion of the debt discount of $2,075 was recorded for the June 2011 Note.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">August 8, 2012 Convertible Note</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 8, 2012, the Company entered into a securities purchase agreement with accredited investors to place a Convertible Note (the &#8220;August 8, 2012 Note&#8221;) with a maturity date of one year after the issuance thereof in the aggregate principal amount of $111,430. Consideration under the notes consisted of $92,000 in cash proceeds after $8,000 payment of finders&#8217; fee and an original issue discount of $11,430. The note holder has the option to convert a portion or all of the outstanding balance of the August 8, 2012 Note including any accrued interest into shares of the Company&#8217;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded price in the 25 trading days prior to conversion.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The August 8, 2012 Note carries no interest if the Company repays the note within 90 days from issuance. If the Company does not repay the note within 90 days, a one-time interest of 5% shall apply to the principal sum.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The finder&#8217;s fee of $8,000 was accounted for as deferred financing costs, and is being amortized over the term of the note. At September 30, 2012, $6,838 of the $12,641 in deferred financing costs relates to the August 8, 2012 Note which remains unamortized, and is presented in current assets on the Company&#8217;s Balance Sheet.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has allocated the net proceeds to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $1155,700 and recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt financing of $55,700. The fair value of the conversion option was calculated using the Binomial option pricing model under the following assumptions: estimated life of one year, risk free rate of 0.19%, dividend yield of 0% and volatility of 139.77%. The debt discount is being accreted over the one year term of the August 8, 2012 Note using the effective interest rate method.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2012, accretion of the debt discount of $16,180 was recorded for the August 8, 2012 Note.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">August 12, 2012 Convertible Note</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 12, 2012, the Company entered into a securities purchase agreement with accredited investors to place a Convertible Note (the &#8220;August 12, 2012 Note&#8221;) with a maturity date of three months after the issuance thereof in the aggregate principal amount of $27,500. Consideration under the notes consisted of $25,000 in cash proceeds after an original issue discount of $2,500. The note holder has the option to convert a portion or all of the outstanding balance of the August 8, 2012 Note including any accrued interest into shares of the Company&#8217;s common stock at a conversion rate of $0.09 per share or on similar terms as of any future financings with more favorable terms. The agreement provides for the Company to issue 50,000 shares to the note holder as risk premium. The 50,000 shares were valued at $6,250 and recorded as loss on debt financing and obligation to issue shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The August 12, 2012 Note bears interest at the rate of 10% per annum.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has allocated the net proceeds to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $31,100 and recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt financing of 6,100. The fair value of the conversion option was calculated using the Binomial option pricing model under the following assumptions: estimated life of three months, risk free rate of 0.11%, dividend yield of 0% and volatility of 138.31%. The debt discount is being accreted over the three month term of the August 12, 2012 Note using the effective interest rate method.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2012, accretion of the debt discount of $15,842 was recorded for the August 12, 2012 Note.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">August 20, 2012 Convertible Note</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 20, 2012, the Company entered into a securities purchase agreement with accredited investors to place a Convertible Note (the &#8220;August 20, 2012 Note&#8221;) with a maturity date of one year after the issuance thereof in the aggregate principal amount of $20,000. The note holder has the option to convert a portion or all of the outstanding balance of the August 8, 2012 Note including any accrued interest into shares of the Company&#8217;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded price in the 25 trading days prior to conversion.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The August 20, 2012 Note bears interest at the rate of 8% per annum.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has allocated the net proceeds to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $36,100 and recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt financing of $16,100. The fair value of the conversion option was calculated using the Binomial option pricing model under the following assumptions: estimated life of one year, risk free rate of 0.19%, dividend yield of 0% and volatility of 140.11%. The debt discount is being accreted over the one year term of the August 20, 2012 Note using the effective interest rate method.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2012, accretion of the debt discount of $2,247 was recorded for the August 20, 2012 Note.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">September 18, 2012 Convertible Note</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 18, 2012, the Company entered into a securities purchase agreement with accredited investors to place a Convertible Note (the &#8220;September 18, 2012 Note&#8221;) with a maturity date of one year after the issuance thereof in the aggregate principal amount of $82,500. Consideration under the notes consisted of $69,000 in cash proceeds after $6,000 payment of finders&#8217; fee and an original issue discount of $7,500. The note holder has the option to convert a portion or all of the outstanding balance of the September, 2012 Note including any accrued interest into shares of the Company&#8217;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded price in the 20 trading days prior to conversion.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The September, 2012 Note carries no interest other than the original issue discount.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The finder&#8217;s fee of $6,000 was accounted for as deferred financing costs, and is being amortized over the term of the note. At September 30, 2012, $5,803 of the $12,641 in deferred financing costs relates to the September, 2012 Note which remains unamortized, and is presented in current assets on the Company&#8217;s Balance Sheet.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has allocated the net proceeds to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $76,400 and recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt financing of $1,400. The fair value of the conversion option was calculated using the Binomial option pricing model under the following assumptions: estimated life of one year, risk free rate of 0.20%, dividend yield of 0% and volatility of 141.43%. The debt discount is being accreted over the one year term of the September, 2012 Note using the effective interest rate method.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the nine months ended September 30, 2012, accretion of the debt discount of $2,626 was recorded for the September, 2012 Note.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 6:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">LOANS PAYABLE</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As at September 30, 2012, there were unsecured loan advances from third parties in the amount of $28,000 (December 31, 2011 - $7,000), which are due on demand. The loans are accruing interest between 10-19% per annum.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 7:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">PROMISSORY NOTE</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the year ended December 31, 2011, the Company issued a note in the amount of $100,000 towards future
legal services, which matured July 24, 2011. As of September 30, 2012, the Company had received legal services in the amount of
$100,000 against the note. The note bears interest at 10% per annum and may be converted into shares at a equal to lower of $0.09 or 65% of the arithmetic average of the lowest closing bid prices of the Company&rsquo;s
shares during the consecutive twenty day trading period prior to notice of conversion.</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended, the Company issued 500,000 shares to the holder of the note in exchange for the note holder&#8217;s agreement to forbear from pursuing collections actions on the outstanding note (Note 9). As of September 30, 2012, the Company is negotiating terms for repayment and settlement of the note.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2012, the Company issued additional promissory notes in the amount of $67,942, of which $38,000 of promissory notes were issued to an officer and a director of the Company (Note 8). The promissory notes had no interest charges and no fixed repayment terms.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 8:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">RELATED PARTY TRANSACTIONS</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the nine months ended September 30, 2012, the Company entered into transactions with certain officers and directors of the Company as follows:</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">incurred $173,500 (September 30, 2011 - $187,200) in management fees and $67,500 (September 30, 2011 - $67,500) in research and development services paid to officers and directors during the period;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">recorded $31,333 (September 30, 2011 - $360,260) in stock based compensation for the fair value of options granted to management that were granted and or vested during the period;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">converted $25,000 (September 30, 2011 - $100,000) of debt due to related parties during the period, which were settled with shares;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">issued $38,000 (September 30, 2011 - $nil) in promissory notes to an officer and director of the Company (Note 7).</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All related party transactions (other than stock based consideration) involving provision of services were recorded at the exchange amount, which is the amount established and agreed to by the related parties as representing fair value. The Company accounted for the debt settlement transactions with related parties at management&#8217;s estimate of fair value, using amounts similar to arm&#8217;s length settlements for debt settled.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2012, the Company had amounts owing to directors and officers of $281,475 (December 31, 2011 - $322,905). Amounts due to related parties are unsecured, non-interest bearing and have no specific terms of repayment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 9:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">CAPITAL STOCK</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Share Capital</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The authorized capital of the Company consisted of 150,000,000 common shares with $0.001 par value and 5,000,000 non-voting preferred shares with $0.001 par value.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">2012 Share Transactions</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 15, 2012, the Company issued 333,334 shares of its restricted common stock to related parties, pursuant to debt settlement agreements to settle $50,000 of outstanding trade payable. At the time of issuance the fair value of the shares was determined to be $50,000 based on the quoted market price of $0.15 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 15, 2012, the Company issued 400,000 shares of its restricted common stock pursuant to a debt settlement and a consulting agreement. At the time of issuance the fair value of the shares was determined to be $71,200 based on the quoted market price of $0.15 per share. The Company recorded $9,930 as gain on settlement of debt.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 15, 2012, the Company issued 789,778 shares of its restricted common stock in settlement of accrued interest on the outstanding 2011 Notes. At the time of issuance the fair value of the shares was determined to be $118,467 based on the quoted market price of $0.15 per share. No gain or loss was recorded on settlement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In March 2012, the Company received subscription proceeds of $85,000. The subscribers purchased 733,334 share units at $0.15 per unit. Each unit consists of 1 share of Company&#8217;s common stock and half a warrant exercisable at $0.40, which expires in two years. The fair value of these warrants was determined to be $5,133.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2012, the Company received subscription proceeds of $345,000. The subscribers purchased 2,300,000 share units at $0.15 per unit. Each unit consists of 1 share of Company&#8217;s common stock and half a warrant exercisable at $0.40, which expires in two years. The fair value of these warrants was determined to be $123,000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April, 2012, the Company issued 100,000 shares of its restricted common stock pursuant to a debt settlement and a consulting agreement. At the time of issuance the fair value of the shares was determined to be $18,500 based on the quoted market price of $0.185 per share. The Company recorded $18,758 as gain on settlement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2012, the Company issued 933,333 restricted common shares, at $0.15 per share, for proceeds of $140,000 received in October 2011, in a private placement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2012, the Company issued 1,000,000 common shares to a consultant pursuant to a consulting agreement effective October 1, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April, 2012, the Company issued 163,334 shares of its restricted common stock in settlement of accrued interest on the outstanding 2011 Notes. At the time of issuance the fair value of the shares was determined to be $24,500 based on the quoted market price of $0.15 per share. No gain or loss was recorded on settlement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May 2012, the Company issued 14,000,000 common shares to consultants pursuant to a consulting agreement (Note 11). At the time of issuance the fair value of the shares was determined to be $1,918,000 based on the quoted market price of $0.137 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2012, the Company issued 35,179 shares of its restricted common stock pursuant to a consulting agreement. The fair value of the shares was determined to be $6,000 based on the quoted market price of $0.17 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In August 2012, the Company issued 500,000 shares of its restricted common stock pursuant to a consulting agreement. The fair value of the shares was determined to be $74,000 based on the quoted market price of $0.148 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">In September 2012, the Company issued <FONT STYLE="font: 10pt Times New Roman, Times, Serif">500,000 shares
of its restricted common stock to the holder of a promissory note in exchange for the note holder&rsquo;s agreement to forebear
from pursuing collection action on that note (Note 7). The fair value of the shares was determined to be $72,750 based on the quoted
market price of $0.146 per share.</FONT></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">2011 Share Transactions</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 21, 2011, the Company issued 641,023 shares of its restricted common stock pursuant to debt settlement and warrant extinguishment agreement to settle $83,333 of the 2010 Notes and partial extinguishment of the Series A, Series B and Series C Warrants. At the time of issuance, the fair value of the shares was determined to be $115,384, based on the quoted market price of $0.18 per share, which has been recorded against the carrying value of the debt. The Company recognized a loss of $87,734 on partial settlement of 2010 Notes and partial extinguishment of the Series A, Series B and Series C Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 23, 2011, the Company issued 1,180,000 shares of its restricted common stock pursuant to various consulting agreements. At the time of issuance the fair value of the shares was determined to be $227,432 based on the quoted market price of $0.18 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 23, 2011, the Company issued 885,295 shares of its restricted common stock pursuant to debt settlement agreements to settle $150,500 of outstanding trade payables. At the time of issuance the fair value of the shares was determined to be $172,633 based on the quoted market price of $0.195 per share. The Company recorded $22,133 as loss on settlement of debt.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 23, 2011, the Company issued 441,177 shares of its restricted common stock to related parties, pursuant to debt settlement agreements to settle $75,000 of its outstanding trade payables. At the time of issuance the fair value of the shares was determined to be $86,030 based on the quoted market price of $0.195 per share. The Company recorded the calculated loss on settlement of $11,030 to the statement of operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 30, 2011, the Company issued 2,048,578 shares of its restricted common stock pursuant to an exchange agreement to settle $233,333 of the 2010 Notes. At the time of issuance the fair value of the shares was determined to be $450,687 based on the quoted market price of $0.22 per share. The discounted carrying amount of the 2010 Note as of March 30, 2011 was $77,421. The Company recorded the difference between the fair value and accreted amount of $373,266 as loss on settlement of debt.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 5, 2011, the Company issued 500,000 shares of its restricted common stock pursuant to a consulting agreement. At the time of issuance the fair value of the shares was determined to be $125,000 based on the quoted market price of $0.25 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 25, 2011, the Company issued 350,000 shares of its restricted common stock pursuant to a consulting agreement. At the time of issuance the fair value of the shares was determined to be $87,500 based on the quoted market price of $0.25 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 25, 2011, the Company issued 366,783 shares of its restricted common stock pursuant to debt settlement agreements to settle $84,315 of outstanding trade payables. At the time of issuance the fair value of the shares was determined to be $91,696 based on the quoted market price of $0.25 per share. The Company recorded $7,381 as loss on settlement of debt.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 25, 2011, the Company issued 20,000 shares of its restricted common stock pursuant to a debt settlement agreement to settle $4,575 of outstanding trade payables. At the time of agreement the fair value of the shares was determined to be $6,800 based on the quoted market price of $0.34 per share. The Company recorded $2,225 as loss on settlement of debt.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 25, 2011, the Company issued 108,696 shares of its restricted common stock to related parties, pursuant to a debt settlement agreement to settle $25,000 of its outstanding accounts payables. At the time of issuance the fair value of the shares was determined to be $27,174 based on the quoted market price of $0.25 per share. The Company recorded the calculated loss on settlement of $2,174 to the statement of operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2011, the Company received subscription proceeds of $90,000 and issued 600,001 shares of common stock in a private placement. The subscribers to the subscription proceeds have agreed to purchase one unit for each $3.00 of subscription proceeds. Each unit consists of 20 share of Company&#8217;s common stock and 6 warrants each exercisable at $0.25, which expire in two years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 1, 2011, 586,858 shares of the Company&#8217;s restricted common stock was returned to treasury due to an adjustment to the final settlement of the $233,333 2010 Notes. The return of the shares resulted in a $134,977 reduction to the previously calculated loss on debt settlement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 7, 2011, the Company received subscription proceeds of $65,000 and issued 325,000 shares of common stock in a private placement. The subscribers purchased one unit for each $2.00 of subscription proceeds. Each unit consists of 10 shares of Company&#8217;s common stock and 6 warrants each exercisable at $0.25, which expire in two years. The fair value of these warrants was determined to be $33,600.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 19, 2011, the Company received subscription proceeds of $45,000 and issued 225,000 shares of common stock in a private placement. The subscribers purchased one unit for each $2.00 of subscription proceeds. Each unit consists of 10 shares of Company&#8217;s common stock and 6 warrants each exercisable at $0.25, which expire in two years. The fair value of these warrants was determined to be $23,400.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Stock Compensation Plan</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 14, 2009, the Company adopted the 2009 Stock Incentive Plan (the &#8220;2009 Plan&#8221;) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows for the issuance of up to 10,000,000 common shares. Options granted under the Plan shall be at prices and for terms as determined by the Board of Directors.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 30, 2012, the Company granted 250,000 stock options to management at an exercise price of $0.18 per share, vesting monthly over a thirty six month period. The aggregate fair value of the new grant was estimated at $45,000, or $0.18 per option, using the Black-Scholes option pricing model with weighted average assumptions as follows: a risk free interest rate of 1.95%, a dividend yield of 0%, an expected volatility of 199%, and an expected life of 10 years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 8, 2012, the Company granted 250,000 stock options to a consultant at an exercise price of $0.17 per share, vesting monthly over a twelve month period. The aggregate fair value of the new grant was estimated at $40,000, or $0.16 per option, using the Black-Scholes option pricing model with weighted average assumptions as follows: a risk free interest rate of 1.71%, a dividend yield of 0%, an expected volatility of 199%, and an expected life of 10 years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The expensed portion of the value of the vesting options during the nine months ended September 30, 2012 was $205,516 (September 30, 2011 - $369,116) which was recorded as stock based consulting and management fees. During the periods, stock-based consulting and management fees also includes share and warrant based compensation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Share purchase options</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of the Company&#8217;s stock options as of September 30, 2012 and changes during the period is presented below:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise Price</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining Life</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,278,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.85</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Issued</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Cancelled</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, September 30, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,778,000</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.61</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2012, the intrinsic value of the vested options was equal to $nil (September 30, 2011 - $nil).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of the status of the Company&#8217;s unvested options as of September 30, 2012 is presented below:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant-Date</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair Value</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unvested, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,037,709</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.17</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Vested</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(843,676</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Cancelled</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unvested, September 30, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">694,033</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.18</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Share Purchase Warrants</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;On February 24, 2011, the Company issued 2,369,388 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant to a securities purchase agreement (Note 5). The fair value of these warrants of $483,355 was recognized under derivative liabilities, using the Binomial option pricing model with an expected life of 5 years, a risk free interest rate of 2.06%, a dividend yield of 0%, and an expected volatility of 199%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In March 21, 2011, the Company issued 250,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant to a debt settlement agreement (Note 5). The fair value of these warrants of $43,750 was recognized under derivative liabilities, using the Binomial option pricing model with an expected life of 5 years, a risk free interest rate of 0.77%, a dividend yield of 0%, and an expected volatility of 199%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 4, 2011, the Company issued 1,000,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant to a debt settlement agreement (Note 5). The fair value of these warrants was determined to be $349,000, using the Black-Scholes option pricing model with an expected life of 5 years, a risk free interest rate of 2.20%, a dividend yield of 0%, and an expected volatility of 252%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 25, 2011, the Company issued 180,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant to the private placement of $90,000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 6, 2011, the Company issued 60,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant to a securities purchase agreement (Note 5). The fair value of these warrants was determined to be $10,146, using the Black-Scholes option pricing model with an expected life of 5 years, a risk free interest rate of 1.60%, a dividend yield of 0%, and an expected volatility of 254%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In March, 2012, the Company issued 366,668 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $0.40 per share for an exercise period of up to two years from the issuance date. The warrants were issued pursuant to the private placement of $110,000 and included within equity. The fair value of these warrants was determined to be $5,133, using the Black-Scholes option pricing model with an expected life of 2 years, a risk free interest rate of 0.37%, a dividend yield of 0%, and an expected volatility of 63%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April, 2012, the Company issued 1,150,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise price of $0.40 per share for an exercise period of up to two years from the issuance date. The warrants were issued pursuant to a private placement and included within equity. The fair value of these warrants was determined to be $123,000, using the Black-Scholes option pricing model with an expected life of 2 years, a risk free interest rate of 0.27%, a dividend yield of 0%, and an expected volatility of 146.6%.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of the Company&#8217;s share purchase warrants as of September 30, 2012 and changes during the period is presented below:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise Price</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted Average</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining Life</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,106,355</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.56</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.81</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Issued</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,516,668</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.40</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.80</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;Extinguished or expired</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(714,400</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.33</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance, September 30, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,908,623</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.43</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.86</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 10:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td align="left" valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160; </font></td>
<td align="left" valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares/warrants</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares issued pursuant to debt settlement agreements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,126,447</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">326,937</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common shares issued pursuant to consulting service arrangements</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,535,179</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,998,000</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td align="left" valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font> <br>
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30, 2011</font></td>
<td nowrap valign="bottom" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares/warrants</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable settled by issuing common shares</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,214,766</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">815,527</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common shares issued pursuant to consulting service arrangements</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,327,059</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">500,527</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the 2010 Note settlement and warrant extinguishment agreements entered during the nine months ended September 30, 2011, the Company issued February 2011 Notes in the amount of $240,000 (Note 5).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See Notes 5 and 9 for additional disclosure on non-cash transactions.</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" style="BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-TOP: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></div>
</td>
<td nowrap valign="bottom" style="BORDER-TOP: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2012</font></td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2011</font></td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest paid in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Income taxes paid</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 11:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">CONTINGENCIES AND COMMITMENTS</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Contingencies</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Tax Filings</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has not filed income tax returns for several years in certain operating jurisdictions, and may be subject to possible compliance penalties and interest. Management is currently not able to make a reliably measurable provision for possible liability for penalties and interest, if any, at this time, and the Company may be liable for such amounts upon assessment. Penalties and interest, if assessed in the future, will be recorded in the period such amounts are determinable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Commitments</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Combined Research and Operating Obligations</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective May 25, 2010, the Company entered into a research and license Option Agreement with the Mayo Clinic for the development and possible commercial use of a cancer vaccine. Subject to the approval and guidance of the United States Food and Drug Administration (&#8220;FDA&#8221;) the Mayo Clinic plans to conduct a Phase I human clinical trial (&#8220;Phase I Trial&#8221;) to test and develop the Company&#8217;s technology.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has agreed that, during the period of the option and upon approval of FDA to conduct Phase I Trials, will pay all the costs incurred by the Mayo Clinic, not to exceed a total of $841,000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 13, 2012, the Company entered into a Patent &amp; Know-How agreement with the Mayo Foundation for Education and Research (&#8220;Mayo&#8221;) to license a proprietary MHC Class I HER2/neu antigen technology. Under the terms of the agreement, the Company acquired from Mayo (i) an exclusive worldwide license to use the patent rights related to patent application numbered 61600480 (titled &#8220;Methods and materials for generating CD8+ T-cells having the ability to recognize cancer cells expressing a Her2/neu polypeptide&#8221;) to make products in the prophylactic and therapeutic field (the &#8220;Licensed Products&#8221;) and (ii) a non-exclusive license to use certain of Mayo&#8217;s know-how to make the Licensed Products. The Company may sublicense the technology with the approval of Mayo, which approval may not unreasonably withheld.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the grant of the licenses, the Company is to (i) make an upfront license payment of $100,000 to Mayo followed by an additional $150,000 in license payments over a 12 month period, (ii) reimburse Mayo for documented patent expenses incurred to date by Mayo in connection with the license, (iii) pay an annual license fees, (iv) make milestone payments and (iv) pay royalties of gross annual sales. In addition, the Company is required to pay Mayo a fee if it fails to initiate a Phase I clinical trial of a Licensed Product within five years and if it fails to initiate a Phase II clinical trial of a Licensed Product within eight years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Management Services Agreement</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In February 2011, the Company approved an employment agreement with Dr. Wilson with an initial term of 2 years, which may be automatically extended for successive one-year terms. This employment agreement provides for annual compensation of $180,000 and the grant of an option to acquire 2,000,000 shares of the Company&#8217;s common stock at $0.19 per share, 50% of which vested on March 16, 2011, while the remainder will vest monthly over a period of two years (41,667 per month). The options shall be exercisable for at least five years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Consultant Agreements</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2012, the Company entered into an investors&#8217; relation consulting agreement for a one year term, with a one-time right to terminate the agreement at its six month anniversary. The consulting agreement provides for the Company to issue 620,690 shares to the consultant and a monthly payment of $7,500.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2012, the Company entered into financial consulting service agreements, which included compensation of 14,000,000 shares of common stock, whereby the Company agreed to issue additional shares to the consultants to restore their holdings to 24.8% of fully diluted capitalization of the Company if the Company completes a re-organization, re-capitalization or a liquidity event during the eighteen months commencing with the signing of these agreements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Rental Lease Agreement</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2011, the Company entered into a lease agreement, which started in January 2012 for a two year period. The Company will pay a monthly basic rent of $7,152 and additional rent for operating costs of 2.20% of total operating expenses of the property.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has obligations under various agreements through December 31, 2014. The aggregate minimum annual payments for the years ending December 31 are as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">R&amp;D Commitments</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Administrative <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Commitments</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,052,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">195,821</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">308,313</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22,284</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,090,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">526,418</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTE 12:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">SUBSEQUENT EVENTS</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 15, 2012, the Company entered into an agreement to issue a note to an investor for $340,000. The Company received $300,000 for the note which carried $30,000 of original issue discount and $10,000 in legal fees.&#160;&#160;The note is due on October 15, 2013 and carries an interest rate of 8%. There are seven installment payments due on the note beginning on the seventh month after its issuance of the note and each month thereafter until maturity.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
lender has the right, at any time after issuance, at its election, to convert all or part of the outstanding and unpaid
principal sum and accrued interest into fully paid and non-assessable shares of the Company&#8217;s common stock at $0.12 per
share. If the Company issues shares (or reduces the conversion or exercise price for outstanding debt or warrants) for less
than $0.12, then the conversion price for the note shall be reduced to that new issuance price. If the holder of the note
converts the full amount of the note (excluding any interest that becomes due thereon), it shall receive 2,833,333 shares of
the Company&rsquo;s common stock.</font><br> &#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provided that there is sufficient volume in the trading of the Company&#8217;s common stock and other criteria are met, the Company may elect to make any payment due on an installment date in shares of common stock. If the Company elects to make a payment in shares of common stock, the number of shares that the Company issues will be equal to the amount to be converted divided by the lesser of the conversion price or 70% of the average of the three lowest closing bid prices of the shares of common stock during the prior twenty consecutive trading days. If the Company elects to pay the full amount of the note in common shares (excluding any interest that becomes due thereon), the holder shall receive at a minimum 2,833,333 shares of the Company&#8217;s common stock, but this amount could be substantially higher. Unless otherwise agreed in writing by both parties, at no time will the holder convert any amount of the debenture into common stock that would result in the holder owning more than 4.99% of the common stock outstanding.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As part of the agreement, the Company also issued 3,000,000 warrants to the note holder exercisable at $0.25/share expiring on October 31, 2016.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The warrants include price adjustment provisions whereby the exercise price will be adjusted downwards based on future grants, which results in a share issuance at a per share amount less than $0.25 per share, or repricing of any existing warrants to a lower price.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;target&#8221;, &#8220;intend&#8221; and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section and elsewhere in this quarterly report on Form 10-Q, and the risks discussed in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis, judgment, belief or expectation only as the date hereof. We assume no obligation to update these forward-looking statements to reflect events or circumstance that arise after the date hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">As used in this quarterly report: (i) the terms &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;TapImmune&#8221; and the &#8220;Company&#8221; mean TapImmune Inc. and its wholly owned subsidiary, GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) &#8220;SEC&#8221; refers to the Securities and Exchange Commission; (iii) &#8220;Securities Act&#8221; refers to the Securities Act of 1933, as amended; (iv) &#8220;Exchange Act&#8221; refers to the Securities Exchange Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The following should be read in conjunction with our unaudited consolidated interim financial statements and related notes for the nine Months Ended&#160;&#160;September 30, 2012 included in this quarterly report, as well as our Annual Report on Form 10-K for the year ended December 31, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Overview</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Taplmmune Inc.</font> is a vaccine technologies company specializing in the development of innovative gene based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidates, include vaccines designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company recently began treating patients in its first Phase 1 immunotherapy clinical trial targeting HER2/neu in breast cancer at the Mayo clinic (see Clinicaltrials.gov). This trial uses patented antigen technologies developed at the Mayo clinic and will follow patients for safety and immune responses as the primary endpoints. During the first year of this trial there will be a safety review interim analysis. TapImmune has the exclusive Option to license this technology. The Company is also developing TAP-based prophylactic vaccines commercially suitable for the prevention of infectious diseases and as Biodefense agents. We have applied for a grant in collaboration with the Mayo Clinic for the biodefense applications of this technology in and expect to file additional grants to support preclinical work on &#8220;boost&#8221; strategies for HER2/neu breast cancer. As a vaccine component, the gene based TAP technology has the potential to significantly improve the efficacy of both prophylactic and immunotherapeutic vaccines as it addresses a fundamental mechanism for T cell recognition and response. Unlike other vaccine technologies that address only the initiation of immune responses, TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches that are designed to enhance cellular responses.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The current standard therapies for cancer treatment include surgery, radiation therapy and chemotherapy. However, we believe that these treatments are not precise in targeting only cancerous cells and often fail to remove or destroy all of the cancer. The remaining cancer cells may then grow into new tumors, which can be resistant to further chemotherapy or radiation, which may result in death. In the United States, deaths from cancer are second only to cardiovascular deaths. Our breast cancer immunotherapeutic vaccine candidate is being developed for use in this setting as an adjuvant treatment to prevent recurrent disease.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management strongly believes that the comprehensive scientific underpinnings of our overall approach, to elicit the production of both T-helper cells and T-killer cells, will provide the Company with highly competitive product candidates for the treatment of HER2/neu positive breast cancer with additional applications in ovarian and colorectal cancer.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May, we entered into a Material Transfer Agreement with the Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;), Seattle, WA. The initial aim of this collaboration is to determine levels of TAP1/TAP2 in tissues taken from melanoma patients in a clinical trial at FHCRC using adoptive T-cell therapy and to correlate these levels with clinical outcomes.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Regarding our programs for the development of vaccines aimed at viral pandemics/biodefense, we believe that collaborations with the Mayo Clinic have progressed well and studies on the immunogenicity of novel smallpox antigens in mice treated with both antigens and TAP expression vectors are ongoing. We plan to complete animal efficacy and human safety studies through non-dilutive grant funding in collaboration with Dr. Greg Poland and colleagues at the Mayo Clinic and anticipate that further development will be completed through strategic corporate partnerships. The use of non-dilutive grant funding to progress this area allows the Company to focus the majority of its internal resources on HER2/neu breast cancer.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The facilities at 1551 Eastlake Avenue, Seattle have exceeded our expectations and allowed us to continue to recruit top-class scientific staff while at the same time effectively leverage world class resources made available to us and manage our cash flow. We have added technical staff in the areas of molecular biology and immunology. Our small core team (7 scientists) has allowed us to establish in-house technical expertise in molecular biology (expression vector development) and immunology to underpin our current and future development projects and to optimally work with external collaborators. It has also allowed us to make significant progress in the refinement and focus of clinical programs to take advantage of new antigens, the emerging field of vaccinomics and vaccine development strategies. In addition, it has allowed us to start generating new intellectual property (IP) to add to our core TAP IP and the antigen IP from the Mayo Clinic that we have either licensed or have exclusive options to license.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Over the past few months we have, in a challenging financing climate, raised sufficient working capital to fund and progress our operations. We believe that we continue to make good progress with the resources available to us. With the start of clinical programs and our focus on securing non-dilutive financing from a number of sources, management is confident that our current pathway will secure longer term capital to finance and accelerate our activities. The strength of our science and development approaches is becoming more widely appreciated, particularly as our clinical program generates data and as we embrace additional collaborations with leading institutions and corporations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While the pathway to successful product development takes time and significant resources, we believe that we have put in place the technical and corporate fundamentals for success. The strength of our product pipeline gives us a unique opportunity to make a major contribution to global health care.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The Immunotherapy Industry for Cancer</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management believes that there is a critical need for more effective cancer therapies. Management further believes that the global market for effective cancer treatments is large and that immunotherapies representing potential treatments for metastatic cancer are an unmet need in the area of oncology.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The human immune system appears to have the potential to clear cancers from the body, based on clinical observations that some tumors spontaneously regress when the immune system is activated. Most cancers are not very &#8220;immunogenic&#8221;, however, meaning that the cancers are not able to induce an immune response because they no longer express sufficient levels of key proteins on their cell surface, known as Major Histocompatability Class I or MHC Class I proteins. These proteins provide the information to the immune system that defines whether the cell is healthy or, in the case of cancer or viral infection, abnormal. If the MHC Class I proteins signal that the cells are abnormal, then the immune system&#8217;s T-cells are activated to attack and kill the infected or malignant cell.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In many solid cancer tumors, the TAP protein system does not function and, therefore, the immune system is not stimulated to attack the cancer. Management believes that although a number of cancer therapies have been developed that stimulate the immune system, these approaches have often proven ineffective because the cancers remain invisible to the immune system due to this apparent lack of or low expression of the TAP protein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By restoring TAP expression to TAP-deficient cells, the MHC Class I protein peptide complexes could signal the immune system to attack the cancer. The strategic vision of TapImmune is to be a product-driven biotechnology company, focusing primarily on use of its patented TAP technology to restore the TAP function within cancerous cells, thus making them immunogenic, or more &#8220;visible&#8221; to cancer fighting immune cells. Management believes that this cancer vaccine strategy will provide the most viable therapeutic approach that addresses this problem of &#8220;non-immunogenicity&#8221; of cancer. Management believes that this therapy may have a strong competitive advantage over other cancer therapies, since restoring the TAP protein will direct the immune system to specifically target the cancerous cells without damaging healthy tissue.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a key part of its overall strategy, and with adequate funding, the Company is pursuing the development of prophylactic vaccines against infectious microbes and will also do so in partnership with other vaccine developers. The Company intends to develop the TAP technology for use as a vaccine that restores normal immune recognition for the treatment of cancer and supplements immune recognition for the development of prophylactic vaccines.</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">TapImmune&#8217;s Target Market Strategy</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With the required funding in place, we plan to focus our resources on the progression of products in our lead oncology indication, HER2/neu positive breast cancer. We will support and expand on our key infectious disease partnerships, including our collaboration efforts with the Mayo Clinic and others using grants. We have applied for a grant in collaboration with the Mayo Clinic to progress our smallpox program and extend it to additional emerging viral threats.. Cancer encompasses a large number of diseases that affect many different parts of the human body. The diversity of cancer types and their overall prevalence create a large need for new and improved treatments. Management believes that there is a significant market opportunity for a cancer treatment that utilizes the highly specific defense mechanisms of the immune system to attack cancers. Vaccines continue to be the success story for pharmaceutical companies, with the world market for preventative vaccines totaling $22.1 billion in 2009, up from $19 billion in 2008, according to healthcare market research publisher Kalorama Information. Kalorama&#8217;s new report, Vaccines 2010. World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, notes that the worldwide vaccine market is predicted to increase at a compound annual rate of 9.7% during the next five years, as new product introductions continue and the use of current products expands further (<font style="DISPLAY: inline; COLOR: #0000ff">http://www.kaloramainformation.com/Vaccines-Key-Players-2684026</font>). Our targeting of the HER2/neu antigen provides commercial opportunities in breast, ovarian and colorectal cancer.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the USA, the second leading cause of death by illness is cancer. The current estimates for cancer treatments such as chemotherapy represent approximately a US$7 billion market. The National Cancer Institute expects cancer to be the leading cause of death in the USA within 5 years. Cancer vaccines will become a major player in the vaccine market. According to the report Cancer Vaccines Markets, (<font style="DISPLAY: inline; COLOR: #0000ff">http://www.pharmaceutical-market</font> research.com/publications/diseases_conditions/cancer/cancer_vaccines_markets.html) cancer vaccines have the potential to become a significant force in future cancer treatments. The approval of two immunotherapy products, Dendreon&#8217;s Provenge&#174; in 2010 for advanced prostate cancer, and Bristol Myers Squibb&#8217;s Yervoy&#174; in 2011 together with several late-stage clinical programs has generated renewed interest and support for this type of cancer immune therapy.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This relatively new commercial market for cancer vaccines is poised to dramatically increase to over $7 billion by 2015.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management also believes that our prophylactic vaccine adjuvant will be a catalyst in the development of new vaccines and will serve to enhance the efficacy of current vaccines in the treatment of infectious disease. It will be a key business development strategy to pursue additional partnerships and joint research and development ventures with vaccine manufacturers and pharmaceutical companies to bring new and improved vaccines to market. This strategy includes the development of vaccines for pandemic diseases and for bioterrorism threats. The global market for vaccines is dominated by five companies&#8212;Merck, GlaxoSmithKline, Sanofi Pasteur (the vaccines division of Sanofi SA [SNY-NYSE]), Pfizer Inc. (PFE-NYSE), and Novartis&#8212;with Pfizer, GlaxoSmithKline, Sanofi, and Novartis collectively accounting for approximately 74% of the market (Source: Transparency Market Research&#8217;s Global Vaccine Market Analysis and Forecast 2011-2016). This market is estimated at roughly $30 billion worldwide, with the U.S. contributing approximately $20 billion. Importantly, there still exist significant development opportunities in the global vaccine market, as there are more than 300 infectious diseases yet effective prophylactic therapies for only approximately 15% of these (Source: The Life Sciences Report&#8217;s &#8220;Vaccine Therapies Hold Promise for Investors: Stephen Dunn,&#8221; April 12, 2012). Management believes that our TAP Platform technology will increase the potency of many of the currently available vaccines and lead to the creation of better, more effective new vaccines, thereby allowing us to participate in this large market through novel new products and in combination with existing vaccines.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and Development Efforts</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We direct our research and development efforts towards the development of immunotherapeutic and prophylactic vaccine products for the treatment of cancer and protection against pathogenic microbes respectively, using our proprietary TAP technology. We have focused our efforts initially on the development of a therapeutic vaccine for applications in cancer treatment while demonstrating the breadth of the TAP technology for the development of prophylactic vaccines and its ability to complement currently approved and emerging products in both cancer therapeutics and prophylactic vaccines against microbes. This approach allows us to pursue our own internal product development while positioning us to enter into multiple partnerships and licensing agreements. We will also rely on our new collaboration agreements with Mayo clinic to demonstrate the use of TAP in new vaccine candidates. In parallel with our viral vector approach we plan to develop non-viral vectors for the delivery of plasmid DNA.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Products and Technology in Development</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">TAP Cancer Vaccine</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on earlier research at UBC Biomedical Research Centre in Vancouver BC, our overall objective is to successfully develop the patented TAP gene vector technology to restore the TAP protein, with the objective being to develop the TAP technology as a therapeutic cancer vaccine that will restore the normal immune recognition of cancer cells. A TAP Cancer Vaccine will be targeted at those cancers that are deficient in the TAP protein, which include breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer and colorectal cancer. TAP gene vectors will be used clinically in concert with proprietary antigen technologies in a &#8220;Prime and Boost&#8221; strategy. In our HER2/neu breast cancer program, which has started at the Mayo Clinic, proprietary HER2/neu antigens licensed from the Mayo Clinic will be used as the &#8220;Prime&#8221; and a TAP gene vector also containing antigens will be used as the &#8220;Boost&#8221;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As part of a vaccine approach a TAP gene vector will deliver the genetic information required for the production of the TAP protein in the target cancer cell. This will trigger the cancer cell&#8217;s ability to effectively identify itself to the body&#8217;s immune system by transporting the cancer antigen peptides to the cell surface using the individual&#8217;s specific MHC Class I proteins. As a result, we believe that the immune response could be targeted to the entire repertoire of cancer antigen peptides produced by the cancer cell, rather than just to a single cancer antigen, as delivered by current cancer vaccines. A TAP Cancer Vaccine could allow the immune response to respond to the cancer even if the TAP protein and genetic information were only delivered to a small portion of the cancer cells. In addition, a&#160;&#160;TAP Cancer Vaccine would generate an immune response to any TAP-deficient cancer, regardless of the patient&#8217;s individual genetic variability either in the MHC Class I proteins or in the cancer-specific proteins and resultant peptides.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In general, a &#8220;cancer vaccine&#8221; is a therapy whose goal is to stimulate the immune system to attack tumors. Management believes that most current cancer vaccines contain either cancer-specific proteins that directly activate the immune system or contain genetic information, such as DNA, that encodes these cancer-specific proteins. Management believes that there are a number of key conditions that must be met before a cancer vaccine can be effective in generating a therapeutic immune response: (i) the cancer antigen peptide delivered by the vaccine has to be recognized by the immune system as &#8220;abnormal&#8221; or &#8220;foreign&#8221; in order to generate a strong and specific T-cell response; (ii) the same cancer antigen peptide has to be displayed on the surface of the cancer cells in association with the MHC Class I proteins; and (iii) these cancer antigen peptides then have to be sufficiently different from normal proteins in order to generate a strong anti-tumor response.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If these conditions are all met, then management believes that such cancer vaccines should generate a sufficiently strong immune response to kill the cancer cells. However, the identification of suitable cancer-specific antigen proteins to use in these therapeutic vaccines has proven extremely complex. In addition, the MHC Class I proteins are highly variable, with over 100 different types in humans and, as a result, any one-cancer antigen peptide will not produce an immune response for all individuals. Cancers are &#8220;genetically unstable&#8221; and their proteins are highly variable, so that the selected cancer antigen protein may result in the immune system only attacking a small subset of the cancerous cells.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Laboratory Testing of the TAP Cancer Vaccine</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management believes that key milestones of efficacy in animal models of cancer have been achieved and that scientific research from other laboratories has validated the efficacy data. The proof of principle for the TAP technology as a cancer vaccine has been established in research conducted at UBC in metastatic models that have multiple defects in the &#8220;antigen presentation pathway&#8221; resulting in poor detection of cancer cells by the immune system. These studies demonstrating that introduction of the TAP gene can restore an immune response have been published in a number of peer-reviewed leading scientific journals (links to publications can be found at www.tapimmune.com). We plan to conduct additional pre-clinical work on novel expression vectors that can express both TAP proteins and peptide antigens.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Pre-Clinical Testing</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Once the formal pre-clinical testing is completed, we intend to compile and summarize the data and submit it to the United States Federal Drug Administration (or &#8220;FDA&#8221;) and/or the Canadian Health Canada (or &#8220;HC&#8221;), and/or other national regulatory agencies, in the form of an investigational new drug application. We anticipate that these applications would include data on vaccine production, animal studies and toxicology studies, as well as proposed protocols for the Phase I human clinical trials, described below.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic; TEXT-DECORATION: underline">Phase I Human Clinical Trials&#8211; </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">HER2/neu Vaccine Technology &#8211; Mayo Clinic</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 1, 2010, we signed an exclusive licensing option agreement with the Mayo Clinic, Rochester MN for clinical development of a new HER2/neu breast cancer vaccine technology. An IND for Phase I human clinical trials on the HER2/neu cancer vaccine in collaboration with the Mayo Clinic was allowed by the FDA in July, 2011 and the Mayo IRB approved the trial on May 4 2012. Patient dosing has started, and we expect to complete an interim safety analysis on these first five patients within the next two months before completing treatment on the remaining patients in the trial.. The primary endpoint for this trial will be vaccine safety. Secondary endpoints will be immune responses including generation of antigen-specific T-cells and time to disease progression in breast cancer patients. As this trial progresses, we plan to add the Class I peptide, licensed from the Mayo Clinic to the four Class II peptides as an extension of the Phase I clinical trial. In parallel, we will complete the manufacturing and toxicity of vector delivered Tap1/2 for subsequent Phase I human clinical trials and for use in combination in later stage clinical trials with the HER2/neu antigens as part of a &#8220;Prime and Boost&#8221; strategy. On April 16, 2012 we announced the licensing of a novel HER2/neu Class I antigen from the Mayo Clinic and are currently evaluating the clinical pathway to include this in our current &#8220;Prime and Boost&#8221; strategy. Management believes that the combination of Class I and Class II HER2/neu antigens plus TAP gives us the leading HER2/neu vaccine platform.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical trials to support new drug applications are typically conducted in three sequential phases, although the phases may overlap. During Phase I there is an initial introduction of the therapeutic candidate into healthy human subjects or patients. The drug is tested to assess metabolism, pharmacokinetics and pharmacological actions and safety, including side effects associated with increasing doses. For immunotherapeutics/vaccine, Phase I studies are conducted in cancer patients and include the measurement of cellular immune responses. Phase II usually involves studies in a limited patient population to assess the clinical activity of the drug in specific targeted indications, assess dosage tolerance and optimal dosage and continue to identify possible adverse effects and safety risks. If the therapeutic candidate is found to be potentially effective and to have an acceptable safety profile in Phase II evaluations, Phase III trials are undertaken to further demonstrate clinical efficacy and to further test for safety within an expanded patient population at geographically dispersed clinical trial sites.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Infectious Disease Application for &#8220;TAP&#8221; Adjuvant</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TapImmune plans to develop or license out our technology for the creation of enhanced viral vaccines, such as for smallpox and others, based on our findings that TAP can augment immune responses. We have presented data showing that increasing TAP expression in TAP-competent antigen presenting cells (APCs) and/or virus infected cells increases the antigenic peptide associated with MHC class I expression on the cell surface, and leads to increased specific T cell-mediated immune responses. We believe this technology can add great value to the creation of new vaccines and enhance those that already exist. We believe our collaborations with the Mayo Clinic is evidence of this and we will continue to pursue additional partnerships and collaborations as a key strategy to expand our research and development (R&amp;D) program to optimize resources and to reduce costs and development times. In our collaboration with the Mayo Clinic, efficacy studies in small animals on a novel smallpox vaccine that includes TAP, were initiated in 2011 and are progressing on schedule. The subsequent regulatory pathway for this product is to use the FDA&#8217;s &#8220;Animal Efficacy Rule&#8221; for completion of efficacy studies in primates followed by Phase I clinical studies on vaccine safety.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The cost of funding our current Phase I clinical program in HER2/neu breast cancer at the Mayo Clinic is approximately $850,000 and we anticipate that on-going preclinical studies and Phase I studies on our TAP expression vectors will cost $5million. We intend to progress our infectious disease programs with non-dilutive grant funding as well. In collaboration with the Vaccine Group at the Mayo Clinic we submitted our first NIH grant in July 2012 to continue development of our smallpox vaccine and to expand the use of our TAP platform to emerging pathogens that could be either pandemic or bioterrorist threats.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Strategic Relationships</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Mayo Foundation for Medical Education and Research</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 26, 2010 we signed a Technology Option Agreement with the Mayo Foundation for Medical Education and Research, Rochester, MN, for the evaluation of HER2/neu peptide epitopes as antigens for a breast cancer vaccine. The agreement grants TapImmune an exclusive worldwide option to become the exclusive licensee of the technology after completion of Phase I clinical trials.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following approval of the IND by the FDA in July, 2011, TapImmune and the Mayo Foundation executed a Sponsored Research Agreement for the clinical trial.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 4, 2012, Mayo IRB approval was confirmed and patient dosing is expected to start in June 2012.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 24, 2010, we signed a Research and Technology License Option Agreement with the Mayo Foundation for Medical Education and Research, Rochester, MN, to evaluate novel smallpox peptide antigens. The Agreement grants TapImmune an exclusive worldwide option to become the exclusive licensee of the smallpox vaccine technology after research studies have been completed under the terms of the agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 16, 2012, we announced an Exclusive Agreement with the Mayo Foundation for Education &amp; Research, Rochester, MN, to License a proprietary MHC Class I HER2/neu antigen technology. This antigen was discovered in the laboratory of Dr. Keith Knutson at the Mayo Clinic. In contrast to Class I antigens in clinical testing this novel antigen is naturally produced in the intracellular proteasome and presented to T-cells as the MHC Class I peptide complex. Scientific details of this new work was presented by Andrea Henle of Dr. Knutson&#8217;s lab at the Annual Meeting of The American Association of Immunologists held in Boston, MA, May 2012 and by Mark Reddish, Head of Development at TapImmune at the Third Annual Cancer Vaccines and Active Immunity Summit, Boston, June 26, 2012. A peer-reviewed manuscript from the Knutson lab, which describes the science in detail, has been accepted for publication in Journal of Immunology and will appear in electronic form later this month.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic">Crucell Holland B.V. Research License and Option Agreement</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective August 7, 2003, we entered into a five-year research license and option agreement with Crucell Holland B.V. (&#8220;Crucell&#8221;), whereby Crucell granted us a non-exclusive worldwide license for the research use of its packaging cell (PerC6) technology. We were required to make certain payments over the five-year term totaling Euro &#8364;450,000 (approximately $510,100). The license was dormant with an outstanding balance owing of 170,000 Euro ($248,938) that was included in research obligations. Management has completed a settlement for the remaining balance including a &#8364;17,000 cash payment and the issuance of 265,000 shares of the Company&#8217;s restricted common stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective August 7, 2008, we negotiated an amended license agreement for the use of Crucell&#8217;s adenovirus technology. We are required to make annual license payments on the anniversary of the effective date for the three year term equal to &#8364;75,000 per annum. As at September 30, 2012, we have accrued $365,970 (&#8364;284,578) under the amended agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Intellectual Property, Patents and Trademarks</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Patents and other proprietary rights are vital to our business operations. We protect our technology through various United States and foreign patent filings, and maintain trade secrets that we own. Our policy is to seek appropriate patent protection both in the United States and abroad for its proprietary technologies and products. We require each of our employees, consultants and advisors to execute a confidentiality agreement upon the commencement of any employment, consulting or advisory relationship with us. Each agreement provides that all confidential information developed or made known to the individual during the course of the relationship will be kept confidential and not be disclosed to third parties except in specified circumstances. In the case of employees, the agreements provide that all inventions conceived of by an employee shall be our exclusive property.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Patent applications in the United States are maintained in secrecy until patents are issued. There can be no assurance that our patents, and any patents that may be issued to us in the future, will afford protection against competitors with similar technology. In addition, no assurances can be given that the patents issued to us will not be infringed upon or designed around by others or that others will not obtain patents that we would need to license or design around. If the courts uphold existing or future patents containing broad claims over technology used by us, the holders of such patents could require us to obtain licenses to use such technology.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Method of Enhancing Expression of MHC Class I Molecules Bearing Endogenous Peptides</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 26, 2002, the United States Patent and Trademark Office issued US Patent No. 6,361,770 to UBC for the use of TAP-1 as an immunotherapy against all cancers. The patent is titled &#8220;Method of Enhancing Expression of MHC Class I Molecules Bearing Endogenous Peptides&#8221; and provides comprehensive protection and coverage to both in vivo and ex vivo applications of TAP-1 as a therapeutic against all cancers with a variety of delivery mechanisms. The inventors were Dr. Jefferies, Dr. Reinhard Gabathuler, Dr. Gerassinmoes Kolaitis and Dr. Gregor S.D. Reid, who collectively assigned the patent to UBC under an assignment agreement. The patent expires March 23, 2014. We have pending applications for patent protection for this patent in Europe and in Japan.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Method of Enhancing an Immune Response</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S. patent No. 7,378,087, issued May 27 2008. The patent claims relate to methods for enhancing the immune response to tumor cells by introducing the TAP molecule into the infected cells. Patent applications are pending on other aspects of the company&#8217;s technology. The inventors were Jefferies, Wilfred A.; Zhang, Qian-Jin; Chen, Susan Shu-Ping; Alimonti, Judie B., who collectively assigned the patent to UBC under an assignment agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Method of Identifying MHC Class I Restricted Antigens Endogenously Processed by a Secretory Pathway</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 11, 1998, the U.S. Patent and Trademark Office issued US Patent No. 5,792,604 to UBC, being a patent for the use of bioengineered cell lines to measure the output of the MHC Class I restricted antigen presentation pathway as a way to screen for immunomodulating drugs. The patent is titled &#8220;Method of Identifying MHC Class I Restricted Antigens Endogenously Processed by a Secretory Pathway.&#8221;&#160;&#160;This patent covers the assay which can identify compounds capable of modulating the immune system. The inventors were Dr. Jefferies, Dr. Gabathuler, Dr. Kolaitis and Dr. Reid, who collectively assigned the patent to UBC under an assignment agreement. The patent expires on March 12, 2016. We have been granted patent protection for this patent in Finland, France, Germany, Italy, Sweden Switzerland and the United Kingdom, and have applied for patent protection in Canada and Japan.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Method of Enhancing an Immune Response</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 27, 2011 The US Patent Office has issued Patent 7,994,146 entitled &#8220;Method of Enhancing an Immune Response&#8221;. The invention relates to a method of enhancing an immune response to an antigen by augmenting the level of TAP (Transporters Associated with Antigen Processing) molecule in a target cell bearing the antigen. This patent details application to treating vaccinia, herpes simplex and influenza virus infections and small cell lung cancer. Levels of TAP in humans correlate with susceptibility to certain diseases and the ability to respond to a vaccine.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">TAP Vaccines and other filings</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We intend to continue to work with our collaborators to file additional patent applications with respect to any novel aspects of our technology to further protect our intellectual property portfolio. An invention that describes the use of bio-acceptable substances to promote the transcription of the TAP-1 gene in TAP-1 expression-deficient cells was filed in July 2009 and was available to us under an option agreement with the University of British Columbia. The patent is entitled &#8220;HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity&#8221;. The Company will not pursue this technology or continue to prosecute this additional patent and has released its option back to the University of British Columbia.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Competition</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The oncology industry is characterized by rapidly evolving technology and intense competition. Many companies of all sizes, including a number of large pharmaceutical companies as well as several specialized biotechnology companies, are developing various immunotherapies and drugs to treat cancer. While management believes that we have a unique platform technology approach there may be products on the market that will compete directly with the products that we are seeking to develop. In addition, colleges, universities, governmental agencies and other public and private research institutions will continue to conduct research and are becoming more active in seeking patent protection and licensing arrangements to collect license fees and royalties in exchange for license rights to technologies that they have developed, some of which may directly compete with our technologies and products. These companies and institutions may also compete with us in recruiting qualified scientific personnel. Many of our potential competitors have substantially greater financial, research and development, human and other resources than us. Furthermore, large pharmaceutical companies may have significantly more experience than we do in pre-clinical testing, human clinical trials and regulatory approval procedures. Such competitors may develop safer and more effective products, obtain patent protection or intellectual property rights that limit our ability to commercialize products, or commercialize products earlier than we do.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management expects technology developments in the oncology industry to continue to occur at a rapid pace. Commercial developments by any competitors may render some or all of our potential products obsolete or non-competitive, which could materially harm the company&#8217;s business and financial condition.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management believes that the following companies, which are developing various types of similar immunotherapies and therapeutic cancer vaccines to treat cancer, could be our major competitors: CellGenSys Inc., Dendreon Corp., Galena, Immune Design, Immunocellular, Oncothyreon, Celldex, BN Immunotherapeutics, and Transgene S.A.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Our Financial Condition</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the next 12 months, we anticipate that we will not generate any sales revenue but may receive grant funding. We had cash of $3,727 and a working capital deficit of $3,323,251 at September 30, 2012 (excluding derivative liabilities). We will require significant additional financial resources and will be dependent on future financings to fund our ongoing research and development as well as other working capital requirements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Plan of Operation and Funding</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a vaccine component, the gene based TAP technology has the potential to significantly improve the efficacy of both prophylactic and immunotherapeutic vaccines as it addresses a fundamental mechanism for T cell recognition and response. Unlike other vaccine technologies that address only the initiation of immune responses, TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches that are designed to enhance cellular responses. Therefore, we envisage establishing multiple collaborative partnerships as we progress gene-based TAP development and research in the clinic. The exploitation of this key mechanism is highlighted by two collaborations with the Mayo Clinic in Rochester, MN and their progress in 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management believes that as a result of our recent personnel additions, our moving into a state of the art facility and our exclusive Licensing Option agreements with the Mayo Clinic in Rochester, Minnesota, the May 2012 initiation of Phase 1 clinical trials, and with adequate funding, the Company will be well positioned for significant growth in 2012.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In August 2011, the FDA approved an IND (Investigational New Drug application) and the Company signed a sponsored research agreement with the Mayo Clinic for a Phase 1 Her2neu Breast Cancer Clinical Trial, which has now started. The trial will use a patented technology developed at the Mayo clinic. TapImmune has the exclusive option to license this technology. Recent clinical trials of Her2neu vaccines have shown considerable promise but have left significant room for improvements, and the technology we are evaluating in our Phase I clinical trial offers a vaccine with broader coverage, making it applicable to a much larger population of women with breast cancer. We anticipate that this technology will be used therapeutically together with our TAP expression technology as it reaches clinical development in combination with the improved Her2neu targeted vaccine. Currently, Herceptin&#174; (trastuzumab: an intravenously delivered monoclonal antibody) is used in the treatment of HER2/neu breast cancer. Sales of this product in 2009 were approximately US$5 billion (source: Roche AG&#8217;s Pharmaceutical Division). As our vaccine approach has the potential to treat a broader HER2/neu positive clinical population, the market potential is significant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our Gene-based TAP vaccines also have the potential to significantly improve the efficacy of prophylactic vaccines for viral pandemics and as agents for biodefense. In a novel approach to the development of a smallpox vaccine, in our collaboration with the Mayo Clinic, research studies have progressed well and are now testing unique and patentable smallpox antigens in combination with TAP technology which we expect to be completed by the third quarter of 2012. Once these feasibility studies are complete, we would move to larger preclinical animal studies, and Phase I safety trials. This study will also act as a platform for more extensive use of gene-based TAP vectors for biodefense. We will be seeking non-dilutive avenues to finance and advance this program by way of biodefense focused grants and contracts. We have the exclusive option to license the patented Mayo technology that is derived from this collaboration.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The opening of our new laboratories and offices at 1551 Eastlake Avenue, Seattle, on January 23, 2012 represents a significant advance for the Company on several fronts. First, our sub-lease and service agreements with the Puget Sound Blood Center Research Institute enables our scientific team to access a wide array of functioning core labs and shared equipment relevant to all aspects of development of our gene-based product candidates. Second, such an arrangement allows us to speed the development of TAP-based products towards the clinic. Third, we now have the capabilities to produce and test a range of proprietary TAP-based expression vectors for both cancer and infectious disease and to expand our external collaborations. Fourth, the development of new TAP constructs in our laboratories allows us to significantly enhance our intellectual property portfolio. US Patent # 7,994,146 issued in 2011 represents the most recent example of this strategy. The opening of these new facilities is consistent with our strategy of managing costs using a small core internal team that leverages external resources.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We will continue to build our technical team in 2012. Under the leadership of Mark Reddish, who joined the TapImmune Management Team as Vice President Product Development, the recruitment of world-class scientists is progressing rapidly. Mark is a recognized leader in vaccine technology development with an impressive track record in taking leading immunotherapy products from early research through development, both in the areas of cancer vaccines and biodefense. He was formerly Vice President of Product Development and Principal Investigator, Biodefense at ID Biomedical, Bothell, WA, prior to the acquisition of the company by Glaxo SmithKline for $1.6 billion. At Biomira Inc, (renamed Oncothyreon) he was responsible for preclinical development of their cancer vaccines program where he led the early research and clinical development of Stimuvax, which is currently in late Stage 3 clinical trials under a partnership with Merck KGaA. The recruitment of Dr Robert Florkiewitcz as Vice President, Molecular Biology, provides the leadership for our TAP expression vector development.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With respect to the broader market, a major driver and positive influence on our activities has been the emergence and general acceptance of the potential of a new generation of immunotherapies that promise to change the standard of care for cancer. The immunotherapy sector has been greatly stimulated by the approval of Provenge&#174; (Dendreon NASD: DNDN) for prostate cancer and Yervoy&#8482; (BMS) for metastatic melanoma, anticipation of the results from Phase III trials on Stimuvax&#174; (Merck KGaA/Oncothyreon NASD: ONTY) and MAGE-3 (GSK) for treatment of lung cancer, and progression of approaches for multiple cancer indications through Phase II and into Phase III.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management believes that TapImmune is well positioned to be a leading player in this emerging market. It is important to note that the late stage immunotherapies in development do not necessarily represent competition to our programs, but rather offer us opportunities as our TAP expression technology is potentially synergistic with many other vaccine approaches. The addition of a TAP expression vector to patients already receiving a therapeutic vaccine could enhance the efficacy of these vaccines, as TAP is designed to help killer T-cells kill tumor cells. This concept of enhancing the effector stage of an immune response differentiates TAP technology from a wide list of immunotherapies currently in development, and offers a great opportunity for collaborations and partnerships. Accordingly we believe that the use of TAP expression vectors represents the next logical step in the development of more effective immunotherapies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In 2011 and the first half of 2012we have made significant progress with very few resources. We believe that our recent progress and our buildup of resources indicate that we will make even greater progress in the future. On the technology and product pipeline side, management believes that the Company is fundamentally strong and poised to be a leading company in a highly attractive and expanding market, a position reinforced by our recruitment of top-class managers, advisors and investors who all share our vision.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Results of Operations</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Three Months Ended September 30, 2012 Compared to Three Months Ended September 30, 2011</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In this discussion of the Company&#8217;s results of operations and financial condition, amounts, other than per-share amounts, have been rounded to the nearest thousand dollars.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are a development stage company. We recorded a net loss of $844,000 during the three months ended September 30, 2012 compared to $768,000 for the three months ended September 30, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating costs increased to $905,000 during the three months ended September 30, 2012 compared to $797,000 in the prior period. Significant changes in operating expenses are outlined as follows:</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Consulting fees increased to $57,000 during the three months ended </font>September 30, 2012<font style="DISPLAY: inline"> from $44,000 during the prior period, due primarily to new business development contracts entered into during the current period.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Consulting fees &#8211; stock-based increased to $308,000 during the three months ended </font>September 30, 2012<font style="DISPLAY: inline"> from $110,000 during the prior period. </font>The higher current period expense is primarily due to increased share based payments to the consultants compared to the prior period.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General and administrative expenses increased to $268,000 in the three months ended September 30, 2012 from $24,000 in the prior period, with the increase resulting from increased staff and rental costs at the Company&#8217; Seattle office and higher travel related expense in the current period.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Interest and finance charges increased to $215,000 during the three months ended </font>September 30, 2012<font style="DISPLAY: inline"> from $104,000 during the prior period. Current and prior period interest charges are primarily interest accruals and accretion of debt discounts.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Management fees decreased to $23,000 during the three months ended </font>September 30, 2012<font style="DISPLAY: inline"> from $62,000 during the prior period due to one less person in management in the current period.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Management fees &#8211; stock-based increased to $31,000 during the three months ended </font>September 30, 2012<font style="DISPLAY: inline"> from $30,000 during the prior period. </font>The current and prior period expense consists of the fair value of option grants earned during the period<font style="DISPLAY: inline">.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Professional fees decreased to $22,000 during the three months ended </font>September 30, 2012<font style="DISPLAY: inline"> from $36,000 during the prior period, due to lower legal fees incurred relating to debt issuance in the current period</font>.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research and development decreased to $71,000 during the three months ended September 30, 2012 from $298,000 during the prior period. This was due to lower technology licensing fee payments in the current period.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign exchange loss increased to $7,000 during the three months ended September 30, 2012 compared to a gain of $15,000 in the prior period primarily due to weaker USD against EURO in the current period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Nine Months Ended September 30, 2012 Compared to Nine Months Ended&#160;&#160;September 30, 2011</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We recorded a net loss of $4,119,000 during the nine months ended September 30, 2012 compared to $2,378,000 for the nine Months Ended September 30, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating costs increased to $4,609,000 during the nine months ended September 30, 2012 compared to $2,707,000 in the prior period. Significant changes in operating expenses are outlined as follows:</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Consulting fees of $120,000 was about the same during the </font>nine months ended September 30, 2012<font style="DISPLAY: inline"> compared to $119,000 during the prior period, which are expenses relating to new business development contracts entered into during the current period.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Consulting fee - stock-based increased to $2,284,000 during the </font>nine months ended September 30, 2012<font style="DISPLAY: inline"> from $692,000 during the prior period. </font>The higher current period expense is primarily due to increased share based payments to the consultants compared to the prior period.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General and administrative expenses increased to $880,000 in the nine months ended&#160;&#160;September 30, 2012 from $66,000 in the prior period, with the increase resulting from increased staff and rental costs at the Company&#8217; Seattle office and higher travel related expense in the current period.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Interest and finance charges decreased to $412,000 during the </font>nine months ended September 30, 2012<font style="DISPLAY: inline"> from $559,000 during the prior period. Current and prior period interest charges are primarily accretion of convertible debt notes.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Management fees decreased to $125,000 during the </font>nine months ended September 30, 2012<font style="DISPLAY: inline"> from $186,000 during the prior period due to one less person in management in the current period.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Management fees &#8211; stock-based decreased to $147,000 during the </font>nine months ended September 30, 2012<font style="DISPLAY: inline"> from $360,000 during the prior period. </font>The current and prior period expense consists of the fair value of option grants earned during the period<font style="DISPLAY: inline">.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Professional fees decreased to $209,000 during the </font>nine months ended September 30, 2012<font style="DISPLAY: inline"> from $317,000 during the prior period, due to lower legal fees incurred relating to absence of debt issuance in the current period</font>.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research and development increased to $432,000 during the nine months ended September 30, 2012 from $407,000 during the prior period. This was due to higher technology licensing fee accrued for payments due to Mayo clinic and Crucell Holland B.V. in the current period.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Liquidity and Capital Resources</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2012, we had $4,000 in cash. Generally, we have financed our operations through the proceeds from convertible notes and the private placement of equity securities as noted in Financing Activities below. We decreased our net cash by $247,000 during the nine months ended September 30, 2012 compared to a increase of $11,000 during the prior period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Operating Activities</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net cash used in operating activities during the nine months ended September 30, 2012 was $1,117,000 compared to $877,000 during the prior period. We had no revenues during the current or prior periods. Operating expenditures, excluding non-cash interest and stock-based charges during the current period primarily consisted of consulting and management fees, office and general expenditures, and professional fees.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Investing Activities</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net cash used in investing activities during the nine months ended September 30, 2012 was $Nil compared to $Nil during the prior period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financing Activities</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net cash provided by financing activities during the nine months ended September 30, 2012 was $870,000 compared to $888,000 during the prior period. Current period financing consisted of proceeds from private placements, debt financing and advances from related parties while prior period financing relates to proceeds from private placements and convertible notes offset by payments to related parties. Management and certain advisors have participated in these most recent financing activities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At September 30, 2012, we had 6,778,000 stock options and 12,908,623 share purchase warrants outstanding. The outstanding stock options had a weighted average exercise price of $0.18 per share, with the warrants having a weighted average exercise price of $0.43 per share. Accordingly, as of September 30, 2012, the outstanding options and warrants represented a total of 19,686,623 shares issuable for proceeds of approximately $6,979,000 if these options and warrants were exercised in full. The exercise of these options and warrants is completely at the discretion of the holders. There is no assurance that any of these options or warrants will be exercised.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of September 30, 2012, we anticipate that we will need significant financing to enable us to meet our anticipated expenditures for the next 24 months, which are expected to be in the range of $5,000,000 assuming a single Phase 1 clinical trial.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Going Concern</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. Our ability to continue as a going concern is dependent upon our ability to obtain the necessary financing to meet our obligations and pay our liabilities arising from our business operations when they come due. We intend to finance our anticipated operating expenses with further issuances of common stock through private placement offerings or loans from private investors. Management believes that the Company will be able to continue limited operations with accommodations from debt holders and additional temporary short term funding over the next twelve months. Due to capital market conditions, funding continues to be challenging. It is unlikely the Company will be able to continue as a going concern past a twelve month horizon if significant equity funding is not raised within this period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Off-Balance Sheet Arrangements</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other than as disclosed in the financial statements, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Critical Accounting Policies</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our consolidated financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We regularly evaluate the accounting policies and estimates that we use to prepare our consolidated financial statements. In general, management&#8217;s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Refer to Note 2 of our consolidated financial statements for our year ended December 31, 2011 for a summary of significant accounting policies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Quantitative and Qualitative Disclosures About Market Risk</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Controls and Procedures</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Evaluation of Disclosure Controls and Procedures</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are not effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It should be noted that any system of controls is based in part upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no assurance that any design will succeed in achieving its stated goals.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Management&#8217;s Report on Internal Control Over Financial Reporting</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as required by Sarbanes-Oxley (SOX) Section 404 A. The Company's internal control over financial reporting is a process designed under the supervision of the Company's Principal Executive Officer and Principal Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external purposes in accordance with United States generally accepted accounting principles (&#8220;US GAAP&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of September 30, 2012, management assessed the effectiveness of the Company's internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control -Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, as at September 30, 2012 such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The matters involving internal controls and procedures that the Company&#8217;s management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) inadequate entity level controls due to an ineffective audit committee resulting from the presence of only one of independent members on the current audit committee and the presence of only one outside director on our board of directors; (2) inadequate segregation of duties consistent with control objectives; (3) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements; (4) ineffective controls over period end financial disclosure and reporting processes.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management believes that none of the material weaknesses set forth above had a material adverse effect on the Company's financial results for the nine months ended September 30, 2012 but management is concerned that the material weakness in entity level controls set forth in item (1) results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, it could result in a material misstatement in our financial statements in future periods.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are committed to improving our financial organization. As part of this commitment, we will continue to enhance our internal control over financial reporting by: i) expanding our personnel, ii) improving segregated duties consistent with control objectives, iii) appointing more outside directors to our board of directors who shall be appointed to our audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management; and iv) preparing and implementing sufficient written policies and checklists which will set forth procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the ineffective audit committee. To this end, Mr. James Fuller was appointed to our audit Committee in the second quarter of 2012. In addition, management believes that preparing and implementing sufficient written policies and checklists will remedy the following material weaknesses (i) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements; and (ii) ineffective controls over period end financial close and reporting processes. Further, management believes that the hiring of additional personnel will result in improved segregation of duties and provide more checks and balances within the financial reporting department.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and are committed to taking further action by implementing additional enhancements or improvements, or deploying additional human resources as may be deemed necessary.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This quarterly report does not include an attestation report of the Company&#8217;s registered public accounting firm regarding internal controls over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting firm pursuant to the rules of the SEC that permit the Company to provide only management&#8217;s report in this report.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Changes in Internal Control Over Financial Reporting</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There have been no changes in our internal control over financial reporting during the nine months ended September 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">__________</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">PART II &#8211; OTHER INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Legal Proceedings</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are not a party to any legal proceedings, and management is not aware of any legal proceedings pending or that have been threatened against us or our properties.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 1A.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Risk Factors</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not required.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Unregistered Sales of Equity Securities and Use of Proceeds</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May 2012, we issued a total of 14,000,000 shares of restricted common stock relating to consulting agreements for three financial consultants to cover 18 months of corporate finance advisory and fund raising activities. These shares have anti-dilution provisions for eighteen months from the date of the agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2012, we issued a total of 35,179 shares of restricted common stock at $0.17 per shares relating to a consulting agreement.</FONT></DIV>

<DIV STYLE="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: justify"><FONT STYLE="display: inline; font: 10pt Times New Roman">&nbsp;</FONT></DIV>

<DIV STYLE="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: justify"><FONT STYLE="display: inline; font: 10pt Times New Roman">In September 2012, the Company issued 500,000 shares of its restricted common stock to the holder of a promissory
note in exchange for the note holder&rsquo;s agreement to forebear from pursuing collection action on that note as interest and
penalties for the outstanding promissory note (Note 7).&nbsp;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The shares mentioned above were issued in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933, as amended, including Rule 506 of Regulation D. These transactions qualified for exemption from registration because among other things, the transactions did not involve a public offering, each investor was an accredited investor, each investor had access to information about our Company and their investment, each investor took the securities for investment and not resale, there was no general solicitation or advertising in connection with the placement and we took appropriate measures to restrict the transfer of the securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Defaults Upon Senior Securities</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Mine Safety Disclosure</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not Applicable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Information</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On November 14, 2012, we entered into an Exchange Agreement with a holder of one of our notes that was outstanding in the amount of $100,000 (the &#8220;Old Note&#8221;) pursuant to which we issued three new notes for $73,529, $15,000 and $16,471 (the &#8220;New Notes&#8221;). Whereas as the Old Note was convertible into shares of our common stock at $0.09, the New Notes are convertible into shares of our common stock at the lesser of (i) $0.09 or (ii) 65% of the arithmetic average of the three lowest closing bid prices of our shares during the twenty consecutive trading day period immediately preceding the date the note holder informs us of its intent to convert all or a portion of any of the applicable New Note. The New Notes also carry interest at the annual rate of 10%. No additional consideration was paid in for the exchange or for the new notes.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Item 6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibits</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following exhibits are included with this Quarterly Report on Form 10-Q:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="top" width="13%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit Number</font></div>
</td>
<td valign="top" width="87%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description of Exhibit</font></div>
</td>
</tr><tr>
<td valign="top" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
<td valign="top" width="87%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Principal Executive Officer and Acting Principal Accounting Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.</font></div>
</td>
</tr><tr>
<td valign="top" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
<td valign="top" width="87%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 101</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">101.INS - XBRL Instance Document</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">101.SCH - XBRL Taxonomy Extension Schema Document</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">101.DEF - XBRL Taxonomy Extension Definition Linkbase Document</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">101.LAB - XBRL Taxonomy Extension Label Linkbase Document</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">__________</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">34</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">TAPIMMUNE INC.</font></font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: November 19, 2012.</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Glynn Wilson</font></font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Glynn Wilson</font></font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman, Chief Executive Officer, Principal Executive Officer and Chief Financial Officer</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">35</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex_31-1.htm
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: a-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 31.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Glynn Wilson, certify that:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this Report on Form 10-Q for the quarterly period ended September 30, 2012 of TapImmune Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this Report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: November 19, 2012.</font></div>
</div>



<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td colspan="2" width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;<font style="DISPLAY: inline; FONT-STYLE: italic"><font style="DISPLAY: inline">Glynn Wilson</font></font></font></td>
<td width="42%" style="PADDING-BOTTOM: 2px"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="33%" style="PADDING-BOTTOM: 2px"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></font></div>
</td>
<td colspan="2" width="63%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Glynn Wilson</font></font></td>
<td width="33%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title</font></td>
<td colspan="2" width="63%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman, Chief Executive Officer, Principal Executive Officer and Acting Principal Accounting Officer</font></td>
<td width="33%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>ex_32-1.htm
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: a-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 32.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18 U.S.C. SECTION 1350,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AS ADOPTED PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned, Glynn Wilson, the Principal Executive Officer and Acting Principal Accounting Officer of TapImmune Inc. (the &#8220;Company&#8221;) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge, the Report on Form 10-Q of TapImmune Inc., for the quarterly period ended September 30, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of TapImmune Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;&#160;November 19, 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: arial; FONT-SIZE: 10pt; FONT-FAMILY: arial">
<tr>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">/s/ Glynn Wilson</font></div>
</td>
<td valign="top" width="75%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Glynn Wilson</font></font></td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="13%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman, Chief Executive Officer,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Principal Executive Officer and Acting Principal Accounting Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>tpiv-20120930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.3e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: tapimmune_10q.xfr; Date: 2012/11/19T20:29:54 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:tpiv="http://tapimmune.com/20120930">
    <link:schemaRef xlink:href="tpiv-20120930.xsd" xlink:type="simple" />
    <xbrli:context id="From2012-01-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-01to2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-01</xbrli:startDate>
        <xbrli:endDate>2011-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From1999-07-27to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>1999-07-27</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf1999-07-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>1999-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2003-08-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2003-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2008-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2008-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2009-01-01to2009-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2009-01-01</xbrli:startDate>
        <xbrli:endDate>2009-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-08-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-08-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-08-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-10-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-10-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2012-01-01to2012-09-30">TAPIMMUNE INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2012-01-01to2012-09-30">0001094038</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2012-01-01to2012-09-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2012-01-01to2012-09-30">2012-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2012-01-01to2012-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2012-01-01to2012-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2012-01-01to2012-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2012-01-01to2012-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2012-01-01to2012-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2012-01-01to2012-09-30">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2012-01-01to2012-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2012-01-01to2012-09-30">2012</dei:DocumentFiscalYearFocus>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2012-11-19" unitRef="Shares" decimals="INF">73861754</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">3727</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">250234</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">23516</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2011-09-30" unitRef="USD" decimals="0">34772</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf1999-07-26" unitRef="USD" xsi:nil="true" />
    <us-gaap:GovernmentContractReceivable contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">1099</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1060</us-gaap:GovernmentContractReceivable>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">12641</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="AsOf2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetsCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">39971</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">307921</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">60739</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">340212</us-gaap:Assets>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">365970</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">259752</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">1184351</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">998790</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">28000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">7000</us-gaap:LoansPayableCurrent>
    <us-gaap:ShortTermBorrowings contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">167942</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">100000</us-gaap:ShortTermBorrowings>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">281475</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">322905</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">4428280</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">3800572</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockValue contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">73864</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">52072</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">43220515</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">39943374</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:DeferredCompensationEquity contextRef="AsOf2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredCompensationEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">35968</us-gaap:DeferredCompensationEquity>
    <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">47840900</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
    <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">43722216</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">-63082</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-60528</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">-4367541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-3460360</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">60739</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">340212</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">73861754</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">52073460</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">73861754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">52073460</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:Depreciation contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Depreciation contextRef="From2012-07-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Depreciation contextRef="From2011-07-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Depreciation contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Depreciation contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">213227</us-gaap:Depreciation>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">880353</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">268286</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">23875</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">66012</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">3797589</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ServiceManagementCosts contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">125100</us-gaap:ServiceManagementCosts>
    <us-gaap:ServiceManagementCosts contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">22500</us-gaap:ServiceManagementCosts>
    <us-gaap:ServiceManagementCosts contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">62100</us-gaap:ServiceManagementCosts>
    <us-gaap:ServiceManagementCosts contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">186300</us-gaap:ServiceManagementCosts>
    <us-gaap:ServiceManagementCosts contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">2897154</us-gaap:ServiceManagementCosts>
    <us-gaap:ProfessionalFees contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">208866</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">21757</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">36173</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">317130</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">5135438</us-gaap:ProfessionalFees>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">432289</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">71061</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">297996</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">406944</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">6343454</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">544576</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">121385</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">46000</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-277118</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">4619716</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-85550</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-85550</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="From2011-07-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-1354263</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-07-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From2011-07-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">33344</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainsLossesOnSalesOfAssets contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnSalesOfAssets contextRef="From2012-07-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnSalesOfAssets contextRef="From2011-07-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnSalesOfAssets contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnSalesOfAssets contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-5399</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-4118684</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-2378036</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-47840900</us-gaap:NetIncomeLoss>
    <tpiv:AdjustmentDepreciation contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:AdjustmentDepreciation contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:AdjustmentDepreciation contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">213228</tpiv:AdjustmentDepreciation>
    <us-gaap:GainLossOnSaleOfDebtInvestments contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">28688</us-gaap:GainLossOnSaleOfDebtInvestments>
    <us-gaap:GainLossOnSaleOfDebtInvestments contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-482474</us-gaap:GainLossOnSaleOfDebtInvestments>
    <us-gaap:GainLossOnSaleOfDebtInvestments contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-11602894</us-gaap:GainLossOnSaleOfDebtInvestments>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">1088575</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">290500</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-5399</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashExpense contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNoncashExpense contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">558577</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">5468499</us-gaap:OtherNoncashExpense>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">2430521</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">1052513</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">13105913</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInContractReceivablesNet contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInContractReceivablesNet contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInContractReceivablesNet contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">1077</us-gaap:IncreaseDecreaseInContractReceivablesNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-34123</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">46504</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">1118</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-54974</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">8160</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">919884</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">85019</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">4501360</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">106218</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">79207</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">584101</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-1116770</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-876729</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-15971200</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">455000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">194750</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">10760575</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">206000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">724535</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">1727906</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">21000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromShortTermDebt contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">446000</us-gaap:ProceedsFromShortTermDebt>
    <tpiv:ProceedsFromShortTermBankLoansAndNotesPayable contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:ProceedsFromShortTermBankLoansAndNotesPayable contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:ProceedsFromShortTermBankLoansAndNotesPayable contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">919845</tpiv:ProceedsFromShortTermBankLoansAndNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">120321</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-31300</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">1707912</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">140000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">870263</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">887985</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">15770180</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">218626</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:CashAcquiredFromAcquisition contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAcquiredFromAcquisition contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAcquiredFromAcquisition contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">423373</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">204747</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-246507</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">11256</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">3727</us-gaap:CashPeriodIncreaseDecrease>
    <tpiv:ProceedsFromPromissoryNotes contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">67942</tpiv:ProceedsFromPromissoryNotes>
    <tpiv:ProceedsFromPromissoryNotes contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:ProceedsFromPromissoryNotes contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">67942</tpiv:ProceedsFromPromissoryNotes>
    <tpiv:ConsultingFees contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">119790</tpiv:ConsultingFees>
    <tpiv:ConsultingFees contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">57260</tpiv:ConsultingFees>
    <tpiv:ConsultingFees contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">43750</tpiv:ConsultingFees>
    <tpiv:ConsultingFees contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">119250</tpiv:ConsultingFees>
    <tpiv:ConsultingFees contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">2158477</tpiv:ConsultingFees>
    <tpiv:ConsultingFeesStockbasedNote9 contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">2283561</tpiv:ConsultingFeesStockbasedNote9>
    <tpiv:ConsultingFeesStockbasedNote9 contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">109728</tpiv:ConsultingFeesStockbasedNote9>
    <tpiv:ConsultingFeesStockbasedNote9 contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">307734</tpiv:ConsultingFeesStockbasedNote9>
    <tpiv:ConsultingFeesStockbasedNote9 contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">692253</tpiv:ConsultingFeesStockbasedNote9>
    <tpiv:ConsultingFeesStockbasedNote9 contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">8005914</tpiv:ConsultingFeesStockbasedNote9>
    <tpiv:InterestAndFinanceChargesNote4 contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">411783</tpiv:InterestAndFinanceChargesNote4>
    <tpiv:InterestAndFinanceChargesNote4 contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">214811</tpiv:InterestAndFinanceChargesNote4>
    <tpiv:InterestAndFinanceChargesNote4 contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">103740</tpiv:InterestAndFinanceChargesNote4>
    <tpiv:InterestAndFinanceChargesNote4 contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">558577</tpiv:InterestAndFinanceChargesNote4>
    <tpiv:InterestAndFinanceChargesNote4 contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">6242796</tpiv:InterestAndFinanceChargesNote4>
    <tpiv:ManagementFeesStockbasedNotes8And9 contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">146960</tpiv:ManagementFeesStockbasedNotes8And9>
    <tpiv:ManagementFeesStockbasedNotes8And9 contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">31334</tpiv:ManagementFeesStockbasedNotes8And9>
    <tpiv:ManagementFeesStockbasedNotes8And9 contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">29563</tpiv:ManagementFeesStockbasedNotes8And9>
    <tpiv:ManagementFeesStockbasedNotes8And9 contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">360260</tpiv:ManagementFeesStockbasedNotes8And9>
    <tpiv:ManagementFeesStockbasedNotes8And9 contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">4471749</tpiv:ManagementFeesStockbasedNotes8And9>
    <tpiv:ResearchAndDevelopmentStockbased contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:ResearchAndDevelopmentStockbased contextRef="From2012-07-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:ResearchAndDevelopmentStockbased contextRef="From2011-07-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:ResearchAndDevelopmentStockbased contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:ResearchAndDevelopmentStockbased contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">612000</tpiv:ResearchAndDevelopmentStockbased>
    <tpiv:TotalExpenses contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">4608702</tpiv:TotalExpenses>
    <tpiv:TotalExpenses contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">796737</tpiv:TotalExpenses>
    <tpiv:TotalExpenses contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">904931</tpiv:TotalExpenses>
    <tpiv:TotalExpenses contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">2706726</tpiv:TotalExpenses>
    <tpiv:TotalExpenses contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">39877798</tpiv:TotalExpenses>
    <tpiv:NetLossBeforeOtherItems contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-4608702</tpiv:NetLossBeforeOtherItems>
    <tpiv:NetLossBeforeOtherItems contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-796737</tpiv:NetLossBeforeOtherItems>
    <tpiv:NetLossBeforeOtherItems contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">-904931</tpiv:NetLossBeforeOtherItems>
    <tpiv:NetLossBeforeOtherItems contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-2706726</tpiv:NetLossBeforeOtherItems>
    <tpiv:NetLossBeforeOtherItems contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-39877798</tpiv:NetLossBeforeOtherItems>
    <tpiv:ForeignExchangeLossGain contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">2304</tpiv:ForeignExchangeLossGain>
    <tpiv:ForeignExchangeLossGain contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-7193</tpiv:ForeignExchangeLossGain>
    <tpiv:ForeignExchangeLossGain contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">14654</tpiv:ForeignExchangeLossGain>
    <tpiv:ForeignExchangeLossGain contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-293</tpiv:ForeignExchangeLossGain>
    <tpiv:ForeignExchangeLossGain contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">55894</tpiv:ForeignExchangeLossGain>
    <tpiv:GainLossOnSettlementOfDebtNote9 contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">28688</tpiv:GainLossOnSettlementOfDebtNote9>
    <tpiv:GainLossOnSettlementOfDebtNote9 contextRef="From2012-07-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:GainLossOnSettlementOfDebtNote9 contextRef="From2011-07-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:GainLossOnSettlementOfDebtNote9 contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-482474</tpiv:GainLossOnSettlementOfDebtNote9>
    <tpiv:GainLossOnSettlementOfDebtNote9 contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-11602894</tpiv:GainLossOnSettlementOfDebtNote9>
    <tpiv:GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4 contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4 contextRef="From2012-07-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4 contextRef="From2011-07-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4 contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">1088575</tpiv:GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4>
    <tpiv:GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4 contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">290500</tpiv:GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4>
    <tpiv:NetLossForPeriod contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-4118684</tpiv:NetLossForPeriod>
    <tpiv:NetLossForPeriod contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-768095</tpiv:NetLossForPeriod>
    <tpiv:NetLossForPeriod contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">-844277</tpiv:NetLossForPeriod>
    <tpiv:NetLossForPeriod contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-2378036</tpiv:NetLossForPeriod>
    <tpiv:NetLossForPeriod contextRef="From1999-07-27to2012-09-30" unitRef="USD" decimals="0">-47840900</tpiv:NetLossForPeriod>
    <tpiv:BasicAndDilutedNetLossPerShare contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">-0.07</tpiv:BasicAndDilutedNetLossPerShare>
    <tpiv:BasicAndDilutedNetLossPerShare contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-0.01</tpiv:BasicAndDilutedNetLossPerShare>
    <tpiv:BasicAndDilutedNetLossPerShare contextRef="From2011-07-01to2011-09-30" unitRef="USD" decimals="0">-0.02</tpiv:BasicAndDilutedNetLossPerShare>
    <tpiv:BasicAndDilutedNetLossPerShare contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">-0.05</tpiv:BasicAndDilutedNetLossPerShare>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2012-01-01to2012-09-30" unitRef="Shares" decimals="INF">62560295</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2012-07-01to2012-09-30" unitRef="Shares" decimals="INF">73128058</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2011-07-01to2011-09-30" unitRef="Shares" decimals="INF">47213710</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2011-01-01to2011-09-30" unitRef="Shares" decimals="INF">44845195</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">22504</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">56627</us-gaap:PrepaidExpenseAndOtherAssets>
    <tpiv:DeferredFinancingCostsNote5 contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">20768</tpiv:DeferredFinancingCostsNote5>
    <tpiv:DeferredFinancingCostsNote5 contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">32291</tpiv:DeferredFinancingCostsNote5>
    <us-gaap:AccountsPayableAndAccruedLiabilities contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">1327984</us-gaap:AccountsPayableAndAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilities contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">794291</us-gaap:AccountsPayableAndAccruedLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">871858</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1317834</us-gaap:DerivativeLiabilities>
    <tpiv:DerivativeLiabilityConversionOptionNote4 contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">200700</tpiv:DerivativeLiabilityConversionOptionNote4>
    <tpiv:DerivativeLiabilityConversionOptionNote4 contextRef="AsOf2011-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesAndWarrantsToBeIssued contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">242062</tpiv:SharesAndWarrantsToBeIssued>
    <tpiv:SharesAndWarrantsToBeIssued contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">362906</tpiv:SharesAndWarrantsToBeIssued>
    <us-gaap:NatureOfOperations contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"&gt;&lt;u&gt;Note&#13;1:&amp;#9;Nature of Operations&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;TapImmune&#13;Inc. (the &amp;#147;Company&amp;#148;), a Nevada corporation incorporated in 1992, is a development stage company which was formed for&#13;the purpose of building a biotechnology business specializing in the discovery and development of immunotherapeutics aimed at&#13;the treatment of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Since&#13;inception, the Company has been party to various Collaborative Research Agreements (&amp;#147;CRA&amp;#148;) working with universities&#13;to carry out development of the licensed technology and providing TapImmune the option to acquire the rights to commercialize&#13;any additional technologies developed within the CRA. The lead product candidate, now wholly owned and with no ongoing license&#13;or royalty, resulting from these license agreements is an immunotherapy vaccine, on which the Company has been completing pre-clinical&#13;work in anticipation of clinical trials. Specifically, the Company has obtained and expanded on three U.S. and international patents,&#13;tested various viral vectors, licensed a viral vector and is working towards production of a clinical grade vaccine. The Company&#13;plans to continue development of the lead product vaccine through to clinical trials in both oncology and infectious diseases&#13;alone or in partnership with other vaccine developers.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt"&gt;These&#13;consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets&#13;and the satisfaction of liabilities in the normal course of business. As at September 30, 2012, the Company had a working capital&#13;deficiency of $3,315,751 (excluding derivative liabilities recorded as current liabilities) and has incurred significant losses&#13;since inception. Further losses are anticipated in the development stage raising substantial doubt as to the Company&amp;#146;s ability&#13;to continue as a going concern. The ability of the Company to continue as a going concern is dependent on raising additional capital&#13;to fund ongoing research and development, maintenance and protection of patents, accommodation from certain debt obligations and&#13;ultimately on generating future profitable operations. Planned expenditures relating to future clinical trials of the Company&amp;#146;s&#13;immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing&#13;research and development as well as working capital requirements. The Company&amp;#146;s future capital requirements will depend on&#13;many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and&#13;scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs&#13;of commercialization activities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt"&gt;Management&#13;is addressing going concern remediation through seeking new sources of capital, restructuring and retiring debt through conversion&#13;to equity and debt settlement arrangements with creditors, cost reduction programs and seeking possible joint venture participation.&#13;Management&amp;#146;s plans are intended to return the Company to financial stability and improve continuing operations. The Company&#13;is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to&#13;meet immediate working capital requirements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt"&gt;Additional&#13;funding was raised through equity and debt placements in 2011 and the first nine months of 2012, and management intends to continue&#13;restructuring outstanding debt and equity instruments. Additional capital is required currently to expand programs including pre-clinical&#13;work and to establish future manufacturing contracts necessary for clinical trials for the lead TAP (Transporters of Antigen Processing)&#13;vaccine and infectious disease adjuvant technology. Strategic partnerships will be needed to continue the product development&#13;portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties&#13;for the Company over the next twelve months. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;There is no certainty that the Company will be able&#13;to arrange sufficient funding to satisfy current debt obligations or to continue development of products to marketability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; text-align: justify"&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <tpiv:WorkingCapitalDeficiency contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">3315751</tpiv:WorkingCapitalDeficiency>
    <tpiv:UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"&gt;&lt;u&gt;Note&#13;2:&amp;#9;UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basis&#13;of Presentation&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;the opinion of management, the accompanying balance sheets and related statements of operations and cash flows include all adjustments,&#13;consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally&#13;accepted in the United States of America (&amp;#147;U.S. GAAP&amp;#148;). Preparing financial statements requires management to make estimates&#13;and assumptions that affect the reported amounts of assets, liabilities, and expenses. Examples include: valuation of the derivative&#13;liabilities and stock-based compensation. Actual results and outcomes may differ from management&amp;#146;s estimates and assumptions.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Interim results are not necessarily indicative of&#13;results for a full year. The information included in this quarterly report on Form 10-Q should be read in conjunction with information&#13;included in the Company&amp;#146;s annual report on Form 10-K filed on April 16, 2012, with the U.S. Securities and Exchange Commission.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; text-align: justify"&gt;&lt;/p&gt;</tpiv:UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"&gt;&lt;u&gt;Note&#13;3:&amp;#9;Research Agreements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Crucell&#13;Holland B.V. (&amp;#147;Crucell&amp;#148;) &amp;#150; Research License and Option Agreement&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effective&#13;August 7, 2003, Crucell and the Company&amp;#146;s subsidiary GeneMax Pharmaceuticals, Inc. (&amp;#147;GPI&amp;#148;) entered into a five-year&#13;research license and option agreement whereby Crucell granted to GPI a non-exclusive worldwide license for the research use of&#13;its adenovirus technology. The Company was required to make certain payments over the five-year term totaling Euro &amp;#128;450,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2008, $243,598 (&amp;#128;172,801) was owing to Crucell under this agreement. During the year ended December 31, 2009,&#13;management negotiated a settlement of the outstanding balance requiring a &amp;#128;17,000 cash payment (paid) and the issuance of&#13;265,000 shares of the Company&amp;#146;s common stock (refer to Note 9).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In addition, retroactively effective August 7, 2008,&#13;the Company negotiated an amended license agreement for the use of Crucell&amp;#146;s adenovirus technology. The Company is required&#13;to make annual license payments on the anniversary of the effective date for the three year term equal to &amp;#128;75,000 per annum.&#13;As at September 30, 2012, the Company had accrued $365,970 (&amp;#128;284,578) under the amended agreement, inclusive of interest&#13;on outstanding amounts. The Company is currently delinquent on making its first annual license payment under the amended license&#13;agreement. Crucell has the right to cancel the agreement however, to date, the Company has not received any notice terminating&#13;the license agreement. Management plans to negotiate an amended payment structure with Crucell that, if successful, would allow&#13;the Company to maintain the license agreement in good standing. However, there is no certainty that the license agreement will&#13;be maintained or that management will successfully negotiate new terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <tpiv:RequiredToMakeCertainPayments contextRef="AsOf2003-08-07" unitRef="USD" decimals="0">450000</tpiv:RequiredToMakeCertainPayments>
    <tpiv:CrucellUnderThisAgreement contextRef="AsOf2008-12-31" unitRef="USD" decimals="0">243598</tpiv:CrucellUnderThisAgreement>
    <tpiv:OutstandingBalanceRequiring contextRef="From2009-01-01to2009-12-31" unitRef="USD" decimals="0">17000</tpiv:OutstandingBalanceRequiring>
    <tpiv:AmendedAgreementAccrued contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">365970</tpiv:AmendedAgreementAccrued>
    <tpiv:DerivativeWarrantLiabilityAndFairValueTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;u&gt;Note 4:&amp;#9;DERIVATIVE&#13;WARRANT LIABILITY AND FAIR VALUE&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The Company has evaluated the application&#13;ASC 480-10 &lt;i&gt;Distinguishing liabilities from equity&lt;/i&gt;, ASC 815-40 &lt;i&gt;Contracts in an Entity&amp;#146;s Own Equity&lt;/i&gt; and ASC 718-10&#13;&lt;i&gt;Compensation &amp;#150; Stock Compensation&lt;/i&gt; to the issued and outstanding warrants to purchase common stock that were issued&#13;with the convertible notes, private placements, consulting agreements, and various debt settlements during 2009 through 2012. Based&#13;on the guidance, management concluded these instruments are required to be accounted for as derivatives either due to a ratchet&#13;down protection feature available on the exercise price (Note 5) or a holder&amp;#146;s right to put the warrants back to the Company&#13;for cash under certain conditions or a conversion option feature with conversion into variable number of shares. Under ASC 815-40-25,&#13;the Company records the fair value of these warrants and conversion options (derivatives) on its balance sheet, at fair value,&#13;with changes in the values reflected in the statements of operations as &amp;#147;Changes in fair value of derivative liabilities&amp;#148;.&#13;The fair value of the share purchase warrants are recorded on the balance sheet under &amp;#145;Derivative liability &amp;#150; warrants&amp;#146;&#13;and the fair value of the conversion options are recorded on the balance sheet under &amp;#145;Derivative liability &amp;#150; conversion&#13;option&amp;#146;.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;ASC 820-10 defines fair value as the&#13;exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous&#13;market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also&#13;establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable&#13;inputs when measuring fair value. ASC 820-10 describes three levels of inputs that may be used to measure fair value: Level 1 &amp;#150;&#13;Quoted prices in active markets for identical assets or liabilities; Level 2 &amp;#150; Observable inputs other than Level 1 prices,&#13;such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable&#13;market data for substantially the full term of the assets or liabilities; and Level 3 &amp;#150; Unobservable inputs that are supported&#13;by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted&#13;cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant&#13;judgment or estimation. The Company&amp;#146;s Level 3 liabilities consist of the derivative liabilities associated with the warrants&#13;issued with the convertible notes during the year ended December 31, 2011. At September 30, 2012, all of the Company&amp;#146;s derivative&#13;liabilities were categorized as Level 3 fair value liabilities. If the inputs used to measure the financial assets and liabilities&#13;fall within more than one level described above, the categorization is based on the lowest level input that is significant to the&#13;fair value measurement of the instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;i&gt;Level 3 Valuation Techniques&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;Financial liabilities are considered&#13;Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and&#13;at least one significant model assumption or input is unobservable. Level 3 financial liabilities consist of the notes and warrants&#13;for which there is no current market for these securities such that the determination of fair value requires significant judgment&#13;or estimation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;Determining fair value of share purchase&#13;warrants, given the Company&amp;#146;s stage of development and financial position, is highly subjective and identifying appropriate&#13;measurement criteria and models is subject to uncertainty. There are several generally accepted pricing models for warrants and&#13;options and derivative provisions. The Company has chosen to value the warrants and conversion option on the notes that contain&#13;ratchet down provisions using the Binomial model under the following assumptions:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2011&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;September 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Share purchase warrants&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;1.09 to 4.80&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.12% to 0.83%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;199%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.33 to 4.03&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.10% to 0.62%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;199%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;At Initial Recognition&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;September 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Conversion Option&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.25 to 1.04&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.11% to 0.20%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;138.31% to 141.43%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.11 to 1.00&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.06% to 0.17%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;138.31% to 141.21%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The foregoing assumptions are reviewed&#13;quarterly and are subject to change based primarily on management&amp;#146;s assessment of the probability of the events described&#13;occurring. Accordingly, changes to these assessments could materially affect the valuations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;i&gt;Financial Assets and Liabilities Measured&#13;at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;Financial assets and liabilities measured&#13;at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability &amp;#150; warrants:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;As of September 30, 2012 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability &amp;#150; conversion option&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;200,700&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;200,700&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;200,700&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 36%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements Using&lt;/td&gt;&#13;    &lt;td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 33%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 6%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The table below provides a summary of&#13;the changes in fair value, including net transfers, in and/or out, of financial assets and liabilities measured at fair value on&#13;a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2012 and the year ended&#13;December 31, 2011:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;&lt;b&gt;Fair Value Measurements Using Level 3 Inputs&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td colspan="2" style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Derivative liability &amp;#150; conversion option&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance,&amp;#160; December 31, 2010&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,819,512&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 175,389&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,994,901&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Additions during the year&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,587,275&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,587,275&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total unrealized (gains) or losses included in net loss&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(631,631)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(37,079)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(668,710)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Debt settlement&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,457,322)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(138,310)&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,595,632)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Transfers in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,317,834&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,317,834&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Additions during the year&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;299,300&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;299,300&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total unrealized (gains) or losses included in net loss&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(445,976)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(98,600)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(544,576)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Debt settlement&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Transfers in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 35%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance, September 30, 2012&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 200,700&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the warrants and conversion&#13;options is determined using a Binomial option pricing model. The valuation of warrants and conversion options is subjective and&#13;is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility&#13;of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield.&#13;Changes in these assumptions can materially affect the fair value estimate. Ultimately, the Company may incur amounts to settle&#13;the warrants at a cash settlement value that is significantly different than the carrying value of the liability in the financial&#13;statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised,&#13;expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair&#13;value of the common stock warrants and conversion options liability are recognized as a component of other income (expense) in&#13;the statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The net cash settlement value at the time of any future&#13;Fundamental Transaction will depend upon the value of the following inputs at that time: the consideration value per share of&#13;the Company&amp;#146;s common stock, the volatility of the Company&amp;#146;s common stock, the remaining term of the warrant from announcement&#13;date, the risk-free interest rate based on U.S. Treasury security yields, and the Company&amp;#146;s dividend yield. The warrant requires&#13;use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day&#13;immediately following announcement of a Fundamental Transaction.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</tpiv:DerivativeWarrantLiabilityAndFairValueTextBlock>
    <tpiv:SharePurchaseWarrantsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2011&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;September 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Share purchase warrants&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;1.09 to 4.80&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.12% to 0.83%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;199%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.33 to 4.03&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.10% to 0.62%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;199%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:SharePurchaseWarrantsTableTextBlock>
    <tpiv:ConversionOptionTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;At Initial Recognition&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;September 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Expected Life (Years)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Conversion Option&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.25 to 1.04&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.11% to 0.20%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;138.31% to 141.43%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.11 to 1.00&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.06% to 0.17%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;138.31% to 141.21%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:ConversionOptionTableTextBlock>
    <tpiv:DerivativeLiabilityTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;As of September 30, 2012 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability &amp;#150; conversion option&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;200,700&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;200,700&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;200,700&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 36%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:DerivativeLiabilityTableTextBlock>
    <tpiv:DerivativeLiabilityWarrantsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements Using&lt;/td&gt;&#13;    &lt;td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,317,834&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 33%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 6%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:DerivativeLiabilityWarrantsTableTextBlock>
    <tpiv:FinancialAssetsAndLiabilitiesTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;&lt;b&gt;Fair Value Measurements Using Level 3 Inputs&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td colspan="2" style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 4pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Derivative liability &amp;#150; conversion option&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance,&amp;#160; December 31, 2010&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,819,512&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 175,389&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,994,901&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Additions during the year&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,587,275&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,587,275&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total unrealized (gains) or losses included in net loss&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(631,631)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(37,079)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(668,710)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Debt settlement&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,457,322)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(138,310)&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,595,632)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Transfers in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,317,834&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,317,834&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Additions during the year&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;299,300&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;299,300&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total unrealized (gains) or losses included in net loss&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(445,976)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(98,600)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(544,576)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Debt settlement&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Transfers in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 35%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance, September 30, 2012&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 871,858&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 200,700&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 1,072,558&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:FinancialAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;u&gt;Note 5:&amp;#9;CONVERTIBLE&#13;NOTES PAYABLE&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;The&#13;following is a summary of debt instrument transactions that are relevant to the current period:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Face Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Principal Repayment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Unamortized&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Discount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Balance at&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;February 2011 Secured Convertible Notes&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Senior Secured Notes, due February 24, 2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,184,694&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160; 225,800&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 958,894&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;April 2011 Secured Convertible Notes&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Senior Secured Notes, due April 4, 2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;215,000&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;51,786&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;163,214&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;June 2011 Secured Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Senior Secured Notes, due June 6, 2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;30,000&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;4,650&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;25,350&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;August 8, 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due August 8, 2013&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;111,430&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;95,250&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;16,180&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;August 12, 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due November 12, 2012&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;27,500&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;11,658&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;15,842&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;August 20, 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due August 20, 2013&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;20,000&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;17,757&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,245&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;September 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due October 1, 2013&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;82,500&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;79,874&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,626&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,671,124&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160; 486,773&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,184,351&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;February 2011 Secured Convertible Notes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On February 24, 2011, the Company entered&#13;into a securities purchase agreement with accredited investors to place Senior Secured Convertible Notes (the &amp;#147;February 2011&#13;Notes&amp;#148;) with a maturity date of three years after the issuance thereof in the aggregate principal amount of $1,184,694. Consideration&#13;under the notes consisted of $944,694 in cash proceeds, including accrued interest, and $240,000 was subscribed for by two of the&#13;holders of outstanding and demandable 2010 secured convertible notes (the &amp;#147;2010 Notes&amp;#148;). The holders of the 2010 Notes&#13;returned their Series A, Series B and Series C warrants to the Company for cancellation. In connection with the issuance of the&#13;February 2011 Notes, the Company entered into a 2011 Security Agreement with the note holders securing the February 2011 Notes&#13;with all of the Company&amp;#146;s assets. One year after the issuance of the February 2011 Notes, the note holders have the option&#13;to convert a portion or all of the outstanding balance of the February 2011 Notes including any accrued interest into shares of&#13;the Company&amp;#146;s common stock at a conversion rate of $0.15 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The February 2011 Notes bear interest&#13;at the rate of 10% per annum except in case of default, in which case they bear interest at the rate of 20% per annum. The interest&#13;is due on the February 2011 Notes at the end of each three month period, starting three months from their issuance. One year after&#13;the issuance of the February 2011 Notes, the Company may elect to prepay a portion of the principal. If the Company makes such&#13;an election, the holders may elect to receive such prepayment in cash or in shares of the Company&amp;#146;s common stock, at a conversion&#13;rate of $0.15 per share, or in a combination thereof.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The Company paid a finders&amp;#146; fee&#13;of $41,500. The finder&amp;#146;s fee was accounted for as deferred financing costs, and is being amortized over the term of the notes.&#13;At September 30, 2012, $18,495 of the $20,768 in deferred financing costs relates to the February 2011 Notes which remains unamortized,&#13;and is presented in long-term assets on the Company&amp;#146;s Balance Sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In connection with the issuance of the&#13;February 2011 Notes, the Company issued 2,369,388 warrants, exercisable into common stock at $0.25 with five year terms. The Company&#13;may force the exercise of the warrants at any time that the average volume weighted average price of the Company&amp;#146;s common&#13;stock over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&amp;#146;s common stock&#13;sold over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of&#13;the shares underlying the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;After reviewing a Fundamental Transaction&#13;clause contained in the warrants, the Company allocated the net proceeds to the warrants based on the calculated fair value at&#13;the date of issuance. The fair value of the warrants was recorded at $483,355 and recognized as derivative liabilities and the&#13;debt was recorded at $701,339. The fair value of the warrants was calculated using the Binomial option pricing model under the&#13;following assumptions: estimated life of five years, risk free rate of 2.06%, dividend yield of 0% and volatility of 199%. The&#13;debt discount is being accreted over the three year term of the February 2011 Notes using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;For the nine months ended September 30,&#13;2012, accretion of the debt discount of $120,839 was recorded for the February 2011 Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;b&gt;April 2011 Secured Convertible Notes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On April 4, 2011, the Company entered&#13;into a securities purchase agreement with accredited investors to place Senior Secured Convertible Notes (the &amp;#147;April 2011&#13;Notes&amp;#148;) with a maturity date of three years after the issuance thereof in the aggregate principal amount of $215,000. Consideration&#13;under the notes consisted of $190,000 in cash proceeds, and $25,000 was subscribed for by a holder of 2010 Notes in exchange for&#13;the extinguishment of the Series A, Series B and Series C warrants related to the 2010 Notes. In connection with the issuance of&#13;the April 2011 Notes, the Company entered into a 2011 Security Agreement with the note holders securing the April 2011 Notes with&#13;a secondary security interest in all of the Company&amp;#146;s assets. One year after the issuance of the April 2011 Notes, the note&#13;holders have the option to convert a portion or all of the outstanding balance of the April 2011 Notes including any accrued interest&#13;into shares of the Company&amp;#146;s common stock at a conversion rate of $0.15 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The April 2011 Notes bear interest at&#13;the rate of 10% per annum except in case of default, in which case they bear interest at the rate of 20% per annum. The interest&#13;is due on the April 2011 Notes at the end of each three month period, starting three months from their issuance. One year after&#13;the issuance of the April 2011 Notes, the Company may elect to prepay a portion of the principal. If the Company makes such an&#13;election, the holders may elect to receive such prepayment in cash or in shares of the Company&amp;#146;s common stock, at a conversion&#13;rate of $0.15 per share, or in a combination thereof.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The Company paid a finders&amp;#146; fee&#13;of $4,550. The finder&amp;#146;s fee was accounted for as deferred financing costs, and is being amortized over the term of the notes.&#13;At September 30, 2012, $2,273 of the $20,768 in deferred financing costs relates to the April 2011 Notes which remains unamortized,&#13;and is presented in long-term assets on the Company&amp;#146;s Balance Sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In connection with the issuance of the&#13;April 2011 Notes, the Company issued 430,000 warrants, exercisable into common stock at $0.25 with 2 year terms. The Company may&#13;force the exercise of the warrants at any time that the average volume weighted average price of the Company&amp;#146;s common stock&#13;over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&amp;#146;s common stock sold&#13;over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of the&#13;shares underlying the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;The Company has allocated the net proceeds&#13;to the warrants based on the calculated fair value. The fair value of the warrants was recorded at $130,720 and recognized as derivative&#13;liabilities and the debt was recorded at $84,280. The fair value of the warrants was calculated using the Binomial option pricing&#13;model under the following assumptions: estimated life of two years, risk free rate of 0.77%, dividend yield of 0% and volatility&#13;of 199%. The debt discount is being accreted over the three year term of the April 2011 Notes using the effective interest rate&#13;method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;For the nine months ended September 30,&#13;2012, accretion of the debt discount of $25,752 was recorded for the April 2011 Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;b&gt;June 2011 Secured Convertible Note&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On June 6, 2011, the Company entered&#13;into a securities purchase agreement with accredited investors to place Senior Secured Convertible Note (the &amp;#147;June 2011 Note&amp;#148;)&#13;with a maturity date of three years after the issuance thereof in the aggregate principal amount of $30,000. In connection with&#13;the issuance of the June 2011 Note, the Company entered into a 2011 Security Agreement with the note holder securing the June 2011&#13;Note with a secondary security interest in all of the Company&amp;#146;s assets. One year after the issuance of the June 2011 Note,&#13;the note holder has the option to convert a portion or all of the outstanding balance of the June 2011 Note including any accrued&#13;interest into shares of the Company&amp;#146;s common stock at a conversion rate of $0.15 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The June 2011 Note bears interest at&#13;the rate of 10% per annum except in case of default, in which case it bears interest at the rate of 20% per annum. The interest&#13;is due on the June 2011 Note at the end of each three month period, starting three months from its issuance. One year after the&#13;issuance of the June 2011 Note, the Company may elect to prepay a portion of the principal. If the Company makes such an election,&#13;the holders may elect to receive such prepayment in cash or in shares of the Company&amp;#146;s common stock, at a conversion rate&#13;of $0.15 per share, or in a combination thereof.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In connection with the issuance of the&#13;June 2011 Note, the Company issued 60,000 warrants, exercisable into common stock at $0.25 with two year terms. The Company may&#13;force the exercise of the warrants at any time that the average volume weighted average price of the Company&amp;#146;s common stock&#13;over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&amp;#146;s common stock sold&#13;over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of the&#13;shares underlying the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;The Company has allocated the net proceeds&#13;to the warrants based on the calculated fair value. The fair value of the warrants was recorded at $8,280 and recognized as derivative&#13;liabilities and the debt was recorded at $21,720. The fair value of the warrants was calculated using the Binomial option pricing&#13;model under the following assumptions: estimated life of two years, risk free rate of 0.43%, dividend yield of 0% and volatility&#13;of 199%. The debt discount is being accreted over the three year term of the June 2011 Note using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;For the nine months ended September 30,&#13;2012, accretion of the debt discount of $2,075 was recorded for the June 2011 Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;b&gt;August 8, 2012 Convertible Note&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On August 8, 2012, the Company entered&#13;into a securities purchase agreement with accredited investors to place a Convertible Note (the &amp;#147;August 8, 2012 Note&amp;#148;)&#13;with a maturity date of one year after the issuance thereof in the aggregate principal amount of $111,430. Consideration under&#13;the notes consisted of $92,000 in cash proceeds after $8,000 payment of finders&amp;#146; fee and an original issue discount of $11,430.&#13;The note holder has the option to convert a portion or all of the outstanding balance of the August 8, 2012 Note including any&#13;accrued interest into shares of the Company&amp;#146;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded&#13;price in the 25 trading days prior to conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The August 8, 2012 Note carries no interest&#13;if the Company repays the note within 90 days from issuance. If the Company does not repay the note within 90 days, a one-time&#13;interest of 5% shall apply to the principal sum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The finder&amp;#146;s fee of $8,000 was&#13;accounted for as deferred financing costs, and is being amortized over the term of the note. At September 30, 2012, $6,838 of the&#13;$12,641 in deferred financing costs relates to the August 8, 2012 Note which remains unamortized, and is presented in current assets&#13;on the Company&amp;#146;s Balance Sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;The Company has allocated the net proceeds&#13;to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $1155,700&#13;and recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt&#13;financing of $55,700. The fair value of the conversion option was calculated using the Binomial option pricing model under the&#13;following assumptions: estimated life of one year, risk free rate of 0.19%, dividend yield of 0% and volatility of 139.77%. The&#13;debt discount is being accreted over the one year term of the August 8, 2012 Note using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;For the nine months ended September 30,&#13;2012, accretion of the debt discount of $16,180 was recorded for the August 8, 2012 Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;b&gt;August 12, 2012 Convertible Note&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On August 12, 2012, the Company entered&#13;into a securities purchase agreement with accredited investors to place a Convertible Note (the &amp;#147;August 12, 2012 Note&amp;#148;)&#13;with a maturity date of three months after the issuance thereof in the aggregate principal amount of $27,500. Consideration under&#13;the notes consisted of $25,000 in cash proceeds after an original issue discount of $2,500. The note holder has the option to convert&#13;a portion or all of the outstanding balance of the August 8, 2012 Note including any accrued interest into shares of the Company&amp;#146;s&#13;common stock at a conversion rate of $0.09 per share or on similar terms as of any future financings with more favorable terms.&#13;The agreement provides for the Company to issue 50,000 shares to the note holder as risk premium. The 50,000 shares were valued&#13;at $6,250 and recorded as loss on debt financing and obligation to issue shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The August 12, 2012 Note bears interest&#13;at the rate of 10% per annum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;The Company has allocated the net proceeds&#13;to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $31,100 and&#13;recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt&#13;financing of 6,100. The fair value of the conversion option was calculated using the Binomial option pricing model under the following&#13;assumptions: estimated life of three months, risk free rate of 0.11%, dividend yield of 0% and volatility of 138.31%. The debt&#13;discount is being accreted over the three month term of the August 12, 2012 Note using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;For the nine months ended September 30,&#13;2012, accretion of the debt discount of $15,842 was recorded for the August 12, 2012 Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;b&gt;August 20, 2012 Convertible Note&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On August 20, 2012, the Company entered&#13;into a securities purchase agreement with accredited investors to place a Convertible Note (the &amp;#147;August 20, 2012 Note&amp;#148;)&#13;with a maturity date of one year after the issuance thereof in the aggregate principal amount of $20,000. The note holder has the&#13;option to convert a portion or all of the outstanding balance of the August 8, 2012 Note including any accrued interest into shares&#13;of the Company&amp;#146;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded price in the 25 trading&#13;days prior to conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The August 20, 2012 Note bears interest&#13;at the rate of 8% per annum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;The Company has allocated the net proceeds&#13;to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $36,100 and&#13;recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt&#13;financing of $16,100. The fair value of the conversion option was calculated using the Binomial option pricing model under the&#13;following assumptions: estimated life of one year, risk free rate of 0.19%, dividend yield of 0% and volatility of 140.11%. The&#13;debt discount is being accreted over the one year term of the August 20, 2012 Note using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;For the nine months ended September 30,&#13;2012, accretion of the debt discount of $2,247 was recorded for the August 20, 2012 Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;b&gt;September 18, 2012 Convertible Note&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On September 18, 2012, the Company entered&#13;into a securities purchase agreement with accredited investors to place a Convertible Note (the &amp;#147;September 18, 2012 Note&amp;#148;)&#13;with a maturity date of one year after the issuance thereof in the aggregate principal amount of $82,500. Consideration under the&#13;notes consisted of $69,000 in cash proceeds after $6,000 payment of finders&amp;#146; fee and an original issue discount of $7,500.&#13;The note holder has the option to convert a portion or all of the outstanding balance of the September, 2012 Note including any&#13;accrued interest into shares of the Company&amp;#146;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded&#13;price in the 20 trading days prior to conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The September, 2012 Note carries no interest&#13;other than the original issue discount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;The finder&amp;#146;s fee of $6,000 was&#13;accounted for as deferred financing costs, and is being amortized over the term of the note. At September 30, 2012, $5,803 of the&#13;$12,641 in deferred financing costs relates to the September, 2012 Note which remains unamortized, and is presented in current&#13;assets on the Company&amp;#146;s Balance Sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;The Company has allocated the net proceeds&#13;to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $76,400 and&#13;recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt&#13;financing of $1,400. The fair value of the conversion option was calculated using the Binomial option pricing model under the following&#13;assumptions: estimated life of one year, risk free rate of 0.20%, dividend yield of 0% and volatility of 141.43%. The debt discount&#13;is being accreted over the one year term of the September, 2012 Note using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the nine months ended September 30, 2012, accretion&#13;of the debt discount of $2,626 was recorded for the September, 2012 Note.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock>
    <tpiv:InstrumentTransactionsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Face Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Principal Repayment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Unamortized&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Discount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Balance at&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;February 2011 Secured Convertible Notes&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Senior Secured Notes, due February 24, 2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,184,694&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160; 225,800&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 958,894&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;April 2011 Secured Convertible Notes&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Senior Secured Notes, due April 4, 2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;215,000&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;51,786&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;163,214&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;June 2011 Secured Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Senior Secured Notes, due June 6, 2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;30,000&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;4,650&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;25,350&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;August 8, 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due August 8, 2013&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;111,430&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;95,250&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;16,180&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;August 12, 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due November 12, 2012&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;27,500&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;11,658&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;15,842&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;August 20, 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due August 20, 2013&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;20,000&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;17,757&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,245&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;September 2012 Convertible Note&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Note due October 1, 2013&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;82,500&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;79,874&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,626&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,671,124&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160; 486,773&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,184,351&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:InstrumentTransactionsTableTextBlock>
    <tpiv:AggregatePrincipalAmount contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">1184694</tpiv:AggregatePrincipalAmount>
    <tpiv:AggregatePrincipalAmount contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">215000</tpiv:AggregatePrincipalAmount>
    <tpiv:AggregatePrincipalAmount contextRef="AsOf2011-06-30" unitRef="USD" decimals="0">30000</tpiv:AggregatePrincipalAmount>
    <tpiv:AggregatePrincipalAmount contextRef="AsOf2012-08-08" unitRef="USD" decimals="0">111430</tpiv:AggregatePrincipalAmount>
    <tpiv:AggregatePrincipalAmount contextRef="AsOf2012-08-12" unitRef="USD" decimals="0">27500</tpiv:AggregatePrincipalAmount>
    <tpiv:AggregatePrincipalAmount contextRef="AsOf2012-08-20" unitRef="USD" decimals="0">20000</tpiv:AggregatePrincipalAmount>
    <tpiv:AggregatePrincipalAmount contextRef="AsOf2012-09-18" unitRef="USD" decimals="0">82500</tpiv:AggregatePrincipalAmount>
    <tpiv:CashProceedsAndAccruedInterest contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">944694</tpiv:CashProceedsAndAccruedInterest>
    <tpiv:CashProceedsAndAccruedInterest contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">190000</tpiv:CashProceedsAndAccruedInterest>
    <tpiv:CashProceedsAndAccruedInterest contextRef="AsOf2012-08-08" unitRef="USD" decimals="0">92000</tpiv:CashProceedsAndAccruedInterest>
    <tpiv:CashProceedsAndAccruedInterest contextRef="AsOf2012-08-12" unitRef="USD" decimals="0">25000</tpiv:CashProceedsAndAccruedInterest>
    <tpiv:CashProceedsAndAccruedInterest contextRef="AsOf2012-09-18" unitRef="USD" decimals="0">69000</tpiv:CashProceedsAndAccruedInterest>
    <tpiv:OutstandingAndDemandable contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">240000</tpiv:OutstandingAndDemandable>
    <tpiv:OutstandingAndDemandable contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">25000</tpiv:OutstandingAndDemandable>
    <tpiv:CommonStockConversionRatePerShare contextRef="AsOf2011-02-28" unitRef="USDPShares" decimals="INF">0.15</tpiv:CommonStockConversionRatePerShare>
    <tpiv:CommonStockConversionRatePerShare contextRef="AsOf2011-04-30" unitRef="USDPShares" decimals="INF">0.15</tpiv:CommonStockConversionRatePerShare>
    <tpiv:CommonStockConversionRatePerShare contextRef="AsOf2011-06-30" unitRef="USDPShares" decimals="INF">0.15</tpiv:CommonStockConversionRatePerShare>
    <tpiv:CommonStockConversionRatePerShare contextRef="AsOf2012-08-08" unitRef="USDPShares" decimals="INF">0.09</tpiv:CommonStockConversionRatePerShare>
    <tpiv:CommonStockConversionRatePerShare contextRef="AsOf2012-08-12" unitRef="USDPShares" decimals="INF">0.09</tpiv:CommonStockConversionRatePerShare>
    <tpiv:CommonStockConversionRatePerShare contextRef="AsOf2012-08-20" unitRef="USDPShares" decimals="INF">0.09</tpiv:CommonStockConversionRatePerShare>
    <tpiv:CommonStockConversionRatePerShare contextRef="AsOf2012-09-18" unitRef="USDPShares" decimals="INF">0.09</tpiv:CommonStockConversionRatePerShare>
    <tpiv:NotesBearInterestRatePerAnnum contextRef="AsOf2011-02-28">10%</tpiv:NotesBearInterestRatePerAnnum>
    <tpiv:NotesBearInterestRatePerAnnum contextRef="AsOf2011-04-30">10%</tpiv:NotesBearInterestRatePerAnnum>
    <tpiv:NotesBearInterestRatePerAnnum contextRef="AsOf2011-06-30">10%</tpiv:NotesBearInterestRatePerAnnum>
    <tpiv:NotesBearInterestRatePerAnnum contextRef="AsOf2012-08-12">10%</tpiv:NotesBearInterestRatePerAnnum>
    <tpiv:NotesBearInterestRatePerAnnum contextRef="AsOf2012-08-20">8%</tpiv:NotesBearInterestRatePerAnnum>
    <tpiv:FindersFee contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">41500</tpiv:FindersFee>
    <tpiv:FindersFee contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">4550</tpiv:FindersFee>
    <tpiv:FindersFee contextRef="AsOf2012-08-08" unitRef="USD" decimals="0">8000</tpiv:FindersFee>
    <tpiv:FindersFee contextRef="AsOf2012-09-18" unitRef="USD" decimals="0">6000</tpiv:FindersFee>
    <tpiv:DeferredFinancingCosts contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">18495</tpiv:DeferredFinancingCosts>
    <tpiv:DeferredFinancingCosts contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">2273</tpiv:DeferredFinancingCosts>
    <tpiv:DeferredFinancingCosts contextRef="AsOf2012-08-08" unitRef="USD" decimals="0">6838</tpiv:DeferredFinancingCosts>
    <tpiv:DeferredFinancingCosts contextRef="AsOf2012-08-12" unitRef="USD" decimals="0">6100</tpiv:DeferredFinancingCosts>
    <tpiv:DeferredFinancingCosts contextRef="AsOf2012-08-20" unitRef="USD" decimals="0">16100</tpiv:DeferredFinancingCosts>
    <tpiv:DeferredFinancingCosts contextRef="AsOf2012-09-18" unitRef="USD" decimals="0">5803</tpiv:DeferredFinancingCosts>
    <tpiv:WarrantsExercisable contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">2369388</tpiv:WarrantsExercisable>
    <tpiv:WarrantsExercisable contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">430000</tpiv:WarrantsExercisable>
    <tpiv:WarrantsExercisable contextRef="AsOf2011-06-30" unitRef="USD" decimals="0">60000</tpiv:WarrantsExercisable>
    <tpiv:WarrantsExercisable contextRef="AsOf2012-08-08" unitRef="USD" decimals="0">1155700</tpiv:WarrantsExercisable>
    <tpiv:FairValueOfWarrants contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">483355</tpiv:FairValueOfWarrants>
    <tpiv:FairValueOfWarrants contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">130720</tpiv:FairValueOfWarrants>
    <tpiv:FairValueOfWarrants contextRef="AsOf2011-06-30" unitRef="USD" decimals="0">21720</tpiv:FairValueOfWarrants>
    <tpiv:FairValueOfWarrants contextRef="AsOf2012-08-12" unitRef="USD" decimals="0">31100</tpiv:FairValueOfWarrants>
    <tpiv:FairValueOfWarrants contextRef="AsOf2012-08-20" unitRef="USD" decimals="0">36100</tpiv:FairValueOfWarrants>
    <tpiv:FairValueOfWarrants contextRef="AsOf2012-09-18" unitRef="USD" decimals="0">76400</tpiv:FairValueOfWarrants>
    <tpiv:DerivativeLiabilitiesAndDebt contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">701339</tpiv:DerivativeLiabilitiesAndDebt>
    <tpiv:DerivativeLiabilitiesAndDebt contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">84280</tpiv:DerivativeLiabilitiesAndDebt>
    <tpiv:DebtDiscount contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">120839</tpiv:DebtDiscount>
    <tpiv:DebtDiscount contextRef="AsOf2011-04-30" unitRef="USD" decimals="0">25752</tpiv:DebtDiscount>
    <tpiv:DebtDiscount contextRef="AsOf2011-06-30" unitRef="USD" decimals="0">2075</tpiv:DebtDiscount>
    <tpiv:DebtDiscount contextRef="AsOf2012-08-08" unitRef="USD" decimals="0">16180</tpiv:DebtDiscount>
    <tpiv:DebtDiscount contextRef="AsOf2012-08-12" unitRef="USD" decimals="0">15842</tpiv:DebtDiscount>
    <tpiv:DebtDiscount contextRef="AsOf2012-08-20" unitRef="USD" decimals="0">2247</tpiv:DebtDiscount>
    <tpiv:DebtDiscount contextRef="AsOf2012-09-18" unitRef="USD" decimals="0">2626</tpiv:DebtDiscount>
    <tpiv:LoansPayablesTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"&gt;&lt;u&gt;Note&#13;6:&amp;#9;Loans payable&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As at September 30, 2012, there were unsecured loan&#13;advances from third parties in the amount of $28,000 (December 31, 2011 - $7,000), which are due on demand. The loans are accruing&#13;interest between 10-19% per annum.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; text-align: justify"&gt;&lt;/p&gt;</tpiv:LoansPayablesTextBlock>
    <tpiv:UnsecuredLoanAdvances contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">28000</tpiv:UnsecuredLoanAdvances>
    <tpiv:UnsecuredLoanAdvances contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">7000</tpiv:UnsecuredLoanAdvances>
    <tpiv:PromissoryNoteTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"&gt;&lt;u&gt;Note&#13;7:&amp;#9;Promissory note&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;During the year ended December 31, 2011, the Company issued a note in the amount of $100,000 towards future&#13;legal services, which matured July 24, 2011. As of September 30, 2012, the Company had received legal services in the amount of&#13;$100,000 against the note. The note bears interest at 10% per annum and may be converted into shares at equal to lower of $0.09&#13;or 65% of the arithmetic average of the lowest closing bid prices of the Company&amp;#146;s shares during the consecutive twenty day&#13;trading period prior to notice of conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the nine months ended, the Company issued 500,000 shares to the holder of the note in exchange for the note holder&amp;#146;s agreement&#13;to forbear from pursuing collections actions on the outstanding note (Note 9). As of September 30, 2012, the Company is negotiating&#13;terms for repayment and settlement of the note.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the nine months ended September 30, 2012, the&#13;Company issued additional promissory notes in the amount of $67,942, of which $38,000 of promissory notes were issued to an officer&#13;and a director of the Company (Note 8). The promissory notes had no interest charges and no fixed repayment terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; text-align: justify"&gt;&lt;/p&gt;</tpiv:PromissoryNoteTextBlock>
    <tpiv:AmountForFutureLegalServices contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">100000</tpiv:AmountForFutureLegalServices>
    <tpiv:SharesIssuedToHolderOfNote contextRef="From2011-01-01to2011-09-30" unitRef="Shares" decimals="INF">500000</tpiv:SharesIssuedToHolderOfNote>
    <tpiv:PromissoryNotesAmount contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">67942</tpiv:PromissoryNotesAmount>
    <tpiv:PromissoryNotesAmountIssuedToOfficerAndDirector contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">38000</tpiv:PromissoryNotesAmountIssuedToOfficerAndDirector>
    <tpiv:PrepaidExpensesAndDeposit contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">11703</tpiv:PrepaidExpensesAndDeposit>
    <tpiv:ConversionPricePerShares contextRef="From2011-01-01to2011-12-31" unitRef="USDPShares" decimals="INF">0.23</tpiv:ConversionPricePerShares>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;u&gt;Note 8:&amp;#9;Related&#13;Party Transactions&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;During&#13;the nine months&lt;/font&gt; ended September 30, 2012&lt;font style="letter-spacing: -0.1pt"&gt;, the Company entered into transactions with&#13;certain officers and directors of the Company as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0 0.75in; text-align: justify; text-indent: -0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;(a)&lt;font style="font: 7pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;&lt;/font&gt;incurred $173,500 (September 30, 2011 - $187,200) in management fees and $67,500 (September 30, 2011 - $67,500) in research&#13;and development services paid to officers and directors during the period;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;(b)&lt;font style="font: 7pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;&lt;/font&gt;recorded $31,333 (September 30, 2011 - $360,260) in stock based compensation for the fair value of options granted to management&#13;that were granted and or vested during the period;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;(c)&lt;font style="font: 7pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;&lt;/font&gt;converted $25,000 (September 30, 2011 - $100,000) of debt due to related parties during the period, which were settled with&#13;shares; &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;(d)&lt;font style="font: 7pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;&lt;/font&gt;issued $38,000 (September 30, 2011 - $nil) in promissory notes to an officer and director of the Company (Note 7).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;All&#13;related party transactions (other than stock based consideration) involving provision of services were recorded at the exchange&#13;amount, which is the amount established and agreed to by the related parties as representing fair value. The Company accounted&#13;for the debt settlement transactions with related parties at management&amp;#146;s estimate of fair value, using amounts similar to&#13;arm&amp;#146;s length settlements for debt settled.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At September 30, 2012, the Company had amounts owing&#13;to directors and officers of $281,475 (December 31, 2011 - $322,905). Amounts due to related parties are unsecured, non-interest&#13;bearing and have no specific terms of repayment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <tpiv:ManagementFees contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">173500</tpiv:ManagementFees>
    <tpiv:ManagementFees contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">187200</tpiv:ManagementFees>
    <tpiv:ResearchAndDevelopmentServices contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">67500</tpiv:ResearchAndDevelopmentServices>
    <tpiv:ResearchAndDevelopmentServices contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">67500</tpiv:ResearchAndDevelopmentServices>
    <tpiv:StockBasedCompensation contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">31333</tpiv:StockBasedCompensation>
    <tpiv:StockBasedCompensation contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">360260</tpiv:StockBasedCompensation>
    <tpiv:DebtDueToRelatedParties contextRef="From2012-01-01to2012-09-30" unitRef="USDPShares" decimals="INF">25000</tpiv:DebtDueToRelatedParties>
    <tpiv:DebtDueToRelatedParties contextRef="From2011-01-01to2011-09-30" unitRef="USDPShares" decimals="INF">100000</tpiv:DebtDueToRelatedParties>
    <tpiv:PromissoryNotesToOfficerAndDirector contextRef="From2012-01-01to2012-09-30" unitRef="USD" decimals="0">38000</tpiv:PromissoryNotesToOfficerAndDirector>
    <tpiv:PromissoryNotesToOfficerAndDirector contextRef="From2011-01-01to2011-09-30" unitRef="USD" decimals="0">0</tpiv:PromissoryNotesToOfficerAndDirector>
    <tpiv:AmountsOwingToDirectorsAndOfficer contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">281475</tpiv:AmountsOwingToDirectorsAndOfficer>
    <tpiv:AmountsOwingToDirectorsAndOfficer contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">322905</tpiv:AmountsOwingToDirectorsAndOfficer>
    <us-gaap:ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;u&gt;Note 9:&amp;#9;Capital&#13;Stock&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Share Capital&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;The&#13;authorized capital of the Company consisted of 150,000,000 common shares with $0.001 par value and 5,000,000 non-voting preferred&#13;shares with $0.001 par value. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;2012 Share Transactions&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 15, 2012, the Company issued 333,334 shares of its restricted common stock to related parties, pursuant to debt settlement&#13;agreements to settle $50,000 of outstanding trade payable. &lt;/font&gt;At the time of issuance the fair value of the shares was determined&#13;to be $50,000 based on the quoted market price of $0.15 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 15, 2012, the Company issued &lt;/font&gt;400,000 shares of its restricted common stock pursuant to a debt settlement and a consulting&#13;agreement. At the time of issuance the fair value of the shares was determined to be $71,200 based on the quoted market price of&#13;$0.15 per share. The Company recorded $9,930 as gain on settlement of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 15, 2012, the Company issued &lt;/font&gt;789,778 shares of its restricted common stock in settlement of accrued interest on the&#13;outstanding 2011 Notes. At the time of issuance the fair value of the shares was determined to be $118,467 based on the quoted&#13;market price of $0.15 per share. No gain or loss was recorded on settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In March 2012, the Company received subscription&#13;proceeds of $85,000. The subscribers purchased 733,334 share units at $0.15 per unit. Each unit consists of 1 share of Company&amp;#146;s&#13;common stock and half a warrant exercisable at $0.40, which expires in two years. The fair value of these warrants was determined&#13;to be $5,133.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In April 2012, the Company received subscription&#13;proceeds of $345,000. The subscribers purchased 2,300,000 share units at $0.15 per unit. Each unit consists of 1 share of Company&amp;#146;s&#13;common stock and half a warrant exercisable at $0.40, which expires in two years. The fair value of these warrants was determined&#13;to be $123,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In April, 2012, the Company&#13;issued 1&lt;/font&gt;00,000 shares of its restricted common stock pursuant to a debt settlement and a consulting agreement. At the time&#13;of issuance the fair value of the shares was determined to be $18,500 based on the quoted market price of $0.185 per share. The&#13;Company recorded $18,758 as gain on settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"&gt;In April 2012, the Company issued 933,333 restricted common&#13;shares, at $0.15 per share, for proceeds of $140,000 received in October 2011, in a private placement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In April 2012, the Company issued 1,000,000&#13;common shares to a consultant pursuant to a consulting agreement effective October 1, 2011.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;April, 2012, the Company issued &lt;/font&gt;163,334 shares of its restricted common stock in settlement of accrued interest on the outstanding&#13;2011 Notes. At the time of issuance the fair value of the shares was determined to be $24,500 based on the quoted market price&#13;of $0.15 per share. No gain or loss was recorded on settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In May 2012, the Company issued 14,000,000&#13;common shares to consultants pursuant to a consulting agreement (Note 11). At the time of issuance the fair value of the shares&#13;was determined to be $1,918,000 based on the quoted market price of $0.137 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;June 2012, the Company issued &lt;/font&gt;35,179 shares of its restricted common stock pursuant to a consulting agreement. The fair&#13;value of the shares was determined to be $6,000 based on the quoted market price of $0.17 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;August 2012, the Company issued &lt;/font&gt;500,000 shares of its restricted common stock pursuant to a consulting agreement. The fair&#13;value of the shares was determined to be $74,000 based on the quoted market price of $0.148 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In September 2012, the Company issued &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000 shares&#13;of its restricted common stock to the holder of a promissory note in exchange for the note holder&amp;#146;s agreement to forebear&#13;from pursuing collection action on that note (Note 7). The fair value of the shares was determined to be $72,750 based on the quoted&#13;market price of $0.146 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;2011 Share Transactions&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 21, 2011, the Company issued &lt;/font&gt;641,023 shares of its restricted common stock pursuant to debt settlement and warrant&#13;extinguishment agreement to settle $83,333 of the 2010 Notes and partial extinguishment of the Series A, Series B and Series C&#13;Warrants. At the time of issuance, the fair value of the shares was determined to be $115,384, based on the quoted market price&#13;of $0.18 per share, which has been recorded against the carrying value of the debt. The Company recognized a loss of $87,734 on&#13;partial settlement of 2010 Notes and partial extinguishment of the Series A, Series B and Series C Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 23, 2011, the Company issued &lt;/font&gt;1,180,000 shares of its restricted common stock pursuant to various consulting agreements.&#13;At the time of issuance the fair value of the shares was determined to be $227,432 based on the quoted market price of $0.18 per&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 23, 2011, the Company issued 885,295 shares of its restricted common stock pursuant to debt settlement agreements to settle&#13;$150,500 of outstanding trade payables. &lt;/font&gt;At the time of issuance the fair value of the shares was determined to be $172,633&#13;based on the quoted market price of $0.195 per share. The Company recorded $22,133 as loss on settlement of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 23, 2011, the Company issued 441,177 shares of its restricted common stock to related parties, pursuant to debt settlement&#13;agreements to settle $75,000 of its outstanding trade payables. At the time of issuance the fair value of the shares was determined&#13;to be $86,030 based on the quoted market price of $0.195 per share. The Company recorded the calculated loss on settlement of $11,030&#13;to the statement of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;March 30, 2011, the Company issued &lt;/font&gt;2,048,578 shares of its restricted common stock pursuant to an exchange agreement to&#13;settle $233,333 of the 2010 Notes. At the time of issuance the fair value of the shares was determined to be $450,687 based on&#13;the quoted market price of $0.22 per share. The discounted carrying amount of the 2010 Note as of March 30, 2011 was $77,421. The&#13;Company recorded the difference between the fair value and accreted amount of $373,266 as loss on settlement of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 5, 2011, the Company issued &lt;/font&gt;500,000 shares of its restricted common stock pursuant to a consulting agreement. At the&#13;time of issuance the fair value of the shares was determined to be $125,000 based on the quoted market price of $0.25 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 25, 2011, the Company issued &lt;/font&gt;350,000 shares of its restricted common stock pursuant to a consulting agreement. At&#13;the time of issuance the fair value of the shares was determined to be $87,500 based on the quoted market price of $0.25 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 25, 2011, the Company issued 366,783 shares of its restricted common stock pursuant to debt settlement agreements to settle&#13;$84,315 of outstanding trade payables. &lt;/font&gt;At the time of issuance the fair value of the shares was determined to be $91,696&#13;based on the quoted market price of $0.25 per share. The Company recorded $7,381 as loss on settlement of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 25, 2011, the Company issued 20,000 shares of its restricted common stock pursuant to a debt settlement agreement to settle&#13;$4,575 of outstanding trade payables. &lt;/font&gt;At the time of agreement the fair value of the shares was determined to be $6,800&#13;based on the quoted market price of $0.34 per share. The Company recorded $2,225 as loss on settlement of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 25, 2011, the Company issued 108,696 shares of its restricted common stock to related parties, pursuant to a debt settlement&#13;agreement to settle $25,000 of its outstanding accounts payables. At the time of issuance the fair value of the shares was determined&#13;to be $27,174 based on the quoted market price of $0.25 per share. The Company recorded the calculated loss on settlement of $2,174&#13;to the statement of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In April 2011, the Company received subscription&#13;proceeds of $90,000 and issued 600,001 shares of common stock in a private placement. The subscribers to the subscription proceeds&#13;have agreed to purchase one unit for each $3.00 of subscription proceeds. Each unit consists of 20 share of Company&amp;#146;s common&#13;stock and 6 warrants each exercisable at $0.25, which expire in two years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;June 1, 2011, &lt;/font&gt;586,858 shares of &lt;font style="letter-spacing: -0.1pt"&gt;the Company&amp;#146;s &lt;/font&gt;restricted common stock&#13;was returned to treasury due to an adjustment to the final settlement of the $233,333 2010 Notes. The return of the shares resulted&#13;in a $134,977 reduction to the previously calculated loss on debt settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On July 7, 2011, the Company received&#13;subscription proceeds of $65,000 and issued 325,000 shares of common stock in a private placement. The subscribers purchased one&#13;unit for each $2.00 of subscription proceeds. Each unit consists of 10 shares of Company&amp;#146;s common stock and 6 warrants each&#13;exercisable at $0.25, which expire in two years. The fair value of these warrants was determined to be $33,600.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On August 19, 2011, the Company received&#13;subscription proceeds of $45,000 and issued 225,000 shares of common stock in a private placement. The subscribers purchased one&#13;unit for each $2.00 of subscription proceeds. Each unit consists of 10 shares of Company&amp;#146;s common stock and 6 warrants each&#13;exercisable at $0.25, which expire in two years. The fair value of these warrants was determined to be $23,400.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Stock Compensation Plan&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On October 14, 2009, the Company adopted&#13;the 2009 Stock Incentive Plan (the &amp;#147;2009 Plan&amp;#148;) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows&#13;for the issuance of up to 10,000,000 common shares. &lt;font style="letter-spacing: -0.1pt"&gt;Options granted under the Plan shall be&#13;at prices and for terms as determined by the Board of Directors.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 30, 2012, the Company granted 250,000 stock options to management at an exercise price of $0.18 per share, vesting monthly&#13;over a thirty six month period. The aggregate fair value of the new grant was estimated at $45,000, or $0.18 per option, using&#13;the Black-Scholes option pricing model with weighted average assumptions as follows: a risk free interest rate of 1.95%, a dividend&#13;yield of 0%, an expected volatility of 199%, and an expected life of 10 years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;May 8, 2012, the Company granted 250,000 stock options to a consultant at an exercise price of $0.17 per share, vesting monthly&#13;over a twelve month period. The aggregate fair value of the new grant was estimated at $40,000, or $0.16 per option, using the&#13;Black-Scholes option pricing model with weighted average assumptions as follows: a risk free interest rate of 1.71%, a dividend&#13;yield of 0%, an expected volatility of 199%, and an expected life of 10 years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;The&#13;expensed portion of the value of the vesting options during the nine months ended September 30, 2012 was $205,516 (September 30,&#13;2011 - $369,116) which was recorded as stock based consulting and management fees. During the periods, stock-based consulting and&#13;management fees also includes share and warrant based compensation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&lt;b&gt;Share&#13;purchase options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;A&#13;summary of the Company&amp;#146;s stock options as of September 30, 2012 and changes during the period is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 47%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Options&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;6,278,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;6.85&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.15pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 500,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 19.9pt; padding-left: 5.4pt; text-align: right"&gt;0.18&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Cancelled&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, September 30, 2012&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;6,778,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;6.61&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;At&#13;September 30, 2012, the intrinsic value of the vested options was equal to $nil (September 30, 2011 - $nil).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;A&#13;summary of the status of the Company&amp;#146;s unvested options as of September 30, 2012 is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Grant-Date&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Unvested, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;1,037,709&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Granted&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;500,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;0.17&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Vested&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;(843,676)&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;0.18&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Cancelled&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Unvested, September 30, 2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;694,033&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="background-color: yellow"&gt;&lt;u&gt;&amp;#160;&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Share Purchase Warrants&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;February 24, 2011, the Company issued 2,369,388 share purchase warrants to acquire an equivalent number of common shares of the&#13;Company, at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants&#13;were issued pursuant to a securities purchase agreement (Note 5). The fair value of these warrants of $483,355 was recognized under&#13;derivative liabilities, using the Binomial option pricing model with an expected life of 5 years, a risk free interest rate of&#13;2.06%, a dividend yield of 0%, and an expected volatility of 199%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;March 21, 2011, the Company issued 250,000 share purchase warrants to acquire an equivalent number of common shares of the Company,&#13;at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued&#13;pursuant to a debt settlement agreement (Note 5). The fair value of these warrants of $43,750 was recognized under derivative liabilities,&#13;using the Binomial option pricing model with an expected life of 5 years, a risk free interest rate of 0.77%, a dividend yield&#13;of 0%, and an expected volatility of 199%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 4, 2011, the Company issued 1,000,000 share purchase warrants to acquire an equivalent number of common shares of the Company,&#13;at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued&#13;pursuant to a debt settlement agreement (Note 5). The fair value of these warrants was determined to be $349,000, using the Black-Scholes&#13;option pricing model with an expected life of 5 years, a risk free interest rate of 2.20%, a dividend yield of 0%, and an expected&#13;volatility of 252%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;April 25, 2011, the Company issued 180,000 share purchase warrants to acquire an equivalent number of common shares of the Company,&#13;at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued&#13;pursuant to the private placement of $90,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;On&#13;June 6, 2011, the Company issued 60,000 share purchase warrants to acquire an equivalent number of common shares of the Company,&#13;at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued&#13;pursuant to a securities purchase agreement (Note 5). The fair value of these warrants was determined to be $10,146, using the&#13;Black-Scholes option pricing model with an expected life of 5 years, a risk free interest rate of 1.60%, a dividend yield of 0%,&#13;and an expected volatility of 254%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;March, 2012, the Company issued 366,668 share purchase warrants to acquire an equivalent number of common shares of the Company,&#13;at an exercise price of $0.40 per share for an exercise period of up to two years from the issuance date. The warrants were issued&#13;pursuant to the private placement of $110,000 and included within equity. The fair value of these warrants was determined to be&#13;$5,133, using the Black-Scholes option pricing model with an expected life of 2 years, a risk free interest rate of 0.37%, a dividend&#13;yield of 0%, and an expected volatility of 63%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In&#13;April, 2012, the Company issued 1,150,000 share purchase warrants to acquire an equivalent number of common shares of the Company,&#13;at an exercise price of $0.40 per share for an exercise period of up to two years from the issuance date. The warrants were issued&#13;pursuant to a private placement and included within equity. The fair value of these warrants was determined to be $123,000, using&#13;the Black-Scholes option pricing model with an expected life of 2 years, a risk free interest rate of 0.27%, a dividend yield of&#13;0%, and an expected volatility of 146.6%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;A&#13;summary of the Company&amp;#146;s share purchase warrants as of September 30, 2012 and changes during the period is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;12,106,355&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.56&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;2.81&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,516,668&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;0.40&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;1.80&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Extinguished or expired&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(714,400)&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;2.33&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, September 30, 2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;12,908,623&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.43&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;1.86&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock>
    <tpiv:SummaryOfCompanysStockOptionsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 47%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Options&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;6,278,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;6.85&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.15pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 500,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 19.9pt; padding-left: 5.4pt; text-align: right"&gt;0.18&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Cancelled&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, September 30, 2012&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;6,778,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;6.61&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:SummaryOfCompanysStockOptionsTableTextBlock>
    <tpiv:SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Grant-Date&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Unvested, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;1,037,709&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Granted&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;500,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;0.17&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Vested&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;(843,676)&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;0.18&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Cancelled&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Unvested, September 30, 2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;694,033&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.18&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock>
    <tpiv:SummaryOfCompanysSharePurchaseWarrantsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, December 31, 2011&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;12,106,355&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.56&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;2.81&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,516,668&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;0.40&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;1.80&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160; Extinguished or expired&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(714,400)&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;2.33&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold"&gt;Balance, September 30, 2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;12,908,623&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; 0.43&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;1.86&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:SummaryOfCompanysSharePurchaseWarrantsTableTextBlock>
    <tpiv:CommonStockShares contextRef="AsOf2012-09-30" unitRef="USD" decimals="0">150000000</tpiv:CommonStockShares>
    <tpiv:CommonStockSharesParValue contextRef="AsOf2012-09-30" unitRef="USDPShares" decimals="INF">0.001</tpiv:CommonStockSharesParValue>
    <tpiv:NonvotingPreferredShares contextRef="AsOf2012-09-30" unitRef="Shares" decimals="INF">5000000</tpiv:NonvotingPreferredShares>
    <tpiv:NonvotingPreferredSharesParValue contextRef="AsOf2012-09-30" unitRef="USDPShares" decimals="INF">0.001</tpiv:NonvotingPreferredSharesParValue>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;u&gt;Note 10:&amp;#9;Supplemental&#13;Cash Flow Information AND NON-CASH INVESTING AND FINANCING ACTIVITIES &lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Nine Months Ended&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;September 30, 2012&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Shares/warrants&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Shares issued pursuant to debt settlement agreements&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,126,447&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;$326,937&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Common shares issued pursuant to consulting service arrangements&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;14,535,179&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$1,998,000&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Nine Months Ended&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;September 30, 2011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Shares/warrants&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Accounts payable settled by issuing common shares&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;4,214,766&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 815,527&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Common shares issued pursuant to consulting service arrangements&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,327,059&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$500,527&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 47%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 6%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 4%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;Pursuant to the 2010 Note settlement and&#13;warrant extinguishment agreements entered during the nine months ended September 30, 2011, the Company issued February 2011 Notes&#13;in the amount of $240,000 (Note 5).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;See Notes 5 and 9 for additional disclosure&#13;on non-cash transactions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td rowspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;Nine Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Interest paid in cash&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income taxes paid&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <tpiv:CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Nine Months Ended&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;September 30, 2012&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Shares/warrants&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Shares issued pursuant to debt settlement agreements&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,126,447&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;$326,937&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Common shares issued pursuant to consulting service arrangements&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;14,535,179&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$1,998,000&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;Nine Months Ended&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;September 30, 2011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Shares/warrants&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Accounts payable settled by issuing common shares&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;4,214,766&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 815,527&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Common shares issued pursuant to consulting service arrangements&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,327,059&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$500,527&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 47%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 6%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 4%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock>
    <tpiv:AdditionalDisclosureOnNoncashTransactionsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td rowspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;Nine Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Interest paid in cash&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income taxes paid&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160; -&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:AdditionalDisclosureOnNoncashTransactionsTableTextBlock>
    <tpiv:NotesInAmount contextRef="AsOf2011-02-28" unitRef="USD" decimals="0">240000</tpiv:NotesInAmount>
    <tpiv:InterestPaidInCash contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <tpiv:InterestPaidInCash contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2012-01-01to2012-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="From2011-01-01to2011-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;u&gt;Note 11:&amp;#9;ContingencIES&#13;AND COMMITMENTs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Contingencies&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Tax Filings&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;The&#13;Company has not filed income tax returns for several years in certain operating jurisdictions, and may be subject to possible compliance&#13;penalties and interest. Management is currently not able to make a reliably measurable provision for possible liability for penalties&#13;and interest, if any, at this time, and the Company may be liable for such amounts upon assessment. Penalties and interest, if&#13;assessed in the future, will be recorded in the period such amounts are determinable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Commitments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Combined Research and&#13;Operating Obligations&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;Effective&#13;May 25, 2010, the Company entered into a research and license Option Agreement with the Mayo Clinic for the development and possible&#13;commercial use of a cancer vaccine. Subject to the approval and guidance of the United States Food and Drug Administration (&amp;#147;FDA&amp;#148;)&#13;the Mayo Clinic plans to conduct a Phase I human clinical trial (&amp;#147;Phase I Trial&amp;#148;) to test and develop the Company&amp;#146;s&#13;technology. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;The&#13;Company has agreed that, during the period of the option and upon approval of FDA to conduct Phase I Trials, will pay all the costs&#13;incurred by the Mayo Clinic, not to exceed a total of $841,000. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;On April 13, 2012, the Company entered&#13;into a Patent &amp;#38; Know-How agreement with the Mayo Foundation for Education and Research (&amp;#147;Mayo&amp;#148;) to license a proprietary&#13;MHC Class I HER2/neu antigen technology. Under the terms of the agreement, the Company acquired from Mayo (i) an exclusive worldwide&#13;license to use the patent rights related to patent application numbered 61600480 (titled &amp;#147;Methods and materials for generating&#13;CD8+ T-cells having the ability to recognize cancer cells expressing a Her2/neu polypeptide&amp;#148;) to make products in the prophylactic&#13;and therapeutic field (the &amp;#147;Licensed Products&amp;#148;) and (ii) a non-exclusive license to use certain of Mayo&amp;#146;s know-how&#13;to make the Licensed Products. The Company may sublicense the technology with the approval of Mayo, which approval may not unreasonably&#13;withheld.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;In connection with the grant of the licenses,&#13;the Company is to (i) make an upfront license payment of $100,000 to Mayo followed by an additional $150,000 in license payments&#13;over a 12 month period, (ii) reimburse Mayo for documented patent expenses incurred to date by Mayo in connection with the license,&#13;(iii) pay an annual license fees, (iv) make milestone payments and (iv) pay royalties of gross annual sales. In addition, the Company&#13;is required to pay Mayo a fee if it fails to initiate a Phase I clinical trial of a Licensed Product within five years and if it&#13;fails to initiate a Phase II clinical trial of a Licensed Product within eight years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Management Services Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In February&#13;2011, the Company approved an employment agreement with Dr. Wilson with an initial term of 2 years, which may be automatically&#13;extended for successive one-year terms. This employment agreement provides for annual compensation of $180,000 and the grant of&#13;an option to acquire 2,000,000 shares of the Company&amp;#146;s common stock at $0.19 per share, 50% of which vested on March 16,&#13;2011, while the remainder will vest monthly over a period of two years (41,667 per month). The options shall be exercisable for&#13;at least five years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Consultant Agreements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In April&#13;2012, the Company entered into an investors&amp;#146; relation consulting agreement for a one year term, with a one-time right to&#13;terminate the agreement at its six month anniversary. The consulting agreement provides for the Company to issue 620,690 shares&#13;to the consultant and a monthly payment of $7,500.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In April&#13;2012, the Company entered into financial consulting service agreements, which included compensation of 14,000,000 shares of common&#13;stock, whereby the Company agreed to issue additional shares to the consultants to restore their holdings to 24.8% of fully diluted&#13;capitalization of the Company if the Company completes a re-organization, re-capitalization or a liquidity event during the eighteen&#13;months commencing with the signing of these agreements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;u&gt;Rental Lease Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;In December&#13;2011, the Company entered into a lease agreement, which started in January 2012 for a two year period. The Company will pay a monthly&#13;basic rent of $7,152 and additional rent for operating costs of 2.20% of total operating expenses of the property.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;The Company&#13;has obligations under various agreements through December 31, 2014. The aggregate minimum annual payments for the years ending&#13;December 31 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.1pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; R&amp;#38;D&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Administrative&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 65pt; font-weight: bold; text-align: center; text-indent: -7.9pt"&gt;Commitments&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; font-weight: bold"&gt;Commitments&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-indent: -8.3pt; text-align: right"&gt;&amp;#160;$ 1,052,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160; 195,821&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;2013&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 37,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 308,313&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;2014&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 22,284&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,090,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-left: 1in; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 526,418&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <tpiv:AggregateMinimumAnnualPaymentsTableTextBlock contextRef="From2012-01-01to2012-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; R&amp;#38;D&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Administrative&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 65pt; font-weight: bold; text-align: center; text-indent: -7.9pt"&gt;Commitments&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; font-weight: bold"&gt;Commitments&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-indent: -8.3pt"&gt;&amp;#160;$ 1,052,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160; 195,821&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;2013&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 37,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 308,313&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;2014&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 22,284&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 1,090,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-left: 1in"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 526,418&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:AggregateMinimumAnnualPaymentsTableTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2012-01-01to2012-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;u&gt;Note 12:&amp;#9;SUBSEQUENT&#13;EVENTS&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 15, 2012, the Company entered into&#13;an agreement to issue a note to an investor for $340,000. The Company received $300,000 for the note which carried $30,000 of original&#13;issue discount and $10,000 in legal fees. The note is due on October 15, 2013 and carries an interest rate of 8%. There are seven&#13;installment payments due on the note beginning on the seventh month after its issuance of the note and each month thereafter until&#13;maturity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The lender has the right, at any time after&#13;issuance, at its election, to convert all or part of the outstanding and unpaid principal sum and accrued interest into fully paid&#13;and non-assessable shares of the Company&amp;#146;s common stock at $0.12 per share. If the Company issues shares (or reduces the&#13;conversion or exercise price for outstanding debt or warrants) for less than $0.12, then the conversion price for the note shall&#13;be reduced to that new issuance price. If the holder of the note converts the full amount of the note (excluding any interest that&#13;becomes due thereon), it shall receive 2,833,333 shares of the Company&amp;#146;s common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Provided that there is sufficient volume in&#13;the trading of the Company&amp;#146;s common stock and other criteria are met, the Company may elect to make any payment due on an&#13;installment date in shares of common stock. If the Company elects to make a payment in shares of common stock, the number of shares&#13;that the Company issues will be equal to the amount to be converted divided by the lesser of the conversion price or 70% of the&#13;average of the three lowest closing bid prices of the shares of common stock during the prior twenty consecutive trading days.&#13;If the Company elects to pay the full amount of the note in common shares (excluding any interest that becomes due thereon), the&#13;holder shall receive at a minimum 2,833,333 shares of the Company&amp;#146;s common stock, but this amount could be substantially&#13;higher. Unless otherwise agreed in writing by both parties, at no time will the holder convert any amount of the debenture into&#13;common stock that would result in the holder owning more than 4.99% of the common stock outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of the agreement, the Company also&#13;issued 3,000,000 warrants to the note holder exercisable at $0.25/share expiring on October 31, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The warrants include price adjustment provisions whereby&#13;the exercise price will be adjusted downwards based on future grants, which results in a share issuance at a per share amount&#13;less than $0.25 per share, or repricing of any existing warrants to a lower price.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <tpiv:NoteToInvestor contextRef="AsOf2012-10-15" unitRef="USD" decimals="0">340000</tpiv:NoteToInvestor>
    <tpiv:LegalFee contextRef="AsOf2012-10-15" unitRef="USD" decimals="0">10000</tpiv:LegalFee>
    <tpiv:ReceivedForNotes contextRef="AsOf2012-10-15" unitRef="USD" decimals="0">300000</tpiv:ReceivedForNotes>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>tpiv-20120930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.3e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: tapimmune_10q.xfr; Date: 2012/11/19T20:29:54 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +agpw7xRiXgOn8uAanhMSaqNibPtz59z+elBuWJ9HYl6/ycjK6ltNCjaz3GGcTEN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:tpiv="http://tapimmune.com/20120930" elementFormDefault="qualified" targetNamespace="http://tapimmune.com/20120930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://tapimmune.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>0001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/NatureOfOperations" id="NatureOfOperations">
	  <link:definition>0006 - Disclosure - NATURE OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod" id="UnauditedConsolidatedFinancialStatementsForInterimPeriod">
	  <link:definition>0007 - Disclosure - UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ResearchAgreements" id="ResearchAgreements">
	  <link:definition>0008 - Disclosure - RESEARCH AGREEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue" id="DerivativeWarrantLiabilityAndFairValue">
	  <link:definition>0009 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
	  <link:definition>0010 - Disclosure - CONVERTIBLE NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/LoansPayable" id="LoansPayable">
	  <link:definition>0011 - Disclosure - LOANS PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/PromissoryNote" id="PromissoryNote">
	  <link:definition>0012 - Disclosure - PROMISSORY NOTE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>0013 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/CapitalStock" id="CapitalStock">
	  <link:definition>0014 - Disclosure - CAPITAL STOCK</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" id="SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities">
	  <link:definition>0015 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ContingenciesAndCommitments" id="ContingenciesAndCommitments">
	  <link:definition>0016 - Disclosure - CONTINGENCIES AND COMMITMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>0017 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables" id="DerivativeWarrantLiabilityAndFairValueTables">
	  <link:definition>0018 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ConvertibleNotesPayableTables" id="ConvertibleNotesPayableTables">
	  <link:definition>0019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/CapitalStockTables" id="CapitalStockTables">
	  <link:definition>0020 - Disclosure - CAPITAL STOCK (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" id="SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables">
	  <link:definition>0021 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ContingenciesAndCommitmentsTables" id="ContingenciesAndCommitmentsTables">
	  <link:definition>0022 - Disclosure - CONTINGENCIES AND COMMITMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/NatureOfOperationsDetailsNarrative" id="NatureOfOperationsDetailsNarrative">
	  <link:definition>0023 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ResearchAgreementsDetailsNarrative" id="ResearchAgreementsDetailsNarrative">
	  <link:definition>0024 - Disclosure - RESEARCH AGREEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
	  <link:definition>0025 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/LoansPayableDetailsNarrative" id="LoansPayableDetailsNarrative">
	  <link:definition>0026 - Disclosure - LOANS PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/PromissoryNoteDetailsNarrative" id="PromissoryNoteDetailsNarrative">
	  <link:definition>0027 - Disclosure - PROMISSORY NOTE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>0028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
	  <link:definition>0029 - Disclosure - CAPITAL STOCK (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" id="SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails">
	  <link:definition>0030 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES - Additional disclosure on non-cash transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" id="SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative">
	  <link:definition>0031 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tapimmune.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>0032 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20120930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20120930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20120930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20120930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="tpiv_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DeferredFinancingCostsNote5" name="DeferredFinancingCostsNote5" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DerivativeLiabilityConversionOptionNote4" name="DerivativeLiabilityConversionOptionNote4" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_SharesAndWarrantsToBeIssued" name="SharesAndWarrantsToBeIssued" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ConsultingFees" name="ConsultingFees" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ConsultingFeesStockbasedNote9" name="ConsultingFeesStockbasedNote9" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_InterestAndFinanceChargesNote4" name="InterestAndFinanceChargesNote4" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ManagementFeesStockbasedNotes8And9" name="ManagementFeesStockbasedNotes8And9" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ResearchAndDevelopmentStockbased" name="ResearchAndDevelopmentStockbased" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_TotalExpenses" name="TotalExpenses" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NetLossBeforeOtherItems" name="NetLossBeforeOtherItems" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ForeignExchangeLossGain" name="ForeignExchangeLossGain" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_GainLossOnSettlementOfDebtNote9" name="GainLossOnSettlementOfDebtNote9" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" name="GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NetLossForPeriod" name="NetLossForPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_BasicAndDilutedNetLossPerShare" name="BasicAndDilutedNetLossPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_AdjustmentDepreciation" name="AdjustmentDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ProceedsFromPromissoryNotes" name="ProceedsFromPromissoryNotes" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable" name="ProceedsFromShortTermBankLoansAndNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" name="UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock" name="DerivativeWarrantLiabilityAndFairValueTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_LoansPayablesTextBlock" name="LoansPayablesTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_PromissoryNoteTextBlock" name="PromissoryNoteTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_SharePurchaseWarrantsTableTextBlock" name="SharePurchaseWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ConversionOptionTableTextBlock" name="ConversionOptionTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DerivativeLiabilityTableTextBlock" name="DerivativeLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DerivativeLiabilityWarrantsTableTextBlock" name="DerivativeLiabilityWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_FinancialAssetsAndLiabilitiesTableTextBlock" name="FinancialAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_InstrumentTransactionsTableTextBlock" name="InstrumentTransactionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_SummaryOfCompanysStockOptionsTableTextBlock" name="SummaryOfCompanysStockOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" name="SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock" name="SummaryOfCompanysSharePurchaseWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" name="CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock" name="AdditionalDisclosureOnNoncashTransactionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_AggregateMinimumAnnualPaymentsTableTextBlock" name="AggregateMinimumAnnualPaymentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_WorkingCapitalDeficiency" name="WorkingCapitalDeficiency" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_RequiredToMakeCertainPayments" name="RequiredToMakeCertainPayments" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_CrucellUnderThisAgreement" name="CrucellUnderThisAgreement" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_OutstandingBalanceRequiring" name="OutstandingBalanceRequiring" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_AmendedAgreementAccrued" name="AmendedAgreementAccrued" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_AggregatePrincipalAmount" name="AggregatePrincipalAmount" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_CashProceedsAndAccruedInterest" name="CashProceedsAndAccruedInterest" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_OutstandingAndDemandable" name="OutstandingAndDemandable" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_CommonStockConversionRatePerShare" name="CommonStockConversionRatePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NotesBearInterestRatePerAnnum" name="NotesBearInterestRatePerAnnum" nillable="true" xbrli:periodType="instant" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_FindersFee" name="FindersFee" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DeferredFinancingCosts" name="DeferredFinancingCosts" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_WarrantsExercisable" name="WarrantsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_FairValueOfWarrants" name="FairValueOfWarrants" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DerivativeLiabilitiesAndDebt" name="DerivativeLiabilitiesAndDebt" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DebtDiscount" name="DebtDiscount" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_UnsecuredLoanAdvances" name="UnsecuredLoanAdvances" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_AmountForFutureLegalServices" name="AmountForFutureLegalServices" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_PrepaidExpensesAndDeposit" name="PrepaidExpensesAndDeposit" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ConversionPricePerShares" name="ConversionPricePerShares" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_SharesIssuedToHolderOfNote" name="SharesIssuedToHolderOfNote" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_PromissoryNotesAmount" name="PromissoryNotesAmount" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector" name="PromissoryNotesAmountIssuedToOfficerAndDirector" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ManagementFees" name="ManagementFees" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ResearchAndDevelopmentServices" name="ResearchAndDevelopmentServices" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_StockBasedCompensation" name="StockBasedCompensation" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_DebtDueToRelatedParties" name="DebtDueToRelatedParties" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_PromissoryNotesToOfficerAndDirector" name="PromissoryNotesToOfficerAndDirector" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_AmountsOwingToDirectorsAndOfficer" name="AmountsOwingToDirectorsAndOfficer" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_CommonStockShares" name="CommonStockShares" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_CommonStockSharesParValue" name="CommonStockSharesParValue" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NonvotingPreferredShares" name="NonvotingPreferredShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NonvotingPreferredSharesParValue" name="NonvotingPreferredSharesParValue" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_InterestPaidInCash" name="InterestPaidInCash" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NotesInAmount" name="NotesInAmount" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_NoteToInvestor" name="NoteToInvestor" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_ReceivedForNotes" name="ReceivedForNotes" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tpiv_LegalFee" name="LegalFee" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>tpiv-20120930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.3e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: tapimmune_10q.xfr; Date: 2012/11/19T20:29:54 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tapimmune.com/role/DocumentAndEntityInformation" xlink:href="tpiv-20120930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheets" xlink:href="tpiv-20120930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="tpiv-20120930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfOperations" xlink:href="tpiv-20120930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tpiv-20120930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/NatureOfOperations" xlink:href="tpiv-20120930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:href="tpiv-20120930.xsd#UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ResearchAgreements" xlink:href="tpiv-20120930.xsd#ResearchAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue" xlink:href="tpiv-20120930.xsd#DerivativeWarrantLiabilityAndFairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayable" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/LoansPayable" xlink:href="tpiv-20120930.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/PromissoryNote" xlink:href="tpiv-20120930.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/RelatedPartyTransactions" xlink:href="tpiv-20120930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStock" xlink:href="tpiv-20120930.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ContingenciesAndCommitments" xlink:href="tpiv-20120930.xsd#ContingenciesAndCommitments" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SubsequentEvents" xlink:href="tpiv-20120930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables" xlink:href="tpiv-20120930.xsd#DerivativeWarrantLiabilityAndFairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayableTables" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStockTables" xlink:href="tpiv-20120930.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ContingenciesAndCommitmentsTables" xlink:href="tpiv-20120930.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/NatureOfOperationsDetailsNarrative" xlink:href="tpiv-20120930.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ResearchAgreementsDetailsNarrative" xlink:href="tpiv-20120930.xsd#ResearchAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/LoansPayableDetailsNarrative" xlink:href="tpiv-20120930.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/PromissoryNoteDetailsNarrative" xlink:href="tpiv-20120930.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tpiv-20120930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStockDetailsNarrative" xlink:href="tpiv-20120930.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SubsequentEventsDetailsNarrative" xlink:href="tpiv-20120930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedBalanceSheets" xlink:title="0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedStatementsOfOperations" xlink:title="0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_tpivNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_tpivNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AdjustmentDepreciation" xlink:label="loc_tpivAdjustmentDepreciation" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivAdjustmentDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_tpivGainsLossesOnRestructuringOfDebt" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivGainsLossesOnRestructuringOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="loc_tpivIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfDebtInvestments" xlink:label="loc_tpivGainLossOnSaleOfDebtInvestments" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivGainLossOnSaleOfDebtInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_tpivGainLossOnSaleOfDerivatives" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivGainLossOnSaleOfDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_tpivGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_tpivOtherNoncashExpense" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_tpivShareBasedCompensation" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="loc_tpivIncreaseDecreaseInContractReceivablesNet" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivIncreaseDecreaseInContractReceivablesNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_tpivIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="1100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_tpivIncreaseDecreaseInDeferredCharges" />
      <link:calculationArc order="1200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivIncreaseDecreaseInDeferredCharges" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_tpivIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="1300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_tpivIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:calculationArc order="1400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tpivIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_tpivNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_tpivProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_tpivProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_tpivProceedsFromConvertibleDebt" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_tpivProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_tpivProceedsFromShortTermDebt" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_tpivProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ProceedsFromShortTermBankLoansAndNotesPayable" xlink:label="loc_tpivProceedsFromShortTermBankLoansAndNotesPayable" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_tpivProceedsFromShortTermBankLoansAndNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_tpivProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_tpivProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_tpivProceedsFromPaymentsForOtherFinancingActivities" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_tpivProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_tpivNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_tpivPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_tpivPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_tpivCashAcquiredFromAcquisition" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_tpivCashAcquiredFromAcquisition" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_tpivCashPeriodIncreaseDecrease" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivCashPeriodIncreaseDecrease" xlink:to="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivCashPeriodIncreaseDecrease" xlink:to="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tpivCashPeriodIncreaseDecrease" xlink:to="loc_tpivNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/NatureOfOperations" xlink:title="0006 - Disclosure - NATURE OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:title="0007 - Disclosure - UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ResearchAgreements" xlink:title="0008 - Disclosure - RESEARCH AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue" xlink:title="0009 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayable" xlink:title="0010 - Disclosure - CONVERTIBLE NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/LoansPayable" xlink:title="0011 - Disclosure - LOANS PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/PromissoryNote" xlink:title="0012 - Disclosure - PROMISSORY NOTE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/RelatedPartyTransactions" xlink:title="0013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStock" xlink:title="0014 - Disclosure - CAPITAL STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:title="0015 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ContingenciesAndCommitments" xlink:title="0016 - Disclosure - CONTINGENCIES AND COMMITMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SubsequentEvents" xlink:title="0017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables" xlink:title="0018 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayableTables" xlink:title="0019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStockTables" xlink:title="0020 - Disclosure - CAPITAL STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:title="0021 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ContingenciesAndCommitmentsTables" xlink:title="0022 - Disclosure - CONTINGENCIES AND COMMITMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/NatureOfOperationsDetailsNarrative" xlink:title="0023 - Disclosure - NATURE OF OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ResearchAgreementsDetailsNarrative" xlink:title="0024 - Disclosure - RESEARCH AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="0025 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/LoansPayableDetailsNarrative" xlink:title="0026 - Disclosure - LOANS PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/PromissoryNoteDetailsNarrative" xlink:title="0027 - Disclosure - PROMISSORY NOTE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="0028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStockDetailsNarrative" xlink:title="0029 - Disclosure - CAPITAL STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:title="0030 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES - Additional disclosure on non-cash transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:title="0031 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SubsequentEventsDetailsNarrative" xlink:title="0032 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>tpiv-20120930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.3e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: tapimmune_10q.xfr; Date: 2012/11/19T20:29:54 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tapimmune.com/role/DocumentAndEntityInformation" xlink:href="tpiv-20120930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheets" xlink:href="tpiv-20120930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="tpiv-20120930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfOperations" xlink:href="tpiv-20120930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tpiv-20120930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/NatureOfOperations" xlink:href="tpiv-20120930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:href="tpiv-20120930.xsd#UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ResearchAgreements" xlink:href="tpiv-20120930.xsd#ResearchAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue" xlink:href="tpiv-20120930.xsd#DerivativeWarrantLiabilityAndFairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayable" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/LoansPayable" xlink:href="tpiv-20120930.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/PromissoryNote" xlink:href="tpiv-20120930.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/RelatedPartyTransactions" xlink:href="tpiv-20120930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStock" xlink:href="tpiv-20120930.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ContingenciesAndCommitments" xlink:href="tpiv-20120930.xsd#ContingenciesAndCommitments" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SubsequentEvents" xlink:href="tpiv-20120930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables" xlink:href="tpiv-20120930.xsd#DerivativeWarrantLiabilityAndFairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayableTables" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStockTables" xlink:href="tpiv-20120930.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ContingenciesAndCommitmentsTables" xlink:href="tpiv-20120930.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/NatureOfOperationsDetailsNarrative" xlink:href="tpiv-20120930.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ResearchAgreementsDetailsNarrative" xlink:href="tpiv-20120930.xsd#ResearchAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/LoansPayableDetailsNarrative" xlink:href="tpiv-20120930.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/PromissoryNoteDetailsNarrative" xlink:href="tpiv-20120930.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tpiv-20120930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStockDetailsNarrative" xlink:href="tpiv-20120930.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SubsequentEventsDetailsNarrative" xlink:href="tpiv-20120930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedBalanceSheets" xlink:title="0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedStatementsOfOperations" xlink:title="0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/NatureOfOperations" xlink:title="0006 - Disclosure - NATURE OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:title="0007 - Disclosure - UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ResearchAgreements" xlink:title="0008 - Disclosure - RESEARCH AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue" xlink:title="0009 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayable" xlink:title="0010 - Disclosure - CONVERTIBLE NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/LoansPayable" xlink:title="0011 - Disclosure - LOANS PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/PromissoryNote" xlink:title="0012 - Disclosure - PROMISSORY NOTE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/RelatedPartyTransactions" xlink:title="0013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStock" xlink:title="0014 - Disclosure - CAPITAL STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:title="0015 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ContingenciesAndCommitments" xlink:title="0016 - Disclosure - CONTINGENCIES AND COMMITMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SubsequentEvents" xlink:title="0017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables" xlink:title="0018 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayableTables" xlink:title="0019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStockTables" xlink:title="0020 - Disclosure - CAPITAL STOCK (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:title="0021 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ContingenciesAndCommitmentsTables" xlink:title="0022 - Disclosure - CONTINGENCIES AND COMMITMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/NatureOfOperationsDetailsNarrative" xlink:title="0023 - Disclosure - NATURE OF OPERATIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ResearchAgreementsDetailsNarrative" xlink:title="0024 - Disclosure - RESEARCH AGREEMENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="0025 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/LoansPayableDetailsNarrative" xlink:title="0026 - Disclosure - LOANS PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/PromissoryNoteDetailsNarrative" xlink:title="0027 - Disclosure - PROMISSORY NOTE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="0028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStockDetailsNarrative" xlink:title="0029 - Disclosure - CAPITAL STOCK (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:title="0030 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES - Additional disclosure on non-cash transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:title="0031 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SubsequentEventsDetailsNarrative" xlink:title="0032 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>tpiv-20120930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.3e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: tapimmune_10q.xfr; Date: 2012/11/19T20:29:54 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DocumentAndEntityInformationAbstract" xlink:label="tpiv_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DocumentAndEntityInformationAbstract" xlink:to="tpiv_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentContractReceivable_lbl" xml:lang="en-US">Due from government agency</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and deposits (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US">Deferred financing costs (Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DeferredFinancingCostsNote5" xlink:label="tpiv_DeferredFinancingCostsNote5" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DeferredFinancingCostsNote5" xlink:to="tpiv_DeferredFinancingCostsNote5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tpiv_DeferredFinancingCostsNote5_lbl" xml:lang="en-US">Deferred financing costs (Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Research agreement obligations (Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability &#8211; warrants (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilityConversionOptionNote4" xlink:label="tpiv_DerivativeLiabilityConversionOptionNote4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DerivativeLiabilityConversionOptionNote4" xlink:to="tpiv_DerivativeLiabilityConversionOptionNote4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DerivativeLiabilityConversionOptionNote4_lbl" xml:lang="en-US">Derivative liability &#8211; conversion option (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable (Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Loans payable (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Promissory note (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Capital stock (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 150,000,000 shares authorized 73,861,754 shares issued and outstanding (2011 &#8211; 52,073,460)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SharesAndWarrantsToBeIssued" xlink:label="tpiv_SharesAndWarrantsToBeIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_SharesAndWarrantsToBeIssued" xlink:to="tpiv_SharesAndWarrantsToBeIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_SharesAndWarrantsToBeIssued_lbl" xml:lang="en-US">Shares and warrants to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="us-gaap_DeferredCompensationEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredCompensationEquity_lbl" xml:lang="en-US">Deferred compensation (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xml:lang="en-US">Deficit accumulated during the development stage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConsultingFees" xlink:label="tpiv_ConsultingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ConsultingFees" xlink:to="tpiv_ConsultingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ConsultingFees_lbl" xml:lang="en-US">Consulting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConsultingFeesStockbasedNote9" xlink:label="tpiv_ConsultingFeesStockbasedNote9" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ConsultingFeesStockbasedNote9" xlink:to="tpiv_ConsultingFeesStockbasedNote9_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ConsultingFeesStockbasedNote9_lbl" xml:lang="en-US">Consulting fees &#8211; stock-based (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_InterestAndFinanceChargesNote4" xlink:label="tpiv_InterestAndFinanceChargesNote4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_InterestAndFinanceChargesNote4" xlink:to="tpiv_InterestAndFinanceChargesNote4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_InterestAndFinanceChargesNote4_lbl" xml:lang="en-US">Interest and finance charges (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ServiceManagementCosts" xlink:label="us-gaap_ServiceManagementCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceManagementCosts" xlink:to="us-gaap_ServiceManagementCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceManagementCosts_lbl" xml:lang="en-US">Management fees (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ManagementFeesStockbasedNotes8And9" xlink:label="tpiv_ManagementFeesStockbasedNotes8And9" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ManagementFeesStockbasedNotes8And9" xlink:to="tpiv_ManagementFeesStockbasedNotes8And9_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ManagementFeesStockbasedNotes8And9_lbl" xml:lang="en-US">Management fees &#8211; stock-based (Notes 8 and 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ResearchAndDevelopmentStockbased" xlink:label="tpiv_ResearchAndDevelopmentStockbased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ResearchAndDevelopmentStockbased" xlink:to="tpiv_ResearchAndDevelopmentStockbased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ResearchAndDevelopmentStockbased_lbl" xml:lang="en-US">Research and development &#8211; stock-based</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_TotalExpenses" xlink:label="tpiv_TotalExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_TotalExpenses" xlink:to="tpiv_TotalExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="tpiv_TotalExpenses_lbl" xml:lang="en-US">Total Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NetLossBeforeOtherItems" xlink:label="tpiv_NetLossBeforeOtherItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NetLossBeforeOtherItems" xlink:to="tpiv_NetLossBeforeOtherItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="tpiv_NetLossBeforeOtherItems_lbl" xml:lang="en-US">Net Loss Before Other Items</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Items</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ForeignExchangeLossGain" xlink:label="tpiv_ForeignExchangeLossGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ForeignExchangeLossGain" xlink:to="tpiv_ForeignExchangeLossGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ForeignExchangeLossGain_lbl" xml:lang="en-US">Foreign exchange (loss) gain</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_lbl" xml:lang="en-US">Changes in fair value of derivative liabilities (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_lbl" xml:lang="en-US">Loss on debt financing</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_GainLossOnSettlementOfDebtNote9" xlink:label="tpiv_GainLossOnSettlementOfDebtNote9" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_GainLossOnSettlementOfDebtNote9" xlink:to="tpiv_GainLossOnSettlementOfDebtNote9_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_GainLossOnSettlementOfDebtNote9_lbl" xml:lang="en-US">Gain (loss) on settlement of debt (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" xlink:label="tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" xlink:to="tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4_lbl" xml:lang="en-US">Gain on extinguishment of derivative liabilities - warrants (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xml:lang="en-US">Loss on disposal of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NetLossForPeriod" xlink:label="tpiv_NetLossForPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NetLossForPeriod" xlink:to="tpiv_NetLossForPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="tpiv_NetLossForPeriod_lbl" xml:lang="en-US">Net Loss for the Period</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_BasicAndDilutedNetLossPerShare" xlink:label="tpiv_BasicAndDilutedNetLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_BasicAndDilutedNetLossPerShare" xlink:to="tpiv_BasicAndDilutedNetLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_BasicAndDilutedNetLossPerShare_lbl" xml:lang="en-US">Basic and Diluted Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AdjustmentDepreciation" xlink:label="tpiv_AdjustmentDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AdjustmentDepreciation" xlink:to="tpiv_AdjustmentDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tpiv_AdjustmentDepreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_2_lbl" xml:lang="en-US">Non-cash loss on debt financing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_2_lbl" xml:lang="en-US">Changes in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfDebtInvestments" xlink:label="us-gaap_GainLossOnSaleOfDebtInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDebtInvestments" xlink:to="us-gaap_GainLossOnSaleOfDebtInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDebtInvestments_lbl" xml:lang="en-US">Loss (gain) on settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Gain on extinguishment of derivative liabilities - warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest and financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:to="us-gaap_IncreaseDecreaseInContractReceivablesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet_lbl" xml:lang="en-US">Due from government agency</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Research agreement obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of shares, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Convertible notes, net</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ProceedsFromPromissoryNotes" xlink:label="tpiv_ProceedsFromPromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ProceedsFromPromissoryNotes" xlink:to="tpiv_ProceedsFromPromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ProceedsFromPromissoryNotes_lbl" xml:lang="en-US">Proceeds from promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds from loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ProceedsFromShortTermBankLoansAndNotesPayable" xlink:label="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable" xlink:to="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Notes and loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Advances from (to) related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Stock subscriptions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash acquired on reverse acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED by INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">INCREASE (DECREASE) IN CASH</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">CASH, BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">CASH, END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="tpiv_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NotesToFinancialStatementsAbstract" xlink:to="tpiv_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" xlink:label="tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" xlink:to="tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock_lbl" xml:lang="en-US">UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">RESEARCH AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock" xlink:label="tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock" xlink:to="tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock_lbl" xml:lang="en-US">DERIVATIVE WARRANT LIABILITY AND FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_LoansPayablesTextBlock" xlink:label="tpiv_LoansPayablesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_LoansPayablesTextBlock" xlink:to="tpiv_LoansPayablesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_LoansPayablesTextBlock_lbl" xml:lang="en-US">LOANS PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNoteTextBlock" xlink:label="tpiv_PromissoryNoteTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_PromissoryNoteTextBlock" xlink:to="tpiv_PromissoryNoteTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_PromissoryNoteTextBlock_lbl" xml:lang="en-US">PROMISSORY NOTE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BrokersAndDealersAbstract" xlink:label="us-gaap_BrokersAndDealersAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BrokersAndDealersAbstract" xlink:to="us-gaap_BrokersAndDealersAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BrokersAndDealersAbstract_lbl" xml:lang="en-US">Brokers and Dealers [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock" xlink:label="us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock" xlink:to="us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock_lbl" xml:lang="en-US">CAPITAL STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">CONTINGENCIES AND COMMITMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SharePurchaseWarrantsTableTextBlock" xlink:label="tpiv_SharePurchaseWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_SharePurchaseWarrantsTableTextBlock" xlink:to="tpiv_SharePurchaseWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_SharePurchaseWarrantsTableTextBlock_lbl" xml:lang="en-US">Share purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConversionOptionTableTextBlock" xlink:label="tpiv_ConversionOptionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ConversionOptionTableTextBlock" xlink:to="tpiv_ConversionOptionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ConversionOptionTableTextBlock_lbl" xml:lang="en-US">Conversion Option</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilityTableTextBlock" xlink:label="tpiv_DerivativeLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DerivativeLiabilityTableTextBlock" xlink:to="tpiv_DerivativeLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DerivativeLiabilityTableTextBlock_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilityWarrantsTableTextBlock" xlink:label="tpiv_DerivativeLiabilityWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DerivativeLiabilityWarrantsTableTextBlock" xlink:to="tpiv_DerivativeLiabilityWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DerivativeLiabilityWarrantsTableTextBlock_lbl" xml:lang="en-US">Derivative liability - warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_FinancialAssetsAndLiabilitiesTableTextBlock" xlink:label="tpiv_FinancialAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_FinancialAssetsAndLiabilitiesTableTextBlock" xlink:to="tpiv_FinancialAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_FinancialAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Financial assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_InstrumentTransactionsTableTextBlock" xlink:label="tpiv_InstrumentTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_InstrumentTransactionsTableTextBlock" xlink:to="tpiv_InstrumentTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_InstrumentTransactionsTableTextBlock_lbl" xml:lang="en-US">Instrument transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SummaryOfCompanysStockOptionsTableTextBlock" xlink:label="tpiv_SummaryOfCompanysStockOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_SummaryOfCompanysStockOptionsTableTextBlock" xlink:to="tpiv_SummaryOfCompanysStockOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_SummaryOfCompanysStockOptionsTableTextBlock_lbl" xml:lang="en-US">Summary of the Company's stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" xlink:label="tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" xlink:to="tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock_lbl" xml:lang="en-US">Summary of the status of the Company's unvested options</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock" xlink:label="tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock" xlink:to="tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock_lbl" xml:lang="en-US">Summary of the Company's share purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" xlink:label="tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" xlink:to="tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock_lbl" xml:lang="en-US">CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock" xlink:label="tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock" xlink:to="tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock_lbl" xml:lang="en-US">Additional disclosure on non-cash transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AggregateMinimumAnnualPaymentsTableTextBlock" xlink:label="tpiv_AggregateMinimumAnnualPaymentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AggregateMinimumAnnualPaymentsTableTextBlock" xlink:to="tpiv_AggregateMinimumAnnualPaymentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_AggregateMinimumAnnualPaymentsTableTextBlock_lbl" xml:lang="en-US">Aggregate minimum annual payments</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_WorkingCapitalDeficiency" xlink:label="tpiv_WorkingCapitalDeficiency" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_WorkingCapitalDeficiency" xlink:to="tpiv_WorkingCapitalDeficiency_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_WorkingCapitalDeficiency_lbl" xml:lang="en-US">Working capital deficiency</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_RequiredToMakeCertainPayments" xlink:label="tpiv_RequiredToMakeCertainPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_RequiredToMakeCertainPayments" xlink:to="tpiv_RequiredToMakeCertainPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_RequiredToMakeCertainPayments_lbl" xml:lang="en-US">Required to make certain payments</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CrucellUnderThisAgreement" xlink:label="tpiv_CrucellUnderThisAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_CrucellUnderThisAgreement" xlink:to="tpiv_CrucellUnderThisAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_CrucellUnderThisAgreement_lbl" xml:lang="en-US">Crucell under this agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_OutstandingBalanceRequiring" xlink:label="tpiv_OutstandingBalanceRequiring" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_OutstandingBalanceRequiring" xlink:to="tpiv_OutstandingBalanceRequiring_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_OutstandingBalanceRequiring_lbl" xml:lang="en-US">Outstanding balance requiring</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AmendedAgreementAccrued" xlink:label="tpiv_AmendedAgreementAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AmendedAgreementAccrued" xlink:to="tpiv_AmendedAgreementAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_AmendedAgreementAccrued_lbl" xml:lang="en-US">Amended agreement accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AggregatePrincipalAmount" xlink:label="tpiv_AggregatePrincipalAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AggregatePrincipalAmount" xlink:to="tpiv_AggregatePrincipalAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_AggregatePrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CashProceedsAndAccruedInterest" xlink:label="tpiv_CashProceedsAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_CashProceedsAndAccruedInterest" xlink:to="tpiv_CashProceedsAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_CashProceedsAndAccruedInterest_lbl" xml:lang="en-US">Cash proceeds and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_OutstandingAndDemandable" xlink:label="tpiv_OutstandingAndDemandable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_OutstandingAndDemandable" xlink:to="tpiv_OutstandingAndDemandable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_OutstandingAndDemandable_lbl" xml:lang="en-US">Outstanding and demandable</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CommonStockConversionRatePerShare" xlink:label="tpiv_CommonStockConversionRatePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_CommonStockConversionRatePerShare" xlink:to="tpiv_CommonStockConversionRatePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_CommonStockConversionRatePerShare_lbl" xml:lang="en-US">Common stock conversion rate per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesBearInterestRatePerAnnum" xlink:label="tpiv_NotesBearInterestRatePerAnnum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NotesBearInterestRatePerAnnum" xlink:to="tpiv_NotesBearInterestRatePerAnnum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NotesBearInterestRatePerAnnum_lbl" xml:lang="en-US">Notes bear interest rate per annum</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_FindersFee" xlink:label="tpiv_FindersFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_FindersFee" xlink:to="tpiv_FindersFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_FindersFee_lbl" xml:lang="en-US">Finders' fee</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DeferredFinancingCosts" xlink:label="tpiv_DeferredFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DeferredFinancingCosts" xlink:to="tpiv_DeferredFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DeferredFinancingCosts_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_WarrantsExercisable" xlink:label="tpiv_WarrantsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_WarrantsExercisable" xlink:to="tpiv_WarrantsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_WarrantsExercisable_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_FairValueOfWarrants" xlink:label="tpiv_FairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_FairValueOfWarrants" xlink:to="tpiv_FairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_FairValueOfWarrants_lbl" xml:lang="en-US">Fair value of the warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilitiesAndDebt" xlink:label="tpiv_DerivativeLiabilitiesAndDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DerivativeLiabilitiesAndDebt" xlink:to="tpiv_DerivativeLiabilitiesAndDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DerivativeLiabilitiesAndDebt_lbl" xml:lang="en-US">Derivative liabilities and the debt</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DebtDiscount" xlink:label="tpiv_DebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DebtDiscount" xlink:to="tpiv_DebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DebtDiscount_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_UnsecuredLoanAdvances" xlink:label="tpiv_UnsecuredLoanAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_UnsecuredLoanAdvances" xlink:to="tpiv_UnsecuredLoanAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_UnsecuredLoanAdvances_lbl" xml:lang="en-US">Unsecured loan advances</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AmountForFutureLegalServices" xlink:label="tpiv_AmountForFutureLegalServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AmountForFutureLegalServices" xlink:to="tpiv_AmountForFutureLegalServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_AmountForFutureLegalServices_lbl" xml:lang="en-US">Amount for future legal services</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PrepaidExpensesAndDeposit" xlink:label="tpiv_PrepaidExpensesAndDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_PrepaidExpensesAndDeposit" xlink:to="tpiv_PrepaidExpensesAndDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_PrepaidExpensesAndDeposit_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConversionPricePerShares" xlink:label="tpiv_ConversionPricePerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ConversionPricePerShares" xlink:to="tpiv_ConversionPricePerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ConversionPricePerShares_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SharesIssuedToHolderOfNote" xlink:label="tpiv_SharesIssuedToHolderOfNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_SharesIssuedToHolderOfNote" xlink:to="tpiv_SharesIssuedToHolderOfNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_SharesIssuedToHolderOfNote_lbl" xml:lang="en-US">Shares issued to the holder of the note</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNotesAmount" xlink:label="tpiv_PromissoryNotesAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_PromissoryNotesAmount" xlink:to="tpiv_PromissoryNotesAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_PromissoryNotesAmount_lbl" xml:lang="en-US">Promissory notes amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector" xlink:label="tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector" xlink:to="tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector_lbl" xml:lang="en-US">Promissory notes amount issued to an officer and a director</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ManagementFees" xlink:label="tpiv_ManagementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ManagementFees" xlink:to="tpiv_ManagementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ManagementFees_lbl" xml:lang="en-US">Management fees</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ResearchAndDevelopmentServices" xlink:label="tpiv_ResearchAndDevelopmentServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ResearchAndDevelopmentServices" xlink:to="tpiv_ResearchAndDevelopmentServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ResearchAndDevelopmentServices_lbl" xml:lang="en-US">Research and development services</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_StockBasedCompensation" xlink:label="tpiv_StockBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_StockBasedCompensation" xlink:to="tpiv_StockBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tpiv_StockBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DebtDueToRelatedParties" xlink:label="tpiv_DebtDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DebtDueToRelatedParties" xlink:to="tpiv_DebtDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DebtDueToRelatedParties_lbl" xml:lang="en-US">Debt due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNotesToOfficerAndDirector" xlink:label="tpiv_PromissoryNotesToOfficerAndDirector" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_PromissoryNotesToOfficerAndDirector" xlink:to="tpiv_PromissoryNotesToOfficerAndDirector_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_PromissoryNotesToOfficerAndDirector_lbl" xml:lang="en-US">Promissory notes to officer and director</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AmountsOwingToDirectorsAndOfficer" xlink:label="tpiv_AmountsOwingToDirectorsAndOfficer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AmountsOwingToDirectorsAndOfficer" xlink:to="tpiv_AmountsOwingToDirectorsAndOfficer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_AmountsOwingToDirectorsAndOfficer_lbl" xml:lang="en-US">Amounts owing to directors and officers</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CommonStockShares" xlink:label="tpiv_CommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_CommonStockShares" xlink:to="tpiv_CommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_CommonStockShares_lbl" xml:lang="en-US">Common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CommonStockSharesParValue" xlink:label="tpiv_CommonStockSharesParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_CommonStockSharesParValue" xlink:to="tpiv_CommonStockSharesParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_CommonStockSharesParValue_lbl" xml:lang="en-US">Common stock shares par value</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NonvotingPreferredShares" xlink:label="tpiv_NonvotingPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NonvotingPreferredShares" xlink:to="tpiv_NonvotingPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NonvotingPreferredShares_lbl" xml:lang="en-US">Non-voting preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NonvotingPreferredSharesParValue" xlink:label="tpiv_NonvotingPreferredSharesParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NonvotingPreferredSharesParValue" xlink:to="tpiv_NonvotingPreferredSharesParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NonvotingPreferredSharesParValue_lbl" xml:lang="en-US">Non-voting preferred shares par value</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_InterestPaidInCash" xlink:label="tpiv_InterestPaidInCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_InterestPaidInCash" xlink:to="tpiv_InterestPaidInCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_InterestPaidInCash_lbl" xml:lang="en-US">Interest paid in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesInAmount" xlink:label="tpiv_NotesInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NotesInAmount" xlink:to="tpiv_NotesInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NotesInAmount_lbl" xml:lang="en-US">Notes in the amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NoteToInvestor" xlink:label="tpiv_NoteToInvestor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NoteToInvestor" xlink:to="tpiv_NoteToInvestor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NoteToInvestor_lbl" xml:lang="en-US">Note to an investor</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ReceivedForNotes" xlink:label="tpiv_ReceivedForNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ReceivedForNotes" xlink:to="tpiv_ReceivedForNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_ReceivedForNotes_lbl" xml:lang="en-US">Received for the note</link:label>
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_LegalFee" xlink:label="tpiv_LegalFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_LegalFee" xlink:to="tpiv_LegalFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_LegalFee_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_DeferredFinancingCostsNote5" xlink:to="tpiv_DeferredFinancingCostsNote5_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_DeferredFinancingCostsNote5_2_lbl" xml:lang="en-US">DeferredFinancingCostsNote5</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationEquity_2_lbl" xml:lang="en-US">Deferred Compensation Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2_lbl" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_TotalExpenses" xlink:to="tpiv_TotalExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_TotalExpenses_2_lbl" xml:lang="en-US">TotalExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NetLossBeforeOtherItems" xlink:to="tpiv_NetLossBeforeOtherItems_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NetLossBeforeOtherItems_2_lbl" xml:lang="en-US">NetLossBeforeOtherItems</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_NetLossForPeriod" xlink:to="tpiv_NetLossForPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_NetLossForPeriod_2_lbl" xml:lang="en-US">NetLossForPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AdjustmentDepreciation" xlink:to="tpiv_AdjustmentDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_AdjustmentDepreciation_2_lbl" xml:lang="en-US">AdjustmentDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDebtInvestments" xlink:to="us-gaap_GainLossOnSaleOfDebtInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDebtInvestments_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Debt Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:to="us-gaap_IncreaseDecreaseInContractReceivablesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract Receivables, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_StockBasedCompensation" xlink:to="tpiv_StockBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tpiv_StockBasedCompensation_2_lbl" xml:lang="en-US">StockBasedCompensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_AdjustmentDepreciation" xlink:to="tpiv_AdjustmentDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tpiv_AdjustmentDepreciation_doc" xml:lang="en-US">The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes depreciation from discontinued operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable" xlink:to="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tpiv_ProceedsFromShortTermBankLoansAndNotesPayable_doc" xml:lang="en-US">Proceeds From Short Term Bank Loans And Notes Payable</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>tpiv-20120930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.3e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: tapimmune_10q.xfr; Date: 2012/11/19T20:29:54 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tapimmune.com/role/DocumentAndEntityInformation" xlink:href="tpiv-20120930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheets" xlink:href="tpiv-20120930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="tpiv-20120930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfOperations" xlink:href="tpiv-20120930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tpiv-20120930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/NatureOfOperations" xlink:href="tpiv-20120930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:href="tpiv-20120930.xsd#UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ResearchAgreements" xlink:href="tpiv-20120930.xsd#ResearchAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue" xlink:href="tpiv-20120930.xsd#DerivativeWarrantLiabilityAndFairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayable" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/LoansPayable" xlink:href="tpiv-20120930.xsd#LoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/PromissoryNote" xlink:href="tpiv-20120930.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/RelatedPartyTransactions" xlink:href="tpiv-20120930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStock" xlink:href="tpiv-20120930.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ContingenciesAndCommitments" xlink:href="tpiv-20120930.xsd#ContingenciesAndCommitments" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SubsequentEvents" xlink:href="tpiv-20120930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables" xlink:href="tpiv-20120930.xsd#DerivativeWarrantLiabilityAndFairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayableTables" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStockTables" xlink:href="tpiv-20120930.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ContingenciesAndCommitmentsTables" xlink:href="tpiv-20120930.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/NatureOfOperationsDetailsNarrative" xlink:href="tpiv-20120930.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ResearchAgreementsDetailsNarrative" xlink:href="tpiv-20120930.xsd#ResearchAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="tpiv-20120930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/LoansPayableDetailsNarrative" xlink:href="tpiv-20120930.xsd#LoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/PromissoryNoteDetailsNarrative" xlink:href="tpiv-20120930.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tpiv-20120930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/CapitalStockDetailsNarrative" xlink:href="tpiv-20120930.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:href="tpiv-20120930.xsd#SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tapimmune.com/role/SubsequentEventsDetailsNarrative" xlink:href="tpiv-20120930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DocumentAndEntityInformationAbstract" xlink:label="loc_tpivDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_tpivEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_tpivEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="loc_tpivDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_tpivDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_tpivAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_tpivCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_tpivEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_tpivEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_tpivEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_tpivEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_tpivEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_tpivEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_tpivDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_tpivDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivDocumentAndEntityInformationAbstract" xlink:to="loc_tpivDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedBalanceSheets" xlink:title="0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_tpivStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_tpivAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfFinancialPositionAbstract" xlink:to="loc_tpivAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_tpivAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsAbstract" xlink:to="loc_tpivAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_tpivCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsCurrentAbstract" xlink:to="loc_tpivCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="loc_tpivGovernmentContractReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsCurrentAbstract" xlink:to="loc_tpivGovernmentContractReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_tpivPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsCurrentAbstract" xlink:to="loc_tpivPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_tpivDeferredFinanceCostsNoncurrentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsCurrentAbstract" xlink:to="loc_tpivDeferredFinanceCostsNoncurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_tpivAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsCurrentAbstract" xlink:to="loc_tpivAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DeferredFinancingCostsNote5" xlink:label="loc_tpivDeferredFinancingCostsNote5" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsCurrentAbstract" xlink:to="loc_tpivDeferredFinancingCostsNote5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_tpivAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAssetsCurrentAbstract" xlink:to="loc_tpivAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_tpivLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfFinancialPositionAbstract" xlink:to="loc_tpivLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_tpivLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_tpivLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilities" xlink:label="loc_tpivAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_tpivOtherLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_tpivDerivativeLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilityConversionOptionNote4" xlink:label="loc_tpivDerivativeLiabilityConversionOptionNote4" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivDerivativeLiabilityConversionOptionNote4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_tpivConvertibleNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_tpivLoansPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_tpivShortTermBorrowings" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_tpivDueToRelatedPartiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_tpivLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivLiabilitiesCurrentAbstract" xlink:to="loc_tpivLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_tpivStockholdersEquityAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfFinancialPositionAbstract" xlink:to="loc_tpivStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStockholdersEquityAbstract" xlink:to="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_tpivCommonStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_tpivAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SharesAndWarrantsToBeIssued" xlink:label="loc_tpivSharesAndWarrantsToBeIssued" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivSharesAndWarrantsToBeIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_tpivDeferredCompensationEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivDeferredCompensationEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_tpivDevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivDevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_tpivAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_tpivStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_tpivLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="loc_tpivLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_tpivStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_tpivCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfFinancialPositionAbstract" xlink:to="loc_tpivCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_tpivCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfFinancialPositionAbstract" xlink:to="loc_tpivCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_tpivCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfFinancialPositionAbstract" xlink:to="loc_tpivCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_tpivCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfFinancialPositionAbstract" xlink:to="loc_tpivCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedStatementsOfOperations" xlink:title="0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_tpivIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_tpivCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivIncomeStatementAbstract" xlink:to="loc_tpivCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConsultingFees" xlink:label="loc_tpivConsultingFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivConsultingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConsultingFeesStockbasedNote9" xlink:label="loc_tpivConsultingFeesStockbasedNote9" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivConsultingFeesStockbasedNote9" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_tpivDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_tpivGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_InterestAndFinanceChargesNote4" xlink:label="loc_tpivInterestAndFinanceChargesNote4" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivInterestAndFinanceChargesNote4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ServiceManagementCosts" xlink:label="loc_tpivServiceManagementCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivServiceManagementCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ManagementFeesStockbasedNotes8And9" xlink:label="loc_tpivManagementFeesStockbasedNotes8And9" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivManagementFeesStockbasedNotes8And9" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_tpivProfessionalFees" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_tpivResearchAndDevelopmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ResearchAndDevelopmentStockbased" xlink:label="loc_tpivResearchAndDevelopmentStockbased" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivResearchAndDevelopmentStockbased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_TotalExpenses" xlink:label="loc_tpivTotalExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivTotalExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NetLossBeforeOtherItems" xlink:label="loc_tpivNetLossBeforeOtherItems" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivCostsAndExpensesAbstract" xlink:to="loc_tpivNetLossBeforeOtherItems" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_tpivNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivIncomeStatementAbstract" xlink:to="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ForeignExchangeLossGain" xlink:label="loc_tpivForeignExchangeLossGain" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivForeignExchangeLossGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="loc_tpivIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_tpivGainsLossesOnRestructuringOfDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivGainsLossesOnRestructuringOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_GainLossOnSettlementOfDebtNote9" xlink:label="loc_tpivGainLossOnSettlementOfDebtNote9" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivGainLossOnSettlementOfDebtNote9" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" xlink:label="loc_tpivGainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivGainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_tpivInvestmentIncomeInterest" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_tpivGainsLossesOnSalesOfAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivGainsLossesOnSalesOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NetLossForPeriod" xlink:label="loc_tpivNetLossForPeriod" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivNetLossForPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_BasicAndDilutedNetLossPerShare" xlink:label="loc_tpivBasicAndDilutedNetLossPerShare" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivBasicAndDilutedNetLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_tpivWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNonoperatingIncomeExpenseAbstract" xlink:to="loc_tpivWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_tpivStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_tpivNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfCashFlowsAbstract" xlink:to="loc_tpivNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_tpivNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AdjustmentDepreciation" xlink:label="loc_tpivAdjustmentDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivAdjustmentDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_tpivGainsLossesOnRestructuringOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivGainsLossesOnRestructuringOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="loc_tpivIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivIncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfDebtInvestments" xlink:label="loc_tpivGainLossOnSaleOfDebtInvestments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivGainLossOnSaleOfDebtInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_tpivGainLossOnSaleOfDerivatives" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivGainLossOnSaleOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_tpivGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_tpivOtherNoncashExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_tpivShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_tpivIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="loc_tpivIncreaseDecreaseInContractReceivablesNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_tpivIncreaseDecreaseInContractReceivablesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_tpivIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_tpivIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_tpivIncreaseDecreaseInDeferredCharges" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_tpivIncreaseDecreaseInDeferredCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_tpivIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_tpivIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_tpivIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_tpivIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_tpivNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tpivNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfCashFlowsAbstract" xlink:to="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_tpivProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_tpivProceedsFromConvertibleDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ProceedsFromPromissoryNotes" xlink:label="loc_tpivProceedsFromPromissoryNotes" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivProceedsFromPromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_tpivProceedsFromShortTermDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ProceedsFromShortTermBankLoansAndNotesPayable" xlink:label="loc_tpivProceedsFromShortTermBankLoansAndNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivProceedsFromShortTermBankLoansAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_tpivProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_tpivProceedsFromPaymentsForOtherFinancingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_tpivNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_tpivNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_tpivNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfCashFlowsAbstract" xlink:to="loc_tpivNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_tpivPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_tpivPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_tpivCashAcquiredFromAcquisition" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_tpivCashAcquiredFromAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_tpivNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_tpivNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_tpivCashPeriodIncreaseDecrease" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfCashFlowsAbstract" xlink:to="loc_tpivCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_tpivCash" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfCashFlowsAbstract" xlink:to="loc_tpivCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_tpivCash_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivStatementOfCashFlowsAbstract" xlink:to="loc_tpivCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/NatureOfOperations" xlink:title="0006 - Disclosure - NATURE OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_tpivOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_tpivNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_tpivNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod" xlink:title="0007 - Disclosure - UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="loc_tpivNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" xlink:label="loc_tpivUnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivUnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ResearchAgreements" xlink:title="0008 - Disclosure - RESEARCH AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_tpivResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_tpivResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivResearchAndDevelopmentAbstract" xlink:to="loc_tpivResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue" xlink:title="0009 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="loc_tpivNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock" xlink:label="loc_tpivDerivativeWarrantLiabilityAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivDerivativeWarrantLiabilityAndFairValueTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayable" xlink:title="0010 - Disclosure - CONVERTIBLE NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_tpivPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:label="loc_tpivAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/LoansPayable" xlink:title="0011 - Disclosure - LOANS PAYABLE">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="loc_tpivNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_LoansPayablesTextBlock" xlink:label="loc_tpivLoansPayablesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivLoansPayablesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/PromissoryNote" xlink:title="0012 - Disclosure - PROMISSORY NOTE">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="loc_tpivNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNoteTextBlock" xlink:label="loc_tpivPromissoryNoteTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivPromissoryNoteTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/RelatedPartyTransactions" xlink:title="0013 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_tpivRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_tpivRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivRelatedPartyTransactionsAbstract" xlink:to="loc_tpivRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStock" xlink:title="0014 - Disclosure - CAPITAL STOCK">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BrokersAndDealersAbstract" xlink:label="loc_tpivBrokersAndDealersAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock" xlink:label="loc_tpivComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities" xlink:title="0015 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_tpivSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_tpivCashFlowSupplementalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivSupplementalCashFlowElementsAbstract" xlink:to="loc_tpivCashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ContingenciesAndCommitments" xlink:title="0016 - Disclosure - CONTINGENCIES AND COMMITMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_tpivAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_tpivCommitmentsAndContingenciesPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAccountingPoliciesAbstract" xlink:to="loc_tpivCommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SubsequentEvents" xlink:title="0017 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_tpivAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_tpivSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAccountingPoliciesAbstract" xlink:to="loc_tpivSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables" xlink:title="0018 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="loc_tpivNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SharePurchaseWarrantsTableTextBlock" xlink:label="loc_tpivSharePurchaseWarrantsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivSharePurchaseWarrantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConversionOptionTableTextBlock" xlink:label="loc_tpivConversionOptionTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivConversionOptionTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilityTableTextBlock" xlink:label="loc_tpivDerivativeLiabilityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivDerivativeLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilityWarrantsTableTextBlock" xlink:label="loc_tpivDerivativeLiabilityWarrantsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivDerivativeLiabilityWarrantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_FinancialAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_tpivFinancialAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivFinancialAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayableTables" xlink:title="0019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_tpivPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_InstrumentTransactionsTableTextBlock" xlink:label="loc_tpivInstrumentTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivInstrumentTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStockTables" xlink:title="0020 - Disclosure - CAPITAL STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BrokersAndDealersAbstract" xlink:label="loc_tpivBrokersAndDealersAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SummaryOfCompanysStockOptionsTableTextBlock" xlink:label="loc_tpivSummaryOfCompanysStockOptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivSummaryOfCompanysStockOptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" xlink:label="loc_tpivSummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivSummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock" xlink:label="loc_tpivSummaryOfCompanysSharePurchaseWarrantsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivSummaryOfCompanysSharePurchaseWarrantsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables" xlink:title="0021 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_tpivSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" xlink:label="loc_tpivCashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivSupplementalCashFlowElementsAbstract" xlink:to="loc_tpivCashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock" xlink:label="loc_tpivAdditionalDisclosureOnNoncashTransactionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivSupplementalCashFlowElementsAbstract" xlink:to="loc_tpivAdditionalDisclosureOnNoncashTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ContingenciesAndCommitmentsTables" xlink:title="0022 - Disclosure - CONTINGENCIES AND COMMITMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_tpivAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AggregateMinimumAnnualPaymentsTableTextBlock" xlink:label="loc_tpivAggregateMinimumAnnualPaymentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAccountingPoliciesAbstract" xlink:to="loc_tpivAggregateMinimumAnnualPaymentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/NatureOfOperationsDetailsNarrative" xlink:title="0023 - Disclosure - NATURE OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_tpivOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_WorkingCapitalDeficiency" xlink:label="loc_tpivWorkingCapitalDeficiency" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_tpivWorkingCapitalDeficiency" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ResearchAgreementsDetailsNarrative" xlink:title="0024 - Disclosure - RESEARCH AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_tpivResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_RequiredToMakeCertainPayments" xlink:label="loc_tpivRequiredToMakeCertainPayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivResearchAndDevelopmentAbstract" xlink:to="loc_tpivRequiredToMakeCertainPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CrucellUnderThisAgreement" xlink:label="loc_tpivCrucellUnderThisAgreement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivResearchAndDevelopmentAbstract" xlink:to="loc_tpivCrucellUnderThisAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_OutstandingBalanceRequiring" xlink:label="loc_tpivOutstandingBalanceRequiring" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivResearchAndDevelopmentAbstract" xlink:to="loc_tpivOutstandingBalanceRequiring" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AmendedAgreementAccrued" xlink:label="loc_tpivAmendedAgreementAccrued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivResearchAndDevelopmentAbstract" xlink:to="loc_tpivAmendedAgreementAccrued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="0025 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_tpivPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AggregatePrincipalAmount" xlink:label="loc_tpivAggregatePrincipalAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivAggregatePrincipalAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CashProceedsAndAccruedInterest" xlink:label="loc_tpivCashProceedsAndAccruedInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivCashProceedsAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_OutstandingAndDemandable" xlink:label="loc_tpivOutstandingAndDemandable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivOutstandingAndDemandable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CommonStockConversionRatePerShare" xlink:label="loc_tpivCommonStockConversionRatePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivCommonStockConversionRatePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesBearInterestRatePerAnnum" xlink:label="loc_tpivNotesBearInterestRatePerAnnum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivNotesBearInterestRatePerAnnum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_FindersFee" xlink:label="loc_tpivFindersFee" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivFindersFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DeferredFinancingCosts" xlink:label="loc_tpivDeferredFinancingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivDeferredFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_WarrantsExercisable" xlink:label="loc_tpivWarrantsExercisable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivWarrantsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_FairValueOfWarrants" xlink:label="loc_tpivFairValueOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DerivativeLiabilitiesAndDebt" xlink:label="loc_tpivDerivativeLiabilitiesAndDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivDerivativeLiabilitiesAndDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DebtDiscount" xlink:label="loc_tpivDebtDiscount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivPayablesAndAccrualsAbstract" xlink:to="loc_tpivDebtDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/LoansPayableDetailsNarrative" xlink:title="0026 - Disclosure - LOANS PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="loc_tpivNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_UnsecuredLoanAdvances" xlink:label="loc_tpivUnsecuredLoanAdvances" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivUnsecuredLoanAdvances" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/PromissoryNoteDetailsNarrative" xlink:title="0027 - Disclosure - PROMISSORY NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesToFinancialStatementsAbstract" xlink:label="loc_tpivNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AmountForFutureLegalServices" xlink:label="loc_tpivAmountForFutureLegalServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivAmountForFutureLegalServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PrepaidExpensesAndDeposit" xlink:label="loc_tpivPrepaidExpensesAndDeposit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivPrepaidExpensesAndDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ConversionPricePerShares" xlink:label="loc_tpivConversionPricePerShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivConversionPricePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_SharesIssuedToHolderOfNote" xlink:label="loc_tpivSharesIssuedToHolderOfNote" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivSharesIssuedToHolderOfNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNotesAmount" xlink:label="loc_tpivPromissoryNotesAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivPromissoryNotesAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector" xlink:label="loc_tpivPromissoryNotesAmountIssuedToOfficerAndDirector" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivNotesToFinancialStatementsAbstract" xlink:to="loc_tpivPromissoryNotesAmountIssuedToOfficerAndDirector" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="0028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_tpivRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ManagementFees" xlink:label="loc_tpivManagementFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivRelatedPartyTransactionsAbstract" xlink:to="loc_tpivManagementFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ResearchAndDevelopmentServices" xlink:label="loc_tpivResearchAndDevelopmentServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivRelatedPartyTransactionsAbstract" xlink:to="loc_tpivResearchAndDevelopmentServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_StockBasedCompensation" xlink:label="loc_tpivStockBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivRelatedPartyTransactionsAbstract" xlink:to="loc_tpivStockBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_DebtDueToRelatedParties" xlink:label="loc_tpivDebtDueToRelatedParties" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivRelatedPartyTransactionsAbstract" xlink:to="loc_tpivDebtDueToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_PromissoryNotesToOfficerAndDirector" xlink:label="loc_tpivPromissoryNotesToOfficerAndDirector" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivRelatedPartyTransactionsAbstract" xlink:to="loc_tpivPromissoryNotesToOfficerAndDirector" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_AmountsOwingToDirectorsAndOfficer" xlink:label="loc_tpivAmountsOwingToDirectorsAndOfficer" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivRelatedPartyTransactionsAbstract" xlink:to="loc_tpivAmountsOwingToDirectorsAndOfficer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/CapitalStockDetailsNarrative" xlink:title="0029 - Disclosure - CAPITAL STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BrokersAndDealersAbstract" xlink:label="loc_tpivBrokersAndDealersAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CommonStockShares" xlink:label="loc_tpivCommonStockShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_CommonStockSharesParValue" xlink:label="loc_tpivCommonStockSharesParValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivCommonStockSharesParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NonvotingPreferredShares" xlink:label="loc_tpivNonvotingPreferredShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivNonvotingPreferredShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NonvotingPreferredSharesParValue" xlink:label="loc_tpivNonvotingPreferredSharesParValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivBrokersAndDealersAbstract" xlink:to="loc_tpivNonvotingPreferredSharesParValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails" xlink:title="0030 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES - Additional disclosure on non-cash transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_tpivSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_InterestPaidInCash" xlink:label="loc_tpivInterestPaidInCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivSupplementalCashFlowElementsAbstract" xlink:to="loc_tpivInterestPaidInCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_tpivIncomeTaxesPaid" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivSupplementalCashFlowElementsAbstract" xlink:to="loc_tpivIncomeTaxesPaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative" xlink:title="0031 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_tpivSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NotesInAmount" xlink:label="loc_tpivNotesInAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivSupplementalCashFlowElementsAbstract" xlink:to="loc_tpivNotesInAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tapimmune.com/role/SubsequentEventsDetailsNarrative" xlink:title="0032 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_tpivAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_NoteToInvestor" xlink:label="loc_tpivNoteToInvestor" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAccountingPoliciesAbstract" xlink:to="loc_tpivNoteToInvestor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_ReceivedForNotes" xlink:label="loc_tpivReceivedForNotes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAccountingPoliciesAbstract" xlink:to="loc_tpivReceivedForNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tpiv-20120930.xsd#tpiv_LegalFee" xlink:label="loc_tpivLegalFee" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpivAccountingPoliciesAbstract" xlink:to="loc_tpivLegalFee" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 18, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 20, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 12, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 08, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
        <td class="nump">$ 82,500<span></span></td>
        <td class="nump">$ 20,000<span></span></td>
        <td class="nump">$ 27,500<span></span></td>
        <td class="nump">$ 111,430<span></span></td>
        <td class="nump">$ 30,000<span></span></td>
        <td class="nump">$ 215,000<span></span></td>
        <td class="nump">$ 1,184,694<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CashProceedsAndAccruedInterest', window );">Cash proceeds and accrued interest</a></td>
        <td class="nump">69,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">92,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">190,000<span></span></td>
        <td class="nump">944,694<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_OutstandingAndDemandable', window );">Outstanding and demandable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">240,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockConversionRatePerShare', window );">Common stock conversion rate per share</a></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="nump">$ 0.15<span></span></td>
        <td class="nump">$ 0.15<span></span></td>
        <td class="nump">$ 0.15<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesBearInterestRatePerAnnum', window );">Notes bear interest rate per annum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8%<span></span></td>
        <td class="text">10%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10%<span></span></td>
        <td class="text">10%<span></span></td>
        <td class="text">10%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_FindersFee', window );">Finders' fee</a></td>
        <td class="nump">6,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,550<span></span></td>
        <td class="nump">41,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DeferredFinancingCosts', window );">Deferred financing costs</a></td>
        <td class="nump">5,803<span></span></td>
        <td class="nump">16,100<span></span></td>
        <td class="nump">6,100<span></span></td>
        <td class="nump">6,838<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,273<span></span></td>
        <td class="nump">18,495<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_WarrantsExercisable', window );">Warrants exercisable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,155,700<span></span></td>
        <td class="nump">60,000<span></span></td>
        <td class="nump">430,000<span></span></td>
        <td class="nump">2,369,388<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_FairValueOfWarrants', window );">Fair value of the warrants</a></td>
        <td class="nump">76,400<span></span></td>
        <td class="nump">36,100<span></span></td>
        <td class="nump">31,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,720<span></span></td>
        <td class="nump">130,720<span></span></td>
        <td class="nump">483,355<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DerivativeLiabilitiesAndDebt', window );">Derivative liabilities and the debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">84,280<span></span></td>
        <td class="nump">701,339<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DebtDiscount', window );">Debt discount</a></td>
        <td class="nump">$ 2,626<span></span></td>
        <td class="nump">$ 2,247<span></span></td>
        <td class="nump">$ 15,842<span></span></td>
        <td class="nump">$ 16,180<span></span></td>
        <td class="nump">$ 2,075<span></span></td>
        <td class="nump">$ 25,752<span></span></td>
        <td class="nump">$ 120,839<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AggregatePrincipalAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_AggregatePrincipalAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CashProceedsAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_CashProceedsAndAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CommonStockConversionRatePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_CommonStockConversionRatePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DebtDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DebtDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DeferredFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DeferredFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DerivativeLiabilitiesAndDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DerivativeLiabilitiesAndDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_FairValueOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_FairValueOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_FindersFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_FindersFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesBearInterestRatePerAnnum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesBearInterestRatePerAnnum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_OutstandingAndDemandable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_OutstandingAndDemandable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_WarrantsExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_WarrantsExercisable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DERIVATIVE WARRANT LIABILITY AND FAIR VALUE<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock', window );">DERIVATIVE WARRANT LIABILITY AND FAIR VALUE</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><font style="text-transform: uppercase"><u>Note 4:&#9;DERIVATIVE
WARRANT LIABILITY AND FAIR VALUE</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The Company has evaluated the application
ASC 480-10 <i>Distinguishing liabilities from equity</i>, ASC 815-40 <i>Contracts in an Entity&#146;s Own Equity</i> and ASC 718-10
<i>Compensation &#150; Stock Compensation</i> to the issued and outstanding warrants to purchase common stock that were issued
with the convertible notes, private placements, consulting agreements, and various debt settlements during 2009 through 2012. Based
on the guidance, management concluded these instruments are required to be accounted for as derivatives either due to a ratchet
down protection feature available on the exercise price (Note 5) or a holder&#146;s right to put the warrants back to the Company
for cash under certain conditions or a conversion option feature with conversion into variable number of shares. Under ASC 815-40-25,
the Company records the fair value of these warrants and conversion options (derivatives) on its balance sheet, at fair value,
with changes in the values reflected in the statements of operations as &#147;Changes in fair value of derivative liabilities&#148;.
The fair value of the share purchase warrants are recorded on the balance sheet under &#145;Derivative liability &#150; warrants&#146;
and the fair value of the conversion options are recorded on the balance sheet under &#145;Derivative liability &#150; conversion
option&#146;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">ASC 820-10 defines fair value as the
exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also
establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820-10 describes three levels of inputs that may be used to measure fair value: Level 1 &#150;
Quoted prices in active markets for identical assets or liabilities; Level 2 &#150; Observable inputs other than Level 1 prices,
such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or liabilities; and Level 3 &#150; Unobservable inputs that are supported
by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted
cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant
judgment or estimation. The Company&#146;s Level 3 liabilities consist of the derivative liabilities associated with the warrants
issued with the convertible notes during the year ended December 31, 2011. At September 30, 2012, all of the Company&#146;s derivative
liabilities were categorized as Level 3 fair value liabilities. If the inputs used to measure the financial assets and liabilities
fall within more than one level described above, the categorization is based on the lowest level input that is significant to the
fair value measurement of the instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><i>Level 3 Valuation Techniques</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">Financial liabilities are considered
Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and
at least one significant model assumption or input is unobservable. Level 3 financial liabilities consist of the notes and warrants
for which there is no current market for these securities such that the determination of fair value requires significant judgment
or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">Determining fair value of share purchase
warrants, given the Company&#146;s stage of development and financial position, is highly subjective and identifying appropriate
measurement criteria and models is subject to uncertainty. There are several generally accepted pricing models for warrants and
options and derivative provisions. The Company has chosen to value the warrants and conversion option on the notes that contain
ratchet down provisions using the Binomial model under the following assumptions:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">December 31, 2011</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">September 30, 2012</td></tr>
<tr>
    <td style="vertical-align: top; width: 26%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Share purchase warrants</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.09 to 4.80</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.12% to 0.83%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">199%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.33 to 4.03</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.10% to 0.62%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">199%</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">At Initial Recognition</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">September 30, 2012</td></tr>
<tr>
    <td style="vertical-align: top; width: 24%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Conversion Option</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.25 to 1.04</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.11% to 0.20%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">138.31% to 141.43%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.11 to 1.00</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.06% to 0.17%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">138.31% to 141.21%</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The foregoing assumptions are reviewed
quarterly and are subject to change based primarily on management&#146;s assessment of the probability of the events described
occurring. Accordingly, changes to these assessments could materially affect the valuations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><i>Financial Assets and Liabilities Measured
at Fair Value on a Recurring Basis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">Financial assets and liabilities measured
at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability &#150; warrants:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&#160;</td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>As of September 30, 2012 </b></p></td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td colspan="5" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Fair Value Measurements</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Carrying Value</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 1</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Total</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Derivative liability - warrants</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Derivative liability &#150; conversion option</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">200,700</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">200,700</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">200,700</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Total</td>
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558</td>
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558</td></tr>
<tr>
    <td style="width: 36%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 13%">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of December 31, 2011</b></p></td>
    <td colspan="2" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Fair Value Measurements Using</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Carrying Value</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 3</td>
    <td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Total</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Derivative liability - warrants</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Total</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td colspan="3" style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td></tr>
<tr>
    <td style="width: 33%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 6%">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The table below provides a summary of
the changes in fair value, including net transfers, in and/or out, of financial assets and liabilities measured at fair value on
a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2012 and the year ended
December 31, 2011:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td colspan="3" style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"><b>Fair Value Measurements Using Level 3 Inputs</b></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></td>
    <td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Derivative liability - warrants</td>
    <td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Derivative liability &#150; conversion option</td>
    <td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Total</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Balance,&#160; December 31, 2010</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,819,512<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 175,389<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,994,901<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Additions during the year</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,587,275<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,587,275<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Total unrealized (gains) or losses included in net loss</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(631,631)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(37,079)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(668,710)</td></tr>
<tr>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Debt settlement</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(1,457,322)</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(138,310)</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(1,595,632)</td></tr>
<tr>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Transfers in and/or out of Level 3</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Balance, December 31, 2011</td>
    <td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,317,834<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,317,834<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Additions during the year</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">299,300&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">299,300&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Total unrealized (gains) or losses included in net loss</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(445,976)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(98,600)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(544,576)</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Debt settlement</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Transfers in and/or out of Level 3</td>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Balance, September 30, 2012</td>
    <td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="width: 19%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858&#160;</td>
    <td style="width: 20%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 200,700<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the warrants and conversion
options is determined using a Binomial option pricing model. The valuation of warrants and conversion options is subjective and
is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility
of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield.
Changes in these assumptions can materially affect the fair value estimate. Ultimately, the Company may incur amounts to settle
the warrants at a cash settlement value that is significantly different than the carrying value of the liability in the financial
statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised,
expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair
value of the common stock warrants and conversion options liability are recognized as a component of other income (expense) in
the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The net cash settlement value at the time of any future
Fundamental Transaction will depend upon the value of the following inputs at that time: the consideration value per share of
the Company&#146;s common stock, the volatility of the Company&#146;s common stock, the remaining term of the warrant from announcement
date, the risk-free interest rate based on U.S. Treasury security yields, and the Company&#146;s dividend yield. The warrant requires
use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day
immediately following announcement of a Fundamental Transaction.</font></p>



<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DerivativeWarrantLiabilityAndFairValueTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%15137U5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0T%3
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3D%455)%
M7T]&7T]015)!5$E/3E,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y53D%51$E4141?0T].4T],241!5$5$7T9)3D%.0TD\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y215-%05)#2%]!1U)%
M14U%3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M1$52259!5$E615]705)204Y47TQ)04))3$E465]!/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].5D525$E"3$5?3D]415-?4$%9
M04),13PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQ/
M04Y37U!!64%"3$4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y04D]-25-33U)97TY/5$4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y214Q!5$5$7U!!4E197U1204Y304-424].4SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-!4$E404Q?4U1/
M0TL\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y355!0
M3$5-14Y404Q?0T%32%]&3$]77TE.1D]234$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y#3TY424Y'14Y#24537T%.1%]#3TU-251-
M14Y44SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-5
M0E-%455%3E1?159%3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1$52259!5$E615]705)204Y47TQ)04))3$E465]!,3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3E9%4E1)0DQ%
M7TY/5$537U!!64%"3$5?5&%B;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D-!4$E404Q?4U1/0TM?5&%B;&5S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U504$Q%345.5$%,7T-!4TA?
M1DQ/5U])3D9/4DU!,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D-/3E1)3D=%3D-)15-?04Y$7T-/34U)5$U%3E137SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DY!5%5215]/1E]/4$52
M051)3TY37T1E=&%I;'-?3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E)%4T5!4D-(7T%'4D5%345.5%-?1&5T86EL<U].83PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3E9%4E1)0DQ%
M7TY/5$537U!!64%"3$5?1&5T83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DQ/04Y37U!!64%"3$5?1&5T86EL<U].87)R871I=CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!23TU)4U-/
M4EE?3D]415]$971A:6QS7TYA<G)A=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E)%3$%4141?4$%25%E?5%)!3E-!0U1)3TY37T1E
M=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-!4$E4
M04Q?4U1/0TM?1&5T86EL<U].87)R871I=CPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-54%!,14U%3E1!3%]#05-(7T9,3U=?24Y&
M3U)-03(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M55!03$5-14Y404Q?0T%32%]&3$]77TE.1D]234$S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,Q
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U5"4T51545.5%]%5D5.5%-?1&5T
M86EL<U].87)R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y
M;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\
M>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T
M4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R
M;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%
M>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@
M(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET
M:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S-U\T
M.3$X7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E82]7
M;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.1T%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I
M;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#$Y+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES
M=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^5$%0
M24U-54Y%($E.0SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`Q,#DT,#,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4
M>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U1/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/E-E<"`S,"P-"@D),C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A
M;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y)<R!%;G1I='D@82!796QL+6MN;W=N(%-E87-O;F5D($ES
M<W5E<C\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<R!%
M;G1I='D@82!6;VQU;G1A<GD@1FEL97(_/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27,@16YT:71Y)W,@4F5P;W)T:6YG(%-T871U<R!#
M=7)R96YT/SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^665S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/E-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM
M;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S,L.#8Q+#<U-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E
M<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^43,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15%#04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0T].4T],241!5$5$($)!3$%.0T4@4TA%1513("A5;F%U9&ET960I("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@07-S971S/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPW,C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U,"PR,S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1U92!F<F]M
M(&=O=F5R;FUE;G0@86=E;F-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#`Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,#8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!D97!O<VET
M<R`H3F]T92`W*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L
M-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-38L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!F:6YA;F-I;F<@8V]S=',@*$YO=&4@-2D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#8T,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%S<V5T<RP@0W5R<F5N="P@5&]T86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,Y+#DW,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-RPY,C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&9I;F%N
M8VEN9R!C;W-T<R`H3F]T92`U*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C`L-S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S(L,CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S+"!4;W1A;#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C`L-S,Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0P+#(Q,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M=7)R96YT($QI86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S(W+#DX-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<Y-"PR.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%G<F5E;65N="!O8FQI9V%T:6]N
M<R`H3F]T92`S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8U
M+#DW,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(U.2PW-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71Y(.*`DR!W87)R86YT
M<R`H3F]T92`T*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<Q
M+#@U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,S$W+#@S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D@XH"3(&-O;G9E
M<G-I;VX@;W!T:6]N("A.;W1E(#0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,#`L-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!N;W1E
M<R!P87EA8FQE("A.;W1E(#4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$X-"PS-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY.3@L-SDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;V%N<R!P87EA8FQE("A.;W1E(#8I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR."PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O;6ES<V]R>2!N;W1E("A.;W1E(#<I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-C<L.30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1'5E('1O(')E;&%T960@<&%R
M=&EE<R`H3F]T92`X*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@Q+#0W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,R,BPY,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI=&EE<RP@0W5R<F5N="P@5&]T86P\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#(X+#(X,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#`P
M+#4W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#87!I=&%L('-T;V-K("A.;W1E(#DI/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:RP@)#`N,#`Q('!A<B!V86QU92P@,34P+#`P,"PP,#`@<VAA<F5S(&%U=&AO
M<FEZ960@-S,L.#8Q+#<U-"!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN
M9R`H,C`Q,2#B@),@-3(L,#<S+#0V,"D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<S+#@V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4R+#`W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A
M<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#(R,"PU
M,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS.2PY-#,L,S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,@86YD('=A<G)A;G1S('1O(&)E(&ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0R+#`V,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V,BPY
M,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(&-O;7!E;G-A=&EO;B`H3F]T92`Y*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4L.38X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE(&1E=F5L;W!M96YT('-T86=E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-RPX-#`L.3`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S
M+#<R,BPR,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-U;75L871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&QO
M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8S+#`X,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,"PU
M,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VMH;VQD97)S)R!%<75I='D@071T<FEB=71A8FQE('1O(%!A
M<F5N="P@5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L
M,S8W+#4T,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S+#0V,"PS-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&EA8FEL:71I97,@86YD($5Q=6ET>2P@
M5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C`L-S,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S-#`L,C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]C83<P.#0U85\Q-#,W7S0Y,3A?835B9E\Q,C)E-&-D93,U96$-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V$W,#@T-6%?,30S-U\T.3$X
M7V$U8F9?,3(R931C9&4S-65A+U=O<FMS:&5E=',O4VAE970P,RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P13)&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].4T],241!
M5$5$($)!3$%.0T4@4TA%1513("A087)E;G1H971I8V%L*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=&%T96UE;G0@;V8@1FEN86YC:6%L(%!O<VET:6]N(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S
M+#@V,2PW-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,BPP-S,L-#8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,L.#8Q
M+#<U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4R+#`W,RPT-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E
M80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C83<P.#0U85\Q-#,W
M7S0Y,3A?835B9E\Q,C)E-&-D93,U96$O5V]R:W-H965T<R]3:&5E=#`T+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%3D="1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY3
M3TQ)1$%4140@4U1!5$5-14Y44R!/1B!/4$52051)3TY3("A5;F%U9&ET960I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$U."!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5X
M<&5N<V5S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;G-U;'1I;F<@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U-RPR-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0S+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$Y+#<Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$Y+#(U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPQ
M-3@L-#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VYS=6QT:6YG(&9E97,@XH"3('-T;V-K+6)A<V5D("A.;W1E
M(#DI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#DL-S(X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`W
M+#<S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,C@S+#4V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8Y,BPR-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P-2PY,30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$S+#(R-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N
M97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(V."PR.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPX-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#`L,S4S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L,#$R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPW.3<L-3@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1E<F5S="!A;F0@9FEN86YC92!C:&%R9V5S("A.;W1E(#0I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,30L.#$Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#<T,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q,2PW
M.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU-3@L-3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPR-#(L-SDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&9E97,@*$YO=&4@."D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#4P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#$P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M-2PQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.#8L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPX.3<L,34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&9E97,@XH"3('-T
M;V-K+6)A<V5D("A.;W1E<R`X(&%N9"`Y*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S$L,S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,CDL-38S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30V+#DV,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V,"PR-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0W,2PW
M-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V9E<W-I;VYA;"!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,2PW-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-BPQ-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,#@L.#8V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$W+#$S,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3,U+#0S.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT("A.;W1E(#@I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,2PP-C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3<L.3DV/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,R+#(X.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-BPY
M-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#,T,RPT-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="#B@),@<W1O
M8VLM8F%S960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q
M,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-SDV+#<S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDP-"PY,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8P."PW,#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<P-BPW,C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PX
M-S<L-SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T($QO<W,@0F5F;W)E($]T:&5R($ET96US/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@W.38L-S,W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DP-"PY,S$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV,#@L
M-S`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(L-S`V+#<R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S.2PX-S<L-SDX*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!)=&5M
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M;W)E:6=N(&5X8VAA;F=E("AL;W-S*2!G86EN/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W+#$Y,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PV-30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,P-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-2PX.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H
M86YG97,@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S
M("A.;W1E(#0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C$L
M,S@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-30T+#4W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(W-RPQ,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV,3DL-S$V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1E
M8G0@9FEN86YC:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X
M-2PU-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.#4L-34P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,S4T+#(V
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=A:6X@*&QO<W,I(&]N('-E='1L96UE;G0@;V8@9&5B="`H3F]T92`Y
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C@L-C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-#@R+#0W-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,2PV,#(L.#DT*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O
M;B!E>'1I;F=U:7-H;65N="!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S("T@
M=V%R<F%N=',@*$YO=&4@-"D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#@X
M+#4W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(Y,"PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=&5R97-T(&EN8V]M93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S,L,S0T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1I<W!O<V%L(&]F
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PS
M.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T($QO<W,@9F]R('1H92!097)I;V0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#<V."PP.34I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#0T+#(W-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#$Q."PV.#0I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS
M-S@L,#,V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0W+#@T,"PY,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@1&EL=71E9"!.970@3&]S
M<R!P97(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,"XP,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M3G5M8F5R(&]F($-O;6UO;B!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<S+#$R."PP-3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPR,3,L-S$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L
M-38P+#(Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0T+#@T-2PQ.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E
M,S5E80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C83<P.#0U85\Q
M-#,W7S0Y,3A?835B9E\Q,C)E-&-D93,U96$O5V]R:W-H965T<R]3:&5E=#`U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%0T-"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("A5;F%U9&ET
M960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-3@@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/
M32!/4$52051)3D<@04-4259)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H-"PQ,3@L-C@T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPS-S@L,#,V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#<L
M.#0P+#DP,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE
M="!L;W-S('1O(&YE="!C87-H(&9R;VT@;W!E<F%T:6YG(&%C=&EV:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C$S+#(R.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@;&]S<R!O
M;B!D96)T(&9I;F%N8VEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#4L-34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-30L,C8S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V5S(&EN(&9A
M:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-30T+#4W-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S<L,3$X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV,3DL-S$V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]S<R`H9V%I;BD@;VX@<V5T=&QE;65N="!O9B!D96)T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R."PV.#@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@R+#0W-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#8P,BPX
M.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=A:6X@;VX@97AT:6YG=6ES:&UE;G0@;V8@9&5R:79A=&EV92!L:6%B
M:6QI=&EE<R`M('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#`X."PU-S4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDP+#4P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@
M9&ES<&]S86P@;V8@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,Y.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@
M:6YT97)E<W0@86YD(&9I;F%N8VEN9R!C:&%R9V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3@L-3<W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT-C@L-#DY
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!B87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-#,P+#4R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#4R+#4Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#$P-2PY,3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1'5E(&9R;VT@9V]V97)N;65N="!A9V5N8WD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#<W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@9&5P;W-I=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,T+#$R,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0V+#4P-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E9F5R<F5D(&9I;F%N8VEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PQ,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-30L.3<T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PQ-C`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA
M8FQE(&%N9"!A8V-R=65D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY,3DL.#@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#4L,#$Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,#$L,S8P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!A9W)E96UE;G0@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P-BPR,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW.2PR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#0L,3`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($-!4T@@55-%
M1"!)3B!/4$52051)3D<@04-4259)5$E%4SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PQ,38L-S<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@W-BPW,CDI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34L.3<Q+#(P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0T%32"!&3$]74R!&4D]-($9)3D%.0TE.1R!!0U1)5DE42453/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F('-H87)E<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DT+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#<V,"PU-S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO
M=&5S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P-BPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,C0L-3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW,C<L.3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('!R;VUI<W-O<GD@
M;F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W+#DT,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8W+#DT,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!L;V%N<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.;W1E<R!A;F0@;&]A;G,@<&%Y86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3$Y+#@T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061V86YC97,@9G)O;2`H=&\I(')E;&%T960@<&%R=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(P+#,R,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,Q+#,P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#<P-RPY,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K('-U8G-C<FEP=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.150@0T%32"!04D]6241%1"!"62!&24Y!3D-)3D<@04-4259)
M5$E%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<P+#(V,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X
M-RPY.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-2PW-S`L,3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!)3E9%
M4U1)3D<@04-4259)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!F=7)N:71U<F4@86YD(&5Q=6EP
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C$X+#8R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86-Q=6ER960@;VX@<F5V
M97)S92!A8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(S+#,W,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!#05-(
M(%!23U9)1$5$(&)Y($E.5D535$E.1R!!0U1)5DE42453/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,#0L-S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^24Y#4D5!4T4@*$1%0U)%05-%*2!)3B!#05-(/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#8L-3`W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#(U-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S(W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M05-(+"!"14=)3DY)3D<@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-3`L,C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,L-3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#05-(+"!%
M3D0@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S-"PW-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/DY!5%5212!/1B!/4$52051)3TY3/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N+"!#;VYS;VQI
M9&%T:6]N(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N
M=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.05154D4@3T8@3U!%4D%424].4SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#$R<'0@,"`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+71R86YS9F]R;3H@=7!P
M97)C87-E)SX\=3Y.;W1E#0HQ.B8C.3M.871U<F4@;V8@3W!E<F%T:6]N<SPO
M=3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1A<$EM;75N90T*26YC
M+B`H=&AE("8C,30W.T-O;7!A;GDF(S$T.#LI+"!A($YE=F%D82!C;W)P;W)A
M=&EO;B!I;F-O<G!O<F%T960@:6X@,3DY,BP@:7,@82!D979E;&]P;65N="!S
M=&%G92!C;VUP86YY('=H:6-H('=A<R!F;W)M960@9F]R#0IT:&4@<'5R<&]S
M92!O9B!B=6EL9&EN9R!A(&)I;W1E8VAN;VQO9WD@8G5S:6YE<W,@<W!E8VEA
M;&EZ:6YG(&EN('1H92!D:7-C;W9E<GD@86YD(&1E=F5L;W!M96YT(&]F(&EM
M;75N;W1H97)A<&5U=&EC<R!A:6UE9"!A=`T*=&AE('1R96%T;65N="!O9B!C
M86YC97(L(&%N9"!T:&5R87!I97,@9F]R(&EN9F5C=&EO=7,@9&ES96%S97,L
M(&%U=&]I;6UU;F4@9&ES;W)D97)S(&%N9"!T<F%N<W!L86YT('1I<W-U92!R
M96IE8W1I;VXN/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@
M,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3:6YC90T*
M:6YC97!T:6]N+"!T:&4@0V]M<&%N>2!H87,@8F5E;B!P87)T>2!T;R!V87)I
M;W5S($-O;&QA8F]R871I=F4@4F5S96%R8V@@06=R965M96YT<R`H)B,Q-#<[
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M;VUP;&5T:6YG('!R92UC;&EN:6-A;`T*=V]R:R!I;B!A;G1I8VEP871I;VX@
M;V8@8VQI;FEC86P@=')I86QS+B!3<&5C:69I8V%L;'DL('1H92!#;VUP86YY
M(&AA<R!O8G1A:6YE9"!A;F0@97AP86YD960@;VX@=&AR964@52Y3+B!A;F0@
M:6YT97)N871I;VYA;"!P871E;G1S+`T*=&5S=&5D('9A<FEO=7,@=FER86P@
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M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&QE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/E1H97-E#0IC;VYS;VQI9&%T
M960@9FEN86YC:6%L('-T871E;65N=',@:&%V92!B965N('!R97!A<F5D(&]N
M('1H92!B87-I<R!O9B!A(&=O:6YG(&-O;F-E<FX@=VAI8V@@8V]N=&5M<&QA
M=&5S('1H92!R96%L:7IA=&EO;B!O9B!A<W-E=',-"F%N9"!T:&4@<V%T:7-F
M86-T:6]N(&]F(&QI86)I;&ET:65S(&EN('1H92!N;W)M86P@8V]U<G-E(&]F
M(&)U<VEN97-S+B!!<R!A="!397!T96UB97(@,S`L(#(P,3(L('1H92!#;VUP
M86YY(&AA9"!A('=O<FMI;F<@8V%P:71A;`T*9&5F:6-I96YC>2!O9B`D,RPS
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M9&ET:6]N86P@8V%P:71A;`T*=&\@9G5N9"!O;F=O:6YG(')E<V5A<F-H(&%N
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M:6%L:7IA=&EO;B!A8W1I=FET:65S+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^36%N86=E;65N=`T*:7,@
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M;F<@8V%P:71A;"!R97%U:7)E;65N=',N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!L971T97(M<W!A8VEN9SH@+3`N,7!T)SY!9&1I=&EO;F%L#0IF
M=6YD:6YG('=A<R!R86ES960@=&AR;W5G:"!E<75I='D@86YD(&1E8G0@<&QA
M8V5M96YT<R!I;B`R,#$Q(&%N9"!T:&4@9FER<W0@;FEN92!M;VYT:',@;V8@
M,C`Q,BP@86YD(&UA;F%G96UE;G0@:6YT96YD<R!T;R!C;VYT:6YU90T*<F5S
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M92!L96%D(%1!4"`H5')A;G-P;W)T97)S(&]F($%N=&EG96X@4')O8V5S<VEN
M9RD-"G9A8V-I;F4@86YD(&EN9F5C=&EO=7,@9&ES96%S92!A9&IU=F%N="!T
M96-H;F]L;V=Y+B!3=')A=&5G:6,@<&%R=&YE<G-H:7!S('=I;&P@8F4@;F5E
M9&5D('1O(&-O;G1I;G5E('1H92!P<F]D=6-T(&1E=F5L;W!M96YT#0IP;W)T
M9F]L:6\@86YD(&9U;F0@9&5V96QO<&UE;G0@8V]S=',N(%1H97-E(&UE87-U
M<F5S+"!I9B!S=6-C97-S9G5L+"!M87D@8V]N=')I8G5T92!T;R!R961U8V4@
M=&AE(')I<VL@;V8@9V]I;F<@8V]N8V5R;B!U;F-E<G1A:6YT:65S#0IF;W(@
M=&AE($-O;7!A;GD@;W9E<B!T:&4@;F5X="!T=V5L=F4@;6]N=&AS+B`\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-
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M8FEL:71Y+CPO9F]N=#X\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ
M(#!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S-U\T.3$X
M7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E82]7;W)K
M<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY53D%51$E4140@0T].4T],241!5$5$($9)3D%.0TE!3"!3
M5$%414U%3E13($9/4B!!3B!)3E1%4DE-(%!%4DE/1#QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&5S('1O($9I
M;F%N8VEA;"!3=&%T96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5.055$251%1"!#3TY33TQ)1$%4140@1DE.04Y#
M24%,(%-4051%345.5%,@1D]2($%.($E.5$5224T@4$5224]$/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P
M="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,3)P="`P(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M=')A;G-F;W)M
M.B!U<'!E<F-A<V4G/CQU/DYO=&4-"C(Z)B,Y.U5.055$251%1"!#3TY33TQ)
M1$%4140@1DE.04Y#24%,(%-4051%345.5%,@1D]2($%.($E.5$5224T@4$52
M24]$/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V
M<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY"87-I
M<PT*;V8@4')E<V5N=&%T:6]N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M82`H)B,Q-#<[52Y3+B!'04%0)B,Q-#@[*2X@4')E<&%R:6YG(&9I;F%N8VEA
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M+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
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M;GDF(S$T-CMS(&%N;G5A;"!R97!O<G0@;VX@1F]R;2`Q,"U+(&9I;&5D(&]N
M($%P<FEL(#$V+"`R,#$R+"!W:71H('1H92!5+E,N(%-E8W5R:71I97,@86YD
M($5X8VAA;F=E($-O;6UI<W-I;VXN/"]F;VYT/CPO<#X-"@T*#0H-"CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%4T5!4D-(($%'4D5%345.5%,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y215-%05)#2"!!
M1U)%14U%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S
M='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,3)P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('1E>'0M=')A;G-F;W)M.B!U<'!E<F-A<V4G/CQU/DYO=&4-"C,Z)B,Y
M.U)E<V5A<F-H($%G<F5E;65N=',\+W4^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@:71A;&EC(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\=3Y#<G5C96QL#0I(;VQL86YD($(N5BX@
M*"8C,30W.T-R=6-E;&PF(S$T.#LI("8C,34P.R!297-E87)C:"!,:6-E;G-E
M(&%N9"!/<'1I;VX@06=R965M96YT/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^169F96-T:79E#0I!=6=U<W0@-RP@,C`P,RP@0W)U8V5L;"!A
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M<B!T:&4@9FEV92UY96%R('1E<FT@=&]T86QI;F<@175R;R`F(S$R.#LT-3`L
M,#`P+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^070-"D1E8V5M8F5R
M(#,Q+"`R,#`X+"`D,C0S+#4Y."`H)B,Q,C@[,3<R+#@P,2D@=V%S(&]W:6YG
M('1O($-R=6-E;&P@=6YD97(@=&AI<R!A9W)E96UE;G0N($1U<FEN9R!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`P.2P-"FUA;F%G96UE;G0@;F5G
M;W1I871E9"!A('-E='1L96UE;G0@;V8@=&AE(&]U='-T86YD:6YG(&)A;&%N
M8V4@<F5Q=6ER:6YG(&$@)B,Q,C@[,3<L,#`P(&-A<V@@<&%Y;65N="`H<&%I
M9"D@86YD('1H92!I<W-U86YC92!O9@T*,C8U+#`P,"!S:&%R97,@;V8@=&AE
M($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:R`H<F5F97(@=&\@3F]T92`Y
M*2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^26X@861D:71I;VXL(')E=')O86-T:79E;'D@
M969F96-T:79E($%U9W5S="`W+"`R,#`X+`T*=&AE($-O;7!A;GD@;F5G;W1I
M871E9"!A;B!A;65N9&5D(&QI8V5N<V4@86=R965M96YT(&9O<B!T:&4@=7-E
M(&]F($-R=6-E;&PF(S$T-CMS(&%D96YO=FER=7,@=&5C:&YO;&]G>2X@5&AE
M($-O;7!A;GD@:7,@<F5Q=6ER960-"G1O(&UA:V4@86YN=6%L(&QI8V5N<V4@
M<&%Y;65N=',@;VX@=&AE(&%N;FEV97)S87)Y(&]F('1H92!E9F9E8W1I=F4@
M9&%T92!F;W(@=&AE('1H<F5E('EE87(@=&5R;2!E<75A;"!T;R`F(S$R.#LW
M-2PP,#`@<&5R(&%N;G5M+@T*07,@870@4V5P=&5M8F5R(#,P+"`R,#$R+"!T
M:&4@0V]M<&%N>2!H860@86-C<G5E9"`D,S8U+#DW,"`H)B,Q,C@[,C@T+#4W
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M="!T:&4@;&EC96YS92!A9W)E96UE;G0@=VEL;`T*8F4@;6%I;G1A:6YE9"!O
M<B!T:&%T(&UA;F%G96UE;G0@=VEL;"!S=6-C97-S9G5L;'D@;F5G;W1I871E
M(&YE=R!T97)M<RX\+V9O;G0^/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G;6%R
M9VEN.B`P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-A-S`X-#5A7S$T,S=?
M-#DQ.%]A-6)F7S$R,F4T8V1E,S5E80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C83<P.#0U85\Q-#,W7S0Y,3A?835B9E\Q,C)E-&-D93,U96$O
M5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^1$52259!5$E612!705)204Y4($Q)04))3$E462!!
M3D0@1D%)4B!604Q513QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DYO=&5S('1O($9I;F%N8VEA;"!3=&%T96UE;G1S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1%
M4DE6051)5D4@5T%24D%.5"!,24%"24Q)5%D@04Y$($9!25(@5D%,544\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I
M;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`Q,G!T(#`@
M,"<^/&9O;G0@<W1Y;&4],T0G=&5X="UT<F%N<V9O<FTZ('5P<&5R8V%S92<^
M/'4^3F]T92`T.B8C.3M$15))5D%4259%#0I705)204Y4($Q)04))3$E462!!
M3D0@1D%)4B!604Q513PO=3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY
M(&AA<R!E=F%L=6%T960@=&AE(&%P<&QI8V%T:6]N#0I!4T,@-#@P+3$P(#QI
M/D1I<W1I;F=U:7-H:6YG(&QI86)I;&ET:65S(&9R;VT@97%U:71Y/"]I/BP@
M05-#(#@Q-2TT,"`\:3Y#;VYT<F%C=',@:6X@86X@16YT:71Y)B,Q-#8[<R!/
M=VX@17%U:71Y/"]I/B!A;F0@05-#(#<Q."TQ,`T*/&D^0V]M<&5N<V%T:6]N
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M=&AR;W5G:"`R,#$R+B!"87-E9`T*;VX@=&AE(&=U:61A;F-E+"!M86YA9V5M
M96YT(&-O;F-L=61E9"!T:&5S92!I;G-T<G5M96YT<R!A<F4@<F5Q=6ER960@
M=&\@8F4@86-C;W5N=&5D(&9O<B!A<R!D97)I=F%T:79E<R!E:71H97(@9'5E
M('1O(&$@<F%T8VAE=`T*9&]W;B!P<F]T96-T:6]N(&9E871U<F4@879A:6QA
M8FQE(&]N('1H92!E>&5R8VES92!P<FEC92`H3F]T92`U*2!O<B!A(&AO;&1E
M<B8C,30V.W,@<FEG:'0@=&\@<'5T('1H92!W87)R86YT<R!B86-K('1O('1H
M92!#;VUP86YY#0IF;W(@8V%S:"!U;F1E<B!C97)T86EN(&-O;F1I=&EO;G,@
M;W(@82!C;VYV97)S:6]N(&]P=&EO;B!F96%T=7)E('=I=&@@8V]N=F5R<VEO
M;B!I;G1O('9A<FEA8FQE(&YU;6)E<B!O9B!S:&%R97,N(%5N9&5R($%30R`X
M,34M-#`M,C4L#0IT:&4@0V]M<&%N>2!R96-O<F1S('1H92!F86ER('9A;'5E
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M;G1S(&%R92!R96-O<F1E9"!O;B!T:&4@8F%L86YC92!S:&5E="!U;F1E<B`F
M(S$T-3M$97)I=F%T:79E(&QI86)I;&ET>2`F(S$U,#L@=V%R<F%N=',F(S$T
M-CL-"F%N9"!T:&4@9F%I<B!V86QU92!O9B!T:&4@8V]N=F5R<VEO;B!O<'1I
M;VYS(&%R92!R96-O<F1E9"!O;B!T:&4@8F%L86YC92!S:&5E="!U;F1E<B`F
M(S$T-3M$97)I=F%T:79E(&QI86)I;&ET>2`F(S$U,#L@8V]N=F5R<VEO;@T*
M;W!T:6]N)B,Q-#8[+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P
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M=F%L=64N($%30R`X,C`M,3`@9&5S8W)I8F5S('1H<F5E(&QE=F5L<R!O9B!I
M;G!U=',@=&AA="!M87D@8F4@=7-E9"!T;R!M96%S=7)E(&9A:7(@=F%L=64Z
M($QE=F5L(#$@)B,Q-3`[#0I1=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K
M971S(&9O<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S.R!,979E
M;"`R("8C,34P.R!/8G-E<G9A8FQE(&EN<'5T<R!O=&AE<B!T:&%N($QE=F5L
M(#$@<')I8V5S+`T*<W5C:"!A<R!Q=6]T960@<')I8V5S(&9O<B!S:6UI;&%R
M(&%S<V5T<R!O<B!L:6%B:6QI=&EE<SL@;W(@;W1H97(@:6YP=71S('1H870@
M87)E(&]B<V5R=F%B;&4@;W(@8V%N(&)E(&-O<G)O8F]R871E9"!B>2!O8G-E
M<G9A8FQE#0IM87)K970@9&%T82!F;W(@<W5B<W1A;G1I86QL>2!T:&4@9G5L
M;"!T97)M(&]F('1H92!A<W-E=',@;W(@;&EA8FEL:71I97,[(&%N9"!,979E
M;"`S("8C,34P.R!5;F]B<V5R=F%B;&4@:6YP=71S('1H870@87)E('-U<'!O
M<G1E9`T*8GD@;&ET=&QE(&]R(&YO(&UA<FME="!A8W1I=FET>2!A;F0@=&AA
M="!A<F4@9FEN86YC:6%L(&EN<W1R=6UE;G1S('=H;W-E('9A;'5E<R!A<F4@
M9&5T97)M:6YE9"!U<VEN9R!P<FEC:6YG(&UO9&5L<RP@9&ES8V]U;G1E9`T*
M8V%S:"!F;&]W(&UE=&AO9&]L;V=I97,L(&]R('-I;6EL87(@=&5C:&YI<75E
M<RP@87,@=V5L;"!A<R!I;G-T<G5M96YT<R!F;W(@=VAI8V@@=&AE(&1E=&5R
M;6EN871I;VX@;V8@9F%I<B!V86QU92!R97%U:7)E<R!S:6=N:69I8V%N=`T*
M:G5D9VUE;G0@;W(@97-T:6UA=&EO;BX@5&AE($-O;7!A;GDF(S$T-CMS($QE
M=F5L(#,@;&EA8FEL:71I97,@8V]N<VES="!O9B!T:&4@9&5R:79A=&EV92!L
M:6%B:6QI=&EE<R!A<W-O8VEA=&5D('=I=&@@=&AE('=A<G)A;G1S#0II<W-U
M960@=VET:"!T:&4@8V]N=F5R=&EB;&4@;F]T97,@9'5R:6YG('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+B!!="!397!T96UB97(@,S`L(#(P
M,3(L(&%L;"!O9B!T:&4@0V]M<&%N>28C,30V.W,@9&5R:79A=&EV90T*;&EA
M8FEL:71I97,@=V5R92!C871E9V]R:7IE9"!A<R!,979E;"`S(&9A:7(@=F%L
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M(&UE87-U<F5M96YT(&]F('1H92!I;G-T<G5M96YT+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3Y,
M979E;"`S(%9A;'5A=&EO;B!496-H;FEQ=65S/"]I/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&:6YA
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
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M<')I8VEN9R!M;V1E;',@9F]R('=A<G)A;G1S(&%N9`T*;W!T:6]N<R!A;F0@
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M,T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[('!A9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/D1E8V5M
M8F5R(#,Q+"`R,#$Q/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A9&1I
M;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/E-E<'1E;6)E<B`S,"P@
M,C`Q,CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@=VED=&@Z(#(V)3L@8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,"4[(&)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!C96YT97(G/D5X<&5C=&5D($QI9F4@*%EE87)S*3PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I
M9'1H.B`Q,"4[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L
M:60[('!A9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/E)I<VL@
M9G)E92!2871E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VED=&@Z(#DE.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#$N-7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SY$:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Y)3L@8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^5F]L871I;&ET>3PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Y)3L@
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN
M9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^17AP96-T960@3&EF92`H
M665A<G,I/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VED=&@Z(#DE.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT
M(#$N-7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SY2:7-K(&9R964@4F%T93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Y)3L@8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^1&EV:61E;F0@>6EE;&0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@.24[
M(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I
M;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/E9O;&%T:6QI='D\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY3:&%R92!P=7)C:&%S92!W
M87)R86YT<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/C$N
M,#D@=&\@-"XX,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/C`N,3(E('1O(#`N.#,E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^,"XP,"4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXQ.3DE/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^,"XS
M,R!T;R`T+C`S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M,"XQ,"4@=&\@,"XV,B4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SXP+C`P)3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/C$Y.24\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q
M,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A9&1I;F<M=&]P
M.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^070@26YI=&EA;"!296-O9VYI=&EO;CPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SY397!T96UB97(@,S`L(#(P,3(\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`R-"4[(&)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M
M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@
M.24[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A
M9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/D5X<&5C=&5D($QI
M9F4@*%EE87)S*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Y)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^4FES:R!F<F5E(%)A=&4\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@.24[(&)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!C96YT97(G/D1I=FED96YD('EI96QD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z
M(#$Q)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@
M<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^5F]L871I;&ET
M>3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=I9'1H.B`Y)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P
M="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M17AP96-T960@3&EF92`H665A<G,I/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#DE.R!B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SY2:7-K(&9R964@4F%T93PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Y
M)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D
M9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^1&EV:61E;F0@>6EE
M;&0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N
M-7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SY6;VQA=&EL:71Y/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M0V]N=F5R<VEO;B!/<'1I;VX\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SXP+C(U('1O(#$N,#0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SXP+C$Q)2!T;R`P+C(P)3PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/C`N,#`E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^,3,X+C,Q)2!T;R`Q-#$N-#,E/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^,"XQ,2!T;R`Q+C`P/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S
M;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^,"XP-B4@=&\@,"XQ-R4\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXP+C`P)3PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/C$S."XS,24@=&\@,30Q+C(Q)3PO
M=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@9F]R
M96=O:6YG(&%S<W5M<'1I;VYS(&%R92!R979I97=E9`T*<75A<G1E<FQY(&%N
M9"!A<F4@<W5B:F5C="!T;R!C:&%N9V4@8F%S960@<')I;6%R:6QY(&]N(&UA
M;F%G96UE;G0F(S$T-CMS(&%S<V5S<VUE;G0@;V8@=&AE('!R;V)A8FEL:71Y
M(&]F('1H92!E=F5N=',@9&5S8W)I8F5D#0IO8V-U<G)I;F<N($%C8V]R9&EN
M9VQY+"!C:&%N9V5S('1O('1H97-E(&%S<V5S<VUE;G1S(&-O=6QD(&UA=&5R
M:6%L;'D@869F96-T('1H92!V86QU871I;VYS+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3Y&:6YA
M;F-I86P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9`T*870@1F%I
M<B!686QU92!O;B!A(%)E8W5R<FEN9R!"87-I<SPO:3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1FEN
M86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A<W5R960-"F%T(&9A
M:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,@87)E('-U;6UA<FEZ960@
M8F5L;W<@86YD(&1I<V-L;W-E9"!O;B!T:&4@8F%L86YC92!S:&5E="!U;F1E
M<B!$97)I=F%T:79E(&QI86)I;&ET>2`F(S$U,#L@=V%R<F%N=',Z/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T
M97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&QE9G0G/CQB/B8C,38P.SPO8CX\+W`^#0H@("`@("`@(#QP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@;&5F="<^/&(^07,@;V8@
M4V5P=&5M8F5R(#,P+"`R,#$R(#PO8CX\+W`^/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q+C5P
M="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q+C5P
M="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@(#QP('-T
M>6QE/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$
M)V9O;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z
M(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q
M-C`[/"]P/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#4@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/D9A:7(@5F%L=64@365A<W5R
M96UE;G1S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y
M;&4],T0G9F]N=#H@-'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G
M9F]N=#H@-'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/B8C,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@
M-'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/B8C,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@-'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P
M.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X
M="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C
M96YT97(G/D-A<G)Y:6YG(%9A;'5E/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/DQE=F5L
M(#$\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^3&5V96P@,CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY,979E;"`S/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P
M+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT
M97(G/E1O=&%L/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^1&5R:79A=&EV92!L:6%B:6QI='D@+2!W
M87)R86YT<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R`X-S$L.#4X/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXD)B,Q-C`[(#@W,2PX-3@\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@
M.#<Q+#@U.#PO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/D1E<FEV871I=F4@;&EA8FEL:71Y("8C,34P
M.R!C;VYV97)S:6]N(&]P=&EO;CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,C`P+#<P
M,#PO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,C`P+#<P,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,C`P+#<P,#PO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P
M="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/E1O=&%L/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`P+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q-C`[(#$L,#<R
M+#4U.#PO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R`Q+#`W,BPU
M-3@\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T
M97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@,2PP-S(L-34X
M/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S8E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$S)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T
M86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M
M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q
M+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S
M;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&QE9G0G/CQB/B8C,38P.SPO8CX\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY!<R!O9B!$96-E;6)E
M<B`S,2P@,C`Q,3PO8CX\+W`^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+71O<#H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9"<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M="<^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@
M("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@
M(#QP('-T>6QE/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#,@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G
M/D9A:7(@5F%L=64@365A<W5R96UE;G1S(%5S:6YG/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#,@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N
M=#H@-'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/B8C,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@-'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C
M,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@-'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO
M<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@-'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"B`@
M("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S
M;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/D-A
M<G)Y:6YG(%9A;'5E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T
M97AT+6%L:6=N.B!C96YT97(G/DQE=F5L(#$\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<B<^3&5V96P@,CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SY,979E;"`S/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/E1O=&%L/"]T9#X\+W1R/@T*
M/'1R/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^
M1&5R:79A=&EV92!L:6%B:6QI='D@+2!W87)R86YT<SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)"8C,38P.R`Q+#,Q-RPX,S0\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B0F(S$V,#L@,2PS,3<L.#,T/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#,@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXD)B,Q-C`[(#$L,S$W+#@S-#PO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY4;W1A;#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B0F(S$V,#L@,2PS,3<L.#,T/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^+28C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q-C`[(#$L,S$W+#@S-#PO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@,2PS
M,3<L.#,T/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,S,E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,3(E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3(E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3(E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!T86)L92!B96QO
M=R!P<F]V:61E<R!A('-U;6UA<GD@;V8-"G1H92!C:&%N9V5S(&EN(&9A:7(@
M=F%L=64L(&EN8VQU9&EN9R!N970@=')A;G-F97)S+"!I;B!A;F0O;W(@;W5T
M+"!O9B!F:6YA;F-I86P@87-S971S(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E
M9"!A="!F86ER('9A;'5E(&]N#0IA(')E8W5R<FEN9R!B87-I<R!U<VEN9R!S
M:6=N:69I8V%N="!U;F]B<V5R=F%B;&4@:6YP=71S("A,979E;"`S*2!D=7)I
M;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,B!A
M;F0@=&AE('EE87(@96YD960-"D1E8V5M8F5R(#,Q+"`R,#$Q.CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`T<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q
M-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`T<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P
M/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`T<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@
M("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T
M('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SX\8CY&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN9R!,979E
M;"`S($EN<'5T<SPO8CX\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<"<^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@
M(#QP('-T>6QE/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W`^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SY$97)I=F%T:79E(&QI86)I;&ET>2`M('=A<G)A;G1S/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SY$97)I=F%T:79E(&QI86)I;&ET>2`F(S$U,#L@8V]N=F5R<VEO;B!O<'1I
M;VX\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N
M.B!C96YT97(G/E1O=&%L/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^0F%L86YC92PF
M(S$V,#L@1&5C96UB97(@,S$L(#(P,3`\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0@
M,2PX,3DL-3$R/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P
M="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"`Q-S4L,S@Y
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"`Q+#DY-"PY,#$\9F]N="!S
M='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^061D:71I;VYS(&1U<FEN9R!T:&4@>65A
M<CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^,2PU.#<L,C<U/&9O;G0@<W1Y;&4],T0G
M;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,2PU.#<L
M,C<U/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/E1O
M=&%L('5N<F5A;&EZ960@*&=A:6YS*2!O<B!L;W-S97,@:6YC;'5D960@:6X@
M;F5T(&QO<W,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B@V,S$L-C,Q*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^*#,W+#`W.2D\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B@V-C@L-S$P*3PO=&0^/"]T<CX-"CQT<CX-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/D1E8G0@<V5T=&QE;65N=#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^*#$L-#4W+#,R,BD\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B@Q,S@L,S$P*3PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M*#$L-3DU+#8S,BD\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY4<F%N<V9E<G,@
M:6X@86YD+V]R(&]U="!O9B!,979E;"`S/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D97(M=&]P.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/D)A;&%N8V4L($1E8V5M8F5R(#,Q+"`R,#$Q/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,2PS,3<L.#,T/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUT;W`Z('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\9F]N="!S='EL93TS
M1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R
M9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^,2PS,3<L.#,T/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP
M+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/D%D9&ET
M:6]N<R!D=7)I;F<@=&AE('EE87(\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(Y.2PS,#`F(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C(Y.2PS,#`F(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T)SY4;W1A;"!U;G)E86QI>F5D("AG86EN<RD@;W(@;&]S<V5S
M(&EN8VQU9&5D(&EN(&YE="!L;W-S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXH-#0U+#DW-BD\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@Y."PV,#`I/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH-30T+#4W-BD\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY$96)T('-E='1L96UE;G0\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V
M,#L\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T)SY4<F%N<V9E<G,@:6X@86YD+V]R(&]U="!O
M9B!,979E;"`S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,S4E.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^
M0F%L86YC92P@4V5P=&5M8F5R(#,P+"`R,#$R/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$S)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,3DE.R!B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@
M.#<Q+#@U."8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R
M,"4[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^)"`R,#`L-S`P/&9O;G0@<W1Y;&4],T0G;&5T=&5R
M+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,R4[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R`Q+#`W
M,BPU-3@F(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^
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M<R!A<F4@97AE<F-I<V5D+`T*97AP:7)E+"!O<B!A<F4@86UE;F1E9"!I;B!A
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M*2!I;@T*=&AE('-T871E;65N="!O9B!O<&5R871I;VYS+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)VUA
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M=`T*9&%T92P@=&AE(')I<VLM9G)E92!I;G1E<F5S="!R871E(&)A<V5D(&]N
M(%4N4RX@5')E87-U<GD@<V5C=7)I='D@>6EE;&1S+"!A;F0@=&AE($-O;7!A
M;GDF(S$T-CMS(&1I=FED96YD('EI96QD+B!4:&4@=V%R<F%N="!R97%U:7)E
M<PT*=7-E(&]F(&$@=F]L871I;&ET>2!A<W-U;7!T:6]N(&5Q=6%L('1O('1H
M92!G<F5A=&5R(&]F(#$P,"4@86YD('1H92`Q,#`M9&%Y('9O;&%T:6QI='D@
M9G5N8W1I;VX@9&5T97)M:6YE9"!A<R!O9B!T:&4@=')A9&EN9R!D87D-"FEM
M;65D:6%T96QY(&9O;&QO=VEN9R!A;FYO=6YC96UE;G0@;V8@82!&=6YD86UE
M;G1A;"!4<F%N<V%C=&EO;BX\+V9O;G0^/"]P/@T*#0H-"@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0G/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T
M8V1E,S5E80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C83<P.#0U
M85\Q-#,W7S0Y,3A?835B9E\Q,C)E-&-D93,U96$O5V]R:W-H965T<R]3:&5E
M=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0T].5D525$E"3$4@3D]415,@4$%904),13QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!A>6%B;&5S(&%N9"!!8V-R
M=6%L<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-/3E9%4E1)0DQ%($Y/5$53(%!!64%"3$4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@
M,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`Q,G!T(#`@,"<^
M/&9O;G0@<W1Y;&4],T0G=&5X="UT<F%N<V9O<FTZ('5P<&5R8V%S92<^/'4^
M3F]T92`U.B8C.3M#3TY615)424),10T*3D]415,@4$%904),13PO=3X\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N
M,7!T)SY4:&4-"F9O;&QO=VEN9R!I<R!A('-U;6UA<GD@;V8@9&5B="!I;G-T
M<G5M96YT('1R86YS86-T:6]N<R!T:&%T(&%R92!R96QE=F%N="!T;R!T:&4@
M8W5R<F5N="!P97)I;V0Z/"]F;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-#,E
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$S)3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^/&(^)B,Q-C`[/"]B/CPO<#X-"B`@("`@("`@
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/B8C
M,38P.SPO8CX\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SX\8CY&86-E(%9A;'5E/"]B/CPO<#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@(#QP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CXF(S$V,#L\+V(^
M/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^/&(^4')I;F-I<&%L(%)E<&%Y;65N=#PO8CX\+W`^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&(^56YA;6]R=&EZ
M960\+V(^/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^/&(^3F]T93PO8CX\+W`^#0H@("`@("`@(#QP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY$:7-C;W5N
M=#PO8CX\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$V)3L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/@T*
M("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^/&(^0F%L86YC92!A=#PO8CX\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY397!T96UB97(@,S`L
M/"]B/CPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!C96YT97(G/CQB/C(P,3(\+V(^/"]P/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E
M>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW
M96EG:'0Z(&)O;&0G/D9E8G)U87)Y(#(P,3$@4V5C=7)E9"!#;VYV97)T:6)L
M92!.;W1E<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^4V5N:6]R(%-E
M8W5R960@3F]T97,L(&1U92!&96)R=6%R>2`R-"P@,C`Q-#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"`Q+#$X-"PV.30\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[("TF(S$V,#LF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B0F(S$V,#LF(S$V,#LF(S$V,#L@,C(U+#@P,"8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"`Y
M-3@L.#DT/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0G/D%P
M<FEL(#(P,3$@4V5C=7)E9"!#;VYV97)T:6)L92!.;W1E<SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P="<^4V5N:6]R(%-E8W5R960@3F]T97,L(&1U92!!
M<')I;"`T+"`R,#$T/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXR,34L,#`P/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[("TF(S$V,#LF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C4Q+#<X-B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,38S+#(Q
M-#QF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SY*=6YE(#(P
M,3$@4V5C=7)E9"!#;VYV97)T:6)L92!.;W1E/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T)SY396YI;W(@4V5C=7)E9"!.;W1E<RP@9'5E($IU;F4@-BP@
M,C`Q-#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M,S`L,#`P/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[("TF(S$V,#LF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/C0L-C4P)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR-2PS-3`\9F]N="!S='EL
M93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^075G=7-T(#@L(#(P,3(@0V]N
M=F5R=&EB;&4@3F]T93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^3F]T
M92!D=64@075G=7-T(#@L(#(P,3,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C$Q,2PT,S`\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@+28C,38P.R8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^.34L,C4P
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXQ-BPQ.#`\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^
M075G=7-T(#$R+"`R,#$R($-O;G9E<G1I8FQE($YO=&4\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/DYO=&4@9'5E($YO=F5M8F5R(#$R+"`R,#$R/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR-RPU,#`\
M9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#L@+28C,38P.R8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^,3$L-C4X)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ-2PX-#(\9F]N="!S='EL93TS1"=L
M971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9"<^075G=7-T(#(P+"`R,#$R($-O;G9E<G1I
M8FQE($YO=&4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/DYO=&4@9'5E
M($%U9W5S="`R,"P@,C`Q,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^,C`L,#`P/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I
M;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[("TF(S$V,#LF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$W+#<U-R8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,BPR
M-#4\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^4V5P=&5M
M8F5R(#(P,3(@0V]N=F5R=&EB;&4@3F]T93PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M="<^3F]T92!D=64@3V-T;V)E<B`Q+"`R,#$S/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXX,BPU,#`\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@+28C,38P.R8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-SDL.#<T)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR+#8R-CQF;VYT('-T>6QE
M/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^5&]T86P\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T
M('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0@,2PV-S$L,3(T/&9O;G0@<W1Y
M;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`M)B,Q-C`[
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q
M-C`[)B,Q-C`[)B,Q-C`[(#0X-BPW-S,F(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B0@,2PQ.#0L,S4Q/&9O;G0@<W1Y;&4],T0G
M;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB/B8C,38P.SPO
M8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^)B,Q-C`[/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CY&96)R=6%R>2`R,#$Q(%-E
M8W5R960@0V]N=F5R=&EB;&4@3F]T97,\+V(^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($9E8G)U
M87)Y(#(T+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D#0II;G1O(&$@<V5C
M=7)I=&EE<R!P=7)C:&%S92!A9W)E96UE;G0@=VET:"!A8V-R961I=&5D(&EN
M=F5S=&]R<R!T;R!P;&%C92!396YI;W(@4V5C=7)E9"!#;VYV97)T:6)L92!.
M;W1E<R`H=&AE("8C,30W.T9E8G)U87)Y(#(P,3$-"DYO=&5S)B,Q-#@[*2!W
M:71H(&$@;6%T=7)I='D@9&%T92!O9B!T:')E92!Y96%R<R!A9G1E<B!T:&4@
M:7-S=6%N8V4@=&AE<F5O9B!I;B!T:&4@86=G<F5G871E('!R:6YC:7!A;"!A
M;6]U;G0@;V8@)#$L,3@T+#8Y-"X@0V]N<VED97)A=&EO;@T*=6YD97(@=&AE
M(&YO=&5S(&-O;G-I<W1E9"!O9B`D.30T+#8Y-"!I;B!C87-H('!R;V-E961S
M+"!I;F-L=61I;F<@86-C<G5E9"!I;G1E<F5S="P@86YD("0R-#`L,#`P('=A
M<R!S=6)S8W)I8F5D(&9O<B!B>2!T=V\@;V8@=&AE#0IH;VQD97)S(&]F(&]U
M='-T86YD:6YG(&%N9"!D96UA;F1A8FQE(#(P,3`@<V5C=7)E9"!C;VYV97)T
M:6)L92!N;W1E<R`H=&AE("8C,30W.S(P,3`@3F]T97,F(S$T.#LI+B!4:&4@
M:&]L9&5R<R!O9B!T:&4@,C`Q,"!.;W1E<PT*<F5T=7)N960@=&AE:7(@4V5R
M:65S($$L(%-E<FEE<R!"(&%N9"!397)I97,@0R!W87)R86YT<R!T;R!T:&4@
M0V]M<&%N>2!F;W(@8V%N8V5L;&%T:6]N+B!);B!C;VYN96-T:6]N('=I=&@@
M=&AE(&ES<W5A;F-E(&]F('1H90T*1F5B<G5A<GD@,C`Q,2!.;W1E<RP@=&AE
M($-O;7!A;GD@96YT97)E9"!I;G1O(&$@,C`Q,2!396-U<FET>2!!9W)E96UE
M;G0@=VET:"!T:&4@;F]T92!H;VQD97)S('-E8W5R:6YG('1H92!&96)R=6%R
M>2`R,#$Q($YO=&5S#0IW:71H(&%L;"!O9B!T:&4@0V]M<&%N>28C,30V.W,@
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M<VEO;B!R871E(&]F("0P+C$U('!E<B!S:&%R92X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE($9E
M8G)U87)Y(#(P,3$@3F]T97,@8F5A<B!I;G1E<F5S=`T*870@=&AE(')A=&4@
M;V8@,3`E('!E<B!A;FYU;2!E>&-E<'0@:6X@8V%S92!O9B!D969A=6QT+"!I
M;B!W:&EC:"!C87-E('1H97D@8F5A<B!I;G1E<F5S="!A="!T:&4@<F%T92!O
M9B`R,"4@<&5R(&%N;G5M+B!4:&4@:6YT97)E<W0-"FES(&1U92!O;B!T:&4@
M1F5B<G5A<GD@,C`Q,2!.;W1E<R!A="!T:&4@96YD(&]F(&5A8V@@=&AR964@
M;6]N=&@@<&5R:6]D+"!S=&%R=&EN9R!T:')E92!M;VYT:',@9G)O;2!T:&5I
M<B!I<W-U86YC92X@3VYE('EE87(@869T97(-"G1H92!I<W-U86YC92!O9B!T
M:&4@1F5B<G5A<GD@,C`Q,2!.;W1E<RP@=&AE($-O;7!A;GD@;6%Y(&5L96-T
M('1O('!R97!A>2!A('!O<G1I;VX@;V8@=&AE('!R:6YC:7!A;"X@268@=&AE
M($-O;7!A;GD@;6%K97,@<W5C:`T*86X@96QE8W1I;VXL('1H92!H;VQD97)S
M(&UA>2!E;&5C="!T;R!R96-E:79E('-U8V@@<')E<&%Y;65N="!I;B!C87-H
M(&]R(&EN('-H87)E<R!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T
M;V-K+"!A="!A(&-O;G9E<G-I;VX-"G)A=&4@;V8@)#`N,34@<&5R('-H87)E
M+"!O<B!I;B!A(&-O;6)I;F%T:6]N('1H97)E;V8N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#
M;VUP86YY('!A:60@82!F:6YD97)S)B,Q-#8[(&9E90T*;V8@)#0Q+#4P,"X@
M5&AE(&9I;F1E<B8C,30V.W,@9F5E('=A<R!A8V-O=6YT960@9F]R(&%S(&1E
M9F5R<F5D(&9I;F%N8VEN9R!C;W-T<RP@86YD(&ES(&)E:6YG(&%M;W)T:7IE
M9"!O=F5R('1H92!T97)M(&]F('1H92!N;W1E<RX-"D%T(%-E<'1E;6)E<B`S
M,"P@,C`Q,BP@)#$X+#0Y-2!O9B!T:&4@)#(P+#<V."!I;B!D969E<G)E9"!F
M:6YA;F-I;F<@8V]S=',@<F5L871E<R!T;R!T:&4@1F5B<G5A<GD@,C`Q,2!.
M;W1E<R!W:&EC:"!R96UA:6YS('5N86UO<G1I>F5D+`T*86YD(&ES('!R97-E
M;G1E9"!I;B!L;VYG+71E<FT@87-S971S(&]N('1H92!#;VUP86YY)B,Q-#8[
M<R!"86QA;F-E(%-H965T+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@
M,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!C;VYN96-T:6]N('=I=&@@
M=&AE(&ES<W5A;F-E(&]F('1H90T*1F5B<G5A<GD@,C`Q,2!.;W1E<RP@=&AE
M($-O;7!A;GD@:7-S=65D(#(L,S8Y+#,X."!W87)R86YT<RP@97AE<F-I<V%B
M;&4@:6YT;R!C;VUM;VX@<W1O8VL@870@)#`N,C4@=VET:"!F:79E('EE87(@
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M96%T97(@=&AA;B`D,C4L,#`P(&%N9"!T:&5R92!I<R!A;B!E9F9E8W1I=F4@
M<F5G:7-T<F%T:6]N('-T871E;65N="!C;W9E<FEN9R!T:&4@<F5S86QE(&]F
M#0IT:&4@<VAA<F5S('5N9&5R;'EI;F<@=&AE('=A<G)A;G1S+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`V<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M069T97(@<F5V:65W:6YG(&$@1G5N9&%M96YT86P@5')A;G-A8W1I;VX-"F-L
M875S92!C;VYT86EN960@:6X@=&AE('=A<G)A;G1S+"!T:&4@0V]M<&%N>2!A
M;&QO8V%T960@=&AE(&YE="!P<F]C965D<R!T;R!T:&4@=V%R<F%N=',@8F%S
M960@;VX@=&AE(&-A;&-U;&%T960@9F%I<B!V86QU92!A=`T*=&AE(&1A=&4@
M;V8@:7-S=6%N8V4N(%1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT<R!W
M87,@<F5C;W)D960@870@)#0X,RPS-34@86YD(')E8V]G;FEZ960@87,@9&5R
M:79A=&EV92!L:6%B:6QI=&EE<R!A;F0@=&AE#0ID96)T('=A<R!R96-O<F1E
M9"!A="`D-S`Q+#,S.2X@5&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S
M('=A<R!C86QC=6QA=&5D('5S:6YG('1H92!":6YO;6EA;"!O<'1I;VX@<')I
M8VEN9R!M;V1E;"!U;F1E<B!T:&4-"F9O;&QO=VEN9R!A<W-U;7!T:6]N<SH@
M97-T:6UA=&5D(&QI9F4@;V8@9FEV92!Y96%R<RP@<FES:R!F<F5E(')A=&4@
M;V8@,BXP-B4L(&1I=FED96YD('EI96QD(&]F(#`E(&%N9"!V;VQA=&EL:71Y
M(&]F(#$Y.24N(%1H90T*9&5B="!D:7-C;W5N="!I<R!B96EN9R!A8V-R971E
M9"!O=F5R('1H92!T:')E92!Y96%R('1E<FT@;V8@=&AE($9E8G)U87)Y(#(P
M,3$@3F]T97,@=7-I;F<@=&AE(&5F9F5C=&EV92!I;G1E<F5S="!R871E(&UE
M=&AO9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/D9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R(#,P+`T*,C`Q,BP@86-C<F5T:6]N(&]F('1H92!D96)T(&1I<V-O=6YT
M(&]F("0Q,C`L.#,Y('=A<R!R96-O<F1E9"!F;W(@=&AE($9E8G)U87)Y(#(P
M,3$@3F]T97,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D%P<FEL(#(P,3$@4V5C=7)E9"!#;VYV
M97)T:6)L92!.;W1E<SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T
M(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@07!R:6P@-"P@,C`Q,2P@
M=&AE($-O;7!A;GD@96YT97)E9`T*:6YT;R!A('-E8W5R:71I97,@<'5R8VAA
M<V4@86=R965M96YT('=I=&@@86-C<F5D:71E9"!I;G9E<W1O<G,@=&\@<&QA
M8V4@4V5N:6]R(%-E8W5R960@0V]N=F5R=&EB;&4@3F]T97,@*'1H92`F(S$T
M-SM!<')I;"`R,#$Q#0I.;W1E<R8C,30X.RD@=VET:"!A(&UA='5R:71Y(&1A
M=&4@;V8@=&AR964@>65A<G,@869T97(@=&AE(&ES<W5A;F-E('1H97)E;V8@
M:6X@=&AE(&%G9W)E9V%T92!P<FEN8VEP86P@86UO=6YT(&]F("0R,34L,#`P
M+B!#;VYS:61E<F%T:6]N#0IU;F1E<B!T:&4@;F]T97,@8V]N<VES=&5D(&]F
M("0Q.3`L,#`P(&EN(&-A<V@@<')O8V5E9',L(&%N9"`D,C4L,#`P('=A<R!S
M=6)S8W)I8F5D(&9O<B!B>2!A(&AO;&1E<B!O9B`R,#$P($YO=&5S(&EN(&5X
M8VAA;F=E(&9O<@T*=&AE(&5X=&EN9W5I<VAM96YT(&]F('1H92!397)I97,@
M02P@4V5R:65S($(@86YD(%-E<FEE<R!#('=A<G)A;G1S(')E;&%T960@=&\@
M=&AE(#(P,3`@3F]T97,N($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N
M8V4@;V8-"G1H92!!<')I;"`R,#$Q($YO=&5S+"!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82`R,#$Q(%-E8W5R:71Y($%G<F5E;65N="!W:71H('1H92!N
M;W1E(&AO;&1E<G,@<V5C=7)I;F<@=&AE($%P<FEL(#(P,3$@3F]T97,@=VET
M:`T*82!S96-O;F1A<GD@<V5C=7)I='D@:6YT97)E<W0@:6X@86QL(&]F('1H
M92!#;VUP86YY)B,Q-#8[<R!A<W-E=',N($]N92!Y96%R(&%F=&5R('1H92!I
M<W-U86YC92!O9B!T:&4@07!R:6P@,C`Q,2!.;W1E<RP@=&AE(&YO=&4-"FAO
M;&1E<G,@:&%V92!T:&4@;W!T:6]N('1O(&-O;G9E<G0@82!P;W)T:6]N(&]R
M(&%L;"!O9B!T:&4@;W5T<W1A;F1I;F<@8F%L86YC92!O9B!T:&4@07!R:6P@
M,C`Q,2!.;W1E<R!I;F-L=61I;F<@86YY(&%C8W)U960@:6YT97)E<W0-"FEN
M=&\@<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@
M870@82!C;VYV97)S:6]N(')A=&4@;V8@)#`N,34@<&5R('-H87)E+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY4:&4@07!R:6P@,C`Q,2!.;W1E<R!B96%R(&EN=&5R97-T(&%T#0IT
M:&4@<F%T92!O9B`Q,"4@<&5R(&%N;G5M(&5X8V5P="!I;B!C87-E(&]F(&1E
M9F%U;'0L(&EN('=H:6-H(&-A<V4@=&AE>2!B96%R(&EN=&5R97-T(&%T('1H
M92!R871E(&]F(#(P)2!P97(@86YN=6TN(%1H92!I;G1E<F5S=`T*:7,@9'5E
M(&]N('1H92!!<')I;"`R,#$Q($YO=&5S(&%T('1H92!E;F0@;V8@96%C:"!T
M:')E92!M;VYT:"!P97)I;V0L('-T87)T:6YG('1H<F5E(&UO;G1H<R!F<F]M
M('1H96ER(&ES<W5A;F-E+B!/;F4@>65A<B!A9G1E<@T*=&AE(&ES<W5A;F-E
M(&]F('1H92!!<')I;"`R,#$Q($YO=&5S+"!T:&4@0V]M<&%N>2!M87D@96QE
M8W0@=&\@<')E<&%Y(&$@<&]R=&EO;B!O9B!T:&4@<')I;F-I<&%L+B!)9B!T
M:&4@0V]M<&%N>2!M86ME<R!S=6-H(&%N#0IE;&5C=&EO;BP@=&AE(&AO;&1E
M<G,@;6%Y(&5L96-T('1O(')E8V5I=F4@<W5C:"!P<F5P87EM96YT(&EN(&-A
M<V@@;W(@:6X@<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@
M<W1O8VLL(&%T(&$@8V]N=F5R<VEO;@T*<F%T92!O9B`D,"XQ-2!P97(@<VAA
M<F4L(&]R(&EN(&$@8V]M8FEN871I;VX@=&AE<F5O9BX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE
M($-O;7!A;GD@<&%I9"!A(&9I;F1E<G,F(S$T-CL@9F5E#0IO9B`D-"PU-3`N
M(%1H92!F:6YD97(F(S$T-CMS(&9E92!W87,@86-C;W5N=&5D(&9O<B!A<R!D
M969E<G)E9"!F:6YA;F-I;F<@8V]S=',L(&%N9"!I<R!B96EN9R!A;6]R=&EZ
M960@;W9E<B!T:&4@=&5R;2!O9B!T:&4@;F]T97,N#0I!="!397!T96UB97(@
M,S`L(#(P,3(L("0R+#(W,R!O9B!T:&4@)#(P+#<V."!I;B!D969E<G)E9"!F
M:6YA;F-I;F<@8V]S=',@<F5L871E<R!T;R!T:&4@07!R:6P@,C`Q,2!.;W1E
M<R!W:&EC:"!R96UA:6YS('5N86UO<G1I>F5D+`T*86YD(&ES('!R97-E;G1E
M9"!I;B!L;VYG+71E<FT@87-S971S(&]N('1H92!#;VUP86YY)B,Q-#8[<R!"
M86QA;F-E(%-H965T+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!C;VYN96-T:6]N('=I=&@@=&AE
M(&ES<W5A;F-E(&]F('1H90T*07!R:6P@,C`Q,2!.;W1E<RP@=&AE($-O;7!A
M;GD@:7-S=65D(#0S,"PP,#`@=V%R<F%N=',L(&5X97)C:7-A8FQE(&EN=&\@
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M96%T97(@=&AA;B`D,"XU,"P@=&AE(&%V97)A9V4@9&%I;'D@9&]L;&%R('9O
M;'5M92!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K('-O;&0-
M"F]V97(@=&AO<V4@=&5N('1R861I;F<@9&%Y<R!I<R!G<F5A=&5R('1H86X@
M)#(U+#`P,"!A;F0@=&AE<F4@:7,@86X@969F96-T:79E(')E9VES=')A=&EO
M;B!S=&%T96UE;G0@8V]V97)I;F<@=&AE(')E<V%L92!O9B!T:&4-"G-H87)E
M<R!U;F1E<FQY:6YG('1H92!W87)R86YT<RX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY
M(&AA<R!A;&QO8V%T960@=&AE(&YE="!P<F]C965D<PT*=&\@=&AE('=A<G)A
M;G1S(&)A<V5D(&]N('1H92!C86QC=6QA=&5D(&9A:7(@=F%L=64N(%1H92!F
M86ER('9A;'5E(&]F('1H92!W87)R86YT<R!W87,@<F5C;W)D960@870@)#$S
M,"PW,C`@86YD(')E8V]G;FEZ960@87,@9&5R:79A=&EV90T*;&EA8FEL:71I
M97,@86YD('1H92!D96)T('=A<R!R96-O<F1E9"!A="`D.#0L,C@P+B!4:&4@
M9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@=V%S(&-A;&-U;&%T960@=7-I
M;F<@=&AE($)I;F]M:6%L(&]P=&EO;B!P<FEC:6YG#0IM;V1E;"!U;F1E<B!T
M:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS.B!E<W1I;6%T960@;&EF92!O9B!T
M=V\@>65A<G,L(')I<VL@9G)E92!R871E(&]F(#`N-S<E+"!D:79I9&5N9"!Y
M:65L9"!O9B`P)2!A;F0@=F]L871I;&ET>0T*;V8@,3DY)2X@5&AE(&1E8G0@
M9&ES8V]U;G0@:7,@8F5I;F<@86-C<F5T960@;W9E<B!T:&4@=&AR964@>65A
M<B!T97)M(&]F('1H92!!<')I;"`R,#$Q($YO=&5S('5S:6YG('1H92!E9F9E
M8W1I=F4@:6YT97)E<W0@<F%T90T*;65T:&]D+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`V<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1F]R('1H92!N
M:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L#0HR,#$R+"!A8V-R971I
M;VX@;V8@=&AE(&1E8G0@9&ES8V]U;G0@;V8@)#(U+#<U,B!W87,@<F5C;W)D
M960@9F]R('1H92!!<')I;"`R,#$Q($YO=&5S+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY*=6YE
M(#(P,3$@4V5C=7)E9"!#;VYV97)T:6)L92!.;W1E/"]B/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/
M;B!*=6YE(#8L(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960-"FEN=&\@82!S
M96-U<FET:65S('!U<F-H87-E(&%G<F5E;65N="!W:71H(&%C8W)E9&ET960@
M:6YV97-T;W)S('1O('!L86-E(%-E;FEO<B!396-U<F5D($-O;G9E<G1I8FQE
M($YO=&4@*'1H92`F(S$T-SM*=6YE(#(P,3$@3F]T928C,30X.RD-"G=I=&@@
M82!M871U<FET>2!D871E(&]F('1H<F5E('EE87)S(&%F=&5R('1H92!I<W-U
M86YC92!T:&5R96]F(&EN('1H92!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N
M="!O9B`D,S`L,#`P+B!);B!C;VYN96-T:6]N('=I=&@-"G1H92!I<W-U86YC
M92!O9B!T:&4@2G5N92`R,#$Q($YO=&4L('1H92!#;VUP86YY(&5N=&5R960@
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M(&]U='-T86YD:6YG(&)A;&%N8V4@;V8@=&AE($IU;F4@,C`Q,2!.;W1E(&EN
M8VQU9&EN9R!A;GD@86-C<G5E9`T*:6YT97)E<W0@:6YT;R!S:&%R97,@;V8@
M=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:R!A="!A(&-O;G9E<G-I
M;VX@<F%T92!O9B`D,"XQ-2!P97(@<VAA<F4N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!*=6YE
M(#(P,3$@3F]T92!B96%R<R!I;G1E<F5S="!A=`T*=&AE(')A=&4@;V8@,3`E
M('!E<B!A;FYU;2!E>&-E<'0@:6X@8V%S92!O9B!D969A=6QT+"!I;B!W:&EC
M:"!C87-E(&ET(&)E87)S(&EN=&5R97-T(&%T('1H92!R871E(&]F(#(P)2!P
M97(@86YN=6TN(%1H92!I;G1E<F5S=`T*:7,@9'5E(&]N('1H92!*=6YE(#(P
M,3$@3F]T92!A="!T:&4@96YD(&]F(&5A8V@@=&AR964@;6]N=&@@<&5R:6]D
M+"!S=&%R=&EN9R!T:')E92!M;VYT:',@9G)O;2!I=',@:7-S=6%N8V4N($]N
M92!Y96%R(&%F=&5R('1H90T*:7-S=6%N8V4@;V8@=&AE($IU;F4@,C`Q,2!.
M;W1E+"!T:&4@0V]M<&%N>2!M87D@96QE8W0@=&\@<')E<&%Y(&$@<&]R=&EO
M;B!O9B!T:&4@<')I;F-I<&%L+B!)9B!T:&4@0V]M<&%N>2!M86ME<R!S=6-H
M(&%N(&5L96-T:6]N+`T*=&AE(&AO;&1E<G,@;6%Y(&5L96-T('1O(')E8V5I
M=F4@<W5C:"!P<F5P87EM96YT(&EN(&-A<V@@;W(@:6X@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VLL(&%T(&$@8V]N=F5R<VEO
M;B!R871E#0IO9B`D,"XQ-2!P97(@<VAA<F4L(&]R(&EN(&$@8V]M8FEN871I
M;VX@=&AE<F5O9BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@8V]N;F5C=&EO;B!W:71H('1H92!I
M<W-U86YC92!O9B!T:&4-"DIU;F4@,C`Q,2!.;W1E+"!T:&4@0V]M<&%N>2!I
M<W-U960@-C`L,#`P('=A<G)A;G1S+"!E>&5R8VES86)L92!I;G1O(&-O;6UO
M;B!S=&]C:R!A="`D,"XR-2!W:71H('1W;R!Y96%R('1E<FUS+B!4:&4@0V]M
M<&%N>2!M87D-"F9O<F-E('1H92!E>&5R8VES92!O9B!T:&4@=V%R<F%N=',@
M870@86YY('1I;64@=&AA="!T:&4@879E<F%G92!V;VQU;64@=V5I9VAT960@
M879E<F%G92!P<FEC92!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T
M;V-K#0IO=F5R('1H92!P<FEO<B!T96X@=')A9&EN9R!D87ES(&ES(&=R96%T
M97(@=&AA;B`D,"XU,"P@=&AE(&%V97)A9V4@9&%I;'D@9&]L;&%R('9O;'5M
M92!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K('-O;&0-"F]V
M97(@=&AO<V4@=&5N('1R861I;F<@9&%Y<R!I<R!G<F5A=&5R('1H86X@)#(U
M+#`P,"!A;F0@=&AE<F4@:7,@86X@969F96-T:79E(')E9VES=')A=&EO;B!S
M=&%T96UE;G0@8V]V97)I;F<@=&AE(')E<V%L92!O9B!T:&4-"G-H87)E<R!U
M;F1E<FQY:6YG('1H92!W87)R86YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY(&AA
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M87)S+"!R:7-K(&9R964@<F%T92!O9B`P+C0S)2P@9&EV:61E;F0@>6EE;&0@
M;V8@,"4@86YD('9O;&%T:6QI='D-"F]F(#$Y.24N(%1H92!D96)T(&1I<V-O
M=6YT(&ES(&)E:6YG(&%C8W)E=&5D(&]V97(@=&AE('1H<F5E('EE87(@=&5R
M;2!O9B!T:&4@2G5N92`R,#$Q($YO=&4@=7-I;F<@=&AE(&5F9F5C=&EV92!I
M;G1E<F5S="!R871E(&UE=&AO9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9O<B!T:&4@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R(#,P+`T*,C`Q,BP@86-C<F5T:6]N(&]F('1H
M92!D96)T(&1I<V-O=6YT(&]F("0R+#`W-2!W87,@<F5C;W)D960@9F]R('1H
M92!*=6YE(#(P,3$@3F]T92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T
M(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^075G=7-T(#@L(#(P,3(@
M0V]N=F5R=&EB;&4@3F]T93PO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@075G=7-T(#@L(#(P
M,3(L('1H92!#;VUP86YY(&5N=&5R960-"FEN=&\@82!S96-U<FET:65S('!U
M<F-H87-E(&%G<F5E;65N="!W:71H(&%C8W)E9&ET960@:6YV97-T;W)S('1O
M('!L86-E(&$@0V]N=F5R=&EB;&4@3F]T92`H=&AE("8C,30W.T%U9W5S="`X
M+"`R,#$R($YO=&4F(S$T.#LI#0IW:71H(&$@;6%T=7)I='D@9&%T92!O9B!O
M;F4@>65A<B!A9G1E<B!T:&4@:7-S=6%N8V4@=&AE<F5O9B!I;B!T:&4@86=G
M<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@)#$Q,2PT,S`N($-O;G-I9&5R
M871I;VX@=6YD97(-"G1H92!N;W1E<R!C;VYS:7-T960@;V8@)#DR+#`P,"!I
M;B!C87-H('!R;V-E961S(&%F=&5R("0X+#`P,"!P87EM96YT(&]F(&9I;F1E
M<G,F(S$T-CL@9F5E(&%N9"!A;B!O<FEG:6YA;"!I<W-U92!D:7-C;W5N="!O
M9B`D,3$L-#,P+@T*5&AE(&YO=&4@:&]L9&5R(&AA<R!T:&4@;W!T:6]N('1O
M(&-O;G9E<G0@82!P;W)T:6]N(&]R(&%L;"!O9B!T:&4@;W5T<W1A;F1I;F<@
M8F%L86YC92!O9B!T:&4@075G=7-T(#@L(#(P,3(@3F]T92!I;F-L=61I;F<@
M86YY#0IA8V-R=65D(&EN=&5R97-T(&EN=&\@<VAA<F5S(&]F('1H92!#;VUP
M86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@870@82!C;VYV97)S:6]N(')A=&4@
M;V8@)#`N,#D@<&5R('-H87)E(&]R(#<P)2!O9B!T:&4@;&]W97-T('1R861E
M9`T*<')I8V4@:6X@=&AE(#(U('1R861I;F<@9&%Y<R!P<FEO<B!T;R!C;VYV
M97)S:6]N+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT
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M<FEN8VEP86P@<W5M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@9FEN9&5R)B,Q-#8[<R!F964@
M;V8@)#@L,#`P('=A<PT*86-C;W5N=&5D(&9O<B!A<R!D969E<G)E9"!F:6YA
M;F-I;F<@8V]S=',L(&%N9"!I<R!B96EN9R!A;6]R=&EZ960@;W9E<B!T:&4@
M=&5R;2!O9B!T:&4@;F]T92X@070@4V5P=&5M8F5R(#,P+"`R,#$R+"`D-BPX
M,S@@;V8@=&AE#0HD,3(L-C0Q(&EN(&1E9F5R<F5D(&9I;F%N8VEN9R!C;W-T
M<R!R96QA=&5S('1O('1H92!!=6=U<W0@."P@,C`Q,B!.;W1E('=H:6-H(')E
M;6%I;G,@=6YA;6]R=&EZ960L(&%N9"!I<R!P<F5S96YT960@:6X@8W5R<F5N
M="!A<W-E=',-"F]N('1H92!#;VUP86YY)B,Q-#8[<R!"86QA;F-E(%-H965T
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^5&AE($-O;7!A;GD@:&%S(&%L;&]C871E9"!T:&4@;F5T('!R
M;V-E961S#0IT;R!T:&4@8V]N=F5R<VEO;B!O<'1I;VX@8F%S960@;VX@=&AE
M(&-A;&-U;&%T960@9F%I<B!V86QU92X@5&AE(&9A:7(@=F%L=64@;V8@=&AE
M(&-O;G9E<G-I;VX@;W!T:6]N('=A<R!R96-O<F1E9"!A="`D,3$U-2PW,#`-
M"F%N9"!R96-O9VYI>F5D(&%S(&$@9&5R:79A=&EV92!L:6%B:6QI='D@86YD
M('1H92!D96)T('=A<R!R96-O<F1E9"!A="`D;FEL+B!4:&4@=')A;G-A8W1I
M;VX@<F5S=6QT960@:6X@86X@86-C;W5N=&EN9R!L;W-S(&]N(&1E8G0-"F9I
M;F%N8VEN9R!O9B`D-34L-S`P+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@8V]N
M=F5R<VEO;B!O<'1I;VX@=V%S(&-A;&-U;&%T960@=7-I;F<@=&AE($)I;F]M
M:6%L(&]P=&EO;B!P<FEC:6YG(&UO9&5L('5N9&5R('1H90T*9F]L;&]W:6YG
M(&%S<W5M<'1I;VYS.B!E<W1I;6%T960@;&EF92!O9B!O;F4@>65A<BP@<FES
M:R!F<F5E(')A=&4@;V8@,"XQ.24L(&1I=FED96YD('EI96QD(&]F(#`E(&%N
M9"!V;VQA=&EL:71Y(&]F(#$S.2XW-R4N(%1H90T*9&5B="!D:7-C;W5N="!I
M<R!B96EN9R!A8V-R971E9"!O=F5R('1H92!O;F4@>65A<B!T97)M(&]F('1H
M92!!=6=U<W0@."P@,C`Q,B!.;W1E('5S:6YG('1H92!E9F9E8W1I=F4@:6YT
M97)E<W0@<F%T92!M971H;V0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P
M="`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&;W(@=&AE(&YI;F4@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<B`S,"P-"C(P,3(L(&%C8W)E=&EO;B!O9B!T:&4@
M9&5B="!D:7-C;W5N="!O9B`D,38L,3@P('=A<R!R96-O<F1E9"!F;W(@=&AE
M($%U9W5S="`X+"`R,#$R($YO=&4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D%U9W5S="`Q,BP@
M,C`Q,B!#;VYV97)T:6)L92!.;W1E/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!!=6=U<W0@
M,3(L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960-"FEN=&\@82!S96-U<FET
M:65S('!U<F-H87-E(&%G<F5E;65N="!W:71H(&%C8W)E9&ET960@:6YV97-T
M;W)S('1O('!L86-E(&$@0V]N=F5R=&EB;&4@3F]T92`H=&AE("8C,30W.T%U
M9W5S="`Q,BP@,C`Q,B!.;W1E)B,Q-#@[*0T*=VET:"!A(&UA='5R:71Y(&1A
M=&4@;V8@=&AR964@;6]N=&AS(&%F=&5R('1H92!I<W-U86YC92!T:&5R96]F
M(&EN('1H92!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D,C<L-3`P
M+B!#;VYS:61E<F%T:6]N('5N9&5R#0IT:&4@;F]T97,@8V]N<VES=&5D(&]F
M("0R-2PP,#`@:6X@8V%S:"!P<F]C965D<R!A9G1E<B!A;B!O<FEG:6YA;"!I
M<W-U92!D:7-C;W5N="!O9B`D,BPU,#`N(%1H92!N;W1E(&AO;&1E<B!H87,@
M=&AE(&]P=&EO;B!T;R!C;VYV97)T#0IA('!O<G1I;VX@;W(@86QL(&]F('1H
M92!O=71S=&%N9&EN9R!B86QA;F-E(&]F('1H92!!=6=U<W0@."P@,C`Q,B!.
M;W1E(&EN8VQU9&EN9R!A;GD@86-C<G5E9"!I;G1E<F5S="!I;G1O('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C,30V.W,-"F-O;6UO;B!S=&]C:R!A="!A(&-O
M;G9E<G-I;VX@<F%T92!O9B`D,"XP.2!P97(@<VAA<F4@;W(@;VX@<VEM:6QA
M<B!T97)M<R!A<R!O9B!A;GD@9G5T=7)E(&9I;F%N8VEN9W,@=VET:"!M;W)E
M(&9A=F]R86)L92!T97)M<RX-"E1H92!A9W)E96UE;G0@<')O=FED97,@9F]R
M('1H92!#;VUP86YY('1O(&ES<W5E(#4P+#`P,"!S:&%R97,@=&\@=&AE(&YO
M=&4@:&]L9&5R(&%S(')I<VL@<')E;6EU;2X@5&AE(#4P+#`P,"!S:&%R97,@
M=V5R92!V86QU960-"F%T("0V+#(U,"!A;F0@<F5C;W)D960@87,@;&]S<R!O
M;B!D96)T(&9I;F%N8VEN9R!A;F0@;V)L:6=A=&EO;B!T;R!I<W-U92!S:&%R
M97,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/E1H92!!=6=U<W0@,3(L(#(P,3(@3F]T92!B96%R<R!I
M;G1E<F5S=`T*870@=&AE(')A=&4@;V8@,3`E('!E<B!A;FYU;2X\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
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M9"!I;B!A;B!A8V-O=6YT:6YG(&QO<W,@;VX@9&5B=`T*9FEN86YC:6YG(&]F
M(#8L,3`P+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@8V]N=F5R<VEO;B!O<'1I
M;VX@=V%S(&-A;&-U;&%T960@=7-I;F<@=&AE($)I;F]M:6%L(&]P=&EO;B!P
M<FEC:6YG(&UO9&5L('5N9&5R('1H92!F;VQL;W=I;F<-"F%S<W5M<'1I;VYS
M.B!E<W1I;6%T960@;&EF92!O9B!T:')E92!M;VYT:',L(')I<VL@9G)E92!R
M871E(&]F(#`N,3$E+"!D:79I9&5N9"!Y:65L9"!O9B`P)2!A;F0@=F]L871I
M;&ET>2!O9B`Q,S@N,S$E+B!4:&4@9&5B=`T*9&ES8V]U;G0@:7,@8F5I;F<@
M86-C<F5T960@;W9E<B!T:&4@=&AR964@;6]N=&@@=&5R;2!O9B!T:&4@075G
M=7-T(#$R+"`R,#$R($YO=&4@=7-I;F<@=&AE(&5F9F5C=&EV92!I;G1E<F5S
M="!R871E(&UE=&AO9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9O<B!T:&4@;FEN92!M;VYT:',@96YD
M960@4V5P=&5M8F5R(#,P+`T*,C`Q,BP@86-C<F5T:6]N(&]F('1H92!D96)T
M(&1I<V-O=6YT(&]F("0Q-2PX-#(@=V%S(')E8V]R9&5D(&9O<B!T:&4@075G
M=7-T(#$R+"`R,#$R($YO=&4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P
M="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D%U9W5S="`R,"P@,C`Q
M,B!#;VYV97)T:6)L92!.;W1E/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!!=6=U<W0@,C`L
M(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960-"FEN=&\@82!S96-U<FET:65S
M('!U<F-H87-E(&%G<F5E;65N="!W:71H(&%C8W)E9&ET960@:6YV97-T;W)S
M('1O('!L86-E(&$@0V]N=F5R=&EB;&4@3F]T92`H=&AE("8C,30W.T%U9W5S
M="`R,"P@,C`Q,B!.;W1E)B,Q-#@[*0T*=VET:"!A(&UA='5R:71Y(&1A=&4@
M;V8@;VYE('EE87(@869T97(@=&AE(&ES<W5A;F-E('1H97)E;V8@:6X@=&AE
M(&%G9W)E9V%T92!P<FEN8VEP86P@86UO=6YT(&]F("0R,"PP,#`N(%1H92!N
M;W1E(&AO;&1E<B!H87,@=&AE#0IO<'1I;VX@=&\@8V]N=F5R="!A('!O<G1I
M;VX@;W(@86QL(&]F('1H92!O=71S=&%N9&EN9R!B86QA;F-E(&]F('1H92!!
M=6=U<W0@."P@,C`Q,B!.;W1E(&EN8VQU9&EN9R!A;GD@86-C<G5E9"!I;G1E
M<F5S="!I;G1O('-H87)E<PT*;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO
M;B!S=&]C:R!A="!A(&-O;G9E<G-I;VX@<F%T92!O9B`D,"XP.2!P97(@<VAA
M<F4@;W(@-S`E(&]F('1H92!L;W=E<W0@=')A9&5D('!R:6-E(&EN('1H92`R
M-2!T<F%D:6YG#0ID87ES('!R:6]R('1O(&-O;G9E<G-I;VXN/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/E1H92!!=6=U<W0@,C`L(#(P,3(@3F]T92!B96%R<R!I;G1E<F5S=`T*870@
M=&AE(')A=&4@;V8@."4@<&5R(&%N;G5M+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`V<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE($-O;7!A;GD@
M:&%S(&%L;&]C871E9"!T:&4@;F5T('!R;V-E961S#0IT;R!T:&4@8V]N=F5R
M<VEO;B!O<'1I;VX@8F%S960@;VX@=&AE(&-A;&-U;&%T960@9F%I<B!V86QU
M92X@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&-O;G9E<G-I;VX@;W!T:6]N('=A
M<R!R96-O<F1E9"!A="`D,S8L,3`P(&%N9`T*<F5C;V=N:7IE9"!A<R!A(&1E
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M(&QI9F4@;V8@;VYE('EE87(L(')I<VL@9G)E92!R871E(&]F(#`N,3DE+"!D
M:79I9&5N9"!Y:65L9"!O9B`P)2!A;F0@=F]L871I;&ET>2!O9B`Q-#`N,3$E
M+B!4:&4-"F1E8G0@9&ES8V]U;G0@:7,@8F5I;F<@86-C<F5T960@;W9E<B!T
M:&4@;VYE('EE87(@=&5R;2!O9B!T:&4@075G=7-T(#(P+"`R,#$R($YO=&4@
M=7-I;F<@=&AE(&5F9F5C=&EV92!I;G1E<F5S="!R871E(&UE=&AO9"X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^1F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L
M#0HR,#$R+"!A8V-R971I;VX@;V8@=&AE(&1E8G0@9&ES8V]U;G0@;V8@)#(L
M,C0W('=A<R!R96-O<F1E9"!F;W(@=&AE($%U9W5S="`R,"P@,C`Q,B!.;W1E
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\8CY397!T96UB97(@,3@L(#(P,3(@0V]N=F5R=&EB;&4@
M3F]T93PO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^3VX@4V5P=&5M8F5R(#$X+"`R,#$R+"!T:&4@
M0V]M<&%N>2!E;G1E<F5D#0II;G1O(&$@<V5C=7)I=&EE<R!P=7)C:&%S92!A
M9W)E96UE;G0@=VET:"!A8V-R961I=&5D(&EN=F5S=&]R<R!T;R!P;&%C92!A
M($-O;G9E<G1I8FQE($YO=&4@*'1H92`F(S$T-SM397!T96UB97(@,3@L(#(P
M,3(@3F]T928C,30X.RD-"G=I=&@@82!M871U<FET>2!D871E(&]F(&]N92!Y
M96%R(&%F=&5R('1H92!I<W-U86YC92!T:&5R96]F(&EN('1H92!A9V=R96=A
M=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D.#(L-3`P+B!#;VYS:61E<F%T:6]N
M('5N9&5R('1H90T*;F]T97,@8V]N<VES=&5D(&]F("0V.2PP,#`@:6X@8V%S
M:"!P<F]C965D<R!A9G1E<B`D-BPP,#`@<&%Y;65N="!O9B!F:6YD97)S)B,Q
M-#8[(&9E92!A;F0@86X@;W)I9VEN86P@:7-S=64@9&ES8V]U;G0@;V8@)#<L
M-3`P+@T*5&AE(&YO=&4@:&]L9&5R(&AA<R!T:&4@;W!T:6]N('1O(&-O;G9E
M<G0@82!P;W)T:6]N(&]R(&%L;"!O9B!T:&4@;W5T<W1A;F1I;F<@8F%L86YC
M92!O9B!T:&4@4V5P=&5M8F5R+"`R,#$R($YO=&4@:6YC;'5D:6YG(&%N>0T*
M86-C<G5E9"!I;G1E<F5S="!I;G1O('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M,30V.W,@8V]M;6]N('-T;V-K(&%T(&$@8V]N=F5R<VEO;B!R871E(&]F("0P
M+C`Y('!E<B!S:&%R92!O<B`W,"4@;V8@=&AE(&QO=V5S="!T<F%D960-"G!R
M:6-E(&EN('1H92`R,"!T<F%D:6YG(&1A>7,@<')I;W(@=&\@8V]N=F5R<VEO
M;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^5&AE(%-E<'1E;6)E<BP@,C`Q,B!.;W1E(&-A<G)I97,@
M;F\@:6YT97)E<W0-"F]T:&5R('1H86X@=&AE(&]R:6=I;F%L(&ES<W5E(&1I
M<V-O=6YT+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY4:&4@9FEN9&5R)B,Q-#8[<R!F964@;V8@)#8L
M,#`P('=A<PT*86-C;W5N=&5D(&9O<B!A<R!D969E<G)E9"!F:6YA;F-I;F<@
M8V]S=',L(&%N9"!I<R!B96EN9R!A;6]R=&EZ960@;W9E<B!T:&4@=&5R;2!O
M9B!T:&4@;F]T92X@070@4V5P=&5M8F5R(#,P+"`R,#$R+"`D-2PX,#,@;V8@
M=&AE#0HD,3(L-C0Q(&EN(&1E9F5R<F5D(&9I;F%N8VEN9R!C;W-T<R!R96QA
M=&5S('1O('1H92!397!T96UB97(L(#(P,3(@3F]T92!W:&EC:"!R96UA:6YS
M('5N86UO<G1I>F5D+"!A;F0@:7,@<')E<V5N=&5D(&EN(&-U<G)E;G0-"F%S
M<V5T<R!O;B!T:&4@0V]M<&%N>28C,30V.W,@0F%L86YC92!3:&5E="X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M;'1E9"!I;B!A;B!A8V-O=6YT:6YG(&QO<W,@;VX@9&5B=`T*9FEN86YC:6YG
M(&]F("0Q+#0P,"X@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&-O;G9E<G-I;VX@
M;W!T:6]N('=A<R!C86QC=6QA=&5D('5S:6YG('1H92!":6YO;6EA;"!O<'1I
M;VX@<')I8VEN9R!M;V1E;"!U;F1E<B!T:&4@9F]L;&]W:6YG#0IA<W-U;7!T
M:6]N<SH@97-T:6UA=&5D(&QI9F4@;V8@;VYE('EE87(L(')I<VL@9G)E92!R
M871E(&]F(#`N,C`E+"!D:79I9&5N9"!Y:65L9"!O9B`P)2!A;F0@=F]L871I
M;&ET>2!O9B`Q-#$N-#,E+B!4:&4@9&5B="!D:7-C;W5N=`T*:7,@8F5I;F<@
M86-C<F5T960@;W9E<B!T:&4@;VYE('EE87(@=&5R;2!O9B!T:&4@4V5P=&5M
M8F5R+"`R,#$R($YO=&4@=7-I;F<@=&AE(&5F9F5C=&EV92!I;G1E<F5S="!R
M871E(&UE=&AO9"X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F]R('1H92!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(L(&%C8W)E=&EO;@T*;V8@
M=&AE(&1E8G0@9&ES8V]U;G0@;V8@)#(L-C(V('=A<R!R96-O<F1E9"!F;W(@
M=&AE(%-E<'1E;6)E<BP@,C`Q,B!.;W1E+CPO9F]N=#X\+W`^#0H-"@T*#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S-U\T.3$X7V$U
M8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E82]7;W)K<VAE
M971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY,3T%.4R!005E!0DQ%/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T97,@=&\@1FEN86YC:6%L(%-T
M871E;65N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3$]!3E,@4$%904),13PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#$R<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+71R86YS9F]R;3H@=7!P97)C87-E)SX\=3Y.
M;W1E#0HV.B8C.3M,;V%N<R!P87EA8FQE/"]U/CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)VUA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^07,@870@4V5P=&5M8F5R(#,P+"`R,#$R+"!T:&5R92!W97)E
M('5N<V5C=7)E9"!L;V%N#0IA9'9A;F-E<R!F<F]M('1H:7)D('!A<G1I97,@
M:6X@=&AE(&%M;W5N="!O9B`D,C@L,#`P("A$96-E;6)E<B`S,2P@,C`Q,2`M
M("0W+#`P,"DL('=H:6-H(&%R92!D=64@;VX@9&5M86YD+B!4:&4@;&]A;G,@
M87)E(&%C8W)U:6YG#0II;G1E<F5S="!B971W965N(#$P+3$Y)2!P97(@86YN
M=6TN/"]F;VYT/CPO<#X-"@T*#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E!23TU)4U-/4ED@3D]413QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&5S('1O($9I;F%N8VEA;"!3
M=&%T96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!23TU)4U-/4ED@3D]413PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#$R<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+71R86YS9F]R;3H@=7!P97)C87-E)SX\
M=3Y.;W1E#0HW.B8C.3M0<F]M:7-S;W)Y(&YO=&4\+W4^/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+"!T
M:&4@0V]M<&%N>2!I<W-U960@82!N;W1E(&EN('1H92!A;6]U;G0@;V8@)#$P
M,"PP,#`@=&]W87)D<R!F=71U<F4-"FQE9V%L('-E<G9I8V5S+"!W:&EC:"!M
M871U<F5D($IU;'D@,C0L(#(P,3$N($%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q
M,BP@=&AE($-O;7!A;GD@:&%D(')E8V5I=F5D(&QE9V%L('-E<G9I8V5S(&EN
M('1H92!A;6]U;G0@;V8-"B0Q,#`L,#`P(&%G86EN<W0@=&AE(&YO=&4N(%1H
M92!N;W1E(&)E87)S(&EN=&5R97-T(&%T(#$P)2!P97(@86YN=6T@86YD(&UA
M>2!B92!C;VYV97)T960@:6YT;R!S:&%R97,@870@97%U86P@=&\@;&]W97(@
M;V8@)#`N,#D-"F]R(#8U)2!O9B!T:&4@87)I=&AM971I8R!A=F5R86=E(&]F
M('1H92!L;W=E<W0@8VQO<VEN9R!B:60@<')I8V5S(&]F('1H92!#;VUP86YY
M)B,Q-#8[<R!S:&%R97,@9'5R:6YG('1H92!C;VYS96-U=&EV92!T=V5N='D@
M9&%Y#0IT<F%D:6YG('!E<FEO9"!P<FEO<B!T;R!N;W1I8V4@;V8@8V]N=F5R
M<VEO;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1U<FEN9PT*=&AE(&YI;F4@;6]N
M=&AS(&5N9&5D+"!T:&4@0V]M<&%N>2!I<W-U960@-3`P+#`P,"!S:&%R97,@
M=&\@=&AE(&AO;&1E<B!O9B!T:&4@;F]T92!I;B!E>&-H86YG92!F;W(@=&AE
M(&YO=&4@:&]L9&5R)B,Q-#8[<R!A9W)E96UE;G0-"G1O(&9O<F)E87(@9G)O
M;2!P=7)S=6EN9R!C;VQL96-T:6]N<R!A8W1I;VYS(&]N('1H92!O=71S=&%N
M9&EN9R!N;W1E("A.;W1E(#DI+B!!<R!O9B!397!T96UB97(@,S`L(#(P,3(L
M('1H92!#;VUP86YY(&ES(&YE9V]T:6%T:6YG#0IT97)M<R!F;W(@<F5P87EM
M96YT(&%N9"!S971T;&5M96YT(&]F('1H92!N;W1E+CPO9F]N=#X\+W`^#0H-
M"CQP('-T>6QE/3-$)VUA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T
M96UB97(@,S`L(#(P,3(L('1H90T*0V]M<&%N>2!I<W-U960@861D:71I;VYA
M;"!P<F]M:7-S;W)Y(&YO=&5S(&EN('1H92!A;6]U;G0@;V8@)#8W+#DT,BP@
M;V8@=VAI8V@@)#,X+#`P,"!O9B!P<F]M:7-S;W)Y(&YO=&5S('=E<F4@:7-S
M=65D('1O(&%N(&]F9FEC97(-"F%N9"!A(&1I<F5C=&]R(&]F('1H92!#;VUP
M86YY("A.;W1E(#@I+B!4:&4@<')O;6ES<V]R>2!N;W1E<R!H860@;F\@:6YT
M97)E<W0@8VAA<F=E<R!A;F0@;F\@9FEX960@<F5P87EM96YT('1E<FUS+CPO
M9F]N=#X\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P=#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S-U\T.3$X7V$U8F9?,3(R
M931C9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-A-S`X
M-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E82]7;W)K<VAE971S+U-H
M965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY214Q!5$5$(%!!4E19(%1204Y304-424].4SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@
M5')A;G-A8W1I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4D5,051%1"!005)462!44D%.4T%#5$E/
M3E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`Q
M,G!T(#`@,"<^/&9O;G0@<W1Y;&4],T0G=&5X="UT<F%N<V9O<FTZ('5P<&5R
M8V%S92<^/'4^3F]T92`X.B8C.3M296QA=&5D#0I087)T>2!4<F%N<V%C=&EO
M;G,\+W4^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,7!T)SY$=7)I;F<-"G1H92!N:6YE(&UO;G1H<SPO9F]N
M=#X@96YD960@4V5P=&5M8F5R(#,P+"`R,#$R/&9O;G0@<W1Y;&4],T0G;&5T
M=&5R+7-P86-I;F<Z("TP+C%P="<^+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN
M=&\@=')A;G-A8W1I;VYS('=I=&@-"F-E<G1A:6X@;V9F:6-E<G,@86YD(&1I
M<F5C=&]R<R!O9B!T:&4@0V]M<&%N>2!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#9P="`P(#`@,"XW-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@+3`N-6EN)SX\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,7!T)SXH82D\9F]N="!S='EL93TS1"=F;VYT.B`W<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.PT*/"]F;VYT
M/FEN8W5R<F5D("0Q-S,L-3`P("A397!T96UB97(@,S`L(#(P,3$@+2`D,3@W
M+#(P,"D@:6X@;6%N86=E;65N="!F965S(&%N9"`D-C<L-3`P("A397!T96UB
M97(@,S`L(#(P,3$@+2`D-C<L-3`P*2!I;B!R97-E87)C:`T*86YD(&1E=F5L
M;W!M96YT('-E<G9I8V5S('!A:60@=&\@;V9F:6-E<G,@86YD(&1I<F5C=&]R
M<R!D=7)I;F<@=&AE('!E<FEO9#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#`N,C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O
M;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C<U:6X[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`M,"XU:6XG/CQF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/BAB*3QF;VYT('-T
M>6QE/3-$)V9O;G0Z(#=P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[#0H\+V9O;G0^<F5C;W)D960@)#,Q+#,S,R`H4V5P=&5M8F5R
M(#,P+"`R,#$Q("T@)#,V,"PR-C`I(&EN('-T;V-K(&)A<V5D(&-O;7!E;G-A
M=&EO;B!F;W(@=&AE(&9A:7(@=F%L=64@;V8@;W!T:6]N<R!G<F%N=&5D('1O
M(&UA;F%G96UE;G0-"G1H870@=V5R92!G<F%N=&5D(&%N9"!O<B!V97-T960@
M9'5R:6YG('1H92!P97)I;V0[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I
M;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P(#`@,"`P+C<U:6X[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`M,"XU:6XG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG
M.B`M,"XQ<'0G/BAC*3QF;VYT('-T>6QE/3-$)V9O;G0Z(#=P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[#0H\+V9O;G0^8V]N=F5R
M=&5D("0R-2PP,#`@*%-E<'1E;6)E<B`S,"P@,C`Q,2`M("0Q,#`L,#`P*2!O
M9B!D96)T(&1U92!T;R!R96QA=&5D('!A<G1I97,@9'5R:6YG('1H92!P97)I
M;V0L('=H:6-H('=E<F4@<V5T=&QE9"!W:71H#0IS:&%R97,[(#PO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XU:6XG/CQF;VYT('-T
M>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N-6EN)SX\9F]N="!S='EL
M93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXH9"D\9F]N="!S='EL93TS
M1"=F;VYT.B`W<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.PT*/"]F;VYT/FES<W5E9"`D,S@L,#`P("A397!T96UB97(@,S`L(#(P
M,3$@+2`D;FEL*2!I;B!P<F]M:7-S;W)Y(&YO=&5S('1O(&%N(&]F9FEC97(@
M86YD(&1I<F5C=&]R(&]F('1H92!#;VUP86YY("A.;W1E(#<I+CPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@-3,N.#5P=#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS
M1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SY!;&P-"G)E;&%T960@<&%R='D@
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M;VUP86YY(&%C8V]U;G1E9`T*9F]R('1H92!D96)T('-E='1L96UE;G0@=')A
M;G-A8W1I;VYS('=I=&@@<F5L871E9"!P87)T:65S(&%T(&UA;F%G96UE;G0F
M(S$T-CMS(&5S=&EM871E(&]F(&9A:7(@=F%L=64L('5S:6YG(&%M;W5N=',@
M<VEM:6QA<B!T;PT*87)M)B,Q-#8[<R!L96YG=&@@<V5T=&QE;65N=',@9F]R
M(&1E8G0@<V5T=&QE9"X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^070@4V5P=&5M8F5R(#,P
M+"`R,#$R+"!T:&4@0V]M<&%N>2!H860@86UO=6YT<R!O=VEN9PT*=&\@9&ER
M96-T;W)S(&%N9"!O9F9I8V5R<R!O9B`D,C@Q+#0W-2`H1&5C96UB97(@,S$L
M(#(P,3$@+2`D,S(R+#DP-2DN($%M;W5N=',@9'5E('1O(')E;&%T960@<&%R
M=&EE<R!A<F4@=6YS96-U<F5D+"!N;VXM:6YT97)E<W0-"F)E87)I;F<@86YD
M(&AA=F4@;F\@<W!E8VEF:6,@=&5R;7,@;V8@<F5P87EM96YT+CPO9F]N=#X\
M+W`^#0H-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?
M,30S-U\T.3$X7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E
M,S5E82]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#05!)5$%,(%-43T-+/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G)O:V5R<R!A
M;F0@1&5A;&5R<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-!4$E404P@4U1/0TL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P)SX\9F]N="!S
M='EL93TS1"=T97AT+71R86YS9F]R;3H@=7!P97)C87-E)SX\=3Y.;W1E(#DZ
M)B,Y.T-A<&ET86P-"E-T;V-K/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(&ET86QI8R!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/'4^4VAA<F4@0V%P:71A;#PO=3X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y
M;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^5&AE#0IA=71H;W)I>F5D
M(&-A<&ET86P@;V8@=&AE($-O;7!A;GD@8V]N<VES=&5D(&]F(#$U,"PP,#`L
M,#`P(&-O;6UO;B!S:&%R97,@=VET:"`D,"XP,#$@<&%R('9A;'5E(&%N9"`U
M+#`P,"PP,#`@;F]N+79O=&EN9R!P<F5F97)R960-"G-H87)E<R!W:71H("0P
M+C`P,2!P87(@=F%L=64N(#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(&ET86QI8R!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/'4^,C`Q,B!3:&%R92!4<F%N<V%C=&EO;G,\+W4^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/D]N#0I-87)C:"`Q
M-2P@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#,S,RPS,S0@<VAA<F5S(&]F
M(&ET<R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!T;R!R96QA=&5D('!A<G1I
M97,L('!U<G-U86YT('1O(&1E8G0@<V5T=&QE;65N=`T*86=R965M96YT<R!T
M;R!S971T;&4@)#4P+#`P,"!O9B!O=71S=&%N9&EN9R!T<F%D92!P87EA8FQE
M+B`\+V9O;G0^070@=&AE('1I;64@;V8@:7-S=6%N8V4@=&AE(&9A:7(@=F%L
M=64@;V8@=&AE('-H87)E<R!W87,@9&5T97)M:6YE9`T*=&\@8F4@)#4P+#`P
M,"!B87-E9"!O;B!T:&4@<75O=&5D(&UA<FME="!P<FEC92!O9B`D,"XQ-2!P
M97(@<VAA<F4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C
M:6YG.B`M,"XQ<'0G/D]N#0I-87)C:"`Q-2P@,C`Q,BP@=&AE($-O;7!A;GD@
M:7-S=65D(#PO9F]N=#XT,#`L,#`P('-H87)E<R!O9B!I=',@<F5S=')I8W1E
M9"!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@82!D96)T('-E='1L96UE;G0@
M86YD(&$@8V]N<W5L=&EN9PT*86=R965M96YT+B!!="!T:&4@=&EM92!O9B!I
M<W-U86YC92!T:&4@9F%I<B!V86QU92!O9B!T:&4@<VAA<F5S('=A<R!D971E
M<FUI;F5D('1O(&)E("0W,2PR,#`@8F%S960@;VX@=&AE('%U;W1E9"!M87)K
M970@<')I8V4@;V8-"B0P+C$U('!E<B!S:&%R92X@5&AE($-O;7!A;GD@<F5C
M;W)D960@)#DL.3,P(&%S(&=A:6X@;VX@<V5T=&QE;65N="!O9B!D96)T+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T
M)SY/;@T*36%R8V@@,34L(#(P,3(L('1H92!#;VUP86YY(&ES<W5E9"`\+V9O
M;G0^-S@Y+#<W."!S:&%R97,@;V8@:71S(')E<W1R:6-T960@8V]M;6]N('-T
M;V-K(&EN('-E='1L96UE;G0@;V8@86-C<G5E9"!I;G1E<F5S="!O;B!T:&4-
M"F]U='-T86YD:6YG(#(P,3$@3F]T97,N($%T('1H92!T:6UE(&]F(&ES<W5A
M;F-E('1H92!F86ER('9A;'5E(&]F('1H92!S:&%R97,@=V%S(&1E=&5R;6EN
M960@=&\@8F4@)#$Q."PT-C<@8F%S960@;VX@=&AE('%U;W1E9`T*;6%R:V5T
M('!R:6-E(&]F("0P+C$U('!E<B!S:&%R92X@3F\@9V%I;B!O<B!L;W-S('=A
M<R!R96-O<F1E9"!O;B!S971T;&5M96YT+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!-87)C:"`R
M,#$R+"!T:&4@0V]M<&%N>2!R96-E:79E9"!S=6)S8W)I<'1I;VX-"G!R;V-E
M961S(&]F("0X-2PP,#`N(%1H92!S=6)S8W)I8F5R<R!P=7)C:&%S960@-S,S
M+#,S-"!S:&%R92!U;FET<R!A="`D,"XQ-2!P97(@=6YI="X@16%C:"!U;FET
M(&-O;G-I<W1S(&]F(#$@<VAA<F4@;V8@0V]M<&%N>28C,30V.W,-"F-O;6UO
M;B!S=&]C:R!A;F0@:&%L9B!A('=A<G)A;G0@97AE<F-I<V%B;&4@870@)#`N
M-#`L('=H:6-H(&5X<&ER97,@:6X@='=O('EE87)S+B!4:&4@9F%I<B!V86QU
M92!O9B!T:&5S92!W87)R86YT<R!W87,@9&5T97)M:6YE9`T*=&\@8F4@)#4L
M,3,S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY);B!!<')I;"`R,#$R+"!T:&4@0V]M<&%N>2!R96-E
M:79E9"!S=6)S8W)I<'1I;VX-"G!R;V-E961S(&]F("0S-#4L,#`P+B!4:&4@
M<W5B<V-R:6)E<G,@<'5R8VAA<V5D(#(L,S`P+#`P,"!S:&%R92!U;FET<R!A
M="`D,"XQ-2!P97(@=6YI="X@16%C:"!U;FET(&-O;G-I<W1S(&]F(#$@<VAA
M<F4@;V8@0V]M<&%N>28C,30V.W,-"F-O;6UO;B!S=&]C:R!A;F0@:&%L9B!A
M('=A<G)A;G0@97AE<F-I<V%B;&4@870@)#`N-#`L('=H:6-H(&5X<&ER97,@
M:6X@='=O('EE87)S+B!4:&4@9F%I<B!V86QU92!O9B!T:&5S92!W87)R86YT
M<R!W87,@9&5T97)M:6YE9`T*=&\@8F4@)#$R,RPP,#`N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG
M.B`M,"XQ<'0G/DEN($%P<FEL+"`R,#$R+"!T:&4@0V]M<&%N>0T*:7-S=65D
M(#$\+V9O;G0^,#`L,#`P('-H87)E<R!O9B!I=',@<F5S=')I8W1E9"!C;VUM
M;VX@<W1O8VL@<'5R<W5A;G0@=&\@82!D96)T('-E='1L96UE;G0@86YD(&$@
M8V]N<W5L=&EN9R!A9W)E96UE;G0N($%T('1H92!T:6UE#0IO9B!I<W-U86YC
M92!T:&4@9F%I<B!V86QU92!O9B!T:&4@<VAA<F5S('=A<R!D971E<FUI;F5D
M('1O(&)E("0Q."PU,#`@8F%S960@;VX@=&AE('%U;W1E9"!M87)K970@<')I
M8V4@;V8@)#`N,3@U('!E<B!S:&%R92X@5&AE#0I#;VUP86YY(')E8V]R9&5D
M("0Q."PW-3@@87,@9V%I;B!O;B!S971T;&5M96YT+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`V<'0@,"`P)SY);B!!<')I;"`R,#$R+"!T:&4@0V]M<&%N
M>2!I<W-U960@.3,S+#,S,R!R97-T<FEC=&5D(&-O;6UO;@T*<VAA<F5S+"!A
M="`D,"XQ-2!P97(@<VAA<F4L(&9O<B!P<F]C965D<R!O9B`D,30P+#`P,"!R
M96-E:79E9"!I;B!/8W1O8F5R(#(P,3$L(&EN(&$@<')I=F%T92!P;&%C96UE
M;G0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/DEN($%P<FEL(#(P,3(L('1H92!#;VUP86YY(&ES<W5E
M9"`Q+#`P,"PP,#`-"F-O;6UO;B!S:&%R97,@=&\@82!C;VYS=6QT86YT('!U
M<G-U86YT('1O(&$@8V]N<W5L=&EN9R!A9W)E96UE;G0@969F96-T:79E($]C
M=&]B97(@,2P@,C`Q,2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R
M+7-P86-I;F<Z("TP+C%P="<^26X-"D%P<FEL+"`R,#$R+"!T:&4@0V]M<&%N
M>2!I<W-U960@/"]F;VYT/C$V,RPS,S0@<VAA<F5S(&]F(&ET<R!R97-T<FEC
M=&5D(&-O;6UO;B!S=&]C:R!I;B!S971T;&5M96YT(&]F(&%C8W)U960@:6YT
M97)E<W0@;VX@=&AE(&]U='-T86YD:6YG#0HR,#$Q($YO=&5S+B!!="!T:&4@
M=&EM92!O9B!I<W-U86YC92!T:&4@9F%I<B!V86QU92!O9B!T:&4@<VAA<F5S
M('=A<R!D971E<FUI;F5D('1O(&)E("0R-"PU,#`@8F%S960@;VX@=&AE('%U
M;W1E9"!M87)K970@<')I8V4-"F]F("0P+C$U('!E<B!S:&%R92X@3F\@9V%I
M;B!O<B!L;W-S('=A<R!R96-O<F1E9"!O;B!S971T;&5M96YT+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY);B!-87D@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#$T+#`P,"PP,#`-
M"F-O;6UO;B!S:&%R97,@=&\@8V]N<W5L=&%N=',@<'5R<W5A;G0@=&\@82!C
M;VYS=6QT:6YG(&%G<F5E;65N="`H3F]T92`Q,2DN($%T('1H92!T:6UE(&]F
M(&ES<W5A;F-E('1H92!F86ER('9A;'5E(&]F('1H92!S:&%R97,-"G=A<R!D
M971E<FUI;F5D('1O(&)E("0Q+#DQ."PP,#`@8F%S960@;VX@=&AE('%U;W1E
M9"!M87)K970@<')I8V4@;V8@)#`N,3,W('!E<B!S:&%R92X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^26X-"DIU
M;F4@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#PO9F]N=#XS-2PQ-SD@<VAA
M<F5S(&]F(&ET<R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T
M;R!A(&-O;G-U;'1I;F<@86=R965M96YT+B!4:&4@9F%I<@T*=F%L=64@;V8@
M=&AE('-H87)E<R!W87,@9&5T97)M:6YE9"!T;R!B92`D-BPP,#`@8F%S960@
M;VX@=&AE('%U;W1E9"!M87)K970@<')I8V4@;V8@)#`N,3<@<&5R('-H87)E
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N
M,7!T)SY);@T*075G=7-T(#(P,3(L('1H92!#;VUP86YY(&ES<W5E9"`\+V9O
M;G0^-3`P+#`P,"!S:&%R97,@;V8@:71S(')E<W1R:6-T960@8V]M;6]N('-T
M;V-K('!U<G-U86YT('1O(&$@8V]N<W5L=&EN9R!A9W)E96UE;G0N(%1H92!F
M86ER#0IV86QU92!O9B!T:&4@<VAA<F5S('=A<R!D971E<FUI;F5D('1O(&)E
M("0W-"PP,#`@8F%S960@;VX@=&AE('%U;W1E9"!M87)K970@<')I8V4@;V8@
M)#`N,30X('!E<B!S:&%R92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T
M(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@4V5P=&5M8F5R(#(P,3(L
M('1H92!#;VUP86YY(&ES<W5E9"`\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,#`L,#`P('-H87)E
M<PT*;V8@:71S(')E<W1R:6-T960@8V]M;6]N('-T;V-K('1O('1H92!H;VQD
M97(@;V8@82!P<F]M:7-S;W)Y(&YO=&4@:6X@97AC:&%N9V4@9F]R('1H92!N
M;W1E(&AO;&1E<B8C,30V.W,@86=R965M96YT('1O(&9O<F5B96%R#0IF<F]M
M('!U<G-U:6YG(&-O;&QE8W1I;VX@86-T:6]N(&]N('1H870@;F]T92`H3F]T
M92`W*2X@5&AE(&9A:7(@=F%L=64@;V8@=&AE('-H87)E<R!W87,@9&5T97)M
M:6YE9"!T;R!B92`D-S(L-S4P(&)A<V5D(&]N('1H92!Q=6]T960-"FUA<FME
M="!P<FEC92!O9B`D,"XQ-#8@<&5R('-H87)E+CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(&ET86QI8R!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/'4^)B,Q-C`[/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@:71A;&EC(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\=3XR,#$Q(%-H87)E(%1R86YS86-T:6]N<SPO=3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O
M;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^3VX-"DUA<F-H
M(#(Q+"`R,#$Q+"!T:&4@0V]M<&%N>2!I<W-U960@/"]F;VYT/C8T,2PP,C,@
M<VAA<F5S(&]F(&ET<R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!P=7)S=6%N
M="!T;R!D96)T('-E='1L96UE;G0@86YD('=A<G)A;G0-"F5X=&EN9W5I<VAM
M96YT(&%G<F5E;65N="!T;R!S971T;&4@)#@S+#,S,R!O9B!T:&4@,C`Q,"!.
M;W1E<R!A;F0@<&%R=&EA;"!E>'1I;F=U:7-H;65N="!O9B!T:&4@4V5R:65S
M($$L(%-E<FEE<R!"(&%N9"!397)I97,@0PT*5V%R<F%N=',N($%T('1H92!T
M:6UE(&]F(&ES<W5A;F-E+"!T:&4@9F%I<B!V86QU92!O9B!T:&4@<VAA<F5S
M('=A<R!D971E<FUI;F5D('1O(&)E("0Q,34L,S@T+"!B87-E9"!O;B!T:&4@
M<75O=&5D(&UA<FME="!P<FEC90T*;V8@)#`N,3@@<&5R('-H87)E+"!W:&EC
M:"!H87,@8F5E;B!R96-O<F1E9"!A9V%I;G-T('1H92!C87)R>6EN9R!V86QU
M92!O9B!T:&4@9&5B="X@5&AE($-O;7!A;GD@<F5C;V=N:7IE9"!A(&QO<W,@
M;V8@)#@W+#<S-"!O;@T*<&%R=&EA;"!S971T;&5M96YT(&]F(#(P,3`@3F]T
M97,@86YD('!A<G1I86P@97AT:6YG=6ES:&UE;G0@;V8@=&AE(%-E<FEE<R!!
M+"!397)I97,@0B!A;F0@4V5R:65S($,@5V%R<F%N=',N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF
M;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/D]N#0I-87)C
M:"`R,RP@,C`Q,2P@=&AE($-O;7!A;GD@:7-S=65D(#PO9F]N=#XQ+#$X,"PP
M,#`@<VAA<F5S(&]F(&ET<R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!P=7)S
M=6%N="!T;R!V87)I;W5S(&-O;G-U;'1I;F<@86=R965M96YT<RX-"D%T('1H
M92!T:6UE(&]F(&ES<W5A;F-E('1H92!F86ER('9A;'5E(&]F('1H92!S:&%R
M97,@=V%S(&1E=&5R;6EN960@=&\@8F4@)#(R-RPT,S(@8F%S960@;VX@=&AE
M('%U;W1E9"!M87)K970@<')I8V4@;V8@)#`N,3@@<&5R#0IS:&%R92X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^
M3VX-"DUA<F-H(#(S+"`R,#$Q+"!T:&4@0V]M<&%N>2!I<W-U960@.#@U+#(Y
M-2!S:&%R97,@;V8@:71S(')E<W1R:6-T960@8V]M;6]N('-T;V-K('!U<G-U
M86YT('1O(&1E8G0@<V5T=&QE;65N="!A9W)E96UE;G1S('1O('-E='1L90T*
M)#$U,"PU,#`@;V8@;W5T<W1A;F1I;F<@=')A9&4@<&%Y86)L97,N(#PO9F]N
M=#Y!="!T:&4@=&EM92!O9B!I<W-U86YC92!T:&4@9F%I<B!V86QU92!O9B!T
M:&4@<VAA<F5S('=A<R!D971E<FUI;F5D('1O(&)E("0Q-S(L-C,S#0IB87-E
M9"!O;B!T:&4@<75O=&5D(&UA<FME="!P<FEC92!O9B`D,"XQ.34@<&5R('-H
M87)E+B!4:&4@0V]M<&%N>2!R96-O<F1E9"`D,C(L,3,S(&%S(&QO<W,@;VX@
M<V5T=&QE;65N="!O9B!D96)T+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V
M<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L
M971T97(M<W!A8VEN9SH@+3`N,7!T)SY/;@T*36%R8V@@,C,L(#(P,3$L('1H
M92!#;VUP86YY(&ES<W5E9"`T-#$L,3<W('-H87)E<R!O9B!I=',@<F5S=')I
M8W1E9"!C;VUM;VX@<W1O8VL@=&\@<F5L871E9"!P87)T:65S+"!P=7)S=6%N
M="!T;R!D96)T('-E='1L96UE;G0-"F%G<F5E;65N=',@=&\@<V5T=&QE("0W
M-2PP,#`@;V8@:71S(&]U='-T86YD:6YG('1R861E('!A>6%B;&5S+B!!="!T
M:&4@=&EM92!O9B!I<W-U86YC92!T:&4@9F%I<B!V86QU92!O9B!T:&4@<VAA
M<F5S('=A<R!D971E<FUI;F5D#0IT;R!B92`D.#8L,#,P(&)A<V5D(&]N('1H
M92!Q=6]T960@;6%R:V5T('!R:6-E(&]F("0P+C$Y-2!P97(@<VAA<F4N(%1H
M92!#;VUP86YY(')E8V]R9&5D('1H92!C86QC=6QA=&5D(&QO<W,@;VX@<V5T
M=&QE;65N="!O9B`D,3$L,#,P#0IT;R!T:&4@<W1A=&5M96YT(&]F(&]P97)A
M=&EO;G,N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,7!T)SY/;@T*36%R8V@@,S`L(#(P,3$L('1H92!#;VUP
M86YY(&ES<W5E9"`\+V9O;G0^,BPP-#@L-3<X('-H87)E<R!O9B!I=',@<F5S
M=')I8W1E9"!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@86X@97AC:&%N9V4@
M86=R965M96YT('1O#0IS971T;&4@)#(S,RPS,S,@;V8@=&AE(#(P,3`@3F]T
M97,N($%T('1H92!T:6UE(&]F(&ES<W5A;F-E('1H92!F86ER('9A;'5E(&]F
M('1H92!S:&%R97,@=V%S(&1E=&5R;6EN960@=&\@8F4@)#0U,"PV.#<@8F%S
M960@;VX-"G1H92!Q=6]T960@;6%R:V5T('!R:6-E(&]F("0P+C(R('!E<B!S
M:&%R92X@5&AE(&1I<V-O=6YT960@8V%R<GEI;F<@86UO=6YT(&]F('1H92`R
M,#$P($YO=&4@87,@;V8@36%R8V@@,S`L(#(P,3$@=V%S("0W-RPT,C$N(%1H
M90T*0V]M<&%N>2!R96-O<F1E9"!T:&4@9&EF9F5R96YC92!B971W965N('1H
M92!F86ER('9A;'5E(&%N9"!A8V-R971E9"!A;6]U;G0@;V8@)#,W,RPR-C8@
M87,@;&]S<R!O;B!S971T;&5M96YT(&]F(&1E8G0N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/D]N#0I!<')I;"`U
M+"`R,#$Q+"!T:&4@0V]M<&%N>2!I<W-U960@/"]F;VYT/C4P,"PP,#`@<VAA
M<F5S(&]F(&ET<R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T
M;R!A(&-O;G-U;'1I;F<@86=R965M96YT+B!!="!T:&4-"G1I;64@;V8@:7-S
M=6%N8V4@=&AE(&9A:7(@=F%L=64@;V8@=&AE('-H87)E<R!W87,@9&5T97)M
M:6YE9"!T;R!B92`D,3(U+#`P,"!B87-E9"!O;B!T:&4@<75O=&5D(&UA<FME
M="!P<FEC92!O9B`D,"XR-2!P97(@<VAA<F4N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T
M>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/D]N#0I!<')I;"`R-2P@
M,C`Q,2P@=&AE($-O;7!A;GD@:7-S=65D(#PO9F]N=#XS-3`L,#`P('-H87)E
M<R!O9B!I=',@<F5S=')I8W1E9"!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@
M82!C;VYS=6QT:6YG(&%G<F5E;65N="X@070-"G1H92!T:6UE(&]F(&ES<W5A
M;F-E('1H92!F86ER('9A;'5E(&]F('1H92!S:&%R97,@=V%S(&1E=&5R;6EN
M960@=&\@8F4@)#@W+#4P,"!B87-E9"!O;B!T:&4@<75O=&5D(&UA<FME="!P
M<FEC92!O9B`D,"XR-2!P97(@<VAA<F4N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE
M/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/D]N#0I!<')I;"`R-2P@,C`Q
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T
M)SY/;@T*07!R:6P@,C4L(#(P,3$L('1H92!#;VUP86YY(&ES<W5E9"`R,"PP
M,#`@<VAA<F5S(&]F(&ET<R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!P=7)S
M=6%N="!T;R!A(&1E8G0@<V5T=&QE;65N="!A9W)E96UE;G0@=&\@<V5T=&QE
M#0HD-"PU-S4@;V8@;W5T<W1A;F1I;F<@=')A9&4@<&%Y86)L97,N(#PO9F]N
M=#Y!="!T:&4@=&EM92!O9B!A9W)E96UE;G0@=&AE(&9A:7(@=F%L=64@;V8@
M=&AE('-H87)E<R!W87,@9&5T97)M:6YE9"!T;R!B92`D-BPX,#`-"F)A<V5D
M(&]N('1H92!Q=6]T960@;6%R:V5T('!R:6-E(&]F("0P+C,T('!E<B!S:&%R
M92X@5&AE($-O;7!A;GD@<F5C;W)D960@)#(L,C(U(&%S(&QO<W,@;VX@<V5T
M=&QE;65N="!O9B!D96)T+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@
M,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T
M97(M<W!A8VEN9SH@+3`N,7!T)SY/;@T*07!R:6P@,C4L(#(P,3$L('1H92!#
M;VUP86YY(&ES<W5E9"`Q,#@L-CDV('-H87)E<R!O9B!I=',@<F5S=')I8W1E
M9"!C;VUM;VX@<W1O8VL@=&\@<F5L871E9"!P87)T:65S+"!P=7)S=6%N="!T
M;R!A(&1E8G0@<V5T=&QE;65N=`T*86=R965M96YT('1O('-E='1L92`D,C4L
M,#`P(&]F(&ET<R!O=71S=&%N9&EN9R!A8V-O=6YT<R!P87EA8FQE<RX@070@
M=&AE('1I;64@;V8@:7-S=6%N8V4@=&AE(&9A:7(@=F%L=64@;V8@=&AE('-H
M87)E<R!W87,@9&5T97)M:6YE9`T*=&\@8F4@)#(W+#$W-"!B87-E9"!O;B!T
M:&4@<75O=&5D(&UA<FME="!P<FEC92!O9B`D,"XR-2!P97(@<VAA<F4N(%1H
M92!#;VUP86YY(')E8V]R9&5D('1H92!C86QC=6QA=&5D(&QO<W,@;VX@<V5T
M=&QE;65N="!O9B`D,BPQ-S0-"G1O('1H92!S=&%T96UE;G0@;V8@;W!E<F%T
M:6]N<RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($%P<FEL(#(P,3$L('1H92!#;VUP
M86YY(')E8V5I=F5D('-U8G-C<FEP=&EO;@T*<')O8V5E9',@;V8@)#DP+#`P
M,"!A;F0@:7-S=65D(#8P,"PP,#$@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I
M;B!A('!R:79A=&4@<&QA8V5M96YT+B!4:&4@<W5B<V-R:6)E<G,@=&\@=&AE
M('-U8G-C<FEP=&EO;B!P<F]C965D<PT*:&%V92!A9W)E960@=&\@<'5R8VAA
M<V4@;VYE('5N:70@9F]R(&5A8V@@)#,N,#`@;V8@<W5B<V-R:7!T:6]N('!R
M;V-E961S+B!%86-H('5N:70@8V]N<VES=',@;V8@,C`@<VAA<F4@;V8@0V]M
M<&%N>28C,30V.W,@8V]M;6]N#0IS=&]C:R!A;F0@-B!W87)R86YT<R!E86-H
M(&5X97)C:7-A8FQE(&%T("0P+C(U+"!W:&EC:"!E>'!I<F4@:6X@='=O('EE
M87)S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@
M+3`N,7!T)SY/;@T*2G5N92`Q+"`R,#$Q+"`\+V9O;G0^-3@V+#@U."!S:&%R
M97,@;V8@/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^
M=&AE($-O;7!A;GDF(S$T-CMS(#PO9F]N=#YR97-T<FEC=&5D(&-O;6UO;B!S
M=&]C:PT*=V%S(')E='5R;F5D('1O('1R96%S=7)Y(&1U92!T;R!A;B!A9&IU
M<W1M96YT('1O('1H92!F:6YA;"!S971T;&5M96YT(&]F('1H92`D,C,S+#,S
M,R`R,#$P($YO=&5S+B!4:&4@<F5T=7)N(&]F('1H92!S:&%R97,@<F5S=6QT
M960-"FEN(&$@)#$S-"PY-S<@<F5D=6-T:6]N('1O('1H92!P<F5V:6]U<VQY
M(&-A;&-U;&%T960@;&]S<R!O;B!D96)T('-E='1L96UE;G0N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D]N($IU;'D@-RP@,C`Q,2P@=&AE($-O;7!A;GD@<F5C96EV960-"G-U8G-C
M<FEP=&EO;B!P<F]C965D<R!O9B`D-C4L,#`P(&%N9"!I<W-U960@,S(U+#`P
M,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&EN(&$@<')I=F%T92!P;&%C96UE
M;G0N(%1H92!S=6)S8W)I8F5R<R!P=7)C:&%S960@;VYE#0IU;FET(&9O<B!E
M86-H("0R+C`P(&]F('-U8G-C<FEP=&EO;B!P<F]C965D<RX@16%C:"!U;FET
M(&-O;G-I<W1S(&]F(#$P('-H87)E<R!O9B!#;VUP86YY)B,Q-#8[<R!C;VUM
M;VX@<W1O8VL@86YD(#8@=V%R<F%N=',@96%C:`T*97AE<F-I<V%B;&4@870@
M)#`N,C4L('=H:6-H(&5X<&ER92!I;B!T=V\@>65A<G,N(%1H92!F86ER('9A
M;'5E(&]F('1H97-E('=A<G)A;G1S('=A<R!D971E<FUI;F5D('1O(&)E("0S
M,RPV,#`N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/D]N($%U9W5S="`Q.2P@,C`Q,2P@=&AE($-O;7!A
M;GD@<F5C96EV960-"G-U8G-C<FEP=&EO;B!P<F]C965D<R!O9B`D-#4L,#`P
M(&%N9"!I<W-U960@,C(U+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&EN
M(&$@<')I=F%T92!P;&%C96UE;G0N(%1H92!S=6)S8W)I8F5R<R!P=7)C:&%S
M960@;VYE#0IU;FET(&9O<B!E86-H("0R+C`P(&]F('-U8G-C<FEP=&EO;B!P
M<F]C965D<RX@16%C:"!U;FET(&-O;G-I<W1S(&]F(#$P('-H87)E<R!O9B!#
M;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@86YD(#8@=V%R<F%N=',@96%C
M:`T*97AE<F-I<V%B;&4@870@)#`N,C4L('=H:6-H(&5X<&ER92!I;B!T=V\@
M>65A<G,N(%1H92!F86ER('9A;'5E(&]F('1H97-E('=A<G)A;G1S('=A<R!D
M971E<FUI;F5D('1O(&)E("0R,RPT,#`N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@:71A;&EC(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\=3Y3=&]C:R!#;VUP96YS871I;VX@4&QA;CPO
M=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^3VX@3V-T;V)E<B`Q-"P@,C`P.2P@=&AE($-O;7!A;GD@
M861O<'1E9`T*=&AE(#(P,#D@4W1O8VL@26YC96YT:79E(%!L86X@*'1H92`F
M(S$T-SLR,#`Y(%!L86XF(S$T.#LI('=H:6-H('-U<&5R<V5D97,@86YD(')E
M<&QA8V5S('1H92`R,#`W(%-T;V-K(%!L86XN(%1H92`R,#`Y(%!L86X@86QL
M;W=S#0IF;W(@=&AE(&ES<W5A;F-E(&]F('5P('1O(#$P+#`P,"PP,#`@8V]M
M;6]N('-H87)E<RX@/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP
M+C%P="<^3W!T:6]N<R!G<F%N=&5D('5N9&5R('1H92!0;&%N('-H86QL(&)E
M#0IA="!P<FEC97,@86YD(&9O<B!T97)M<R!A<R!D971E<FUI;F5D(&)Y('1H
M92!";V%R9"!O9B!$:7)E8W1O<G,N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S
M='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SY/;@T*07!R:6P@,S`L
M(#(P,3(L('1H92!#;VUP86YY(&=R86YT960@,C4P+#`P,"!S=&]C:R!O<'1I
M;VYS('1O(&UA;F%G96UE;G0@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N
M,3@@<&5R('-H87)E+"!V97-T:6YG(&UO;G1H;'D-"F]V97(@82!T:&ER='D@
M<VEX(&UO;G1H('!E<FEO9"X@5&AE(&%G9W)E9V%T92!F86ER('9A;'5E(&]F
M('1H92!N97<@9W)A;G0@=V%S(&5S=&EM871E9"!A="`D-#4L,#`P+"!O<B`D
M,"XQ."!P97(@;W!T:6]N+"!U<VEN9PT*=&AE($)L86-K+5-C:&]L97,@;W!T
M:6]N('!R:6-I;F<@;6]D96P@=VET:"!W96EG:'1E9"!A=F5R86=E(&%S<W5M
M<'1I;VYS(&%S(&9O;&QO=W,Z(&$@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@
M;V8@,2XY-24L(&$@9&EV:61E;F0-"GEI96QD(&]F(#`E+"!A;B!E>'!E8W1E
M9"!V;VQA=&EL:71Y(&]F(#$Y.24L(&%N9"!A;B!E>'!E8W1E9"!L:69E(&]F
M(#$P('EE87)S+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T
M(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T
M=&5R+7-P86-I;F<Z("TP+C%P="<^3VX-"DUA>2`X+"`R,#$R+"!T:&4@0V]M
M<&%N>2!G<F%N=&5D(#(U,"PP,#`@<W1O8VL@;W!T:6]N<R!T;R!A(&-O;G-U
M;'1A;G0@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,3<@<&5R('-H87)E
M+"!V97-T:6YG(&UO;G1H;'D-"F]V97(@82!T=V5L=F4@;6]N=&@@<&5R:6]D
M+B!4:&4@86=G<F5G871E(&9A:7(@=F%L=64@;V8@=&AE(&YE=R!G<F%N="!W
M87,@97-T:6UA=&5D(&%T("0T,"PP,#`L(&]R("0P+C$V('!E<B!O<'1I;VXL
M('5S:6YG('1H90T*0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E
M;"!W:71H('=E:6=H=&5D(&%V97)A9V4@87-S=6UP=&EO;G,@87,@9F]L;&]W
M<SH@82!R:7-K(&9R964@:6YT97)E<W0@<F%T92!O9B`Q+C<Q)2P@82!D:79I
M9&5N9`T*>6EE;&0@;V8@,"4L(&%N(&5X<&5C=&5D('9O;&%T:6QI='D@;V8@
M,3DY)2P@86YD(&%N(&5X<&5C=&5D(&QI9F4@;V8@,3`@>65A<G,N/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N
M,7!T)SY4:&4-"F5X<&5N<V5D('!O<G1I;VX@;V8@=&AE('9A;'5E(&]F('1H
M92!V97-T:6YG(&]P=&EO;G,@9'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,3(@=V%S("0R,#4L-3$V("A397!T96UB97(@
M,S`L#0HR,#$Q("T@)#,V.2PQ,38I('=H:6-H('=A<R!R96-O<F1E9"!A<R!S
M=&]C:R!B87-E9"!C;VYS=6QT:6YG(&%N9"!M86YA9V5M96YT(&9E97,N($1U
M<FEN9R!T:&4@<&5R:6]D<RP@<W1O8VLM8F%S960@8V]N<W5L=&EN9R!A;F0-
M"FUA;F%G96UE;G0@9F5E<R!A;'-O(&EN8VQU9&5S('-H87)E(&%N9"!W87)R
M86YT(&)A<V5D(&-O;7!E;G-A=&EO;BX\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#$R<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SX\8CXF(S$V,#L\
M+V(^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`Q,G!T(#`@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P
M86-I;F<Z("TP+C%P="<^/&(^4VAA<F4-"G!U<F-H87-E(&]P=&EO;G,\+V(^
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C%P="<^00T*<W5M;6%R>2!O9B!T:&4@0V]M<&%N>28C,30V.W,@<W1O
M8VL@;W!T:6]N<R!A<R!O9B!397!T96UB97(@,S`L(#(P,3(@86YD(&-H86YG
M97,@9'5R:6YG('1H92!P97)I;V0@:7,@<')E<V5N=&5D(&)E;&]W.CPO9F]N
M=#X\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0W)3L@8F]R9&5R+71O<#H@=VEN9&]W
M=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$W)3L@8F]R9&5R+71O<#H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^3G5M8F5R(&]F/"]P/@T*("`@
M("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M3W!T:6]N<SPO<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E
M.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@
M(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY796EG
M:'1E9"!!=F5R86=E/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^17AE<F-I<V4@4')I8V4\+W`^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^5V5I9VAT960@079E<F%G93PO<#X-
M"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT
M97(G/E)E;6%I;FEN9R!,:69E/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#8N-#5P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#$X+CAP=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#(Q+CDU<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^0F%L86YC92P@1&5C96UB97(@,S$L
M(#(P,3$\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`V
M+C0U<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXV+#(W."PP,#`F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`Q."XX<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXD)B,Q-C`[(#`N,3@\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-BXX-3PO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/B8C,38P.R!)<W-U960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`V+C$U<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M(#4P,"PP,#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`Q.2XY<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXP+C$X/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@,C$N.35P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/BT\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L@0V%N8V5L;&5D/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,C$N.35P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I
M;F<M<FEG:'0Z(#(Q+CDU<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXM/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0G
M/D)A;&%N8V4L(%-E<'1E;6)E<B`S,"P@,C`Q,B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#8N-#5P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C8L-S<X+#`P,"8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#$X+CAP=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@,"XQ.#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#(Q+CDU<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXV+C8Q/"]T9#X\
M+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG
M.B`M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/D%T#0I397!T96UB97(@,S`L(#(P
M,3(L('1H92!I;G1R:6YS:6,@=F%L=64@;V8@=&AE('9E<W1E9"!O<'1I;VYS
M('=A<R!E<75A;"!T;R`D;FEL("A397!T96UB97(@,S`L(#(P,3$@+2`D;FEL
M*2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN
M9SH@+3`N,7!T)SY!#0IS=6UM87)Y(&]F('1H92!S=&%T=7,@;V8@=&AE($-O
M;7!A;GDF(S$T-CMS('5N=F5S=&5D(&]P=&EO;G,@87,@;V8@4V5P=&5M8F5R
M(#,P+"`R,#$R(&ES('!R97-E;G1E9"!B96QO=SH\+V9O;G0^/"]P/@T*#0H\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T-R4[(&)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q-R4[(&)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!C96YT97(G/DYU;6)E<B!O9CPO<#X-"B`@("`@("`@
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/E-H87)E
M<SPO<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E.R!B;W)D
M97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@(#QP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY796EG:'1E9"!!=F5R86=E
M/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^1W)A;G0M1&%T93PO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/D9A:7(@5F%L=64\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9"<^56YV97-T960L($1E8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-BXT-7!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XS<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#`S-RPW,#DF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`R,2XY-7!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C
M,38P.R`P+C$X/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[($=R86YT960\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`V+C0U<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C-P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C4P
M,"PP,#`F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^,"XQ-SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.R!697-T
M960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`V+C0U
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C-P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B@X-#,L-C<V*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#(Q+CDU<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXP+C$X/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[($-A;F-E;&QE9#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#8N-#5P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N,W!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3QF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#8N-#5P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#4N,W!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@,C$N.35P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD)SY5;G9E<W1E9"P@4V5P=&5M8F5R(#,P+"`R,#$R/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-BXT-7!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XS<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXV.30L,#,S)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,C$N.35P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@,"XQ.#PO
M=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B!I=&%L:6,@
M8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('EE;&QO=R<^/'4^)B,Q-C`[/"]U/CPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&ET86QI8R!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T
M(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^4VAA<F4@4'5R8VAA<V4@
M5V%R<F%N=',\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^/&9O
M;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^3VX-"D9E8G)U
M87)Y(#(T+"`R,#$Q+"!T:&4@0V]M<&%N>2!I<W-U960@,BPS-CDL,S@X('-H
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M(#4I+B!4:&4@9F%I<B!V86QU92!O9B!T:&5S92!W87)R86YT<R!O9B`D-#@S
M+#,U-2!W87,@<F5C;V=N:7IE9"!U;F1E<@T*9&5R:79A=&EV92!L:6%B:6QI
M=&EE<RP@=7-I;F<@=&AE($)I;F]M:6%L(&]P=&EO;B!P<FEC:6YG(&UO9&5L
M('=I=&@@86X@97AP96-T960@;&EF92!O9B`U('EE87)S+"!A(')I<VL@9G)E
M92!I;G1E<F5S="!R871E(&]F#0HR+C`V)2P@82!D:79I9&5N9"!Y:65L9"!O
M9B`P)2P@86YD(&%N(&5X<&5C=&5D('9O;&%T:6QI='D@;V8@,3DY)2X\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M
M,"XQ<'0G/DEN#0I-87)C:"`R,2P@,C`Q,2P@=&AE($-O;7!A;GD@:7-S=65D
M(#(U,"PP,#`@<VAA<F4@<'5R8VAA<V4@=V%R<F%N=',@=&\@86-Q=6ER92!A
M;B!E<75I=F%L96YT(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]F('1H92!#
M;VUP86YY+`T*870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,C4@<&5R('-H
M87)E(&9O<B!A;B!E>&5R8VES92!P97)I;V0@;V8@=7`@=&\@9FEV92!Y96%R
M<R!F<F]M('1H92!I<W-U86YC92!D871E+B!4:&4@=V%R<F%N=',@=V5R92!I
M<W-U960-"G!U<G-U86YT('1O(&$@9&5B="!S971T;&5M96YT(&%G<F5E;65N
M="`H3F]T92`U*2X@5&AE(&9A:7(@=F%L=64@;V8@=&AE<V4@=V%R<F%N=',@
M;V8@)#0S+#<U,"!W87,@<F5C;V=N:7IE9"!U;F1E<B!D97)I=F%T:79E(&QI
M86)I;&ET:65S+`T*=7-I;F<@=&AE($)I;F]M:6%L(&]P=&EO;B!P<FEC:6YG
M(&UO9&5L('=I=&@@86X@97AP96-T960@;&EF92!O9B`U('EE87)S+"!A(')I
M<VL@9G)E92!I;G1E<F5S="!R871E(&]F(#`N-S<E+"!A(&1I=FED96YD('EI
M96QD#0IO9B`P)2P@86YD(&%N(&5X<&5C=&5D('9O;&%T:6QI='D@;V8@,3DY
M)2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C
M:6YG.B`M,"XQ<'0G/D]N#0I!<')I;"`T+"`R,#$Q+"!T:&4@0V]M<&%N>2!I
M<W-U960@,2PP,#`L,#`P('-H87)E('!U<F-H87-E('=A<G)A;G1S('1O(&%C
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M<G)A;G1S('=A<R!D971E<FUI;F5D('1O(&)E("0S-#DL,#`P+"!U<VEN9R!T
M:&4@0FQA8VLM4V-H;VQE<PT*;W!T:6]N('!R:6-I;F<@;6]D96P@=VET:"!A
M;B!E>'!E8W1E9"!L:69E(&]F(#4@>65A<G,L(&$@<FES:R!F<F5E(&EN=&5R
M97-T(')A=&4@;V8@,BXR,"4L(&$@9&EV:61E;F0@>6EE;&0@;V8@,"4L(&%N
M9"!A;B!E>'!E8W1E9`T*=F]L871I;&ET>2!O9B`R-3(E+CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^
M3VX-"D%P<FEL(#(U+"`R,#$Q+"!T:&4@0V]M<&%N>2!I<W-U960@,3@P+#`P
M,"!S:&%R92!P=7)C:&%S92!W87)R86YT<R!T;R!A8W%U:7)E(&%N(&5Q=6EV
M86QE;G0@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;V8@=&AE($-O;7!A;GDL
M#0IA="!A;B!E>&5R8VES92!P<FEC92!O9B`D,"XR-2!P97(@<VAA<F4@9F]R
M(&%N(&5X97)C:7-E('!E<FEO9"!O9B!U<"!T;R!F:79E('EE87)S(&9R;VT@
M=&AE(&ES<W5A;F-E(&1A=&4N(%1H92!W87)R86YT<R!W97)E(&ES<W5E9`T*
M<'5R<W5A;G0@=&\@=&AE('!R:79A=&4@<&QA8V5M96YT(&]F("0Y,"PP,#`N
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN
M9SH@+3`N,7!T)SY/;@T*2G5N92`V+"`R,#$Q+"!T:&4@0V]M<&%N>2!I<W-U
M960@-C`L,#`P('-H87)E('!U<F-H87-E('=A<G)A;G1S('1O(&%C<75I<F4@
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M86YT<R!W87,@9&5T97)M:6YE9"!T;R!B92`D,3`L,30V+"!U<VEN9R!T:&4-
M"D)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96P@=VET:"!A;B!E
M>'!E8W1E9"!L:69E(&]F(#4@>65A<G,L(&$@<FES:R!F<F5E(&EN=&5R97-T
M(')A=&4@;V8@,2XV,"4L(&$@9&EV:61E;F0@>6EE;&0@;V8@,"4L#0IA;F0@
M86X@97AP96-T960@=F]L871I;&ET>2!O9B`R-30E+CPO9F]N=#X\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^26X-
M"DUA<F-H+"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@,S8V+#8V."!S:&%R
M92!P=7)C:&%S92!W87)R86YT<R!T;R!A8W%U:7)E(&%N(&5Q=6EV86QE;G0@
M;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;V8@=&AE($-O;7!A;GDL#0IA="!A
M;B!E>&5R8VES92!P<FEC92!O9B`D,"XT,"!P97(@<VAA<F4@9F]R(&%N(&5X
M97)C:7-E('!E<FEO9"!O9B!U<"!T;R!T=V\@>65A<G,@9G)O;2!T:&4@:7-S
M=6%N8V4@9&%T92X@5&AE('=A<G)A;G1S('=E<F4@:7-S=65D#0IP=7)S=6%N
M="!T;R!T:&4@<')I=F%T92!P;&%C96UE;G0@;V8@)#$Q,"PP,#`@86YD(&EN
M8VQU9&5D('=I=&AI;B!E<75I='DN(%1H92!F86ER('9A;'5E(&]F('1H97-E
M('=A<G)A;G1S('=A<R!D971E<FUI;F5D('1O(&)E#0HD-2PQ,S,L('5S:6YG
M('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L('=I=&@@
M86X@97AP96-T960@;&EF92!O9B`R('EE87)S+"!A(')I<VL@9G)E92!I;G1E
M<F5S="!R871E(&]F(#`N,S<E+"!A(&1I=FED96YD#0IY:65L9"!O9B`P)2P@
M86YD(&%N(&5X<&5C=&5D('9O;&%T:6QI='D@;V8@-C,E+CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^
M26X-"D%P<FEL+"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@,2PQ-3`L,#`P
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M('=A<R!D971E<FUI;F5D('1O(&)E("0Q,C,L,#`P+"!U<VEN9PT*=&AE($)L
M86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96P@=VET:"!A;B!E>'!E
M8W1E9"!L:69E(&]F(#(@>65A<G,L(&$@<FES:R!F<F5E(&EN=&5R97-T(')A
M=&4@;V8@,"XR-R4L(&$@9&EV:61E;F0@>6EE;&0@;V8-"C`E+"!A;F0@86X@
M97AP96-T960@=F]L871I;&ET>2!O9B`Q-#8N-B4N/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`V<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^00T*<W5M
M;6%R>2!O9B!T:&4@0V]M<&%N>28C,30V.W,@<VAA<F4@<'5R8VAA<V4@=V%R
M<F%N=',@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$R(&%N9"!C:&%N9V5S(&1U
M<FEN9R!T:&4@<&5R:6]D(&ES('!R97-E;G1E9"!B96QO=SH\+V9O;G0^/"]P
M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`T-R4[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-R4[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!C96YT97(G/DYU;6)E<B!O9CPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/E=A<G)A;G1S/"]P/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O<F1E<BUT;W`Z('=I
M;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!C96YT97(G/E=E:6=H=&5D($%V97)A9V4\+W`^#0H@("`@
M("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY%
M>&5R8VES92!0<FEC93PO<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,3@E.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@
M(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY796EG
M:'1E9"!!=F5R86=E/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^4F5M86EN:6YG($QI9F4\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<"<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^0F%L86YC
M92P@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/C$R+#$P-BPS-34F(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`R,"XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q-C`[(#`N-38\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`R,RXU<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXR+C@Q/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P="<^)B,Q-C`[($ES<W5E9#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,2PU,38L-C8X)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,C`N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,"XT,#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#(S+C5P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$N.#`\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T)SXF(S$V,#L@17AT:6YG=6ES:&5D(&]R(&5X<&ER960\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@W,30L-#`P*3PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#(P+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(N,S,\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`R,RXU<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG
M:'0Z(&)O;&0G/D)A;&%N8V4L(%-E<'1E;6)E<B`S,"P@,C`Q,CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,3(L.3`X+#8R,R8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#(P+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@,"XT
M,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#(S+C5P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$N.#8\+W1D
M/CPO='(^#0H\+W1A8FQE/@T*#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-54%!,14U%3E1!3"!#
M05-(($9,3U<@24Y&3U)-051)3TX@04Y$($Y/3BU#05-(($E.5D535$E.1R!!
M3D0@1DE.04Y#24Y'($%#5$E6251)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@0V%S:"!&
M;&]W($5L96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4U504$Q%345.5$%,($-!4T@@1DQ/5R!)
M3D9/4DU!5$E/3B!!3D0@3D].+4-!4T@@24Y615-424Y'($%.1"!&24Y!3D-)
M3D<@04-4259)5$E%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#$R<'0@,"`P)SX\9F]N="!S='EL93TS1"=T97AT+71R86YS
M9F]R;3H@=7!P97)C87-E)SX\=3Y.;W1E(#$P.B8C.3M3=7!P;&5M96YT86P-
M"D-A<V@@1FQO=R!);F9O<FUA=&EO;B!!3D0@3D].+4-!4T@@24Y615-424Y'
M($%.1"!&24Y!3D-)3D<@04-4259)5$E%4R`\+W4^/"]F;VYT/CPO<#X-"@T*
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#,@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$-2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@
M("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY.
M:6YE($UO;G1H<R!%;F1E9#PO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/E-E<'1E;6)E<B`S,"P@,C`Q,CPO
M<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#`N-7!T('-O;&ED)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N
M-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI
M9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/E-H
M87)E<R]W87)R86YT<SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,R!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N
M-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY!;6]U;G0\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^4VAA<F5S(&ES<W5E9"!P=7)S=6%N
M="!T;R!D96)T('-E='1L96UE;G0@86=R965M96YT<SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(L,3(V+#0T-SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)#,R
M-BPY,S<\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^0V]M;6]N('-H
M87)E<R!I<W-U960@<'5R<W5A;G0@=&\@8V]N<W5L=&EN9R!S97)V:6-E(&%R
M<F%N9V5M96YT<SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$T+#4S-2PQ-SD\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#,@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXD,2PY.3@L,#`P/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO
M<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,R!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<CX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$-"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@
M("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF
M(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY.:6YE($UO;G1H<R!%;F1E
M9#PO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!C96YT97(G/E-E<'1E;6)E<B`S,"P@,C`Q,3PO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`P+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL
M93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/E-H87)E<R]W87)R86YT<SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T
M97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY!;6]U;G0\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0S('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^06-C
M;W5N=',@<&%Y86)L92!S971T;&5D(&)Y(&ES<W5I;F<@8V]M;6]N('-H87)E
M<SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#,@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C0L,C$T+#<V-CPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B0@.#$U+#4R-SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/D-O;6UO;B!S:&%R97,@:7-S=65D('!U<G-U86YT
M('1O(&-O;G-U;'1I;F<@<V5R=FEC92!A<G)A;F=E;65N=',\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0S('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXR+#,R-RPP-3D\+W1D/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXD-3`P+#4R-SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&-O;'-P86X],T0S('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-#<E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`W)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$T)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-B4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`T)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E!U<G-U86YT
M('1O('1H92`R,#$P($YO=&4@<V5T=&QE;65N="!A;F0-"G=A<G)A;G0@97AT
M:6YG=6ES:&UE;G0@86=R965M96YT<R!E;G1E<F5D(&1U<FEN9R!T:&4@;FEN
M92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&4@0V]M<&%N
M>2!I<W-U960@1F5B<G5A<GD@,C`Q,2!.;W1E<PT*:6X@=&AE(&%M;W5N="!O
M9B`D,C0P+#`P,"`H3F]T92`U*2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M-G!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E-E92!.;W1E<R`U(&%N9"`Y
M(&9O<B!A9&1I=&EO;F%L(&1I<V-L;W-U<F4-"F]N(&YO;BUC87-H('1R86YS
M86-T:6]N<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[
M(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!R;W=S<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@(#QP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/B8C,38P.SPO<#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/DYI;F4@36]N=&AS($5N9&5D(%-E<'1E;6)E
M<B`S,"P\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,C`Q,CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,C`Q,3PO=&0^/"]T<CX-
M"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@
M=VED=&@Z(#8X)3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q.24[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Q,R4[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/DEN=&5R97-T('!A:60@:6X@8V%S:#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M<FEG:'0Z(#$R+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B0F(S$V,#L@+3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$U+CEP=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V
M,#L@+3PO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/DEN8V]M92!T87AE<R!P86ED/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,3(N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P
M.R`M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@
M<&%D9&EN9RUR:6=H=#H@,34N.7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R`M/"]T9#X\+W1R/@T*/"]T86)L
M93X-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S
M-U\T.3$X7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E
M82]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#3TY424Y'14Y#2453($%.1"!#3TU-251-14Y4
M4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TY424Y'14Y#2453
M($%.1"!#3TU-251-14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#$R<'0@,"`P)SX\9F]N="!S='EL93TS1"=T97AT+71R
M86YS9F]R;3H@=7!P97)C87-E)SX\=3Y.;W1E(#$Q.B8C.3M#;VYT:6YG96YC
M2453#0I!3D0@0T]-34E4345.5',\+W4^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@:71A;&EC(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\=3Y#;VYT:6YG96YC:65S/"]U/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@:71A;&EC(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\=3Y487@@1FEL:6YG<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@-G!T(#`@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4]
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M93TS1"=F;VYT.B!I=&%L:6,@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CQU/D-O;6UI=&UE;G1S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@:71A;&EC(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\=3Y#;VUB:6YE9"!297-E87)C:"!A;F0-"D]P97)A=&EN9R!/8FQI9V%T
M:6]N<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I
M;F<Z("TP+C%P="<^169F96-T:79E#0I-87D@,C4L(#(P,3`L('1H92!#;VUP
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M=F5L;W`@=&AE($-O;7!A;GDF(S$T-CMS#0IT96-H;F]L;V=Y+B`\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ
M<'0G/E1H90T*0V]M<&%N>2!H87,@86=R965D('1H870L(&1U<FEN9R!T:&4@
M<&5R:6]D(&]F('1H92!O<'1I;VX@86YD('5P;VX@87!P<F]V86P@;V8@1D1!
M('1O(&-O;F1U8W0@4&AA<V4@22!4<FEA;',L('=I;&P@<&%Y(&%L;"!T:&4@
M8V]S=',-"FEN8W5R<F5D(&)Y('1H92!-87EO($-L:6YI8RP@;F]T('1O(&5X
M8V5E9"!A('1O=&%L(&]F("0X-#$L,#`P+B`\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N
M($%P<FEL(#$S+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D#0II;G1O(&$@
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M<'!L:6-A=&EO;B!N=6UB97)E9"`V,38P,#0X,"`H=&ET;&5D("8C,30W.TUE
M=&AO9',@86YD(&UA=&5R:6%L<R!F;W(@9V5N97)A=&EN9PT*0T0X*R!4+6-E
M;&QS(&AA=FEN9R!T:&4@86)I;&ET>2!T;R!R96-O9VYI>F4@8V%N8V5R(&-E
M;&QS(&5X<')E<W-I;F<@82!(97(R+VYE=2!P;VQY<&5P=&ED928C,30X.RD@
M=&\@;6%K92!P<F]D=6-T<R!I;B!T:&4@<')O<&AY;&%C=&EC#0IA;F0@=&AE
M<F%P975T:6,@9FEE;&0@*'1H92`F(S$T-SM,:6-E;G-E9"!0<F]D=6-T<R8C
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M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@9W)A;G0@;V8@=&AE
M(&QI8V5N<V5S+`T*=&AE($-O;7!A;GD@:7,@=&\@*&DI(&UA:V4@86X@=7!F
M<F]N="!L:6-E;G-E('!A>6UE;G0@;V8@)#$P,"PP,#`@=&\@36%Y;R!F;VQL
M;W=E9"!B>2!A;B!A9&1I=&EO;F%L("0Q-3`L,#`P(&EN(&QI8V5N<V4@<&%Y
M;65N=',-"F]V97(@82`Q,B!M;VYT:"!P97)I;V0L("AI:2D@<F5I;6)U<G-E
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M:6-E;G-E9"!0<F]D=6-T('=I=&AI;B!F:79E('EE87)S(&%N9"!I9B!I=`T*
M9F%I;',@=&\@:6YI=&EA=&4@82!0:&%S92!)22!C;&EN:6-A;"!T<FEA;"!O
M9B!A($QI8V5N<V5D(%!R;V1U8W0@=VET:&EN(&5I9VAT('EE87)S+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="\Q,34E(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`Q,'!T)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&ET86QI8R!B;VQD(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@-G!T(#`@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/'4^36%N86=E;65N="!397)V:6-E<R!!9W)E
M96UE;G0\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M
M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R
M+7-P86-I;F<Z("TP+C%P="<^26X@1F5B<G5A<GD-"C(P,3$L('1H92!#;VUP
M86YY(&%P<')O=F5D(&%N(&5M<&QO>6UE;G0@86=R965M96YT('=I=&@@1'(N
M(%=I;'-O;B!W:71H(&%N(&EN:71I86P@=&5R;2!O9B`R('EE87)S+"!W:&EC
M:"!M87D@8F4@875T;VUA=&EC86QL>0T*97AT96YD960@9F]R('-U8V-E<W-I
M=F4@;VYE+7EE87(@=&5R;7,N(%1H:7,@96UP;&]Y;65N="!A9W)E96UE;G0@
M<')O=FED97,@9F]R(&%N;G5A;"!C;VUP96YS871I;VX@;V8@)#$X,"PP,#`@
M86YD('1H92!G<F%N="!O9@T*86X@;W!T:6]N('1O(&%C<75I<F4@,BPP,#`L
M,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K
M(&%T("0P+C$Y('!E<B!S:&%R92P@-3`E(&]F('=H:6-H('9E<W1E9"!O;B!-
M87)C:"`Q-BP-"C(P,3$L('=H:6QE('1H92!R96UA:6YD97(@=VEL;"!V97-T
M(&UO;G1H;'D@;W9E<B!A('!E<FEO9"!O9B!T=V\@>65A<G,@*#0Q+#8V-R!P
M97(@;6]N=&@I+B!4:&4@;W!T:6]N<R!S:&%L;"!B92!E>&5R8VES86)L92!F
M;W(-"F%T(&QE87-T(&9I=F4@>65A<G,N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@:71A;&EC(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`V<'0@,"`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\=3XF(S$V,#L\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B!I=&%L:6,@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU
M/D-O;G-U;'1A;G0@06=R965M96YT<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G
M;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SY);B!!<')I;`T*
M,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&EN=F5S=&]R<R8C
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M86YT(&%N9"!A(&UO;G1H;'D@<&%Y;65N="!O9B`D-RPU,#`N/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M
M,"XQ<'0G/DEN($%P<FEL#0HR,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN
M=&\@9FEN86YC:6%L(&-O;G-U;'1I;F<@<V5R=FEC92!A9W)E96UE;G1S+"!W
M:&EC:"!I;F-L=61E9"!C;VUP96YS871I;VX@;V8@,30L,#`P+#`P,"!S:&%R
M97,@;V8@8V]M;6]N#0IS=&]C:RP@=VAE<F5B>2!T:&4@0V]M<&%N>2!A9W)E
M960@=&\@:7-S=64@861D:71I;VYA;"!S:&%R97,@=&\@=&AE(&-O;G-U;'1A
M;G1S('1O(')E<W1O<F4@=&AE:7(@:&]L9&EN9W,@=&\@,C0N."4@;V8@9G5L
M;'D@9&EL=71E9`T*8V%P:71A;&EZ871I;VX@;V8@=&AE($-O;7!A;GD@:68@
M=&AE($-O;7!A;GD@8V]M<&QE=&5S(&$@<F4M;W)G86YI>F%T:6]N+"!R92UC
M87!I=&%L:7IA=&EO;B!O<B!A(&QI<75I9&ET>2!E=F5N="!D=7)I;F<@=&AE
M(&5I9VAT965N#0IM;VYT:',@8V]M;65N8VEN9R!W:71H('1H92!S:6=N:6YG
M(&]F('1H97-E(&%G<F5E;65N=',N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3%P="\Q,34E(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`@,"`Q,'!T)SX\8CXF(S$V,#L\+V(^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B!I=&%L:6,@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#9P="`P(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQU/E)E;G1A;"!,96%S92!!9W)E96UE;G0\+W4^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P
M.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
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M9&1I=&EO;F%L(')E;G0@9F]R(&]P97)A=&EN9R!C;W-T<R!O9B`R+C(P)2!O
M9B!T;W1A;"!O<&5R871I;F<@97AP96YS97,@;V8@=&AE('!R;W!E<G1Y+CPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P
M="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A
M8VEN9SH@+3`N,7!T)SY4:&4@0V]M<&%N>0T*:&%S(&]B;&EG871I;VYS('5N
M9&5R('9A<FEO=7,@86=R965M96YT<R!T:')O=6=H($1E8V5M8F5R(#,Q+"`R
M,#$T+B!4:&4@86=G<F5G871E(&UI;FEM=6T@86YN=6%L('!A>6UE;G1S(&9O
M<B!T:&4@>65A<G,@96YD:6YG#0I$96-E;6)E<B`S,2!A<F4@87,@9F]L;&]W
M<SH\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M
M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D
M97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W=I9'1H.B`R,24[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G=VED=&@Z(#<E.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W=I9'1H.B`S,B4[('!A9&1I
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M,#LF(S$V,#LF(S$V,#L@4B8C,S@[1#PO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=W:61T:#H@-B4[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=W:61T:#H@,S0E.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[($%D;6EN:7-T<F%T:79E/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M=&]P.B`V<'0[('!A9&1I
M;F<M;&5F=#H@-C5P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@=&5X="UI;F1E;G0Z("TW+CEP="<^0V]M;6ET;65N=',\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W!A9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M;&5F=#H@,6EN
M.R!F;VYT+7=E:6=H=#H@8F]L9"<^0V]M;6ET;65N=',\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P="<^,C`Q,CPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M=&]P.B`V<'0[('!A9&1I
M;F<M;&5F=#H@,6EN.R!T97AT+6EN9&5N=#H@+3@N,W!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[)"`Q+#`U,BPU,#`\+W1D/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+71O<#H@-G!T.R!P861D:6YG
M+6QE9G0Z(#%I;CL@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.R0F(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#L@,3DU+#@R,3PO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXR,#$S/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUL969T
M.B`Q:6X[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#L@,S<L-3`P/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUL969T.B`Q
M:6X[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#L@,S`X+#,Q,SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T)SXR,#$T/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUL
M969T.B`Q:6X[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@+28C,38P.R8C,38P.SPO
M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M
M=&]P.B`V<'0[('!A9&1I;F<M;&5F=#H@,6EN.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[(#(R+#(X-#PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED
M.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@<&%D9&EN
M9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD(#$L,#DP+#`P,#PO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D:6YG+6QE
M9G0Z(#%I;CL@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#L@-3(V+#0Q.#PO=&0^/"]T<CX-"CPO=&%B;&4^#0H-
M"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-A-S`X-#5A7S$T,S=?-#DQ
M.%]A-6)F7S$R,F4T8V1E,S5E80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]C83<P.#0U85\Q-#,W7S0Y,3A?835B9E\Q,C)E-&-D93,U96$O5V]R
M:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4U5"4T51545.5"!%5D5.5%,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O
M;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4U5"4T51545.5"!%5D5.5%,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`Q,G!T(#`@,"<^/&9O;G0@
M<W1Y;&4],T0G=&5X="UT<F%N<V9O<FTZ('5P<&5R8V%S92<^/'4^3F]T92`Q
M,CHF(SD[4U5"4T51545.5`T*159%3E13/"]U/CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($]C=&]B97(@,34L(#(P
M,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;PT*86X@86=R965M96YT('1O
M(&ES<W5E(&$@;F]T92!T;R!A;B!I;G9E<W1O<B!F;W(@)#,T,"PP,#`N(%1H
M92!#;VUP86YY(')E8V5I=F5D("0S,#`L,#`P(&9O<B!T:&4@;F]T92!W:&EC
M:"!C87)R:65D("0S,"PP,#`@;V8@;W)I9VEN86P-"FES<W5E(&1I<V-O=6YT
M(&%N9"`D,3`L,#`P(&EN(&QE9V%L(&9E97,N(%1H92!N;W1E(&ES(&1U92!O
M;B!/8W1O8F5R(#$U+"`R,#$S(&%N9"!C87)R:65S(&%N(&EN=&5R97-T(')A
M=&4@;V8@."4N(%1H97)E(&%R92!S979E;@T*:6YS=&%L;&UE;G0@<&%Y;65N
M=',@9'5E(&]N('1H92!N;W1E(&)E9VEN;FEN9R!O;B!T:&4@<V5V96YT:"!M
M;VYT:"!A9G1E<B!I=',@:7-S=6%N8V4@;V8@=&AE(&YO=&4@86YD(&5A8V@@
M;6]N=&@@=&AE<F5A9G1E<B!U;G1I;`T*;6%T=7)I='DN/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@;&5N9&5R(&AA<R!T:&4@
M<FEG:'0L(&%T(&%N>2!T:6UE(&%F=&5R#0II<W-U86YC92P@870@:71S(&5L
M96-T:6]N+"!T;R!C;VYV97)T(&%L;"!O<B!P87)T(&]F('1H92!O=71S=&%N
M9&EN9R!A;F0@=6YP86ED('!R:6YC:7!A;"!S=6T@86YD(&%C8W)U960@:6YT
M97)E<W0@:6YT;R!F=6QL>2!P86ED#0IA;F0@;F]N+6%S<V5S<V%B;&4@<VAA
M<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@870@)#`N
M,3(@<&5R('-H87)E+B!)9B!T:&4@0V]M<&%N>2!I<W-U97,@<VAA<F5S("AO
M<B!R961U8V5S('1H90T*8V]N=F5R<VEO;B!O<B!E>&5R8VES92!P<FEC92!F
M;W(@;W5T<W1A;F1I;F<@9&5B="!O<B!W87)R86YT<RD@9F]R(&QE<W,@=&AA
M;B`D,"XQ,BP@=&AE;B!T:&4@8V]N=F5R<VEO;B!P<FEC92!F;W(@=&AE(&YO
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M;B!S=&]C:RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
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M('1H92!L97-S97(@;V8@=&AE(&-O;G9E<G-I;VX@<')I8V4@;W(@-S`E(&]F
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M.24@;V8@=&AE(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9RX\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D%S('!A<G0@;V8@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A;GD@86QS
M;PT*:7-S=65D(#,L,#`P+#`P,"!W87)R86YT<R!T;R!T:&4@;F]T92!H;VQD
M97(@97AE<F-I<V%B;&4@870@)#`N,C4O<VAA<F4@97AP:7)I;F<@;VX@3V-T
M;V)E<B`S,2P@,C`Q-BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
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M=`T*;&5S<R!T:&%N("0P+C(U('!E<B!S:&%R92P@;W(@<F5P<FEC:6YG(&]F
M(&%N>2!E>&ES=&EN9R!W87)R86YT<R!T;R!A(&QO=V5R('!R:6-E+CPO9F]N
M=#X\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T
M-6%?,30S-U\T.3$X7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T
M8V1E,S5E82]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%0T%#
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1%4DE6051)5D4@5T%24D%.5"!,
M24%"24Q)5%D@04Y$($9!25(@5D%,544@*%1A8FQE<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E<R!T;R!&
M:6YA;F-I86P@4W1A=&5M96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!P=7)C:&%S92!W87)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E
M<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY$96-E
M;6)E<B`S,2P@,C`Q,3PO=&0^#0H@("`@/'1D(&-O;'-P86X],T0T('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!P861D
M:6YG+71O<#H@-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY397!T96UB97(@,S`L
M(#(P,3(\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`R-B4[(&)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,3`E.R!B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SY%>'!E8W1E9"!,:69E("A996%R<RD\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:61T:#H@,3`E.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O
M;&ED.R!P861D:6YG+71O<#H@-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY2:7-K
M(&9R964@4F%T93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Y)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^1&EV:61E;F0@>6EE;&0\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@.24[(&)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!C96YT97(G/E9O;&%T:6QI='D\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@.24[
M(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I
M;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/D5X<&5C=&5D($QI9F4@
M*%EE87)S*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=I9'1H.B`Y)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^4FES:R!F<F5E(%)A=&4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@.24[(&)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!C96YT97(G/D1I=FED96YD('EI96QD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#DE
M.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D
M:6YG+71O<#H@-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY6;VQA=&EL:71Y/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^4VAA<F4@<'5R8VAA<V4@
M=V%R<F%N=',\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXQ
M+C`Y('1O(#0N.#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXP+C$R)2!T;R`P+C@S)3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C
M96YT97(G/C`N,#`E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^,3DY)3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/C`N
M,S,@=&\@-"XP,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/C`N,3`E('1O(#`N-C(E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^,"XP,"4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXQ.3DE/"]T9#X\+W1R/@T*/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@3W!T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/D%T($EN:71I86P@4F5C;V=N:71I;VX\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^4V5P
M=&5M8F5R(#,P+"`R,#$R/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@,C0E.R!B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+71O<#H@
M-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#DE.R!B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+71O<#H@-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SY%>'!E8W1E9"!,:69E("A9
M96%R<RD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:61T:#H@.24[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/E)I<VL@9G)E92!2871E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#DE.R!B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+71O<#H@-G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SY$:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[
M(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I
M;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/E9O;&%T:6QI='D\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:61T:#H@.24[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L
M:60[('!A9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/D5X<&5C
M=&5D($QI9F4@*%EE87)S*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Y)3L@8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^4FES:R!F<F5E(%)A=&4\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@.24[(&)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M
M=&]P.B`V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/D1I=FED96YD('EI96QD/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VED=&@Z(#$Q)3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S
M;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^5F]L
M871I;&ET>3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-O;G9E
M<G-I;VX@3W!T:6]N/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^,"XR-2!T;R`Q+C`T/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^,"XQ,24@=&\@,"XR,"4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SXP+C`P)3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C
M96YT97(G/C$S."XS,24@=&\@,30Q+C0S)3PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/C`N,3$@=&\@,2XP,#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!C96YT97(G/C`N,#8E('1O(#`N,3<E/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S
M;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^,"XP,"4\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SXQ,S@N,S$E('1O(#$T,2XR,24\+W1D/CPO
M='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!L969T)SX\8CXF(S$V,#L\+V(^/"]P/@T*("`@("`@
M("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&QE9G0G/CQB/D%S
M(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,B`\+V(^/"]P/CPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[
M(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!C96YT97(G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\
M<"!S='EL93TS1"=F;VYT.B`T<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S='EL
M93TS1"=F;VYT.B`T<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F
M;VYT.B`T<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/B8C,38P.SPO<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0U('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY&86ER(%9A;'5E($UE
M87-U<F5M96YT<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@(#QP
M('-T>6QE/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE
M/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O
M;G0Z(#1P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SXF(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#1P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF
M(S$V,#L\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[
M/"]P/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SY#87)R>6EN9R!686QU93PO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY,
M979E;"`Q/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/DQE=F5L(#(\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<B<^3&5V96P@
M,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E
M>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SY4;W1A;#PO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/D1E<FEV871I=F4@;&EA8FEL:71Y
M("T@=V%R<F%N=',\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@.#<Q+#@U
M.#PO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)"8C,38P.R`X-S$L.#4X/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q
M-C`[(#@W,2PX-3@\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY$97)I=F%T:79E(&QI86)I;&ET>2`F
M(S$U,#L@8V]N=F5R<VEO;B!O<'1I;VX\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(P
M,"PW,#`\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BTF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C(P,"PW,#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(P,"PW,#`\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T)SY4;W1A;#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R`Q
M+#`W,BPU-3@\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/BTF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/BTF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M=&]P.B!W
M:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@,2PP
M-S(L-34X/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`P+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q-C`[(#$L,#<R
M+#4U.#PO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#,V)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3(E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4G/B8C,38P.SPO=&0^/"]T<CX-
M"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET>2`M('=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUT;W`Z('=I;F1O
M=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED
M.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@
M("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@;&5F="<^/&(^
M)B,Q-C`[/"]B/CPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!C96YT97(G/CQB/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q
M/"]B/CPO<#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT
M(#$N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T
M('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M=&]P
M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#`N-7!T('-O;&ED)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@
M("`@/'`@<W1Y;&4],T0G9F]N=#H@-'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"B`@("`@("`@/'`@
M<W1Y;&4],T0G9F]N=#H@-'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4]
M,T0G9F]N=#H@-'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/B8C,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SXF(S$V,#L\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S
M='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<B<^1F%I<B!686QU
M92!-96%S=7)E;65N=',@57-I;F<\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,R!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`T<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[
M/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`T<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*
M("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`T<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@
M("`\<"!S='EL93TS1"=F;VYT.B`T<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<B<^0V%R<GEI;F<@5F%L
M=64\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T
M97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^3&5V96P@,3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY,979E;"`R/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97(G/DQE=F5L(#,\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=B;W)D97(M=&]P
M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^5&]T86P\+W1D/CPO='(^#0H\='(^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY$97)I=F%T:79E
M(&QI86)I;&ET>2`M('=A<G)A;G1S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q
M-C`[(#$L,S$W+#@S-#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P
M.R`Q+#,Q-RPX,S0\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F
M(S$V,#L@,2PS,3<L.#,T/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/E1O=&%L/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^)"8C,38P.R`Q+#,Q-RPX,S0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@,2PS,3<L.#,T/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R`Q+#,Q-RPX,S0\+W1D
M/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S,R4G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$S)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#8E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS
M1"=F;VYT.B`T<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT
M.B`T<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`T<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q
M-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO
M<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY&86ER(%9A;'5E($UE87-U<F5M96YT
M<R!5<VEN9R!,979E;"`S($EN<'5T<SPO8CX\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M="<^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#1P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H@
M("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXF(S$V,#L\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SY$97)I=F%T:79E(&QI86)I;&ET>2`M('=A
M<G)A;G1S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA
M;&EG;CH@8V5N=&5R)SY$97)I=F%T:79E(&QI86)I;&ET>2`F(S$U,#L@8V]N
M=F5R<VEO;B!O<'1I;VX\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!T97AT+6%L:6=N.B!C96YT97(G/E1O=&%L/"]T9#X\+W1R/@T*/'1R/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M="<^0F%L86YC92PF(S$V,#L@1&5C96UB97(@,S$L(#(P,3`\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B0@,2PX,3DL-3$R/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P
M86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^)"`Q-S4L,S@Y/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP
M+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"`Q+#DY
M-"PY,#$\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^061D:71I;VYS(&1U
M<FEN9R!T:&4@>65A<CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,2PU.#<L,C<U/&9O
M;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+28C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,2PU.#<L,C<U/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/E1O=&%L('5N<F5A;&EZ960@*&=A:6YS*2!O<B!L;W-S97,@
M:6YC;'5D960@:6X@;F5T(&QO<W,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B@V,S$L-C,Q*3PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^*#,W+#`W.2D\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@V-C@L-S$P*3PO=&0^/"]T<CX-
M"CQT<CX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/D1E8G0@<V5T=&QE;65N=#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M*#$L-#4W+#,R,BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@Q,S@L,S$P*3PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^*#$L-3DU+#8S,BD\+W1D/CPO='(^#0H\='(^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M)SY4<F%N<V9E<G,@:6X@86YD+V]R(&]U="!O9B!,979E;"`S/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXM)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!B;W)D
M97(M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/D)A;&%N8V4L($1E8V5M8F5R
M(#,Q+"`R,#$Q/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^,2PS,3<L.#,T/&9O;G0@<W1Y;&4],T0G;&5T
M=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUT
M;W`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\
M9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^,2PS,3<L.#,T/&9O;G0@<W1Y;&4],T0G;&5T=&5R
M+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<CX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/D%D9&ET:6]N<R!D=7)I;F<@=&AE('EE87(\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/BTF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(Y.2PS,#`F(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(Y.2PS,#`F(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY4;W1A;"!U;G)E86QI>F5D("AG86EN
M<RD@;W(@;&]S<V5S(&EN8VQU9&5D(&EN(&YE="!L;W-S/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH-#0U+#DW-BD\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@Y."PV,#`I/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH-30T+#4W
M-BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY$96)T('-E='1L
M96UE;G0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/BTF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/BTF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/BTF(S$V,#L\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY4<F%N<V9E<G,@:6X@
M86YD+V]R(&]U="!O9B!,979E;"`S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXM)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S
M;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,S4E.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT
M(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P="<^0F%L86YC92P@4V5P=&5M8F5R(#,P+"`R,#$R/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3DE.R!B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B0F(S$V,#L@.#<Q+#@U."8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`R,"4[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"`R,#`L-S`P/&9O;G0@<W1Y
M;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[(&)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)"8C,38P.R`Q+#`W,BPU-3@F(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T
M-6%?,30S-U\T.3$X7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T
M8V1E,S5E82]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY615)424),12!.3U1%4R!005E!
M0DQ%("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4&%Y86)L97,@86YD($%C8W)U86QS(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YS=')U;65N="!T<F%N<V%C=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0S)3L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@
M("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/CQB
M/B8C,38P.SPO8CX\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SX\8CXF(S$V,#L\+V(^/"]P/@T*("`@("`@
M("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&(^
M1F%C92!686QU93PO8CX\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$S)3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^/&(^)B,Q-C`[/"]B/CPO<#X-"B`@("`@("`@/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/E!R:6YC:7!A
M;"!297!A>6UE;G0\+V(^/"]P/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-24[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!C96YT97(G/CQB/E5N86UO<G1I>F5D/"]B/CPO<#X-"B`@("`@("`@
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/DYO
M=&4\+V(^/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^/&(^1&ES8V]U;G0\+V(^/"]P/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-B4[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/D)A;&%N8V4@870\+V(^
M/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^/&(^4V5P=&5M8F5R(#,P+#PO8CX\+W`^#0H@("`@("`@(#QP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CXR,#$R
M/"]B/CPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I
M;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD
M;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SY&96)R=6%R
M>2`R,#$Q(%-E8W5R960@0V]N=F5R=&EB;&4@3F]T97,\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/E-E;FEO<B!396-U<F5D($YO=&5S+"!D=64@1F5B
M<G5A<GD@,C0L(#(P,30\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B0@,2PQ.#0L-CDT/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P
M86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`M)B,Q-C`[)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q-C`[
M)B,Q-C`[)B,Q-C`[(#(R-2PX,#`F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0@.34X+#@Y-#QF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SY!<')I;"`R,#$Q(%-E8W5R960@0V]N
M=F5R=&EB;&4@3F]T97,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/E-E
M;FEO<B!396-U<F5D($YO=&5S+"!D=64@07!R:6P@-"P@,C`Q-#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,C$U+#`P,#QF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R`M)B,Q-C`[)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXU,2PW.#8F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C$V,RPR,30\9F]N="!S='EL93TS1"=L971T
M97(M<W!A8VEN9SH@+3`N,7!T)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9"<^2G5N92`R,#$Q(%-E8W5R960@0V]N=F5R=&EB
M;&4@3F]T93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^4V5N:6]R(%-E
M8W5R960@3F]T97,L(&1U92!*=6YE(#8L(#(P,30\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C,P+#`P,#QF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`M)B,Q-C`[
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXT+#8U,"8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^,C4L,S4P/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG:'0Z
M(&)O;&0G/D%U9W5S="`X+"`R,#$R($-O;G9E<G1I8FQE($YO=&4\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/DYO=&4@9'5E($%U9W5S="`X+"`R,#$S
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ,3$L
M-#,P/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[("TF(S$V,#LF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/CDU+#(U,"8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,38L,3@P/&9O;G0@<W1Y;&4]
M,T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0G/D%U9W5S="`Q,BP@,C`Q,B!#;VYV
M97)T:6)L92!.;W1E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY.;W1E
M(&1U92!.;W9E;6)E<B`Q,BP@,C`Q,CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^,C<L-3`P/&9O;G0@<W1Y;&4],T0G;&5T=&5R
M+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[("TF(S$V,#LF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$Q+#8U
M."8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^,34L.#0R/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P
M="<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0G
M/D%U9W5S="`R,"P@,C`Q,B!#;VYV97)T:6)L92!.;W1E/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SY.;W1E(&1U92!!=6=U<W0@,C`L(#(P,3,\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(P+#`P,#QF
M;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R`M)B,Q-C`[)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXQ-RPW-3<F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(L,C0U/&9O;G0@<W1Y;&4],T0G;&5T
M=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M9F]N="UW96EG:'0Z(&)O;&0G/E-E<'1E;6)E<B`R,#$R($-O;G9E<G1I8FQE
M($YO=&4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/DYO=&4@9'5E($]C=&]B97(@
M,2P@,C`Q,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^.#(L
M-3`P/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C%P="<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[("TF(S$V,#LF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/C<Y+#@W-"8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^,BPV,C8\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@
M+3`N,7!T)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UW96EG
M:'0Z(&)O;&0G/E1O=&%L/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXD(#$L-C<Q+#$R-#QF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG
M.B`M,"XQ<'0G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/B0F(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#L@+28C,38P.R8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L
M:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R8C,38P.R8C,38P.R`T.#8L
M-S<S)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD
M(#$L,3@T+#,U,3QF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ
M<'0G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S
M-U\T.3$X7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E
M82]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(2#X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#05!)5$%,(%-43T-+("A486)L97,I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G)O
M:V5R<R!A;F0@1&5A;&5R<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@=&AE($-O;7!A
M;GDG<R!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`T-R4[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q-R4[(&)O<F1E<BUT;W`Z('=I;F1O
M=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!C96YT97(G/DYU;6)E<B!O9CPO<#X-"B`@("`@("`@
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/D]P=&EO
M;G,\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@8F]R
M9&5R+71O<#H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^5V5I9VAT960@
M079E<F%G93PO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!C96YT97(G/D5X97)C:7-E(%!R:6-E/"]P/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O<F1E<BUT;W`Z('=I;F1O=W1E
M>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!C96YT97(G/E=E:6=H=&5D($%V97)A9V4\+W`^#0H@("`@
M("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY2
M96UA:6YI;F<@3&EF93PO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T
M('-O;&ED.R!P861D:6YG+7)I9VAT.B`V+C0U<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O
M;&ED.R!P861D:6YG+7)I9VAT.B`Q."XX<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M9F]N="UW96EG:'0Z(&)O;&0G/D)A;&%N8V4L($1E8V5M8F5R(#,Q+"`R,#$Q
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-BXT-7!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-BPR
M-S@L,#`P)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@,3@N.'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)"8C,38P.R`P+C$X/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@,C$N.35P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C8N.#4\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V
M,#L@27-S=65D/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@-BXQ-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C
M96YT97(G/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`U,#`L
M,#`P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,3DN
M.7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M,"XQ.#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#(Q
M+CDU<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXM/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`G/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P="<^)B,Q-C`[($-A;F-E;&QE9#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L
M:60[('!A9&1I;F<M<FEG:'0Z(#(Q+CDU<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SXM/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D
M9&EN9RUR:6=H=#H@,C$N.35P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/BT\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I
M9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^+3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SY"86QA
M;F-E+"!397!T96UB97(@,S`L(#(P,3(F(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`V+C0U<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('1E>'0M86QI9VXZ(')I9VAT)SXV+#<W."PP,#`F(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T
M('-O;&ED.R!P861D:6YG+7)I9VAT.B`Q."XX<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXD)B,Q-C`[(#`N,3@\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^-BXV,3PO=&0^/"]T<CX-
M"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F('1H92!S=&%T=7,@;V8@=&AE($-O;7!A
M;GDG<R!U;G9E<W1E9"!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T-R4[(&)O
M<F1E<BUT;W`Z('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q-R4[(&)O
M<F1E<BUT;W`Z('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O
M<F1E<BUT;W`Z('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/DYU;6)E<B!O9CPO<#X-
M"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT
M97(G/E-H87)E<SPO<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,3@E.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@(#QP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY796EG:'1E
M9"!!=F5R86=E/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^1W)A;G0M1&%T93PO<#X-"B`@("`@("`@/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/D9A:7(@5F%L
M=64\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9"<^56YV97-T960L($1E8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-BXT-7!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XS<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#`S-RPW
M,#DF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`R,2XY-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^)"8C,38P.R`P+C$X/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[
M($=R86YT960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`V+C0U<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C-P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/C4P,"PP,#`F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`R,2XY-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^,"XQ-SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C
M,38P.R!697-T960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`V+C0U<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C-P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B@X-#,L-C<V*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#(Q+CDU<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXP+C$X/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[($-A
M;F-E;&QE9#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#8N-#5P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N,W!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3QF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ<'0G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`R,2XY-7!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#8N-#5P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N,W!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@,C$N.35P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD)SY5;G9E<W1E9"P@4V5P=&5M8F5R(#,P+"`R
M,#$R/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-BXT-7!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XS<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXV.30L,#,S)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,C$N.35P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V
M,#L@,"XQ.#PO=&0^/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F('1H92!#
M;VUP86YY)W,@<VAA<F4@<'5R8VAA<V4@=V%R<F%N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0W)3L@8F]R9&5R+71O
M<#H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$W)3L@8F]R9&5R+71O
M<#H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^3G5M8F5R(&]F/"]P/@T*("`@("`@
M("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^5V%R
M<F%N=',\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@
M8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/@T*("`@("`@("`\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^5V5I9VAT960@079E
M<F%G93PO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!C96YT97(G/D5X97)C:7-E(%!R:6-E/"]P/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!C96YT97(G/E=E:6=H=&5D($%V97)A9V4\+W`^#0H@("`@("`@(#QP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SY296UA:6YI;F<@
M3&EF93PO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C
M96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!C96YT97(G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD)SY"86QA;F-E+"!$96-E;6)E<B`S,2P@,C`Q,3PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,3(L,3`V+#,U-28C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#(P+C1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F
M(S$V,#L@,"XU-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#(S+C5P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/C(N.#$\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L@27-S=65D/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#4Q-BPV
M-C@F(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT
M.B`R,"XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXP+C0P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@,C,N-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,2XX,#PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.R!%>'1I;F=U:7-H960@;W(@
M97AP:7)E9#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^*#<Q
M-"PT,#`I/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,C`N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,BXS
M,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#(S+C5P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@
M<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^0F%L86YC92P@4V5P=&5M8F5R(#,P
M+"`R,#$R/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXQ,BPY
M,#@L-C(S)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@
M,C`N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^)"8C,38P.R`P+C0S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@,C,N-7!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,2XX-CPO=&0^/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I&/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-54%!,14U%3E1!3"!#05-(($9,3U<@24Y&3U)-051)3TX@
M04Y$($Y/3BU#05-(($E.5D535$E.1R!!3D0@1DE.04Y#24Y'($%#5$E6251)
M15,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@0V%S:"!&;&]W($5L96UE;G1S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0T%32"!&3$]7($E.1D]234%424].($%.1"!.3TXM0T%32"!)
M3E9%4U1)3D<@04Y$($9)3D%.0TE.1R!!0U1)5DE42453/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T
M('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0S('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0U('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!C96YT97(G/DYI;F4@36]N=&AS($5N9&5D/"]P/@T*("`@
M("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M4V5P=&5M8F5R(#,P+"`R,#$R/"]P/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M=&]P.B!W
M:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU
M<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L
M:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S
M;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^4VAA<F5S+W=A<G)A;G1S/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/D%M
M;W5N=#PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0S('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SY3
M:&%R97,@:7-S=65D('!U<G-U86YT('1O(&1E8G0@<V5T=&QE;65N="!A9W)E
M96UE;G1S/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^,BPQ,C8L-#0W/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0S('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXD,S(V+#DS-SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE
M9G0Z(#4N-'!T)SY#;VUM;VX@<VAA<F5S(&ES<W5E9"!P=7)S=6%N="!T;R!C
M;VYS=6QT:6YG('-E<G9I8V4@87)R86YG96UE;G1S/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^,30L
M-3,U+#$W.3PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T
M('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0Q+#DY."PP,#`\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U
M+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^#0H@("`@("`@(#QP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/B8C,38P.SPO<#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0S('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI
M9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0S('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S
M;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N
M-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0S('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT97(G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0T('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SX-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO<#X-"B`@("`@("`@/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO<#X-
M"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!C96YT
M97(G/DYI;F4@36]N=&AS($5N9&5D/"]P/@T*("`@("`@("`\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^4V5P=&5M8F5R(#,P+"`R
M,#$Q/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L
M:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUT;W`Z('=I;F1O=W1E
M>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU
M<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P
M+C5P="!S;VQI9#L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`P+C5P="!S
M;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^4VAA<F5S+W=A<G)A;G1S/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[(&)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/D%M;W5N=#PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P
M86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#,@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SY!8V-O=6YT<R!P87EA8FQE('-E='1L960@8GD@
M:7-S=6EN9R!C;VUM;VX@<VAA<F5S/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,R!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^-"PR,30L-S8V/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"`X,34L
M-3(W/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^0V]M;6]N('-H
M87)E<R!I<W-U960@<'5R<W5A;G0@=&\@8V]N<W5L=&EN9R!S97)V:6-E(&%R
M<F%N9V5M96YT<SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#,@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C(L,S(W
M+#`U.3PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0U,#`L-3(W/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L:60[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,R!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#$N-7!T('-O;&ED.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,2XU<'0@<V]L
M:60[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D
M:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0R('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T-R4G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#<E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,B4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,30E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061D:71I;VYA;"!D:7-C;&]S=7)E(&]N(&YO;BUC87-H
M('1R86YS86-T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*("`@(#QT9"!R;W=S
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT(#$N-7!T
M('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#`N-7!T('-O;&ED
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^
M#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*("`@
M("`@("`\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T
M97AT(#$N-7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/DYI;F4@36]N=&AS
M($5N9&5D(%-E<'1E;6)E<B`S,"P\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R
M:6=H="<^,C`Q,CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,"XU<'0@<V]L:60[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^
M,C`Q,3PO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@=VED=&@Z(#8X)3L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q.24[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,R4[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L
M:6=N.B!C96YT97(G/B8C,38P.SPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/DEN=&5R97-T('!A:60@:6X@
M8V%S:#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('!A9&1I;F<M<FEG:'0Z(#$R+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B0F(S$V,#L@+3PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M<FEG:'0Z(#$U+CEP=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B0F(S$V,#L@+3PO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/DEN8V]M92!T87AE<R!P86ED/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR
M:6=H=#H@,3(N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N
M.B!R:6=H="<^)"8C,38P.R`M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q+C5P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,34N.7!T.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)"8C,38P.R`M/"]T
M9#X\+W1R/@T*/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E
M,S5E80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C83<P.#0U85\Q
M-#,W7S0Y,3A?835B9E\Q,C)E-&-D93,U96$O5V]R:W-H965T<R]3:&5E=#(R
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].
M5$E.1T5.0TE%4R!!3D0@0T]-34E4345.5%,@*%1A8FQE<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT
M:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E(&UI;FEM=6T@86YN=6%L
M('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B
M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T
M:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=W:61T:#H@,C$E.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W=I9'1H.B`W)3L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=W:61T
M:#H@,S(E.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%(F(S,X.T0\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=VED=&@Z(#8E.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=&5X="UA
M;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=VED=&@Z(#,T)3L@<&%D9&EN9RUR:6=H=#H@-2XT
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M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+71O
M<#H@-G!T.R!P861D:6YG+6QE9G0Z(#8U<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`M-RXY<'0G/D-O
M;6UI=&UE;G1S/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+71O<#H@-G!T.R!P861D
M:6YG+6QE9G0Z(#%I;CL@9F]N="UW96EG:'0Z(&)O;&0G/D-O;6UI=&UE;G1S
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/C(P,3(\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+71O
M<#H@-G!T.R!P861D:6YG+6QE9G0Z(#%I;CL@=&5X="UI;F1E;G0Z("TX+C-P
M="<^)B,Q-C`[)"`Q+#`U,BPU,#`\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!S='EL93TS1"=P861D:6YG+71O<#H@-G!T.R!P861D:6YG+6QE9G0Z
M(#%I;B<^)B,Q-C`[)"8C,38P.R8C,38P.R8C,38P.R8C,38P.R`Q.34L.#(Q
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/C(P,3,\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=P861D:6YG+71O
M<#H@-G!T.R!P861D:6YG+6QE9G0Z(#%I;B<^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[(#,W+#4P,#PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`U+C1P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W!A9&1I;F<M=&]P.B`V<'0[('!A9&1I;F<M;&5F=#H@
M,6EN)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#L@,S`X+#,Q,SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T
M)SXR,#$T/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUL969T.B`Q:6XG/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`M)B,Q-C`[
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUL969T.B`Q:6XG/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R`R,BPR.#0\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS
M1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@=VEN9&]W=&5X="`P+C5P="!S;VQI9#L@8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[('!A9&1I;F<M=&]P.B`V<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!T
M97AT+6%L:6=N.B!R:6=H="<^)"`Q+#`Y,"PP,#`\+W1D/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1"=B;W)D97(M=&]P.B!W:6YD;W=T97AT
M(#`N-7!T('-O;&ED.R!B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@<&%D9&EN9RUT;W`Z(#9P=#L@<&%D9&EN9RUL969T.B`Q:6XG/B0F
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@-3(V+#0Q.#PO=&0^/"]T
M<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15)%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DY!5%5212!/
M1B!/4$52051)3TY3("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N
M=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V]R:VEN
M9R!C87!I=&%L(&1E9FEC:65N8WD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPS,34L-S4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P131-04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4D5314%20T@@04=2145-14Y44R`H1&5T86EL<R!.87)R871I=F4I("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#D\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`X
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,#<L(#(P
M,#,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4F5S96%R8V@@86YD($1E=F5L;W!M96YT(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5Q=6ER960@
M=&\@;6%K92!C97)T86EN('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-R=6-E;&P@=6YD97(@=&AI<R!A9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T,RPU.3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]U='-T86YD:6YG(&)A;&%N8V4@<F5Q=6ER:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD960@86=R965M96YT(&%C
M8W)U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S8U+#DW
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V$W
M,#@T-6%?,30S-U\T.3$X7V$U8F9?,3(R931C9&4S-65A#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V-A-S`X-#5A7S$T,S=?-#DQ.%]A-6)F7S$R
M,F4T8V1E,S5E82]7;W)K<VAE971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$55
M34%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3E9%4E1)0DQ%($Y/5$53
M(%!!64%"3$4@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,3@L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`R,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#$R
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@
M,#@L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!
M<'(N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D9E8BX@,C@L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4&%Y86)L97,@86YD($%C8W)U86QS(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@.#(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W+#4P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$Q+#0S
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R,34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#$X-"PV.30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<')O8V5E9',@
M86YD(&%C8W)U960@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDR+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#0L-CDT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S
M=&%N9&EN9R!A;F0@9&5M86YD86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&-O;G9E<G-I
M;VX@<F%T92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F]T97,@8F5A<B!I;G1E<F5S="!R871E('!E<B!A;FYU;3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^."4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;F1E
M<G,G(&9E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L-34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#$L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!F:6YA;F-I;F<@8V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.#`S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#@S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@L-#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!E>&5R8VES86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-34L-S`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,S8Y+#,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+#0P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#$P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#$P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q
M+#<R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S,"PW,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT.#,L,S4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S(&%N
M9"!T:&4@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0L
M,C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S`Q+#,S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R+#8R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,BPR-#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U+#@T,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38L,3@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C4L-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q,C`L.#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P131'/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG
M/DQ/04Y3(%!!64%"3$4@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.;W1E<R!T;R!&:6YA;F-I86P@4W1A=&5M96YT<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G-E8W5R
M960@;&]A;B!A9'9A;F-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P13)*04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4%)/34E34T]262!.3U1%("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3F]T97,@=&\@1FEN86YC:6%L(%-T871E;65N=',\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO
M=6YT(&9O<B!F=71U<F4@;&5G86P@<V5R=FEC97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A
M;F0@9&5P;W-I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q
M+#<P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R<VEO;B!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XR,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!T;R!T
M:&4@:&]L9&5R(&]F('1H92!N;W1E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]M:7-S;W)Y(&YO=&5S(&%M;W5N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<L.30R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]M:7-S;W)Y
M(&YO=&5S(&%M;W5N="!I<W-U960@=&\@86X@;V9F:6-E<B!A;F0@82!D:7)E
M8W1O<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S."PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-A-S`X
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1%!!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY214Q!5$5$(%!!4E19(%1204Y3
M04-424].4R`H1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E
M9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT(&9E97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<S+#4P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@W
M+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT('-E<G9I8V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPU,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPU,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S$L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S8P+#(V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!D=64@=&\@<F5L871E9"!P87)T
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O;6ES<V]R>2!N;W1E<R!T;R!O9F9I8V5R(&%N9"!D:7)E
M8W1O<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UO=6YT<R!O=VEN9R!T;R!D:7)E8W1O<G,@86YD(&]F9FEC97)S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X,2PT-S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,R,BPY,#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-A-S`X
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5T)!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#05!)5$%,(%-43T-+("A$971A
M:6QS($YA<G)A=&EV92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)R;VME<G,@86YD
M($1E86QE<G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VL@<VAA<F5S('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]N+79O=&EN9R!P<F5F97)R960@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO
M;BUV;W1I;F<@<')E9F5R<F5D('-H87)E<R!P87(@=F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-A-S`X-#5A7S$T,S=?-#DQ.%]A
M-6)F7S$R,F4T8V1E,S5E80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]C83<P.#0U85\Q-#,W7S0Y,3A?835B9E\Q,C)E-&-D93,U96$O5V]R:W-H
M965T<R]3:&5E=#,P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1D)!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY355!03$5-14Y404P@0T%32"!&3$]7($E.1D]234%424].
M($%.1"!.3TXM0T%32"!)3E9%4U1)3D<@04Y$($9)3D%.0TE.1R!!0U1)5DE4
M2453("T@061D:71I;VYA;"!D:7-C;&]S=7)E(&]N(&YO;BUC87-H('1R86YS
M86-T:6]N<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L($-A
M<V@@1FQO=R!%;&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T('!A:60@:6X@8V%S
M:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X97,@<&%I9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15)%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E-54%!,14U%3E1!3"!#05-(($9,3U<@
M24Y&3U)-051)3TX@04Y$($Y/3BU#05-(($E.5D535$E.1R!!3D0@1DE.04Y#
M24Y'($%#5$E6251)15,@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@
M,C@L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5P<&QE;65N=&%L($-A<V@@1FQO=R!%;&5M96YT<R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYO=&5S(&EN('1H92!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S-U\T.3$X7V$U8F9?,3(R931C
M9&4S-65A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-A-S`X-#5A
M7S$T,S=?-#DQ.%]A-6)F7S$R,F4T8V1E,S5E82]7;W)K<VAE971S+U-H965T
M,S(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5.2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY3
M54)315%514Y4($5614Y44R`H1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T
M+B`Q-2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92!T
M;R!A;B!I;G9E<W1O<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y296-E:79E9"!F;W(@=&AE(&YO=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE9V%L(&9E97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL(B\^#0H\
M+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?8V$W,#@T-6%?,30S-U\T.3$X7V$U
38F9?,3(R931C9&4S-65A+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CAPITAL STOCK (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BrokersAndDealersAbstract', window );"><strong>Brokers and Dealers [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockShares', window );">Common stock shares</a></td>
        <td class="nump">$ 150,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockSharesParValue', window );">Common stock shares par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NonvotingPreferredShares', window );">Non-voting preferred shares</a></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NonvotingPreferredSharesParValue', window );">Non-voting preferred shares par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_CommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CommonStockSharesParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_CommonStockSharesParValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NonvotingPreferredShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NonvotingPreferredShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NonvotingPreferredSharesParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NonvotingPreferredSharesParValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BrokersAndDealersAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BrokersAndDealersAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ManagementFees', window );">Management fees</a></td>
        <td class="nump">$ 173,500<span></span></td>
        <td class="nump">$ 187,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ResearchAndDevelopmentServices', window );">Research and development services</a></td>
        <td class="nump">67,500<span></span></td>
        <td class="nump">67,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_StockBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump">31,333<span></span></td>
        <td class="nump">360,260<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DebtDueToRelatedParties', window );">Debt due to related parties</a></td>
        <td class="nump">$ 25,000<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_PromissoryNotesToOfficerAndDirector', window );">Promissory notes to officer and director</a></td>
        <td class="nump">38,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AmountsOwingToDirectorsAndOfficer', window );">Amounts owing to directors and officers</a></td>
        <td class="nump">$ 281,475<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 322,905<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AmountsOwingToDirectorsAndOfficer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_AmountsOwingToDirectorsAndOfficer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DebtDueToRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DebtDueToRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ManagementFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ManagementFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_PromissoryNotesToOfficerAndDirector">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_PromissoryNotesToOfficerAndDirector</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ResearchAndDevelopmentServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ResearchAndDevelopmentServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_StockBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_StockBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES - Additional disclosure on non-cash transactions (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_InterestPaidInCash', window );">Interest paid in cash</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_InterestPaidInCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_InterestPaidInCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowElementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesInAmount', window );">Notes in the amount</a></td>
        <td class="nump">$ 240,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesInAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowElementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RESEARCH AGREEMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">RESEARCH AGREEMENTS</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><u>Note
3:&#9;Research Agreements</u></font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Crucell
Holland B.V. (&#147;Crucell&#148;) &#150; Research License and Option Agreement</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Effective
August 7, 2003, Crucell and the Company&#146;s subsidiary GeneMax Pharmaceuticals, Inc. (&#147;GPI&#148;) entered into a five-year
research license and option agreement whereby Crucell granted to GPI a non-exclusive worldwide license for the research use of
its adenovirus technology. The Company was required to make certain payments over the five-year term totaling Euro &#128;450,000.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2008, $243,598 (&#128;172,801) was owing to Crucell under this agreement. During the year ended December 31, 2009,
management negotiated a settlement of the outstanding balance requiring a &#128;17,000 cash payment (paid) and the issuance of
265,000 shares of the Company&#146;s common stock (refer to Note 9).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In addition, retroactively effective August 7, 2008,
the Company negotiated an amended license agreement for the use of Crucell&#146;s adenovirus technology. The Company is required
to make annual license payments on the anniversary of the effective date for the three year term equal to &#128;75,000 per annum.
As at September 30, 2012, the Company had accrued $365,970 (&#128;284,578) under the amended agreement, inclusive of interest
on outstanding amounts. The Company is currently delinquent on making its first annual license payment under the amended license
agreement. Crucell has the right to cancel the agreement however, to date, the Company has not received any notice terminating
the license agreement. Management plans to negotiate an amended payment structure with Crucell that, if successful, would allow
the Company to maintain the license agreement in good standing. However, there is no certainty that the license agreement will
be maintained or that management will successfully negotiate new terms.</font></p>



<p style="margin: 0pt; text-align: justify"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 68<br><br> -Paragraph 14<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 68<br><br> -Paragraph 14<br><br> -Footnote 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENH">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Oct. 15, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NoteToInvestor', window );">Note to an investor</a></td>
        <td class="nump">$ 340,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ReceivedForNotes', window );">Received for the note</a></td>
        <td class="nump">300,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_LegalFee', window );">Legal fees</a></td>
        <td class="nump">$ 10,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_LegalFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_LegalFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NoteToInvestor">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NoteToInvestor</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ReceivedForNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ReceivedForNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 3,727<span></span></td>
        <td class="nump">$ 250,234<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Due from government agency</a></td>
        <td class="nump">1,099<span></span></td>
        <td class="nump">1,060<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and deposits (Note 7)</a></td>
        <td class="nump">22,504<span></span></td>
        <td class="nump">56,627<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred financing costs (Note 5)</a></td>
        <td class="nump">12,641<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Assets, Current, Total</a></td>
        <td class="nump">39,971<span></span></td>
        <td class="nump">307,921<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DeferredFinancingCostsNote5', window );">Deferred financing costs (Note 5)</a></td>
        <td class="nump">20,768<span></span></td>
        <td class="nump">32,291<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets, Total</a></td>
        <td class="nump">60,739<span></span></td>
        <td class="nump">340,212<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">1,327,984<span></span></td>
        <td class="nump">794,291<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Research agreement obligations (Note 3)</a></td>
        <td class="nump">365,970<span></span></td>
        <td class="nump">259,752<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability &#x2013; warrants (Note 4)</a></td>
        <td class="nump">871,858<span></span></td>
        <td class="nump">1,317,834<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DerivativeLiabilityConversionOptionNote4', window );">Derivative liability &#x2013; conversion option (Note 4)</a></td>
        <td class="nump">200,700<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable (Note 5)</a></td>
        <td class="nump">1,184,351<span></span></td>
        <td class="nump">998,790<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable (Note 6)</a></td>
        <td class="nump">28,000<span></span></td>
        <td class="nump">7,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Promissory note (Note 7)</a></td>
        <td class="nump">167,942<span></span></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties (Note 8)</a></td>
        <td class="nump">281,475<span></span></td>
        <td class="nump">322,905<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Liabilities, Current, Total</a></td>
        <td class="nump">4,428,280<span></span></td>
        <td class="nump">3,800,572<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Capital stock (Note 9)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 150,000,000 shares authorized 73,861,754 shares issued and outstanding (2011 &#x2013; 52,073,460)</a></td>
        <td class="nump">73,864<span></span></td>
        <td class="nump">52,072<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">43,220,515<span></span></td>
        <td class="nump">39,943,374<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_SharesAndWarrantsToBeIssued', window );">Shares and warrants to be issued</a></td>
        <td class="nump">242,062<span></span></td>
        <td class="nump">362,906<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Deferred compensation (Note 9)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(35,968)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(47,840,900)<span></span></td>
        <td class="num">(43,722,216)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="num">(63,082)<span></span></td>
        <td class="num">(60,528)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity Attributable to Parent, Total</a></td>
        <td class="num">(4,367,541)<span></span></td>
        <td class="num">(3,460,360)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Equity, Total</a></td>
        <td class="nump">$ 60,739<span></span></td>
        <td class="nump">$ 340,212<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DeferredFinancingCostsNote5">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DeferredFinancingCostsNote5</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DerivativeLiabilityConversionOptionNote4">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DerivativeLiabilityConversionOptionNote4</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_SharesAndWarrantsToBeIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_SharesAndWarrantsToBeIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable. pertaining to goods and services received from vendors; and for costs that are statutory in nature, are incurred in connection with contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent, salaries and benefits, and utilities. For classified balance sheets, used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer); for unclassified balance sheets, used to reflect the total liabilities (regardless of due date).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 14, 17, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 123R<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of long-term deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 21<br><br><br><br> -Paragraph 16<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNoncurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, net of the effects of master netting arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FIN39-1<br><br><br><br> -Paragraph 10A, 10B<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 133<br><br><br><br> -Paragraph 4, 17<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 7<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 57<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of receivables that are derived from government contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 912<br><br><br><br> -SubTopic 310<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471842&amp;loc=d3e55295-109406<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GovernmentContractReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LoansPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amount for an unclassified balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs and the carrying amount as of the balance sheet date of assets not otherwise specified in the taxonomy. Also includes assets not individually reported in the financial statements, or not separately disclosed in notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),16(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 16<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph 2, 3<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermBorrowings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><u>Note
1:&#9;Nature of Operations</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">TapImmune
Inc. (the &#147;Company&#148;), a Nevada corporation incorporated in 1992, is a development stage company which was formed for
the purpose of building a biotechnology business specializing in the discovery and development of immunotherapeutics aimed at
the treatment of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since
inception, the Company has been party to various Collaborative Research Agreements (&#147;CRA&#148;) working with universities
to carry out development of the licensed technology and providing TapImmune the option to acquire the rights to commercialize
any additional technologies developed within the CRA. The lead product candidate, now wholly owned and with no ongoing license
or royalty, resulting from these license agreements is an immunotherapy vaccine, on which the Company has been completing pre-clinical
work in anticipation of clinical trials. Specifically, the Company has obtained and expanded on three U.S. and international patents,
tested various viral vectors, licensed a viral vector and is working towards production of a clinical grade vaccine. The Company
plans to continue development of the lead product vaccine through to clinical trials in both oncology and infectious diseases
alone or in partnership with other vaccine developers.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">These
consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. As at September 30, 2012, the Company had a working capital
deficiency of $3,315,751 (excluding derivative liabilities recorded as current liabilities) and has incurred significant losses
since inception. Further losses are anticipated in the development stage raising substantial doubt as to the Company&#146;s ability
to continue as a going concern. The ability of the Company to continue as a going concern is dependent on raising additional capital
to fund ongoing research and development, maintenance and protection of patents, accommodation from certain debt obligations and
ultimately on generating future profitable operations. Planned expenditures relating to future clinical trials of the Company&#146;s
immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing
research and development as well as working capital requirements. The Company&#146;s future capital requirements will depend on
many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and
scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs
of commercialization activities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">Management
is addressing going concern remediation through seeking new sources of capital, restructuring and retiring debt through conversion
to equity and debt settlement arrangements with creditors, cost reduction programs and seeking possible joint venture participation.
Management&#146;s plans are intended to return the Company to financial stability and improve continuing operations. The Company
is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to
meet immediate working capital requirements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.1pt">Additional
funding was raised through equity and debt placements in 2011 and the first nine months of 2012, and management intends to continue
restructuring outstanding debt and equity instruments. Additional capital is required currently to expand programs including pre-clinical
work and to establish future manufacturing contracts necessary for clinical trials for the lead TAP (Transporters of Antigen Processing)
vaccine and infectious disease adjuvant technology. Strategic partnerships will be needed to continue the product development
portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties
for the Company over the next twelve months. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">There is no certainty that the Company will be able
to arrange sufficient funding to satisfy current debt obligations or to continue development of products to marketability.</font></p>



<p style="margin: 0pt; text-align: justify"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001554757-12-000408-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001554757-12-000408-xbrl.zip
M4$L#!!0````(`'9]<T$GH:%X@W0``$,*!0`1`!P`='!I=BTR,#$R,#DS,"YX
M;6Q55`D``P":JE``FJI0=7@+``$$)0X```0Y`0``W%U;<^,VEG[?JOT/',]6
M*E-EV;Q?W.F><KO;*5<2V]-V)SM/6S0)29Q0I$*0OLROWW-`4B(E2B)`T--.
M'A)')/!].#@W7/G#WY\7L?)(,AJER?LC[40]4D@2I&&4S-X??;V;G-]=7%T=
M*7__\-__I<`_/_QE,E$N(Q*'9\JG-)A<)=/TG7+M+\B9\B-)2.;G:?9.^=6/
M"_PEO8QBDBD7Z6(9DYS`@Q+I3#%.#*),)CVJ_94D89I]_7*UJG:>Y\NST].G
MIZ>3)'WTG]+L=WH2I/VJNTN++""KNG)_&2T614+^3U/_.'F>`OE/?@X/=%73
M3S7M5//N=?5,]\XLLR=`[N<%70&HSVKU3UG\A^>'+([.\-\*R#ZA9\\T>G_4
M:-.3<9)FLU-=5;73__WEY[M@3A;^)$IH[B<!.:I+Q5'R>U<YS?.\4_:T?G7K
M302O,8Q3?/S@TW7-2'#/^UM,X&F8KPHT7[9.RX>M5Z/.5^WRU:A^-20;[U$2
MG,S2QU-X<(J=,U&UB:'5KV=DNI.R?0I/ZQ<CFIJZYNQK7_E&7:"@DYGO+U<%
MICY]8"]7#SK(P),LC0GM+,.>=!1*TB0I%MV\PCP[S5^6Y!1>FL!;)(N"5;G#
MA=H%@`/^W,V./>E@ER^CQU6!E=&`U2W8RZIGJ$>U<:!"G5&FME_(5&&Z>#9G
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MC!\50'?^%'YCW9QOR&]404Q]ZT%,'3.(K2+]6U3`5J0?.1U:J;C]1H6T;L"8
MFJ0:$]4%F#<JI'4#1A62^\9]4MV`,1-KL.=5(@)_OT6!-1.1NCE<`;)N]Z@!
M$ECI$]U]8[)M^WYLP-@!TGSK`=(<?[Y`M=^ZD.RQA:2S^/*&S:UJP/A"TO0W
M+B1-'U](^ALVMZH!XT_T:F_;W+`!H\YAMN=\WGJJ)3KG,WZJI4]P-&^],=FV
MEV:P`?*4L4BB4D)?[SYMB65!?%IDY$.UO'L&[]25U8_:$%C;COKOYGY&Z$Z(
M2E/82\(8P.]V!TX8/4)_;,L6RU[C8B_NPF@\YI?!)L>N6AN@GTB2+J+D$.QA
MN6SB=E5</V])H4N@(8G./C/E_$)F$<TST"[<HZ%4RO,%5Z3WK2??G]]>_?++
MU^O/RM7UQ0^GN^K;QKL`F\C\^"H)R?-/Y*4W8-/N=M;6A/N4!M`S27[_LNS?
M++"Z?Y3U-XMW57O+3.]SZ;UZU]^<B]U96Q/N')Z&^,9E[,]ZPTS]F)(2H55!
ML^:+(LOPYX@&?OQ/XF>\;9G4CGQ?;=L*\!N)XY^2]"FY`_5.$Q)>45J`X^T+
M>YTV%6!';=NPOZ9QD4"`>F'[KJ@@W$8M'>I=RN$+6:99'B6S<LM3;[1_HO4?
MJFT;E;&Y`''/TJR_2=TM_!CWH*VJ9[O1_.2E2:%5=9<AE%U>*O`E_-:_L?\P
MVD:P5=-N.-0P/C#\NPMN55-'7Z:+19K<Y6GP>QEM;HH<XS#N`&SA;FP(4=#3
ML@=5D%)"$D0@;/K^Z.KZ\NB#8[BVYEAFJZOW@-74JFU59Q<^G7<3*!N[)H#1
MOH$.<C`<7#QJUM2W]CIAW5>[;JFZ88K5K_:IW[`T6Y1^#^&8CJ,+5-]8M-BH
M_IE&9TD4OS_*LZ*Y>ZNN[L?TD60)JN-%BJ$L@+(!B1[]AYB(=C'$26_=B'T(
M0]GT40E-M54Q-I_(E(#_"R\ARTD"<I'2G%ZG25`ZQ6N2"PM(MTUMS>D@CA1B
M.V1U2$'.*24YK0*!L-%[GM-H<*M.;L`^G6ZHCJ?S(8JVS58=P]M$Z@_1JS6F
MJFOZ(8R;?$ZRGR/_(8JC/"*#^\RV/*=A.3NJ'\"BGT/W'$OG9@'&#7:>1V#5
MUVE.Z*W_@A8^4"2:YIH0`!H.>B_,<%)]).1YKN.IHIQ^3OU$DG1T%\9(:QX=
M-0N"]Y&"PXM]-X><\YYDBX]IEJ5/D.4(>P#-=CRSH:,=50NB]XMO:JOM/=`_
M%>0^_4)BR*K#6S^3X"QT5S,=JQ'2=B(,X]++6^JZIPIQD><\35-WP1X:&GG0
M9<GSF088HM7,(_OXRU7VSP['B+8;1Q;-]'NC6A'8/BVV=+65-Q^`/0]#$$::
MP&#/C\*KY,)?1KD?-XH)]SLHGVII#>T[C"6'72_%\#S3,!QS"+LZ]\2A.DFH
MCZ4__U'`"))#9H>23CZ07DVW/-O=3KFW`;:I/)(X7>*(X2[W9P1&RR1;9A$E
M4$<41/EY`,/Y@GF73T4&[G:SA+`N.:ZI>DW7/IS+Z[2N3X>8AJ/K>G,P+;]U
MC0(L;\3>SL@<.CQZ)%=)D"[(SRFE,&"ZF=[[SZ(=-;$-U6VFYWRP([#NTP$3
M6[5T5QIKYBSF:1R2C'+[@S8QT[`=JSE`WJY;#+V76`S35HWFE,%A]$9\/4]"
M>9+8&%H>@I%!2V0XRLNK$5T@'[O)<%:9A"Q2WY*,S3[VEMCMCBE.]415M<Z,
M8!>D)):=`GP5EB7&>9'#`"#Z-PG[R7`',\VJCD9WLMN$&LAJ6V:OPXJMU0R3
MTWHJ_0#*`#*]Q8-I,+JOX60.KC3($\^^=09.6C(%M8?6)P*!,8A8TMAW_8<[
M`3X(L74843)$USD\^1!;1]!D0NPX?;5W(D.#$9S33$K7]6^M5K!;-6*(>>?A
M(DK8MH,<DJ7/SSBFZ+V0O8^.ZZJ&9326+_9#RF%X2+/:`K-=W;5?DV$/Q=Q8
MLW.;4U.O0O"06K?3/%MMIE,C$Q0P"L/Q',OUA"G>D>PQ"L@O?@*#M'+MC>:]
ME\[WKZ196FORLQ-I$!\^:]"M,>GPJKZMCRH=7D777!@IC\5'Q-F[GJ,UDY-^
MA&ZS=$HH9=-FEX1(461==5V[X48W,00Y\"DO9&J.7`J\"FM`MFA(I\"EI(;F
M:(8JD8.`8EJ:89F&VY_$%T*)GP5S\,B-23&)B0A.;#<CP%Y`&>RX--?15%M[
M+7+<^8?G>)[]BNRXU-U4;<\T7X6=@"'8AFF8EBB]JR3(B(_SQ^5_KY)+/\K8
M?,K-]&LR)^&,0#59],BREZL$\ABV-4^*2[=,TW(:_2[.9O1V<1F;!F,DU_KV
MV\5KIZ;=FECZAIO%9>!@;HZFN=]XPP1\@VEKD+Z-8F`_^E%"<;6#T)L$7`Z\
M%^1LR>EF^HD\Y#+<P\2U+*NY,_$`IB2.7*;^G^`H8=Y)$';H7!0WK(#23S`S
MU&U#O$^NDD=X"=6^7-2[PF56^&6DF4Q.N*&SFCQP$C2-$VZHAO6&$YGD,8QF
M'K@+:J_2W_DQ_&?:L=M5GD)Q`PY5*3Y`V>ZK#Z!4Q[4?4,1E64;K/,!.L$U:
MUR1?[SN0$G)-2(1LMZ'E+0AN?/Y4S'!<U;"EX(OTQ/:6HDX">!7PV7GXKZ)T
M`".N=W$B#=!U'B31=2-(LO?`=%D=2KVT@C)8K[VNG%E%T':W;7I[$"40Y+8(
MT]7-YH;$D2D*95R:K>JN)Y-D/009,T9R('+/XZNN:[76U';C#:$F8H>>VEJ!
M&<#L-DN7),M?;F,_R7$G$YMJ>J4>ZP\N*?X+@,O)!0X#=QXQPO-N/IT/F^(^
M))B>2+SV8UE@/HV5E@X8$28B"PTFI$/-'NE!A>V/^>C3]NYI*>'*-%2K>6RO
M&TJ<$+^CLW1+,T8B)-!?F@&4/'Y&VU-CV\=?Z>;!49F3`.+P4H;-@O`B/:0V
M+;LO\F'&MQE9^E%8'URH;/,\*3=K#QIQ;^Y_UG1C7POZ,!FO/:.H@Q`9H2EK
M2S7'E^WJ=`OXAIF<_0G:@26$#4@I'+D'$Y;I.7O%*YVE@`ZXFKUWE8F;XWD0
MI`4,.ZKSKK@I*PA`\\/&OGP9*N!IGNON%6\?)N.UAU==7$O5O&^T.2*^!9IC
M[%<M.0UBKNAFB9>.1<E,LI)IJJWO]S0[X24SYU4GQ]/5O9'_58B+C`%<4VN>
M0AG`'#(9O)\&AG%X_UOX\>4KY*50OBYZ'L#(6YJN3"`HV8[3GLWLB2^7.7>D
M<AW;T;W_,'&AR3#+<S1=E2)S*!(0$E+D@N=2\"Z;F^FN<\ZB&]<LJ[6MXR"H
M%);<`TW/=*S792DVMK'5UL3?()Z-FTID;:K057MG;V_`#63&'1YTTS)V2$XB
M,Y%>=73'4^W!U%87CTCK3&UG7[:P!I&2,)[LCR>2UIF[-;I3"FP%JO.MCW[R
M.[L9!Q*_YM5`8ZSI#28P=*EO&`&!CL+AD6E5*X!<Z/OTZ0M9^B]L5>EFVKC#
MYD66C4$L-YHSKGVQ97+FSIX,S=AE$J_"6<C)JH[7/.4E@_1M5>HRS5B*7MX'
M*"//YG%Y@BPD.UX1%B+]:*H[W7$/"CVS=WD=V9[Q<-36UL'^Z')Y<\_4N([7
MW''^'^$MHBP6C$XU]_!@J0?S6KGNT_/@CR+*2&NM%"+*V"O4PPC(L'9Q`D(;
M>EQ;;R;%O=&W;C&`#J_*A$B&_4VC$6\/X$24T#<\B"))L&X8S7.!>^!Z6GRY
M7><U0N4P`A+Z9@`!$;M13<=T#GJ\#O0NG2HO8]^<D90R>:CC8MS&5>3=<,.(
M<4\%:;IECTQ+Z`Z`S7O;][/:&@;!WXN(TC1[86,?&7U8W;MZ"&H()9G#T$-P
M(N<C!21PD2:TB-'V9!U>US2/74'<43T_,M<!)<O1;2G`/;;M;YR'9O.U4H`Y
MW8.G2T`6RH@LU\3-+7S0;!KX`3<HH2IZ4B8&==>P\,#W8;C!Q/B.QJJ>L]H%
M/B(O7FTU5,?!SV*\`B\N9;8]7<?KC4;E);)'0\5==OP"JP])P7"@_C9#N8L#
M7S6E+&=IFN/6$ML/-YP9Y^TAIJMIK\&,5_LUU7!,]968"6T$'IF92&*AF[J#
MMU;P4EO?G;-M+-2%"J1$`,VTO57@/PPIAR&7.1B:L?*XKT*0URITS[*-5R;(
M91R&K>JOV,=":W..YIB>&,7NFTS6Q<98E1/$%#U!*XS90Y?'P!PTTN/&%/'*
MN/6F-HE#@"UV]VGNQ]5V8BEC/M-6<3FAXM*JGAN8[ZXGSW8,9S@NK[_T5-,S
M-"FX7&Y0=U3;T>V!P"(S/I[K.([G'D2^)CD>XOI(IFE&V,K754X6DDYLM]1L
M!](`-GS7H;1T3S(97GV<M!12/AF^)?FVELID([)+<4-U^]"YA$?1+/G\',S]
M9,:.P^/I1"G3%89:9X([4`8PX51@S3/&H<(]*#-M:R2I\"OO*$(1V8IML7/F
MO:DTSL^2/(]9\ED>1Y<WUU9>(=`'3@*U09FF`.301%,,DD\[ZRL21N^"89<C
M"-&[`?W&B;4BHO/ZW?J`?N.<P6]^AE]T'S2-=K`?)7(9K,:RN,C0;XE<^%8Z
MZELF!C$9ISD#;J:0UYHJK8%`42[%RKTBJ1-"!)\S0[%=U;-DP7,GU:YIZHXC
M$9XS$ZDOB)*`/^R"J,,$/OHT"G#R(8J+G(35NYW?1A)51O5$K?MB/]IP8GQ:
M"L2TUR#&K;]`3'\E8GR:#<0L+F+U5I/?(`N>PVOGCR3S9^2Z6#R0#'QE67C_
M=X%ZZ=V.;P39N@6IC=?8=LK)9)R&[-'3G=]@TG17M=QOJ2'[]7I'0TQ'UPQ'
M4[^QANRQ@UT-,5W3TB2J5G5MQ.%[*W@^Z:RW[JK8!S&43J]/_-JV[O#18<ZF
MODYAM<6:?=(#DRE+6#*J8]=#XCW5#Z'1]SO76G\:M>2X[R/@^1*ZH3M>\XX(
MD1L'1`GV^DR\9S*A#>'7F:6+2LQU--=J?9BXHW)A!KV^'V_@CA*S)X5*VS;?
M>"G/B>('2FZ6N`U[>]C$96"JL\I!^X))8[A#:'O'R=6G)Y.P'JW=IQ\)S^<E
MNRY#TU6[SN7VU#^$1R\W8^OL='!?'JN-WWY>9.1F6ET$D":]%X0^?!?G[Y8*
MS5]B\OYHX6>S*#E3U&5^]-TL?X</3Y?LK[]J1O6O9H$IH)PI#VD<*AH44NZC
M!5C'-7E2OJ0+/SDN?SA6[D!'IN^4NGY-AW=517VG(,>)'T<S^!4O<HVF+RMD
MK+P-U`>#U9B#P.@TS19G2K$$H00^):MZ"_P#59*U1SO[SE\LW_W5>U=*44FG
MREJ.3`+%2A9(@T,P/#*QQQ()*WSO+Z\6BR(IVWR5!"?*]Q#%E;+MFNF\PROM
M_.2E_L%]][=CQ8<Z'_W0!VW*EFDI$B5*ZO\#18\2!<:^^K$247@[7*^-`\OR
MB^6L5N5I'@5SY<FG"O8*%(3_,"I(8EE`?91)_J&(8I;_^<I#!%T4S),T3F<O
M\(!&":%4H4N\Y#>._HUO`3Q6$$8T2,'CO"B0L[580)41MCO%E,5?DB*/`F`:
M(04_7S'(,^+G=8$`-UUEQZRNLABZ?"`,<%,2@!`*BI"X!1^$[!=YRC`8CS3#
MCS&795$)EWAD2<DCM%LE(_]BY9.3MZU-=Z`#I2;A'\S%'[..J)1(F4-'/Q"2
M*$L\6ZODJ?+H9TQN%VD<^P]I^0U#I=Y7H9S/,D+*>X2_;^CDE_.&/BI/:?8[
M]OI3E,_1C;(8@Q&S[,<4>BX#'4B+?%,'D%L<!9B_0K^LM0J[:<F.RV"]*R-A
M[Z>L7<C=+X\_L5\S'#Q0_!54>P&>A>EB*0QLN1^&[&R4'Z]Q4'TJ0@"/["N]
MA?:=*/?(C?B,2%@$.>I?&(5@7L=*DCZ!Z8#(H%5/">IL4E8`3Y0TF:5(NVH8
MHP!*FJ4O?IR_'(.V55MIE2D$``2D*RDH_EK@:+I)RTQ>H+L"2&V!`4B@M-W.
M[D7SC@G#6&9D$L11$@5^S*A@;Z&!@OY'0;0LG0>:5_42V`?(CIXH=VC14_PI
M?ME6H_0A]Z.ZZ>09?@_A?[!CYM`"Y>O)W0E[%.&^R<2O9`]PV+;C4C,(15]5
MJ^!CE,$;CV"):09JO=(+O_6DK)2NE"Y/G_PLI'4O58WQU\V997Y(:L&5W5K[
M5"2!CJ#2&Q!(`MZ@2T>;>E!5A0U-B]F<E6W+#L7[`'T&X@C6"MWAI4KUC%.H
MC;DQ9I<)F,\\6I;ZQ'I^!5EK:T;?KJ=Z!]+,02<F=.GC,.U,F:@G6I79W*,Q
M,/K0'32-F;U!5"K'="!@BM^#+^UC[H.G*KT9CH2S6OW@1Y^"AC`U*$T1*H/0
M49L,R\'`0'P\@<2<!T%GL;($GPVA*]?!8HV"5\K2J;_2K[@QZ*B<1@(!%`C"
M8"JK8V89&D^4<[#D'%J_!-@'Z$Y#/58PV=NT*M3U6J\#"&]Y9;(A`3.,2!*\
M8+W_8QP;FG7L6)KR/7D.XH(YR7"5[K?(923`T`<U0^Y9P/@8.JSQ_&],,]&>
M(6+@XU"AT-/,[/%-]HT*QH%B2%%6<>5$N2PRIIOE.PI.DJY<2IF!L!1@*_7(
M_(@B85H\X%Q.CKT:IL5#CA3!EAHBJ8.,_0[J+X<PJY!26ZM/-WNYM/'J_=J"
M:R'O+XJ.)21+`KX,C3]9D6V$CV;'0&W3(@E7+C^KX^9&OG,,9H6.D.T;KZ-;
M3E;J5+M%"&D8OM*PU$46'X`7>EJH#D24/H`A5D,)J(:1P&"R@`HP&"7*C'V7
MN`PO!4N<`6H*C/&.EW250)\H>&@;_3?!^2-H';R*ZA*795G+6/%-W]86:*.+
MRL2C*UR!*XMCJ+L,UTT%:\@5!0G(+0^]U1\5IVD]QT.5C2Y@)'9U`_;X$P$J
M/MVTLYH=<RWM*-%0PEHD'67*-I9D@0SCL<`FH->`@(:F4YDJ<SG0857HS*M`
M0]'$<Y0,=AGD`93YEBBG._6J?-%?T-*3@!Y`_<>@S31?J0>DX$LTW,<T?BSM
M<J-'CZM87BKPK``-2#%E7V(&QI[#0(`6I4:5-E_J:T.):9V55QS8_R*-4BLP
MO6BD9:5V^ZMCSW_28+;>#5^:!D5UQVY%`;7]#BI16'V*I<XK*"%,0Q.`IA!5
M`D++81!3/I9'KC]TQ@2>0<J7E<$`?,7_M_>NS6T;2\+P]ZW:_X!R.55VO1!#
M``0O=I(J^7:.]DDLKRWGU'Z$2%#""0@PN$C6^?5O=\\,,`!!$B!!$*2PFY-0
M)##3,]/W[ND6XTP3KX_@68BVD3#*X,DP2511R*=QEZ`T:"!3$`H.4\D(K^!/
MKF<)Y*.!!+1@,898*DWY-RP0E"48B)@0*#:)NMDC0*3MD4B,Z6,H38AAHN@"
MB&%E<>#E.7E&+>#\GC2M!:*N+3@]@B5SOKP*Z(3RDT`(D<.[<>#,(`%2BA=[
MNB1A:R.T4[99*N.=`"ZSK5S?XE3!5#C'`VR+8L[LQ'E&/F,4MAVAID\X8&_F
M3>=)*Y>)(*`U<&%`G@DZ@5FR]7GD38\`>1MZ]!)>-'<"0%@/)=`"@+PG^F&*
M%SZR2!"0XUK&#A"21*(Q7PJ$T=S$P!D\3MI*$Q2^%74!)1D_QIE0Q%Q"8F8[
MI<24RHEBTXT6!Z\ARKM.>"^$$JPF1EG#0,558(W]$-@'(%IH`4='5TE>FN-W
MB85S<_E%>75#[A$_B-!?`OMU"=L!2H5"=^N)=[TF8(1L+S9M@-7].WX@'TMB
MUH-)&:'<NT,)EQHZ7'3>@@IMVYS>$QV-_%#<\)($'S/=`,@YV`@^P4!:@"P;
M2?P0M0,X"P`*-1Q5<4#2QE-<RCQV43%[8IOEW,9`>L1K8#;A50C_PCW(,NO8
MXSI9XN,0NRAX$SJ]F%$`-*1$H',\"!3L*2=+P.QEQJN'_8J>U\2'?2A/*C!9
M&ZG,\X7*C!ZN>RO*G(Q`-52'A3CD,@_08L[LK$@HHX@.S/1[2JRG%3T<SWZ]
M^X`C+[$6V(._;"&I2C#R+3NYC#;O)1M/JD.S$H[(!$[^Q:3.>\:P/J0VYX[1
M&P.L5#!2>=ADW>@9$+Y[%K"^"!NYI-;_)R'EOR6V_R<_H/NXSH(E9=T`>._<
M"N62N_B*GL17OG^^_/[AZN;C!^7]]>=OU[]??;C$/SY=?;[\_/[J\G?EVPU\
M\<?'SS??E$_77Y7+S\K5YYN/7Z_^4+[`OZ\_[!>,J;R+A^5OF)F5&"U?T/#R
M(B*6TV;;5UX25/&7H`(POT.J`3$#DMP/R">1]]U:+KDKPGL;DU:8@<%47,D+
M!Z.DNC4S^RQ42ES_4>@R,"[:W$E'2.[^10^?0P6PP%YVR5/#?6B!C<R6E'&\
MI*3F=!B`U`G`KH9_+:4#4M@%%$1_5,C(>+%8<@/3I@`:9^G"1C$?B>LR]1^>
M0<]<XK+Z[B$'4HC;,`T(#%?0F>0("+FW_W%Y^46*@_04RL@AN`L=EES_"V7%
MDZ3"7S:J<^3$2=V.5AC&BR7;5A)CUAR5+.ZP)`4-'EI0[D;JM51E[YXJG/-T
M8;&G?/QA+6@#^+F\4<"^CQ._)_/7"3<B`2*[$LG*PZNU%^(R;]IL"U1>T#SI
MZ#"XP0V?.,*VJB'I6#,'P`^82VM1:/DE6Z#DEG^Z)D^K-28N0=,C"]")'27$
MYKAHU<P`\\FK[,^%141/(R%:H"<!93_95L"L:H>H+XE'(XYQL@+%[._80J,"
M1F7HB_X\$.0+@/?B?X'+^#$(@EORQL\X+?\;5&T:C(A9&ET$.:49BKW&GL>P
M,C_A_P,2=5G$X!(X@ZMH0^&3I[F($2"1?T->E!*`N(N&DV%YL7)!XYH4N7IT
MI'R62O$E^LO4$?2>VY(W/HR$1R"J^X:=WE59[S(2O:L@R+Z?)H6*-9C6+5.H
MDBUX'X!9[3)/QC\QW0#(Z5WOSUXFLX`_(V47\,\FP)?LV.\B6@Y#L%2V=!//
M)37H(XE[(8@OXSL86!DAD^H;JL(W*G%U%?`^#+`Y,P>UIG^`PO.']4/Y<F\!
M`YU2N@UY]EG&4;K___AR)>^]346/*(CO([<':"Z0VV>C+*YT&CP[(TEC4![1
M+K]]2@"^PYPYYN2!R6!0S_<N*(P9HI1Y]`-W]NC,THP(X5M)IHO#1!AA;,2:
MV9[_X`1QF'$UR5$D\B(*YYO0N$1<3=2=3YTVR3)A0)`6$59]0*7N8QSX`AWU
M\=N!V5?[_?Z):R>7S)?V`80^BTUKA&)C57FI#PS5G(P3_(`U:R-='?>UU[2E
M_B-WD8BSC;T9;2%&.@0"])0/S".).TN;RISZ^0DGJ@B9"=78L^]\],13"H@4
MHN":JNR,%:8*.V26IR8#C>?$[!)^VLHK3)U_G9"/PQOW",32AR:]$U*RY_J8
M)X6U`-])+U9>!9B#CCN"[%Z9O#YQW&BOYIH$CC'L$@4^Q1(Q`FX+KJED..98
M3<Q?P11D](+Q%@PM5_*P$O[#V(Z2DU"D9&[G0)+W7W@=B0EQ_53,FO(BIM'"
MSY1-ASR<XV"Z0%3\$NA8UE7*M&`R=/++_&K$4!K4$YIVP:)P%7)3V+4`Y:4!
MQ#$9]66^H(\'JCD:OTY8@)WL:+*3*C,)0F9,L,0PL/F8K\7+T#,W:U?V,`V<
MS&Q@R7_'/"T`]I)Y"T(>\RG>UP+HY"0]B6<)CH:9,4EZ(;EYD4NX;(@$1>[]
M1U"<`Q4?8`F"^6PYM*L":G=,Z/:$7S@89("S<CQ*N4@0=`4%>TH:*E62?+4$
M?V7T%0L542N;63-B.>A'6(F`/)+A9;FN_[A")(2G<%(6-[%6R0-^N/-]<@GQ
M_(U_)KNQV26_.A8ZYPF$6SN9%FVT@+TDR09RXZ>+<"5RIG@Y[FL9OT'-'O8Z
M3*E<137&-&[\/X!=O&>;*/HP%#CF^\9%?WS1'VUKDRJ74-LP0[;D+$.B[TA#
M-R#C$XV["(YQB6L5H%^828&BM:-G8)`N`+YC,O]K(O)735"P.1,3%#Z7N`@T
M2C=FPU09D"X9Z27P\MM3.T=-AN9D)&!8,_::>S[\0DIRW0=+E5I.\*?EQO:)
M6>J%.D(%4UL9)&;VAX]?K_Z\O+GZ\R-!^:_+KU\O/]\HOU]=OKOZ_>KF_Y3+
MSQ^43Y=77Y4_+W___K%%YN--3HC8S%MK,Y756BY=\LUQ;]CEM_?*8-R_T/H4
M879PA`_,OX[E-5A&>NK-)4<LRUV@M='SJH*CC#7S8B"-(IA6R-+&E8]>A&])
M&M#U(WR;&XMT:QQNI`$SZ"<[QH=,?<>RA<_Z=,J_2@/RY%"'W>7B'N9$9WCD
MU['PL64,3)AU?9#4<Q(BCTPFX1`LIT)X^Z9IFT>4SGA@15D^TZ02MI2KSQSM
M(I$]EU,%7S`+")E0DL:"I-93WJ$G76A`"`6<U0QYC2I+.TP\8)Y.=EE`RC4A
MKZULV][:(NC!;O-@KF/JU`<D<B@=:193KH.%B8C3>YMI83/_T9,S4^<VNWIE
M/5B.RQ)(&93V#TSE0\4J0"WF%9&<^5HAG_`]$+T=R.B1:$_+F(G^Y*QN+3R7
M;-*O2*@@>XUI;,)6AXU@:G_(IDI3VX3C08#,4M?2G\F#@0=$R_#H<CDE79*!
MUU-([DC8?Z&;JR8#2Z9F&B&%GY`@;:Z9A]*R6/9C#K90>24=Q&O<2X>V0`JS
MJ:B,IT.K*8HRMW.2;4X_HU$Q=^&P4A_X^LA<*%\J2P?+KJ,XBSQU"3&;X:9H
M_6PK4])+-X,PE*>A)QGZTJ+Y(8M9S+<?5J%XDKF$&#K%L4RR_BIH!6=1/U2Y
M/$LV40IB[Q@BA!!:)Z&`EP@\9/SI[C#CA@"Q15R#431CE6E$AELNQ$\\%FI$
M"D0G"I$O"64T+*6M>05/VC^<B`WY6F`HC\."=08#+"A3>8:)8L#L@'ER)Q#F
MR22V;3)=.C831'2I#[/H<'I^.>/6CA[Q3@@?(\D[E:QJG@M&K!7-M9XB;1/H
M82PG,TFPP\B/O&OW#A`5(+FX/9F$=7&])!J9V?3#63C_L67?@7\;VL$#<2#'
M`U[(&`48@"M/QE[Z+(]UT?./][@T@I_"S`E4F37,['`:.+=TNP7=`B[:(B$S
MNFD8;DX]X>'&(7>*LEV1QGRC_(XO*IJ$Y03,_\8^);KBN3*E@'DDV)[S.YF8
MLD^9ABPP+9\?L)2W?&Q=IJ#KE?UAN;,`KI?`PF9EG!$LP'O$XK\S`.'T(6RI
M:P7K)H>_15INNB'($J0C(A&$"(77;`/_EE^MO7U2<F?#40U0R6)SIS=;$#F1
M(V&8E/PRG"&M`0O1@:W3D/?EN[>*.0G$(:C!E`S`+.<G&!$U#QS;$REG(M?^
MB3L\^:MIEH*L43S>XZ5?+F#PL9G-W!2P^#CDJ128P`O4.[,QBD#W?$GC8(D=
M(@$$<"JZ]V?\KJ6J2.="CC+G[YB2%-);&3(<N)7I'4<!1)*M(%%D0H'2U1*"
MY-_Q[([YC`.17D#)"FNN=XBM=[,E)3!+934_(O,4G*<_9<[$1*%,I!3+,2>E
M=;VV*93$S6YR30-"+W;788[->C_UAKP.THBGF)?K!\"&Z*J8V`EIDZ57>LH5
MFXCC8IZ%L""*P"V.ZXAYLDY!:AX"S2_>+GQZ$]FZQUE6PL@`IEO_@?O5$E!Y
MG@&J4&$JQ`'OX*CY``0@0W@G@QY<Z>10)(N418,OUBA0\B@2/#&9Q)'\F:3L
MW"0TE!I)QP`Q23[(D@2KFA:"(!!>;[$$DF)2%M=NO$99PV>*V4QR'\I"W+"0
MHKWL732:0<H[8E=R$7\`=62!W$O)HW#E.9;!R)MNB,L<(</>4C\ISS+.JD#`
MC\,T#X6D7N)&K<H8%<$4F9::88S'P)X/'/ZL/I/89HE!P4PAOH.J<@>L;&W:
M#[MI2O:,=/G/DR\2+_V0!Y!@X^_!0`51#8+[WSRX0K<:2(694S(DW88#7+1X
M&H?,*(!%89Z-Q;0YPE/B-FPTY#3IC0$6%T*;&D4W^LGQBKK(1U227,0LVC-9
M*%F7DH41\JLPB5RBP@GARE4G<B%-4;9[K/"#RZ]7;+9:!5ME6$Q8AQY$6`M+
M`F#N`T6X#OC,G'CQQ7>.YR]PQQE]I2&8N8\A!]K<--?OS3H49!=8T47,KP^A
MMY3^7F(LD/]=&4T?G5ETCX_V?WJKW))!<3'%Y)1E"/JO^/0BA0=!"<0\),)!
MQQ5X'?G+]%%TT=+C,_$X'__6CR)_\0;F]F#;D"X4#2"E9*ZW"E_.!8Q%U)-^
M0VZ4-XK9&\C?NO8\_7*M%,E&<J-9$92P6MA;[]<7@Q?'@7A*^2:<*^3TGA.!
M>U4SDP&GCT$.F38@3`%^)2BK#U.,+5IGSVP#3JU9"`-8(K\CK$4Z-:RA2%ZT
MWYVYK;SZ/]"_P]<GOZJO>'MMC@Z`KRBV]EW.Y+BK^>!@]VP044^.[<Y.?35_
M^EAHP141DQ->R6%HY\B+ZDBGO:LI)IU"T5J_GE:TN#UDZ+?BF,GV(SHLB-)N
M:ST,6OK*H#?NMPBL?D_3?T*X^KVQ\5.K``-3HD7P:)-)F\#I]PR#H5/?:!58
MH*PQ=!KJ[=JO=J-3`=O]F4SUS%=[^(\VN4:S!DCG-'CN3H/+2+FBZCVN\M6>
M^G>>DV00M1_X!CT'@_/Q''3&3V?\-&K\:%H;K9]3/)B.=EJ_FF=!.Z?I.4A[
M>?`;T"TR$OH]W41C2NOU!ZT""Q"0&7EZJXRJUAEYQKAGL*W2!EIOT#('BZ9Q
MY&J70ZH_Y,BEC=JU7ZU&+EUKUI^P/>%JJU?AT'=^YGY@LXJ34F($3UA_<.Q'
MGDV5UM.A>DF4"IIDG/!L;I89MPR<!:OG0W=EBXHO89)>&,IY;\O`O\T54;<?
MV'46D97'LE"FO%@7UH#"?'KXB`TCQ(4%EF@7VM(4F"*%J>58[2E@6;)2<:ND
M)E5XW(2[-*WM,LU@E+N-_<%R@)*T,KQL1^EY=$_&0A\$+V/&BLJU)$FO.!]3
MI#XFJY%SL7`U:5$VUEZ!(=P"$0N31F]M3,2C5"0GG+I^N/E:1=DK'FOS@8[+
M`BHY%LNY"]\JU6HS;-=5&2\OH:Z2CETSQ\<?=O`BZGE'W$;8U@NM_DY+R.Z5
M@*\^[W6Z*3#L;<'NW!:PAZ9`N:0;(JMN2*40LM:?Y5H%Y)00<K]%G`[@E6SP
MTGRM6;XPJ$"+F\7,LYBD$N]:/\M6[-\19>GQ'?B%N8U?[$I/N&L7CS9[$`LK
MK"4Q20_](TU3+Y%4<J"MJIFX.ZH]]TF:8@U'H]#WV!`332FBTEK4D,,#S2_@
MGA2T>HN1@%\B:S&$-UCYLLXL!!$/JL;""WT%%Q62)?<&8YV\>YGR'64\TM2Q
M.:Y&'H5I&GN#=;&KB7.PC2H'4;N.Z\C0M(C6"HN<\/N!1]Q`O=]71QN#0!W%
M'9GBMA_1$2`XC+-AHWBN.[I6+)[;`U\9GJ>I_9&NFE5%9IN6LS/9G]XB6@AX
M560ZQ254U0)XK,D8_E3932S"5,;NKVJ[O[K[F_HQ)MUCDS:^6G#>SRK_X<1"
MKSMH-.V+N1I;M=$N%GM04.3P6#8:6UP&8Z]8;)O.N);PYMDMJ!1073#U1((9
M9Q4Q:3B8:AP_CK`FF*I\QP)7U=;0A5=/F<3.9Y(NO-H60+>'5-L!X6F'4=LD
M3KJ0:B6/F*&-U+%1XA+9,<,ZSR.44_5@*K@7#@];,R$?K8QA>;2`SP&AJYF8
MV[.`.F(C'=@-LI@36LRNH9T]0@][A$J.$Z`YL=C.QJC;<P_MX-56%KQA=P6I
M6OB,NNNP>X1/HOLR=7DH:E'%6\@B"2J>'25]AT*5=02:_8R-7>)(I3KX96\\
M*OG;CNP*Y,J-1U;37"ZE'Q<T9GG%#9+7<D</S_%L90%[>A_RQAX%]ZQ$_ZJT
M_0<!LA(#.,2=R/,)R>U8N:-S>ST?C]2!PCVU>;EKA*^\9R*)/&[T>">M3ZZ(
MV^7"D756U%F?-56N-M\)$7)-H>.:26*7/:V"<'O[H%H&^GY9TL=;S.XNR=K3
MJPD>WFU;E>RGO`ITS(3BEV#-C;6):K("G7*#:M>.8%,ON!+T1KGH][1EH43(
MM)4^VCI&IFJ,)Z>^"G4R&:B3OE;O.HY,!)<ST>@XUQ?PB'NMJ>9XI.HC\Z0Q
MIAW>]`/M95U^[@*DWL%5#?9Q8,-D6!_HU9WE>"&U"'=]K`3%37G6NAJ->?QZ
M^XGLO?.OAB!$X'\E2HWN/Y<Q4ONC22-3#8=C=:3U7Q^*B>T::+P%U+:Q(RV5
M'#M2(.^5I@[,D6KH^AX59FN`PABK1NZ,&MX&<V("]NLM0Y,;X<C+^O'0C5?Z
MFG0+0\#G#D+M2M+V\,UNML2:1.I:\XIK]!]EXD7'TK0:6.?%F:_O0.?8V28M
MU>KUR40U^OWVP]+9"=MUI<'`5">C82/*^V2L#OME],+]IS('`]7,+:LUZ%#9
M7&B6<9S';(=0]P^3[W8HJZ"5>5@=I+4C]>X9GB+9RJS>L:2B9;*Y[]>V3*7F
M]GV73*H=VM?4DF\GRBE5!UG?H6?W'L$+J3K-H<V@8^!,<7F+YY@=MZWE@Y1^
MQGHMB#`X986E\62"Q><M(1SLQ0"(LG`\4(]9>IJEO',\?X%I;^PQ[/Z`6*0L
M_)GM]I0;N<4"SK9F)D6:A3>6P'@W/$0P8`<`ZMF`M?^?Y'0]G@?'^CY(4]'\
M4@(?:S+A3.'?P/Q"ZH0,X$S]Q0*>#B-_^I=*#]T[\$>`_%MY2#LXT4:PO:)G
MV5@J8%_XUP5UX`JL""!B+3!@Q.^];[#Z@%):GD#)G(+Q&CVQUE8AF\D6+<EP
M4PM/8I;IB-4C*-ZG:T\Z721M.Z:6MZ;/A73F-F`#/M13OKOL$W;0P(?>^PO0
MP)Y@B"?<NCA0K(4?>VQ_F:*<I$RF@$:`!E,KO)=4:3Y3=`\_XHFF68P`U<P!
ML`)\"GYG31NFX@Y=!BO3;`>VV#3)DJ`((P"=LH48G@GH'QW71=2*'`]A\)6I
M"WL$!)#?B)4MQ^S0=%)8N./FG@CPV.Q@ZL`QJP0%G*(3`":`MHB_6@N6<8DZ
M)+SWQ/;@D3J0>#Z8DW!X@1+8?\?P%C_!9'B`]=86X#J8*YJ!J*=D#Y_60D!D
MUB/C]%9Z2Y?+6KY0(]/_B*EAJ*7O\3XM/@P>(%[X"UMYA=CKA?9K^"+!B>1$
MZ'$@M,-U5MF2_[0Z19G<TYQ@K)04BAB(#H-B2K`8%0*YT3$AFL[C*`X8/7V*
MO1DB#GHGR`RQIL3$")-G]A)90+SD#4XR9SWW7==_1,KAC)`FPG_!3&\X.G@A
M<!%V%OQMF0<FI\?I1V[4L\H>4YXH0"CU6F`O+,<C1KS*[)1YX"]@3SS@-5-F
MBB-,,T`F_G;"91U,)`(&1NRV-+<5N<X%H.98+#$2`1:GTI"@B4-V<O(.I*Q7
M@4?A\+@8N@-(`$Y\'C./D_GACXL9\`1IB#DLF0:09*L5B@V*`HND%[S$Y.!B
M8<\<XMC2T<L[QV!<@U"]52TN3S);B$?HA<FKO_P<+9V'-VF.VK_8YHG614^7
MW@QS/"G%\P8([YT+2/';?_\7ZHR_T+O?$!&_Q`%(]5"\'MZ@-I8\3^P<_OAJ
MSW]]\0FP!2V7B[X&_T0^^SRY,/HO?B,MM.O#75&'/ND^W%6";6V"N\$6W,/S
M:<&M[6`RM[^/\+%7U342;N]JNA[<K5Y41SKM7<TYM>`F+5E9<C6YGHLK-??:
M[?4G:`$->N-V]4K6=-XK>=RRWM(MZY4\F;0)G'[/,!@Z]<NWK6D$G?H<G89Z
MN_:KW>BT,>;"W0@E7`$9U\'[Q*%Y36Z8SFO0>0W*8>=EI%QY3H21JZ_,Z;WE
MYF2;@&_0=3`X']=!9_UTUD^CUH^FM='\.<6#Z6BG]:MY%K1SFJZ#5$M6KO<O
M$%&WU:*;:$UIO7[Y6HV-6'D:M_+T5EE5K;/RC''/8%NE#;3>H&4>%DWCR-4N
MCU1_R)%+&[5KOUJ-7+I6V:&PV4&0\26D*0Q)[D)3[H1C5:G;O?;P\?I';6UK
MV/6).A0HK$M402W)0LA:?Y;[M4\ZBT6<#N"5-.^NS=0Y3'*F;:;,X_<%65-T
M\VA;53-Q=U1[[I-T3:6JJR%M:##5/FA/N]G4L2'L&DSM<$^X$GD<L\C7(0JP
MM;ND3K7C.C(T+:*U_:I1'ZXJ47KAO:.X=E+<]B,Z`@2'<39L%,\M;.%V4/BJ
M%7&H7:-L5Z6;LUA$"P&OBDRGN(2J6H"H-;2Q>]C&5_=H6;9/8[=GT]=M\ZME
MHIY;0YG;`I]-W\(^=`!T![VB?9'/[:UMNXCH04$IZE_%8J+%=]#WBHBVZ8QK
M"3*>W8)*`=6%-$\DI'!6<8N&0YI;.R(?+:3)^@A66T,7Y#QE$CN?2;H@9UL`
MW1[8;`>$IQW,;),XZ0*;E?Q24N.1%C4,:GA+V@%%U8.IX%XX/&S-!%ZTP[EQ
M:PB['!"ZFHFY/0NH(T+1@=T@BSFAQ>P:8-DC`+!'P.(X89(3B[!LC'WM&&`I
M4:WFDRA??AF&=A1>>C/QMF.?3:AEQ]O0G3OC^7@:#N3&K\U[62-\Y2W.)**T
MT9,I6E$I5U3N/1=FJK-*P?J<E'+UCDZ(D&L*"=9,$KNU!BV/<'O[%EH&^GXY
MJ,=;S.ZNIL,T7!6]PB2].!_>/F:ZYDO0TL?:1#59T;-C]?.M8QTC4S7&DU-?
MA3J9#-1)7ZMW'4<F@LM9^[H.:ZHY'JGZR#QIC&F'E_1`>UF7__*<.QT/08C`
M_QII/VR,U/YHTLA4P^%8'6G][9V.=V1BNP:0*K8X/DR`YI6F#LR1:NCZ'E7[
M:H#"&*N&5J;S]<&VP9R8@/UZR]#D8+V/CRLNSAV$VI6D[6[YW6R)-0FRM>:+
MUN@_RL0!CJ5I-;#.BS-?WX'.L;--6JK5ZY.):O3[[8>ELQ.VZTJ#@:E.1L-&
ME/?)6!WVR^B%^T]E#@:JF5M6:]"ALKG0+.,XC]D.H>X?)H_I4%9!*_-K.DAK
M1^K=,_=$$HU9O0I\1<MD<R^5;1DHS>W[+ADR.[0$J"6/2A2KJ0ZROD,CU#V"
M%U+MCT.;0<?`F>+B`3MG/57(7Q)Y3W%X<6=9RS>7TZD?>U'XQ7K"Y^#/(+;E
MUV&P:[!C`NFK#TXX!64S#NS/OC>-@P`TDMT2I$KT,6>K%DO/)0A@_+92EH"F
MP[-]D9*0PRXZJXADJQ_`\<?+I1U,+=$%#)Z.\<-G/[(5\PT[KLG;]]>?__SX
M]>;JW>\?"<S/US<?ORE?+O_O$K_!=<3)BC9V>%]=7I65#7%A&]HUE:>DFWN;
M`$K[V#NA8BEAO("YGE#)F*$V"M9(%,34VCY*.]F'8/1:D8(M,0/;M1\L_-DG
M2YACB@*;ZOBS-Z4VY!R:O_')!LA@=N0<U0H3%#"V>I-_:KZJWZJZ`:T"YI,U
MM:5+>'E@.A0X"#!?`@>DZ9(Z$"ZMI\3@WGG[S;9O_W?/6OC`U/YCSUJP_RA@
M6P`&JCFH&^UW]L.VGSTWN!2K>*'-`I,Q^EH`3V)V;CC_FBWL6J_65E8::K[8
MN[_)W`'48H!J1OU]TGAIW$_V;1"CD8*1;"!W,#GLF<)Z344.FA(H6X[73Z&;
M[*31[@4349[C!PER$4*IRBRVE13[!N2P+'%3MY8\7VT\4(>31G(BZO1\U?-)
MN2C\_>@K473=5,?58MXU8,/$'*OCNG'AJ/36`G[337;2;'N=MG"Y#!RW4Q7.
M>K*6J@H,]9I3$W3-5/O-Q-/J/,C3UA!,31V-AXU.J0T-5=<Z\7^Z#.M\)VN;
M^/^?V+,W2__G<2[G.UE+A3\AWK`QV6_T.]'?M.@?J$.S6=-?-U7#K/F4.\'?
M37;";'BMW1_?Q6&DC%E6:2?USVRRHW(M2@XD"U]&LA+Y^/N;?IJF#HQ.SC>*
M@1-3U1L6]-I0U<:=H#]=_G2^D[54T&MZ)^G/<K)V2/K/_@-+61-XUH2U-U+-
MSJ9O%@=!OQI6NSNU_Y2F.A[47$ZOD_7=9"?,>[?(>KW?R?JSG*P=LCZ+94V8
M]7KGO6]>TH_4D3EJUGVOZH.6UKSL!/VSGJQM@CZ](M3)^3.<K&9T.TB-DD0=
MN)Y&/EG^9=6!I@I,C/6F_`-'*+-R5.6BJ?6.)NIX-&@C9+HZU(>M5E7JWXEB
M452MGV`#97,T=3C25$UOY"[0$8KE/`_2WW:S:#`>JJ.1T4K0^74TPSQ\VXFT
M#%+RU?[ML]SR!2G.9M8JMV8/!=*0U65:7\#HVENY7PE:%]85>N\OEI;WI-#U
M?7M&T#A>Y&/-(EP+U:Q2EG$PO;="6['N`IN*:`(51/>*-9W"2TY$=50?[##R
M@Q`K%BU=K+V22^)<V1/E%4+`CVTPRFXE0<*VCC\P?ON:SPH+CQ"T)V5F@3+I
MSV$I`!>5"PX5:PY+H<4Y81A3>0:LP67#8XY'WUMWL(P[?'695"NQ%EBN`L=Z
MF5P*[2',H0/$;U&_)00I]F9\=(_6,,4G0MP!?'4RH!=QHJD5WL/X_M2V9W!D
MK.`L$"]M6DP[AEL>1BI6H51>Z@-R5BF/5JB$\6TX#9Q;>&H..WC[I$2//ELG
M*R]U#U(42UC"5WX<A1&,0$/#0#,;,&5&I9^PJ1$[1GO&VT>Q[?>*MI^>SN]X
M3[F!AZ3I\!WI200FL.$T/)@"?G,"0DX8_5(5G]X17/R/]TDO+E':2J`@KG2*
MQ^6ZM-T]Y<I#J#V;BF.QL\\<J[0A63+D^<(%"*YPY$ZI%='H,HO6XG23=3-2
MX$6I"Z8B$!ANNJ[8)3ZSV,SA6T!-*C'74ZX]AJQ%N,K?7KN@#&#WU@-AM^@(
MAG#`^OA9PSJ76)D&.X8%,F@RSMSR$B;KYY5Q%W8RC[]L2\-["_Z`41@,Q>N?
M^HL%``-\8OJ7@I7.Y*9F`:?EER#;3"QTQL;L'8-AWJS9B5L\-+%P@@16@8L5
MP&O]GPATR_/BA6+_F-K+B',#FU5_FUNQ&R$_4![OG>D]^P6&>,H.KN0&UN6!
M&55FX'!",JI];^TI\@%MCUB5;4WO.=N$(P',997E5-A4"U"&<#WY,53F@;_@
M]"TP-8_&R<&71F5!FPL+Z-,%,B?9$6#=*!EUV2@)JP:^,,^]_I>-/'-ZST[$
M8X/!NVP:02R9:0)[:F.K/7R-STD,0'!N'X\BQ>IU%"UCM)I':<8=B]%:Y3/@
M\XM;QR.6)P35T7!>;.G2<F8`VMQ!:1>F"U;F-N.WN*"!AGX2AHOL27EGX$F2
M918KDLE%&7P!)&`'R(KGK/(FH-K4#Z.0R4$'B8Q8C2BJI?@/G$<"DBW$69`(
MZQ$LEU%!O5L5Y/A8'4Q,\<)+O:^.AF/<\W408-5%"TF%2Z8B*F)$&X"0=;Q0
MB=/:7RI'/EH"(%1H>TPO4EP?]'^"G?%_0:0%Z"3J27V[M^WH*%A0I\S%EV`+
M=-483E1C/$Y$OPJ<T0ZF3DAJ"LF/O&@`<M%--O\<Z93X#&YBR!!.;!X"@H0-
MR,44/3%TPGX2?0.I$Z"*8&-8H4W2!0&YK#M;>?#=&+YG;@H`6GP/;"?E9&L9
M`('!8$^P%=[T$60/2WR2])Q93R%B!V@;%I/[P*M@H69?S<`RLQP7=%NLI!D(
MP,JQ(`8'%G;E8/@H7+:"H-,%9Z(_XD!4M!38Z'R.>/"`Y4CO0,EE:C!*B(AI
M2U.<1>A%@/*6:\L:`.>>I#*[3^(Y<1X'0^_UR'U)ZE9@/S@VU6:UE$\`G(5K
M`1/@)JW$2K!,72N&[<.:O$#LC);E!621'=0K?VI%3`VFGA)"^1?L)$'$6Q#Y
M,\$%II8[C5UZ<8Y-DA^H2;(5);LH;)Q4[A+#39_-XSER71!OZ+68$2D-QH9J
MF":=+_YPYQ%?)5Z\TG,6E72."`0"U:M=&7+4UU3#F)2"15IA'`HL>.=X_L*!
M76>:*]$9_K;P9[:K)%86@9`6TP4&&B_HA?"-`JJ/LZ!A76=.4R><`LXF<,*_
M0&VQ)16JUQ_^I"HSYP%,.ECADV.[I`N!:H4K!DJ#K:"VNZC)328_T?+279CQ
MHH:2D$(#.,K(J,02S8BK(E&2;D9*:(GZ1T`O;*#@V1$(Y9//;5S`>Z$"PI;9
MLZRD)4B8M&4[(>EKV1TCNQHD\-B89)%ISF<JV*"CR+_$L5.ZP,DQO3IR*8P6
M>G32/3RB.X>7[ZCNS-$FS".SZLQA#AMS@[_&XE8',]V$NP2'`IL09"Y(>7@R
MX?%PPL`+8B>\IZ/@)%3:D\+TUID0-.F$97PH"1`2QA_4@9*?A]YAVC,^Z(-$
M!CX0BK$E/T-][I7BM2+,&?]:SK^B[.=;65GX9L=*2KJ5S-#6.U96MB'O^$@P
MLF5>E17`C^92V4RJM?E38%\(A,Z?TH@_137-%KM3=%4?&7MX4U;9?N=*$1;.
M9GKF?I2!(2)$NWA1]'4N%*1C;F8=TX4B.3".ZD+!</Y,!N,8+I0$,5KG0I$1
MYQ[YT5JWAPA&571]5'=O:$`7([V_T;U!P!2X.)1B]\9XH.KC?NW>#>:MS'HX
ME-+>#8P!KW5N]'NC43GGAI`WB8-#V=>YL<+9MWHVV$:<E7<#&,#(U(N=&_D-
M.JYGHV3MMF/Z-:0J7\=W:^2]&NG^T5ZE_@PI#>#`/@VF"119]VM-ABS4M=GV
M6=,^F23Q]P@?3U.&?6Z9R7;((*/<JLVHSTY8;-(+;"W*ES@+DSZW";>$Y0>P
MZ)UH=>P]#/H<V/N;\TX4KC7F$YVN"F76:<JG:1')<1S-E$^U@%,PY2M8<IL.
MD]MQPWW,.*$$=H9<9\B=FR$W1J.K3C-.U]`P/"TS;F`<RXS+2</G%I[6U?[(
M++;?LCMSY+ATB0*<1PU)9^`[O/%F;;77<CM6Q6CS-Q@<U2PV7F$R%X5F_"-C
MI*Q<*=`+@]`<(N"9^*M0T2@'IB#&0+S#0JO&@8,$R$@5R:5G,``)F)M#6DP%
MYY$UFYC[?W.:^;YF4W^2*IP(^@@8+!\5V#C.AVH"QU6F^/"#!DTLHT%PW<:7
M)CI>:+5@:Z<@YI"\/#]G"F5-!=+SP]2\1Y*`%4_Z;)7,O$E,FYR=,?-I@HB-
MLFX08,-(41>H=69-8MAY\R<\#$`@:[D$C8_K&RDM@4P]VK86A^,0D<8B!T3@
M[*&"<SUE75QNJ(Z-L:QJOH2OAP.M4FRN`&_6A^>4HM"<Z%#/?#5,.SER<*YN
MY5?B))P1[JX%KXZU&M?03%,=]?M)-#2K%5M%V9M/6S1BSW$91%&:[(K62NSR
M8P0AP;$8D<7U0XJQXF#,M$SP"+&?P5=MB<UE@PKA7:QG:Y,*N:#&!,,K.Z2#
M)@I$)EY20&W/3=MFE9C7A$M6]Z<5.O?F6K@M4+H%@"W2NI,]JQXKX:BV?P+H
MB-U3JJIY<T_0&LU[BS:MIW>C2BG2//^Q?F5ZVWW--2*:W8#849G&=YR%XPHW
M)8HK>))N^<9PUG:JC[#L3SAK_-)Z\`/R@C+G9F**I*@)AX`<.TQXA4!R6!([
M!9-Y5_GZN.26CP`Y#LH#T%X6C@@29-]Z1+\?R3)&-2@YAUBL/G%.,8$:9@2D
MI&3A8_XMD*HECID!Q\8_MGF0H<E<0$6L=VVPIM/6BK4U0U,UYC=F:8HMT]6&
M"%USFEKJ#F4(M<4E*O'[-=J:5D5;&_<,37**,I6MM&.41?L*%+8LW3P[C8WJ
M:6_4V#(;U`J5;7-)XQ:H;'J_=2I;LF?'\93J/+=EC>K$/`N-^"$WJDXB_M*0
M'U)9XX-DO*VE?L@,)I50-,:=GK%=SQBV6L\@P_Y9^(0&I)74[!/*4LS158PC
M!&'UP6BCCI'9H>/J&.DZM=:&8U=A;(.F4;!SQU$VQOI:WU#"7(I\0\/)QJCL
ML+:H+/-='3XHFYS(J49E^^V-RA;N[;JPK(\(S'+1Z,B*<:.%H=#A\4.A8*'V
MQ17%74.AA8>U6RQ4N#[:<%'QQ+7>T5`=M%KK1?#:ZE[;K/3J_2I*KX8)B@7Y
MAB*[OI+26TAK]2F]2<G>S;J<7&BY+'55T8"5G/8K>PZ*-."A/BS6@(NVJ[=:
M]3F_)5LV1]213E[]Y><XO+BSK.6;2X;_X1?K"<,RETSX_Y[FWUYZLVN45])7
M'V`Q0"QQ8'_V/<X(;V#WWP%7^>NW__XOK*_]2[1T'MY<>6$4Q*@A296WPAN<
M*7F!JF_!'U_M^:\O/@7^`A=^T=?@G\AGGR<71O_%;U2RFV)'6$"6%\K^]47_
M!?W-JW#3WY7YZ*,SB^[QT?Y/;Q5>#'R*">G+T'ZCB$]I3?W-%?@C?[FI_#Z?
M#(ALYXKB^$/ECB1BD97FS2Y$#+I/<>WL2J9DG50N\_U,@?F$MM>?*'@*@>E0
MX"#`?$G,RJ_BIM1^VV^V??N_I^IO"_9_HY>E.3`^"#UHK[,?MOWLA;%B%2^T
M66"R?L;CPY/TK]YP_NY!NO6`4I%I3-+?O3_7#IU1ZIF]CKYJ'4`M!JAFU-^[
M`U65UBUGWSKP?"<[%MJ]8"(J4UJ$%_?"$@3YACR#!C9(=)@:3AII<G8^W<L.
MWI9,U]%WW6\6)F5BCM5QW;AP5'IK`;_I)CMIMKU.6RA=#_SL3^9\)VNIJB!7
M>6]"3>`5TT]"13@;#<'4U-%XV.B4VM!0=:T3_Z?+L,YWLK:)_Y)%,\_^7,YW
MLI8*?ZD4:A.RGU46[41_D_@X4(=FLZ:_;JJ&6?,I=X*_F^R$V?!:N[]$O;6S
M/Y3SG>RH7(OR'<G"EY',:,+T8]7>.CG?)`9.3*PAT;")CV5V.D%_LOSI?"=K
MJ:#?7.3I[$_E?"=KAZ3_[#_PBX\<SYJP]N@282?K&Q6\&ACUXV:GI`(MG:P_
M60YUOI.U5-9OK@YT]J=ROI.U0]9GL:P)LU[OO/?-2_J1.C)'S;KO57U@=H+^
M9-G3^4[6-D&?7A'JY/P93E8SNO'+,>S!S/T8;?<+58DZ<#V-?++\RZH#=8.S
M;F]9$:0FM(:F5M06Y:*I]8XFZG@T:"-D5,ZBU:I*_3M1+(IN_,ARVW,P>!=H
M.-)436_D+E!CRWINI+_M9M%@/%1'(Z.5H//K:(:I'9Q#_$S%8?"K7WXN77TF
M4Z[F4E023"H^7+(Z@G*)FLOP>HY9HA=]_4(?OU!BSV$_?/_VX84RLZ?.PG)#
MK$/SFP9+'TX&')QUH^\#P@`KXVP"0==`[O</",%P&P1&_X``Z!?],?RSY12T
M@7%8"#1]\R&,S`-O@;X%"PY\!I,+;?,9C/6*._#>"N^_\*)TE]Z,UZ6Z$D7"
M=B3(R4"BQ\U3[`_-5MK4)M*Q'!2:,F0RT9L$9AO%F,T!LQ5YAY.=@+E.2['"
MDQ_L!7QFY<MV0UY](*'+NL'W@6"[,#$K`O">BL)^PYJP[Y,*B5^1].W@&U6`
M+;L77^CQ4`;HZO.G%[]A7WEQ--LFJP6TU4UJ#6BKHK@=H!5RG_6@]2<-@Y;G
M12T"+2_76P/:*M.L'32Z(?/.M@+!7?F3E]@[8A/C^$WK_\1GW#C&WK,1+VAL
MMF%SLPFR:'`V';7$ZI-]8E77/]D[B]6!EJJFZ6C5)MDJ.0>FN=<<912X<7^_
M=912A;;.\8$7X?XDBB>_IQ+<NUK0X\%$2*KBD7>??+NZHX^,0\Q=YC"'8V-\
ML+FW*-]#+3GD^N?>8JEJ!YQ\*W:;XWZ%`_^7%026%X4??]C!U`GW4NV-X<08
MBP,O&'C'B;?S)=D[4]^\6YU"P_JG+><*,LU1Z8D_64Y`Q7:OY^+1G87,V#!,
MP<@*QMUQWNTN!J,_TONUS[OU?'6M]FG+<"Y#2[E'G=-N85K&\!#3;F57H^&@
M]+0?DO8)V=KN'[`Z_8Y(/>IKAC%)&.;Z"?:%9"N:CP?ZN%\=D-M(U/3=63_1
M^V-I"](!J\Y4PO<R,O4:)MI.NOV1N>\\I7CQ4)/.;)^)MC`%S03TJ&6B;5YV
M?3"J89ZM=*\/]>&V>7[W+4\T=0B3:%>E7@LE^DBPV)L(P.5*+V-8O%+]94TO
MTY=MEUX>?$3J`S/W@\4;)5XN0>A;HJD#C!N+3!Y:S_`-"T).WM).*DNVE;3T
M.-F$C4TY"K?P0'U*+D/L>%/4DX2:I;%VY[$7\N(C+JR)@+1F#UCL.U3F@`SP
MK!/,8*D!=883[=6DOJUC:@#UZH,]Y=.P1"=-N<`V9O#;:Y4W4D+/$69$43\=
M]`VSAC(N;2;^2&W&'-[=)FG^<FM'C[;MP;(OM,E*J]#]>J!LWGK1&&4#]60(
M[+O83'SV4FSC.HK>QG,EV[UPX-VFUH`U7AC:%B%>8>8O@"5.&/K!$Q)*QU8J
MLY51PE;2K:2.9[LREMI[A7V(`X<W9Z)F3JS;T0K%9UM,4N>ZF6*QYH6KC`/4
M8^(<D?]H!3/@-G$$>$:K<>T[RU5".WAPI@@M8Q_4#Q)&_)_83<HG:SWEDCH0
MKF%S4HNS&796LD$%!%:7&7\%-H(A@<^ZP^YOD=2'+NG(F&UMC-Q6ZTL,BCII
M+:PG>$[T:&0]%)/6B?"&_7<,L,!7V.DP2!HB$@Q^H`S-I!6B%3C1_<*.G*EB
MP5C6G9UKDH@-F/"<;AW>-WI3;T8.P2P]6FQU";1.G;>`XWK4>9/U?Q0]%F%I
MCC]+NRS"+CBLF60#_18/)"89<K-E%G7U*L1JDR,'WT7>'8]WZ)2:%B)NV3^F
M]Y9W9R<-O:1NGO*)),U6&2P^/H\8QN3P,@Y"E(W4><IF:4L*3U\2[??D1I\T
MR2O*0IZ\+DLE3JAX]AT<JA4E>V('BY!`#T2C&\+KT(XBUQ:-3A/B:)<*)#&N
M<MW:1`?)/!.;S1S<::#4999'%ZE$PY$Z&<!@\)EQKI<&4Y+@BY7720OCTV`?
M7NR2/`>B"I@NAJUBE9D#K"OR@QPY\^,=OV8L:65HY'E2GU$%T#"X0Z[CT?=S
MYX<]DTZ53KIAI6J-\I#-.Z*=_>0'GTA"_([,^YO@W05:AB9I&66T':TO9T)M
MF"P#%8ML7M'!W?C_)&J^GK,>K]M@RBM_:Z*DI@S8^ODV:&-A0896*8@*O+.C
M26(Q%TZR'0P!_#5#</2_",2N`4!#TI<K3I\#'2C"F7W\L;1!'C(OT1($:XE=
M+(%KVB@))ZR=*!>,%X+U"XIT$17?#?/7Q^-U`=6Z^010HDGD5^J?._L"AN&3
MG$J;-H(\,5.@4-I4T.65<:+'\[TA$&F#%'F'&E;KJPC7#?G7Z]6DS"K6RM8*
M4Q6VJF=ZL]2U-Z2>]`004',$2KJ0G$S"":&95X*Q=3#KHQN^.?0!](M2UP]R
MQDJ_-S(=K_"H^9<8F\?18:?AR:KG_\IZ7:R*C4II8G7?SZC]4W)C0*"#P]K8
MSL!2'1EX4TYYM8+5Y.32QB-5[_=?HR8(BP>[C-2IN<U5+=0'-[S.?J6WL9FX
M%4SO$]5O9C_8KK^D\1)S%84&JHIKL%VRZ)BY=G`VT^<(J*]#P*JXMNFNQV%`
M/S#MW#XSVDEZ6+\T--4PC'6X;PS[JCYDR!]B"B!O)S\%5@U*D47-T(79G.VP
MSCJEA\H=QC69[902'Q=35L3,*_$,$@H,]@#&$/QU/$+9`87.CB2FSXPD4@?@
M2]UD(9,UXH2YEEXCDK,^\8#P@-T!4RJ34,P*^@H_*:$\<\_,4AV)>:K>*AV.
M-X?CLV>&X]R-)=Q=:Q#<<UQB^"O^JHS[*Z/5%#N^1J\KNAMW1133Z(W-;7ZM
MUB%YG=;?I>L22#(3>LI:8Z]\#"O#,5EY6>Z%SLP.2)CCP3_X[@,%$P+_P4%'
M`YYNHMT2]TKT!XO%780+G2G&Y,T1W,X)9?<K2';KUG7">R[MR:=.RL'M$SV7
MYZ)@#`;V$A5O#UW>DI+!G*J)T3BE?`INU`N5A/BSY`E?,4]7YXMD-47R_@/D
MS@(>Q<U(@5"5F$(Z;'FA$CH+Q[4P]L*V(EC(8[BV=P=SI@`QQ[T$Y>S@%%,9
MZRHY]'>EGH/G6JQ-M,A$(,4Q^H^)+\673#?23X55QY(K-'4P,M=D5QBZKD[Z
M)D9W^+AK5`5+3O10@=MZ%R(H0$!@E(FP#.:_MQXPE*.$2WOJ`"@L+(#0))&"
M.F($*^&`'?R*&3_I'PE5?;*+O:-%+L>-OMJ1D=X"R0Y?<>:JKFQM/-++S/R5
M^PO(=9QX"C;%1JKNP5"ZI;YYMCT!JQZ.V`DPNF?V#N72>]G$K&&G#`WL7!&K
M*9QE1T`JQT&&?3"IRT-"Z8*Q?>-+E.?LB#WKX@OR)>$U\^T*T];M60=3)NQ7
M!JA<4*EL'*LR(JV/8Y6(7>T$8E44VQ4\+J:N4?K=^.(1C'SQ%W?/E=,&28;R
MUEGVAZE,J`^D,PCGJC`),8CD&D=$K=?SSW;TWEHZD>5^Q_MUU"Y.I+!_Y*HQ
MWJ.%L\#+L_9=[-*;)Q*!&]84@)LD`3B^6P0AL<#]8FXX%FA"NRYLL\Y)4+%K
MU0+L++#MM0IO>+:,%4?W?N#\!ZT]MH2\P4Y&('E=X0?-)`\7^0BF=/U;Y%&1
MR83Y;WT-E5?N[46UU$S>0.WUP8^8!<EOY$D>KN(Q>COYO0Y_[E2>E!W^AA!Q
M>S'@FJ6,_X'J%YQK<4X9.85`.U(-8R!.&M#`B=#V#J/`F4;,YT^80*Z#52-&
M91EP%EK9?M[P9E@H\N?(D\1^5%XR7*.(@90=APF-MDC@SR'')?,Y@#E.QCC"
MCUG/!3$(_$9@G076EXVVDN-Q?$2G0PH`<X;P1+V_8Q^7!B?REQVQ7$V>^:F9
ME#]*HQXLD[+QP\_L[R";.[D%$^13MU8<+BP_#KE+["8IBPDB@&&\_UDJ_!Q'
M&D9YRYPCRQ_.G67&FY3&QR;JQ.BC%^J.$AB\7%XEKO=,T6`TGJBCT;@D&CCY
MG;%8E:4TNY$="<N;EBB=G"6DGM:*#9HV5@?#41$Z$`C;2!M`XD<>**X?LFD2
MM,C@P5'._\I3V(&N'F:21A_&M^$T<"@02T`M>1$L6O"81#;#>_[D+?JU@*!!
M8\5=&\DB@51I\H^F6X5?]92/%H"!'X460>-K_#7XN)K=SK*"9/QAKBT7\`9V
MFN["*K9T=YQ-.^@+K[+]8^D$/+GWT:=;#R%;R@J>A+88<:,44#7#.-9)7@(:
MNKN?I#'8>I2Z:LA<_<P/4],-VI##98R5Y[[B>`O8+KM&QUBOEN&]!Y3`2K'T
M97QY3YX[ICRJLIK4."]^,YG]J0B&84?FN%@&'Y!BMQ$G/[@),4EC]70DFT?-
M4AI]J5+H)T/'VH`=>T+VL%I1G9[=WX(O+-S$!PQ$+5UK>E0!M&5G-&$29AA$
M<B$G04I$W2P.%V&K8L_G>*WF(5^Q7VN[_G7%4&$=%RA4OK1A%6NLK/(EFU@$
MTX&4+WU0BA$(GG.2NM?3!L0?;,;\%._#,HC/DBDT[?5N9T0PK&'8ZD0;5[)^
MC='IF+^<[OXG]NR25&>`%CB:["1VBP6LT&$(D/+T,ZQT)J=W)$D'MC*'8NZA
M#-5Z*J-!I6,9C(]\+L"FLGV6UN[USFD5V;-)=,C-CL/L35PKGV>VTY5<A5W'
MM3%3@F4`K;F3RZ_DLO,#K4RZACMZO<;HV((6.JBGA6BQUM$P&.91HW6.[UPB
M3Q5?=R->>>ULO/+ZINH,&>08#D"EUHT=.&&14<CM:(($E@0PQDYXSWZ6R4HX
MZL?,SN$D`1#WF>9(@U$0P'*5W$#\8=Q*>/!2%9_>T4O\C_<$@JB`ME;)47=S
M`YJJ,1ZHE731L6RE,1?%/8Q^BT5NTLQ'J>S$%&!_0CZ3`8Q\PRMNY3N/XG`6
MTVS)$3=21Z#J"\\.W\FL0E_G=BO)5I\4F1AER02[U^RJ,CQ8@>/'8:'B`/M%
MRDN-=I(^4@>&7MYC@HB9^A7.Y_S&8U/5)V8=G*T@R,CB/1C5-K=$&L/Z0XT)
M)P(]86@8+)^SY'E/2@2H=!T]U^@=8PSEY"-4&Q%E`")0&XT:CU*/3!&EQODV
MX4_-T>DQV()&>:.C!,8P@>5.8[8QQ5@#@A/G%9`0J!$\+W[WE_S"0)F")"U%
M-''G9;M$T=7^8*R:I8.A&2-4LF9DO8JQ<8Y>NK%&N:K5+3<`#C@<IS%1=KH;
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M3_)6"`RZDIK>Y!999W`>+-&,HCBV184V>PP#"P=;EWVFBZRUPO2S3+I-DGXV
M3//$:.;5_#,D4CG_+)M^=AKLAF+;2?P@:P>,@56;LL5:87@Y24W:Z<P$:SA6
MDFX`1ED<<,D1!;85QL&3N``-1K$UPZ4+'D5LQ?%6_-[X?6(=RV8Q(BF;(<>#
MX'^@#W/N0RC^4C,&ZF0T@I]F,8O^\1F7@?V`[E[WJ8B7Y!CK45#BVF/EM$=%
M`D4P!H;Z111%C&%HYAF#P47!GHPA32\%2B<@<M2N[T+MF@S76G)7UI(Z#VA5
M(_>JV:9"'0+,'!XFT;0,:O`\"FVR!W8,5K!#[["C)NS0#75P).RH7-.R@3N4
M=":9Z_1?7,L[;M3^.DVQU:AE07^2)2-KYB^%.&'>S?Y$84NY`H78HXQ47(?R
M"G\6N#AZ2P_2`OE7X[>O.8Z%,6B>0!D\FAO81$8A]Y[V1WQ\?)GA7C*68E%A
M5);BPG-C$MT<T#)>(NYI:^YO]JKH`->Y`GXQ7FVF"0D0&-%U`<N9O1&)A@:X
M'@*,JI)DJ8*7^'GG6P'=,TVN61]?_=[5TBLN)2.V3!>./3I.41$Q4PD1^0^%
M"(@CV07Q7I&(@%41T5BCHKXNNSS@/V`A+@5[`$5/2NC\8+_R@G,,=ZP[T,SO
MD%FOVFT>;!P!2PQ,E#BBLDY<,*B8A)O"PM;`JQXE-/$.T/>OBV_3>]]%QBPX
MN3-E\,YLE]WZ?;2=NWL:G_?'L`!U%WQ;I+*_L*3`"?]2YF!2I#G,`:^^I/4F
MYD\JE=U_<&:VQVCSR;%=PJH^_H8[NK1).7WP\;*]Z\`&X<N3"?T^RSSC.G.;
M2Q=)_3\MA,24Y/%.V)C)Q-^$CZ.R^/AHNP]VG;C8S^#B<!47DQ!%T[@XTCI<
M7*TX8+.B^3-EZ0<1+R&'AYPY<8%!`A5GU;J!L$BBWC=5$S`B6\PPO=U`56PG
MJJ8-A?3-W":`S_EB>"*<0LV!,N6B>\J'?%%/V$YZ_Z+H?9X`FBLY[8;8\V/J
MQBC_F6-#RL<KJ+![<`RHWFUK4P%%>/2V0`6]38`_N950JBGSN"6^K66:<MK(
MRBJV6-I4*Y);A`L8^DG08E$'JHR<L-8T*"+<9?D-!35OL?PCK]Z("J`-++5<
M4?^(M8RV79<O`6OVT-]+;/;#_^:+?71FT3UN9_^GMTKYK;U%%A!<8'*XM0SM
M-XKX]"*%!T$)Q#Q8(-B96JXX@,A?IH]B>2!Z?)8#:S#Z*9D+WG@#\L>;^8]X
MDB`_3(`S]%UG]E;A*[L(4#*]4<S>`&N:BF]=>YY^*:/!E#HP%%E]T6P[=%KM
MT&6W1$R\SYW;M>O]'!,N^O,<&AU\XFN)_)<)'I?:[_$)[_>_A-)TR92FIK?]
MHU!+J?=-M_O-[OY7>V$Y'C+XWT%'+=Y]^AC4PS_Y.=WZ4>0O,D?5W^.H*K#(
MW0`8]@9F*<9-SS<$E#;NC5L'E(ZF?"U0U8EV%<0P4M<%LR1973T:]YWEL@LK
M*U6!MV_D_K@T5/417>JM<G[[8\O+=#H%W465Y]P%&8:]L7ET-,BAI<+ZV.UP
MU%JYY1?K>T?Z)#JM5D>Q26]2\;0;0ZN+$Y5HRGOD.ZY;!ON:X]@7'3#MP;-=
M#<XMDJZ@GV`MVL,F<'>2C:/JLG$WZ!H1H;N!MIND'6I;L/5G\MEDOFJ%OZOA
MCB[U^.A8'N>ZGA6.%P6.%SK358<ZYEMPEQW%443[>FSKLZGC3S-AAL,Y,#&S
M,\[W$I7=F;&7VYZU'LW#^BQI[;^^X%I<H0MSK6.RO'>SK`N3L8XZO9AUZSA'
M<7:V>A%E?5B'T3;/V['+FE$<TK-XPJ=R;`?D/S!`>O'!BAJ?^1.F*_R)LK8&
MM^=VGMLL7^EFJS[;\0Z\V!+[SK6;(SD=]SH2H^)D6)I@I([ZDSUFW<4&VF2?
M'0L?\AZ@?[!DK[,[<^%F;/;$,>>MC:?\)]'ZV1WRJ_'`4(>CX>NF#O>0)'SR
MOMY6QC&K(]5%3:ZBD_<9'XX?G1TC:EC,-*)B-A432#71@J!`>T(!AX\`5$>[
MX60`JJUQ>-`:T'ZW1P,.>N-,9OBWUO2ON\"/O1FZ5/W@C?)D8W)_]GK:VHJW
MK:O-RRK??A&IR**<9P[LYBX)\"\!]6P<%B2>X^UXB>63?1O$Z-77!YO*K*B8
MTF^,^>WVM.)`<A\3;[5,_XX=RJW'((CS8+F8@N\)QV*NLR&+&Q`,?#)UTU48
MN4(%W7?+/,A2GY/K>'.\(DAW.10J2YVYM#>S(E[C0@!/0#S:@2V6FZWW$2;=
M1=-UYYL%F.M*6<M[1+=_L:JO:29W(GAU6KKK1W#`?_&F+Z[`=:Q;O+M"-4B2
M2S?*.\?S%UB,=OU=FZ+K+2;;$77C_1IVC:/7'V;NV"BY^S6S+7=L3NH&S57I
MVM"Z7#:L/AH0T[`[-$>B`47"?W'QHE2QI*KX;U#Q]B+T5]:@/H'3#/H#*QV-
M"E"?W;4[2_3/W*[=)`.2[D(=_N^(_VLJ6@PF[*ZEA.+RE4J&>P?`=;VG]\NS
M>0(CB^NZJ9\PKF^N&39^IJC.JO3D:HU(Y:Y.\;RI:--PPVD/G^EAUZC;KBD]
MVU>UP7#7&^.[LS:M-]S`VMAY;!3CNCDX+=8F:[&;FHX/A^IP6+L95QK5!_T*
MJ)[4`SHD6],TJ8P?NR0^(_1SV/JCIQVQGV!@;6[7RO:*R*^7U&&-T=82"9N0
M?VB<).YOZ_>HJ=J1#;AC87]!^;#Z\3WI`KQKL9I],%XOLMJ$/Z.$U388]H8-
M(7VS)0768/K)%!=H,#.WYN("K<YH/=8BGD-&:R8\T.6TMBVGM;F2!MTAG4SE
M@_/(D3WGV8YTV@<O.%!V@Z1L7%W5^D.,(NZ3-=.O/&\V'\$<5I_3Z%7-@=![
MXVVW($^FWL`.)XV%]M!?T^Q!HZ':Q.%JO7'_4(=[Z&30CTDC6+S@&/`JU@=+
M#:V..Z]&V@"+89=([=TQE[(Z8ND]PS@8.-7Q[ZRK`1PLQVX'<37!#CQZ$VEV
M^TJUP5[XN1&TG?CC<`N*YI/^BCU5B;XMU=ED^O0O/\?AQ9UE+=^@\RB.J/SI
M]?RS';VWEIA8]QTS,[XE4:)+;_:1-]>$%Q9.&,+S7^T[[.0!GVY@'>]<?_K7
M;__]7[AQOT1+Y^'--^:FNIYS!U5(U=9Y1;\;7$#R'M9SQ<WX:L]_??$I\!>(
MRQ=]#?Z)?/9Y<F'T7_RVGU>I*UG9E:P\^,1=R<HS]^]TNW]\QTU7LK(K6=F5
MK.Q*5FXJI-65K.Q*5M:.5EW)RN=1);)5P)R;DZHK6?EL2U;^\G-5WU"Q3^D;
ME2%,WQ>WH9MR+W75!4_`+]7J13R#=)*NNF`;3^78OJ*NNN!)9>"<\VS'._"N
MNF!77;"K+MA5%SS#0^ZJ"[;)+=?*D%-77;"%_.CL&%%77;"K+MA5%ZRINF#>
M<5O)`;LE+Q"]-:+,GKA&=Y0$P>[:Z5GY:Y^#J[.[=MIJ9V=W[?0$#JF[=MK-
M]CR2!KMKI]VUT^[::>V'VUT[[:Z='L[E=P(9?0=SOG373EMY[71M&M]V5T[&
M%_2>ZNI1\A_+V<DX>B[#Z[GDW%%BSV$_?/_VX84RLZ?.PG)#].;\IIE]]G\<
MLI6!-T_[Q0HH+Z3T]%_8>S(45Y\_O?BMW^OWM74PB%DRL'SVO0<?V?N7P)[;
M`;#U*CNQ!@PSLQGKIB@%QT&V9MMD`K+DFK(5WG]R_<=O\7+):G%;[@<GG+I^
M&,-KN_D)2UR47G.SFAF?E5N/:#HK?YE,(@>TB"HC()AP[@=`Z;!2.YA:XLJQ
MRYN24&U>K?^&,9+)6WE'"%#<*@7W2KGR<"2ZH:U<?OZ@?+[^?/'^\ML_E:O/
M?W[\=G/U^1_T]:>KSY>?W]-?[V^N_KRZN?KXC9A0A=XLE5RNY4WW<L[9&K)D
M/?\QL):_OF#_?7$HJ57>OLT#!&N%G?5^?:%WP'7`=<"EP!G'`*Y0?Z_`6(I9
MT[%.M4%H2LP.YDYC@:H26'5,\!)PS)K`:3(BYGBV\@<,>!\J'[T9]U8T>0F@
MV$PM&7XIY1=H(.]CLV:2CPCU#Q\1JE>2=`MH+BK?+:I#M?U/A1GJ/S_*>0?[
MJFSM6-GEPH_!S&V.B1\'F[I9NUGK4X\/9DTUE0#-O:T%/6#7=O_;B>F=#'KL
ME6M[^LMOUZ;KJJ8/U<%@U"25OC1@SHEQD$M337I:WV>Z-A50^-3WPMC%.`30
M>?"`+9M(K;FK@\Q;Z"L[''"'9AK/:C-;#=S:^/%`-0U3U4:3=GEQUX;B-74R
M&><+E+5+XZ_33U:$5/5[X];/<L[2NYOU!&9MI\W2B9=G`5SK`#IN_/24C_*X
MP.T<>3YNW+==T+0LS'LJ4>C!Z46A#Z[PMG#F]D7>M6([H'D=JHL!/JL%U,N6
MSV8A+0G$GB]ZU1`C;^G*FHN1/TL?1:.SGKP/II6[>J!9ZR*SO<&[G$Z1!83P
MP!/=^F`1\IER^T0A-@RF3>7`V_'W[E2"Y1U!5M_H@:IK`W4TW%0@H`DX7BIC
MS51-_2!!\[WIXKB1\!-%K8Z&&TMR,?21VC=WBAS72<-8G_A`)-PN+W('7!?G
M:1-P;3S*%L9Y.K/Z!&;M-(`3FK5T.)7/F=9E+;^4[*O::;UI'&'2W3=7/ZW-
M'1QATN'.;VZ$MH"0TG)!R5=[A!N'6#LEJ[G_.PXC9_Y$4'V1C-GHWL:H8U^A
M8BGR#0YO1J!PQ[QB)W75<A<\%/)X@XT\BP.TB7%$#\.J"Q96M3&LNEH(2U/I
M25X-2=C9G^S;(+:")WJ"8`H)"L>CIRURJ2O^7'FI#Z@_BO**`#=?]V@;MU>B
MJ7$?O]DV`U$Q<;N4B3+W`P5Y*M:1L5QEEI3=(6A\#UBU=S'%JC-4O<::4@'P
M(X"^-N*>LO:=*X.7!W;O,C7KRKT%_F/)T-")U05N;V9R^6A<O;GI*QD<65:S
MLYW0<!G+M?Z>/4L&U@[-]JJO&^`LS(42PA:K=Q]`.]Z2,B=8UZ3*[+449-X&
MD7%`B&HYN&J'=45J0AC!`\Y,`8&.<G#W7<I-KNG579A2@<D2#<W+`F+V)G4!
M4LLI'<01<^5-_86M1-8/.Z0#W7W_=FP,?K3SWA'>PZ)%WGXH5B/7%V_\Y>>J
MY2.S14+Y2U(9Q4MO]MGWD,:OJ-T-+!J^^N1XEH?:Y"6HO@^@)]N-=:_I2BF>
MFE^W`ZX#KJW`=:443_(22U=*L2NE>%@`NE**7>K[F2W@+*L.GN6B3GX!72G%
MPS/QT\U`Z&9]WK.VLRS)3B!UI10/F5E^>LMOUZ9WI12[4HJGX,CK2BD^%^"Z
M4HI=*<6NE&(WZ\G-VDZ;I1,OSP*XU@'47;$[3>!VCCQWI10+XJKM"/.>2A2Z
M*Z5X$C.W+_+>E5(\R1C@R2^@*Z78YD#L^:)75TJQJ_G0_EE/W@?3REWM2BEV
MI10[@FQLH[M2BNV/A)\H:G4TW%B22U=*L7-QGP5PK0.HB_.<)G"=67VJLW8:
MP`G-6CJ<RN?L2BDV,&E72O&`DQZCE.(O/]=<G"13\^1R)NK\I>51KCT^[(U4
MWJ^I`B==$;YGG]/:%>'KBO!M52:Z(GP5(.J*\%5(DNN*\*T[I:X(W[,JPL<U
MSQU5Q(R:206FKSR6`9%1'B_#ZSG*@HN^?J&/7RBQY[`?OG_[\$*9V5-G8;DA
M:HB_Z8,^_!^'*C-B9B[!';X`+EUYJ#>7U59SD_\(G3>>X_[Z(@IB^X7R\PZS
M:-(L6K591"E#1A\W2!XX5\UKJ3!+#6O!4)H3450,+)7W,`<@L`W6"LP*N#Y]
MVLW`*%$:DJ&WP/&<1GOKN[-*:JVF8V%RH=W"@#B.&)-(D"JCHZ7V1HF72SL`
M6K&3IV/2-K'BNZ:]8:0Y>9ONQM7';P3IY></ROOK/_ZXNOGCX^<;%D>,DV7A
ME!76Z$3`%:;5ESID*]U0A%TL*'.<.6#;`!\@M_+)<0'$ZM#5#I&,,*X=`2^Y
MX,;Q&^6BW],X`M_<LZ+[HL'`O14JGA\I<P>S1IQ$="J!'<6!%U+M_M`&@6.Y
MRI-M!2&I1R!_+/BO#XAH49SZWW'@A#.'\6V5ZOXOK"?EUE;"^/;?]I3BVDL_
M#!TRW6%VU[&\*0-F:8,L0+\"O>=P1MA3_K`\B\6\%2=4IG$0P$?WB0`F%P",
MN;#^LA4+P(7Q;N&WA6V!/*%?EX'_X(0`$"TBF1P?A%.+GMC78FZ"1)Y?59PY
M`/0$JP'H[P&""(Z'K4WNT<#72?/;;+_BZ3UORA`"M0(`5AC:88@KZ2E?"E>+
MLS$0Z%$Z#)IF'L-!P+2/CNOB/($]12F?_`Y'X/BS[)Q68(.D@X$7CH=0]=I*
MX`GW;B%Y`W2W8,#/E*]V"(B/V\N;?UPG:']]"P.0[^QT6,#'^=Q&3QZCO3\`
M>W63+@;TL[U'1`,3P%"?*"S=!4!V,.-"6[E>XMJ52U&,!;`TNJ=18%Q?>0_,
M$0X):0*_FP$?<?VE:*22D"0!@FEJ(-8<X#,QC.P#[8$9!BPB4!ZL*:S"[BG?
M4EY"?4^62.+P`@YV%SLS?!S?Q!^_@R*!'I?(PE8DGWR@$7SL0Q#?*9<S(`PG
MC`(Z.N45UV8'H[>?/ER*/\9O7Q-@^=4L79#$/$UG%@,TEO(%V*BM7"GW,9RA
M,J7G`*PHP-5(HXOG;O`':1Y:$-J?""'?)?DLQ*/#MXQ-1?;TWO-=_^ZII^Q"
MVFV2/E3(!SFJ!3Q0:I;#^1H_39\A&NX/8ZCBZ.%W.#/Y.#*;''+&N00TM^"_
M.-;4#R/1/X>$"J5+YHY9)2D#P]H_I@B?!9\C-M_+\4##4@4MV/MKH+UEX+B*
M9K"JFH4DS-=*9/P%R`'.BF&4,7ZK_#_/?[SXI_^85E3*$?$GD"DS1BA(R!]A
MDZWD,!+>*&$YOI5#;L$O+!3*`+`=6<$3XS__?`\[#D(/3NR?'[_J/WMV#"-'
M#NA]BHSGWSTP;0DJE&NA0(P$ZNS*K>G?L8,G.P=5GZWCE?,:!L;S=.,0V)_R
MZ`?N[-&9,9P4(`*TR'\(!=E>D=D;HHIA(4=!18;]`$@(;['-\&)TZ\+/0S"*
M^X-Q7WD5.92**VV,'=W[LY!K1[`,1%#:5%@L%RF,/CZ,_S_EYH(B'$`D#X(F
MA.("(*`:<.<Y_[$%DV0/VS^6P*A#?,%2_FD';#^7OONTM(&$8*W9@R'U"<X$
M*2=,5`HXH_LG%ZWP::(6P0^!M;3C"!FZ8X/8?87/IJO[G6W@3/G"AY.GPA%>
M.7@"U.PI/83<MB>:Y5R1T0@8G_(7(NJ]_\@X(`<=05B9N*?<Y/0S4$*3B0B#
M!%ZEN"YS%)P:&,>]@^).?(_C($^(O0!T3!\5*X;".,0];,C!&E9MX@!7'C(^
MSR;-.UW-'74GXS3"EQZJB3Q+^XOAQB-E,#W:`^X*%`.OBNT"QDD\`?F>UF?-
MQ>`5HJBY[[K^(V.?\*J5^'7@49,]"D>9&XEQ7A\L"L`%36?]T#BW5QF.!+:S
MN(V#T!;3!,K,G\;X-F;*,N(#3*=%*0D3QRIQ\!M"0^\YQ5O#X6&;`?/!A"0=
MD*%Y,0`O`)[;>""OG`>^.PNPD<+(]]*E<+1^8",$_A-7[&&S[@)0;L2(H05O
M]I2K=(\RW(KQ9^0PG&D1B^&KL!`.-$4<L-(LQZ43`PD5.;C65/?(:1VD/^4I
M@S8!MF6.E,>L.;)!<'`"8L,$U6:PD6>R*:J0Q<^:9OY4.A8(_Z_UB^,M;3`@
M)//U&TOC#E--^:#F0CW:6FY+#ZCGU`,OD)=HE$A`K;939+P<M3G`T,72]9^R
MM209D_@0])1_`1T(I@$/,W)P2?5`Q-<9:@L9P5T`5ASYF$D!-,)%`RR*-7KD
M;H$IRF:@/6`B%S@"TV507@'Y%T)$3HR9S=0$SD[0?0)4QQ0/8LQCQFV%:T)P
M?RZ\A?:,"B#3BQ0=GZ=W^#4$+BI6#8[D_E"$7E0K4E["CD^08;-75<7L_X2O
MLZW`O!%8+[SP!^F%VE"5#@.><9D(#NP%R'E4Z4@_Q]>8*'"?%"X<)`O@T>?L
MZA6HWL/AB*:GQU\S8<]6&")(S$UB_T!C,A0^&;83(-9`=$<2_VNI9R1'>FUS
MC-#U%$2QRVP5UHZ?U<S/R+@3]%-LW''_#/(H)"(_"%/B938+DKYTI2CE+<12
MD!<I"2]2.<LC#H7^3F;]`.O@C@=R*49VUO9"MN"`.A0Z/[@^!YP*:"P(@1<S
M`BT$(,/<Y+6A!H+WHI2AWE>'$\&EA.H?I0-:W)=D)=Q#UEA'J@EV^FD<]SFC
MYYSE$)+L6KW;EC`1(4]!I7=C%)MY2:<-"N06$U`$!@DI'`6FYCZ=1/9S/Y/`
M+,E:X4.M(%;(#&TD*D)X)U#N@:UBP`=_T0>],4F^>0SR7IDY;AQQ9\O46A(?
M_D\"><;JROY)T1`;O93H9;WP@SO+XV^J^$5^,"1:UP$Y/D-?@/V`R"XYSDCU
MMFVV(;S;-#E7*8DSM8-".'S\@@$7RN>P&\5H>^GO,.!M`1G<MDKT?:7&?\KO
M-II$G2Y_4.;RP9Y2JN0:73X7GG#I2"1O(.,D860%$0N6_8_EB1[J.A=]0J_D
MJF;6;Y3ZC85H(4ANK1!P+$@EC&;J3`*E#"40TC4-D)+3F4R'GL[T9>Y/3IY(
M'!J<6Z`7S@ZBITY\'03>FYS_!6,1?AK.4V(R3AXL0(PXE'@CG$W@QW?W"7XJ
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ML"1H2)-^OE'9,]S"K6166L&2Z,?$]IK:>`L!I1=*)7?BB@]T_=6]7WZN?GTP
M6^-$N'C_8![>2W+P?N'^W:8*FW0.T<XA^MP_=0[1#FLZA^BQE>W.(=HY1%N,
MGNL<HF?K_>Q<G2=S-L_+K]DY,9_K<74>R^/O=^>>/!'?6N>>K,\]V9@O4A2W
MJ^`;S%<S^Q;?AO;?,3SX$9/ZN0_RF18RTY-"9M^^O_OV\7^_?_Q\0V!^_!,^
M?:,%[%R\K,;"Q@?.OKWVE.MIY&-6L&9NJ/%!>?#BOF=ZPRJ][H*U"ZC,@G15
MC%*17QJ#/BMG(F>_!_;4=O"J[$N#7[@1:<LT#LNNGUI!X+!GZ!%_KOC`/AS/
M8K>"V-0S)Z0N=90E_U)+"P,`G;ATRYY-30,[H3*+\8)L?MD&O<YF#-DB>-'6
M`).M8>KQ3S0.)DX'-A4M8W=@'"^,+-=E-\Y$$C:?)%G0K0U@L_LP[%MZ/[H7
M]]GF,!G=<<,UR76&Z&T$S;:FXFFLE6&S5V#=_(K4PHKBP!'Y_.>$HWAXKDWY
M\IA%3]=[48A0Y32ZSH<7"6D_$K3`+53%O4';944:5%['!S4/*M>#!=JL("ED
MX<<1'"4ES+-20!X5[%T&CC=UEGB3B]+M9XHUG0:QG597X[?0Z)X6E81EA#*C
M8B0655QC[1-WN0RMIY>A>\I5[JH74D`HQGT%ZP%:C;$20'0OZE[A<D-^LXM?
M6\;;'W@UCNZ02(N>V;<1/B::V;ZF)UP`'PLH>0P<X@^>N,LF!D\'3+"6+DNS
M2RTVAVO&;L'!RCQ`B`37Z>5D<7@)#E8L$P`_M)"7K(.C8[7H,@^]HK(O_/2>
MTL/!^3@86'^0$2?1D.^]5K'P!;O6S7F2HJMCPU`-PZAV7@<AO)QG"72853V^
M46+\PN[4LHI:;!>1J8;Q?.Y,'>2!#[X;`STZC#M2/9S`HE,IB_=`.#Z.K$R!
MH6$9(^*X"SM7A`G+(A!IIX4:O?1^+N?`UBJ3IBHNCK=RQ9,?8Y[&:(I0*@8I
M9E@[!`.3E6S"W^3;Q7S7\A0LRB^"?H9U('@!.H;C\-=M0@*P\S.'G0"_@8KD
MF9++"DD"18[XC3#.$BPLMWF72)CH'J2Y@I5V@%:P7C(>U2WC>],4^XN7FBFI
M%CA(_H^P-T]TS=6>QA@>2<Y_9CV%/0)A[1;CA;A--$Y%=^3^EIN(7BDF>+$/
MG,]DB1]%2G*U:D=.H"JW,:_I:8D*TC%HNJQ<*7);K/;!+_S=@RBS`RQ`1GR6
M$/_1$9<-Z6KA(Y`!'<H3&LGW)+,<)%ODHSX3?X1`$O=,Q!S>3<[L(S!Y.*$8
MZ5;H=)D3I9U[)(!AR;$;B;I=@B\_DAZS8+>602H,>I/)3RG^24-)LN60W+'H
M5MF1V.-EF-$HUI6/<T,_U6!GBI%<.Q>25[``0GJ^\7+-$:8;Z.;/A)AXN=,)
MN'8I%%M^;W#8WIW?X79@65`3Q3'94'[IGW-%:X:SI%4B0KJ4R2_V)X(KIRX)
M)LU>1DX,M``3S$+EU@I961I63Y>5R$D*#C`ZH@)X%F,EJ>Y##"?1\#BM$@09
MO4LWY9HXI.@A4%RL$A/]X5!/I0P.6<38`ZYA;;=E=T]V*N5=6"FR?^-?"6.Q
MH,J^?J'U+S1S8Y5](U]E/QTR,]OO:`Y^LNU=Y]&D:<18F0F^<I/VDQ]0L?^=
M%]279LH/"C/^\O./V\!UWN"_X<__'U!+`P04````"`!V?7-!/G9/'00*``!4
M8@``%0`<`'1P:78M,C`Q,C`Y,S!?8V%L+GAM;%54"0`#`)JJ4`":JE!U>`L`
M`00E#@``!#D!``#57$UWXC@6W<\Y\Q_4]*9FX0"AJKN3KDP?!TR5SQ";P28U
MM:JCV")XRDB4;/+Q[_O)@`HPMF6"B9-%$HST?.^[3T]?MC[^]30+T0/A4<#H
M5:-]UFH@0CWF!_3^JC%V--WIFF8#13&F/@X9)5<-RAI__?N?_T#P\_$734/]
M@(3^)>HQ3S/IA/V)+#PCE^@3H83CF/$_T2T.%^(*ZP<AX:C+9O.0Q`2^6-[X
M$G7..@1IFH+96T)]QL<C4YJ=QO'\LME\?'P\H^P!/S+^/3KSF)HYARVX1Z2M
M&,^#V6Q!R;=VZ\?9TP3`]W`,7YRWVN?-=KO9OG#/6Y?G%Y<?WBO>(,;Q(I(W
M:#VU5C_+ZA_#@'Z_%+_N<$00J$&CRZ<HN&ILT'KLG#%^WSQOM=K-_]T,'&]*
M9E@+J%#%(XUU+6%E7[WVQ<5%,_EV7315\NF.A^M[=)IK.-(R?!ODE-]`$@67
M40)OP#P<)T%5>!N464)\TM;%-'%):Y]KG?;94^0WULY//,A92$9D@L1?"`YY
M5RDH1,2L*;YM@D*+&:&Q3GV#QD'\+.3BLP0M,$C,33F97#7B>?"@">5;%YV6
MN.>O*G7CYSFTDB@00=Y`S4-A=AF-6!CX$'[^-0Z%?YTI(7%4A+&P8M4`AYB#
MBZ8D#CP<'HQVKY4*H(L&2H2FD3VQYR)E@9:EG)QOH6+(71Q-^R%[/!AQRL"1
M`%N0]S@IX]/L&D>"-*9XX0?`?],7_8!"T`4X_.F4/N,FC0D/9D/XQ?PBX"^U
M>R1Z(Q(1S+VI?L_)\H9%P+-K'`E2#W@^@)8/Y`OF'--X$."[((3$"1FTCP.>
M=(N%6;>4E>,U.!@7Q<%=2"P6$\A'S_@N+,1:4.U(X`8,4U5$^\H>"<:0LUD0
M18P_"ZY%0/:7/EKPAZ+50:\1/[L0(Q'VE)).4;UC11-<BD4N8-[WPA#:4_9(
M,)S%'`R(EH[#=>+?&,)`<[(8U<0W)H1Q%,,T0#2Q92J#_\$W#T$<D$*W'OU&
MQVO5XEXPQP';<$>8B\R"6"E9*E0]FDIW$?FQ`,O&@PJRK/(G3>*NR"^%4`^Q
M56U"5\.M5+F"7*&(+K-&W?*&&I^*;E=]#E$.)C4#E0W%>R3&01A9H@V*QEA^
M:)YEH;*Q;%G(ZA:JS2]E<9<T4\&`LBQBE;J5##C+`E6K7?&`M'P<E[-302=4
M.H05ZM:M8])T'Z;P4`6'O2#R0A:)A$?7M?=X_F2=V.'0ZN;DLH%4^8TK&K"7
MYZE6/P^NAT-O$29^&<#GK1KD*2;4)W+!28!^Z1(Y7!9&6JU6&VEH76/S7TQ]
MM*R.MNI7A[MXZ5N"/@>D<F4._N_:EF,/S)[N&CUTK0]TJVL@Y[-AN`YZ)Q?X
M_O4JZ/<OA4LJG3)4MFR=C$[!$KFD\CZ/BN/"GQO#`AIV']E#8Z2[)A1X#7WR
M5]`EGP_J?+JZ\QGU!_:7;3XK-FL^(?.V.(1BFXWQ[02SHI#LI4UP=)=LJ"TB
M[1[C>3/9R21A'*VO)*E(:[57^VJ_KBY_LT@LF,&@Z2$`+UT_CR/BFW0EW[XU
MFA#?D3#!]$WDN#(&FJ_*TZ0@,AFP*(?*9IE=M!M1IG,/,>X3?M5HMUIK<S`1
MV8JN]%;GJD0S6LR6>5(#_6?K^A,8N1[FV)4362:732\#B`9Z),']-`;X!ZJ2
M[M[$E6^Z__]%E$QR>V3.B1=L]28[_LXJK.;X\WHZ/M\#1U3@..WB$PYH)&*$
M1#:%V73,%UZ\X$#3GO3(79PA77$U-1$[]111U2M[Y-1>5T]H])S@".:]R[\F
ME>NM]F1,I\2_)_[/]5F3"FY;R]L[2K_$H%H,O*]G#+S<D_6+#A'7(JQMZN"0
M+&-Y.:G*"X'"6FHZ?ZBGSHH^>0MBKF-17<B-&FHB_O961$SYHOX"`G=@&S\/
M8588&S\6P5Q$H**669759/W];<B:[Z'Z*6S#')Q;C'K@`N-I3FA$,N3<6U)-
MNS_JJ5T.]]J-@ITIYN0:.GFQ2R>@YDU;L@JKJ7513[7R/5`[P=*#,['=RK$7
MCXA'(/6+#5;PB/*@-JNZ\B)`+54MZZ;Z9=`T@R$G<QS`R'M"."?^*K7HU$\2
MC@YSMA)S&35CBD%0TZ6@E[GP+83$FD@7DMA]YNA7H9ZBT#5=>E)VS%O05/<\
MMJ#Q^I$#"$ZXPA?$7S]+EKTD?:@Q1?5KNF;U,A>^@1X^24[2&8>$08X%1>W?
MS%I5H;-J)WB&!W*>%E;;B=IKX!5Y`CZ/$#_J@_YF%"W$#K`]$4\',KKU-/@.
M/85Z]=RQRGO>FY7B5]/(W42^\6!?SO9);HUZ;G\=H&*&+VJMGS-E/'8)GRFJ
MMU.^GKM>!VBWUP_5[Q_OA7"-Z??D\=/D4;#TZU8J\F3;J.<FU4LD*_)7K1O@
M"*:FSZMG;C:?BE5LC_G5Z[E1=8#6*EZJM<S#%?P^X\E057V85]I*/3>V#A"]
MA,]JIWV&%WX^T7O@Z'ZO@=>,\95&+M.]'XN`DZTM*_&H;<&^7AD#]1SOYVBZ
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M=*L/QD;%+ZCDGCVS)M!N[1*``+HU1JYY/3"09;N&@X;Z5QT^50EW[\$T$F-[
M%^/`UJV3X,HXIT8B.]]%-AS9-Z;CV*.OB?.J;58%Q]5(E)UTXQHD^6&HCR`J
M78A21^]6GO_V'F8C0;Y/!:(^--TD==G=_U2)Z_@'U$A2'W9).>/A<)"D,V`F
MW_."9`Q9^2;I@I(D8=F6EGQK0F-T7-/ZM,P=RWPN/H%<MZ9K&M4JIG#.C>2:
MZE\ADPCD!B"&+"+P=^V;&].M/)EG'H(CL:8Z4&=\[1C_'0,R9-S6H[/9.?]#
M8D]UE26Z'/1N:;7JER,5#LB1?%)=:&8/=!KTV0?HK"&?ISO-S5QU$IA5G8LC
M.:8ZW>.GKE-%H^().Y)ZJE?/S60G85'BU!U)(]7M[YOPH'<K0TA:JI1(B;-X
M))'4T&#/Y.#4/,J>S2/)I(8$.>GNM)24#N^1/%+=_=:@_-38%<_SD>A3`X"=
M@?OIFT7)HWTDDSTSYZS!_<G;B,KA/Y)(>ARPW:F>%GL=CNQ9NZ:3&F]4T!=K
MZ"=0Y/^\&:.(`E;Q@@Z*-\!*0=Z&#(7QUSG)@.?40:QXF)!T0FKHDYH897-8
MK?F*7^*0?KCR-U!+`P04````"`!V?7-!3`AF,.4&``"?-P``%0`<`'1P:78M
M,C`Q,C`Y,S!?9&5F+GAM;%54"0`#`)JJ4`":JE!U>`L``00E#@``!#D!``#5
MF]USXC80P-\[T_]!I2_7!X>O2]MPEW8<,'>>.C:U#==[Z@BL')HS4LX6^?CO
MNS)!!QBPG4.^-`\)V-K5;[6K7=D[>?OGPR)&=R1)*6>7C?99JX$(F_&(LD^7
MC7%@F$'?MALH%9A%..:,7#88;_SYQX\_(/AY^Y-AH"$E<=1#`SXS;';#WR`7
M+T@/O2.,)%CPY`V:X'@IK_`AC4F"^GQQ&Q-!X,9JXA[JGG4),HP2:B>$13P9
M^[92.Q?BMM=LWM_?GS%^A^]Y\CD]F_%RZ@*^3&9$Z1+XEBX62T;^;;>^G#W<
M`/P`"[C1:;4[S7:[V;X(.ZU>YZ)W_KKD!`*+9:HF:#VTGGY6XF]CRC[WY*\I
M3@D";["T]Y#2R\:&6??=,YY\:G9:K7;SGVLGF,W)`AN42:_,2&,M);7LDVM?
M7%PTL[OKH;F1#],D7L_1;:YQE&:X&PDEL#GXO+FZN3F4'E&]`9W27II9XO`9
M%EG\%1*A@R/D-V,]S)"7C';'Z+;/'M*HL?93MM@)CXE/;I#\"W&D9E6^A^!9
M-.7=)CASN2!,F"RRF*#B47HV662T8$&F;IZ0F\N&N*5WA@R2UD6W)>?\N8RL
M>+R%#952N1\:J/E<S#YG*8]I!)$:7>%8KF\P)T2D18R%@KH!1SB!)9H306<X
M?C;M7BT:T.5>)M*GJ7?CW<KL!KZLM,C'-6A&[N-T/HSY_;.)<PI.!.Q"BDQ(
ME34]+'$BI#'#RXB"_9MK,:0,@H[B^.NB#'EB,T$2NAC!+QX5@7^KWA.9YY.4
MX&0V-S\E9#5A$?AAB1,A#<#.._#E'?F`DP0SX5`\I3$D3LB@0TR3K((69MU*
M6DZWX>`()>@T)BX7!/+1(Y[&A:P%8B>"<SAF98GVC3T1QBCA"YJF/'F4MA:!
M[!]]LN"/Y:Z#JB$>0XB1%,]*)9TBN5-%$UP2,A?PV>?"$-HS]D08P?(6%,B=
MCN-UXM\XPL!V<CDSY!T;PC@5\,0@M]@JE<%G6)L[*B@I7-:33W2Z72WG@L<A
MT`TSPF/+@HI2R;*$Z,F\-$W)ER5HMN[*D!T:7VL2#V5^*41]CBZ]";T<=REA
M#;FB)-U!B9>6-\K9HVDZ_3FD=#"54Z#M*#X@`M,X=>4>E)NQ^M'\D`9M9]FJ
MR.4UZ,TO5;DKJM%PH*Q*7$96RX&S*F@Y:<T'TNIQ7$V/AB)4.81+R+ZTPF28
M$3S"@PB.!S2=Q3R5"8^MI?>L?&U%[/EH+VV1JP:2]HDU'=BKVUE._A@NU+HU
M\;[!FP`'WK>O7_O+%^WG&=<<5"2SY908$04OI-E;[J>)-I=$::%,-&%H\VE,
M<Z\"_=QJ,B/B"TPK0N>E:R#.9C(69#$E247<;5']K#B.JQ%F`OJY&!=F5;2U
M3*TQ26[P,A;/#LJU^#8S7*8L*Q,.?-WB)@^"L(BH]\U2X;=VR."R5-)JM=K(
M0&N)S8^816@ECK;DM6$7-[X4<P=`U7MY^-SWW,!S[($96@-T93JFV[=0\-ZR
MP@"]4J_W?_D>\/O[8,J2;A5+MG3594U!>TQ9\OJ8)4$(?ZXM%ZSPAL@;6;X9
MVC#@.WCG>/-,F7->WIR^&;Q'0\?[4)<Y1SIMBO]7N9?5<1.^N&8X]JWMY=?(
M^,U--67);[N6C%US/+"E'[:<,K1=V"VVZ6RZ9^CYR'21[8:6;U\CL-SV!AK-
M/M*24P;]OFN0;P66Z???(_.=;ZW`=9:':NTXA7VQBSV`Q9Q`($TL],'T?=,-
MD6.;5[9CAQ]AT<$CINVCB>F,+;U[^VC';LW?;NWR0_1,+#^TKQP+N5YH!6AD
M?C3AFT;:O=T\A=C>170\TZT#ZT!O3X%U=L%&OG=M!X'G?\R63NN.*NCP*<AN
M?E\Y6688F3Y$9`@1&IA]W8EO;_M/,;[.!:$YLL,L9WG]OS1BG;ZCIVPZW[4I
M&(]&3I;'P#!5'2$)0S:^SBI/EAY<SS6RNS;LPR"TW7>KK+'*X_(;.&MBA[:E
MU5\E^H+*U%Q5A1PBP2T`AOPA\?O>];4=ZD[B!WN&"C57-H/Q56#]/08P9$U>
M1(W9Z98H]%R!K%!IT*N55LW'R1+=1&5.KG`>+#RUP!]N-JZ)._E2N9FEZJ#4
MU4)4)N9*[>F35DVA6+(7J2S/U?*C.:P.(RJT)Y45N6*_[_D&O7I2A)0FG794
MZ%DJ.W('@CT/`S6;4;6%J6S)'02.)+I:+2K5XE1FY(K\UBF\9O2234\%GRO[
M.R?UVK=$Q?:G,F3/4_*ATWS=^Z-,?U39D:_^V[6T5O27T-1<KTPW=\K04((-
M]!4415\GXPPQ8)T!*Q(;L,H?_PLO%$9?MY9C3LTA7++9JM8@=^#)/0D=-N%M
M]F].ZI_!X,I_4$L#!!0````(`'9]<T$#;R1+G"8``,?@`0`5`!P`='!I=BTR
M,#$R,#DS,%]L86(N>&UL550)``,`FJI0`)JJ4'5X"P`!!"4.```$.0$``.5=
M^W/;.)+^_:KN?\!EKVXR579B)_-*9G:W9%O.J,:1=):<N:FKJRF*A&1N*$+#
MAV/O7W]XD!1)/"F+(.9NJW;7D;JA#\1'H-'=:/ST]\=M!!Y@DH8H_NN+\U=G
M+P",?12$\>:O+^X6IZ/%Y63R`J29%P=>A&+XUQ<Q>O'WO_WKOP#\GY_^[?04
M7(<P"MZ#*^2?3N(U^A%,O2U\#S[`&"9>AI(?P2<ORLDGZ#J,8`(NT787P0SB
M+]@/OP=O7[V%X/34H-E/,`Y0<G<[J9J]S[+=^]>OOWSY\BI&#]X7E'Q.7_G(
MK+D%RA,?5FUEWB[<;O,8_GY^]L>KQS4&?^5E^(LW9^=O7I^?OSY_MWQS]O[-
MN_???F/X`YF7Y6GU`V>/9\5_F/I/41A_?D_^9^6E$.#1B-/WCVGXUQ>U;GUY
M^PHEF]=OSL[.7__7QYN%?P^WWFD8DU'QX8M2B[0BTCM_]^[=:_IM*<I)/JZ2
MJ/R-MZ]+.%7+^-M0(5]#DH;O4PKO!OE>1DFE_1D@E2#_.BW%3LE'I^=O3M^>
MOWI,@Q?EPZ=/,$$1O(5K0+OY/GO:8:*F(>'9B^*S^P2NQ6"B)'E-]%_'<(,'
M.R`_]([\T/EWY(?^4GQ\XZU@]`(024P_:;_>-=HJE%[;!CN'28B"<7P8ZK;V
M0/#QNY-DS^A`7=]Z%Y8H\Z*#P-<UK<.>PL.>^%[/_I/&JP@\[$G7-)NP(_+A
M#?ZK`1P^9GCY@4$)G;2EF.#H3]%YMVB[:AWYC78C,EFBI/E$LEWX<$K6G;-W
M;\]H?\DGO^,%)M_".!O%^`7-PNR)K#;)EDZVHU6:)9Z?E0W17K"6#/5>MY&2
M%D9)"==+?$V?"XG7/L(+PBX[C=C39>KK!&T[P2D>$NJ@]'NTJGZ//5T,2=*Q
MAE@"4VH,=!K<>N^Z/NT"Z3;"FL3<@O'IW>+%WTI5@'4!4P8U[9]>[W_L$%H5
M':*=2:'_:H,>7@<P?$TM'/P'I=SIV7FQS/X%?_0[0W$+-R%!'F?$M&GU6BYF
M@U(ZD(1!,IG!":,!UN9'08F]++4TAZ/%)>9JXD43/#$^_@*?I)WCY.P20P*S
MR8R6D$/4$".3<*,0!E0:8/$AV%'.8TO<K*!;S:]M<4$$JJ1`_3LG1EX`2+I8
M$)DA1[G:,I#]LJ(O+3G;XRZ$V29`0\@I)HB022G!A+$)$5`GQA#L&&$@`0%S
M'7D;0;]:W]MB@Q!6R8+&ETZ,O@A1>]0K&4"$AACKRSQ)",8P];WH-^@E\LE`
M+FJ+`3JP)1ED<D[P0@.N39%"'#!Y0!0&G1R8L?(KC*)?8O0E7D`O13$,)FF:
MPT3078V\77-2`[MI5DJ$G2"1"<(VDR9IN3'U`-$\_4Q40:D+F/+?AR/5)Q3E
M<>8E3S3BD$J[S<G9)9$$9I,\+2&'2"-&IB)+I0&HRH`,*2;#6[A#21;&&Q:G
MD6^_).*6][!*T*VMK%#6(?8H`4I)]%4**HTBN`:*E@9D$V7S)5Y'-RB1>T!:
M4G:Y(X38I$Q#Q"&FB'!)/!]%A+F0'8X0\WP5A?YUA+RV,UXB8Y<,`GA-*M0$
M'"("CTI"`R8(J.2`:PS:;E&\R)#_>7'OX<<QRS.:28'G+OFTJ%2RO-X8=*"U
MZB@T'"*2`4R9:Y5J`JIZ`I@RJ&D/Z8-C&SOF]KG&GXG,&86L;5^<%&[;'\<)
M.L$D'3JI7Z[8?Q?N.:HR/&N(-\",,S7)81C#017SI1)SD"UM;#JN4%_-T9FR
M]M(5A9^GIQO/VS&ZP"A+RT_:O"D^_IT8WI``G*VOP]B+_1"_`2@-%4D(W51M
M,.N0SA"J==$;G'L'@&V3L5(%:`TJ95!J@_\N]?_'#7*.TA1FJ8:&;2&;A!,#
MK%.K*>$,B82PN$C$8C%>+ERB0N$?,&($)VN?&!*X/#]:@H[11(Q.%I1@.FZP
MYM)+[R5=8U_9Y$0=3)T"Y'-G1KP&AAM@_)4;P_H!/<`D)@O9)8HI)V^A#\,'
M;Q6U@Y1F*C9I8`*^3@^5O#.T,0#)6<8Y!.3)@$VE"[P-C/VC.OL.)]D\@3LO
M#,:/.QBG<!0'L^P>)FQVDSP%M8I-DIF`KY-,)>\,R0Q`MDE6J`#(=%+@Q0$(
MX(Y8O"EX.449!-]_[0;AKN`:XB4T8(8YO$1IED[Q4+-U=0IEYHZ!GDWJ&7>C
MSC^MDC,D-$7*37>%'EBS?5>\`3[1+4CXK2,D;%A\)E;A@':UUIZV2IJL=MA'
M_]AD6RXJ<U(&0D\`/4+T7&K(#J`TJ(P969`Y@]^VNJ`7MW?<1`]Z?\I$+FN5
M&MB^6:'J?%*G)_M_8391O@]#S!_RB</%&4,S51QEACC.<-^$WBJ,PBR$*;;.
M:&3M'D4!3-+Q'WF8/6G\-N;J-BG3M5-U4IGJ.F/==`3<YN3-9'0QN9DL)^,%
M&$VOP&(YN_SEY]G-U?AV\1]_^>'-^?<_@JOQ]>1RLG2.L6:^197"0*PT\#+*
MI5UD7C=_8TW1#4Z-?!_E<9;.O2?B_L#O$?XDR6%00RJ;\(U4K2Z8'3K36$X-
M])SA7@>PW"I<J((=TZ4.!H]I@\@U:E*'"?^F21Z+5-HF`360ZYR3B#I#,S6^
M-K-N80HQT'O@;1)81&U74;BA9\=+0_^M(X;^%4S"!XSL`>HG.8FL71^5`F[3
M+R40=(90*G3\CK&4K::E)T!MLO,?P1<O(>?/2U9]\VQ623T.;<!/ER@NJE;-
M=H39!,`WXDVRJ:Y%7T2W[M0<$V:*@S/M$+2=F.=7#0%$6SH:!8\40:;XLA`O
M[017:2*H%TZ=DM6HLU$'&O%HI<;@E.P$D]LT[)5`3+0JN\TMQ]D-\F(SK@DE
MK>Y$Y5`;6U!>S!DJR;%Q#@XBV>+,=XYP9G&/DFP)D^T%2A+T)8PW,@M,*&DU
M45,.M9&7R8LYPQDY-CX&C;9AFJ+DB4XYKD6=<[A$MS"BQ?:\1+\K5"E8M>&U
MP!N&O%3:&49I(8HR:#($$J:"9R6J4_#K!T?X9>QM&-K18.9C&-B]H`T9&;L7
M:H+'#C<?ZV1"Q_"1*P&C;B&B/T%0J',8J*Y0A7W@.O3#HY[A?,ZNKCHU.,VW
M*YC,UNP`()YW:7WG,KGL*DS]"*4Y_DK#ON<U:7='^/S.-_>+A[?G#,>/T`D^
M7WH7XMD4I*318E5^Y\BJ7.LN[9W^J11B`Q&U`5)"/BKC(J'JP'B'!#V%G+)3
MR/]^]NKL[)Q8<N"!*)V`\V_/3L[.Z']!RLXH>WF&]Q[A/[')]_W;DQ^^.S_Y
M_MMORB]#4K`GH%$HM#_+#%YB'IQ73K=OWYR<8=5OOCMSA(ZC(*`GT+QH[H7!
M)"Y>G=HSE$7N#!2MADN-.]((EFJUG*&U,50N4%HI`I*1?1K&P&>Z/<4:V/2-
MI^U?B^#&$EU`6L\J:/5-+VXMHF``N@HB*&0'IXLA0,YP+&8X/'M5(2F\PUW!
M8EYS8[8JDR_)]2<P3FE`EMG%TCB=7&&(U'PY<%%./B]MAU["^S<Z/E]=^JQ?
MTW#,1+N"#S!".Q+X7V3>!H[C#":[)$QAL94:^7Z^S:GOYRI/\"K?UI`^K><W
M;)>UQWH0378_MU7WWH(C]4CPMA!UDM94ZH.`-@#PC@@$^U;(]5*;HY8@?58:
M7HF6;MS(Y)#`>_RVAP]P$N,W']Z@-)W";+9>>H_RU+!NK5A.SCNDBZT\O2Y-
M#&Y8/`^W('NO8C0BS=`%H6H'X(V^(YE[O`_.V%DWM/?3S.OIEAM=BD_EZOP*
M,%$PRK(D7.49#1)C^W7N.>==UR7ZZ\,+$C67CF9H`CA"';=X:(A6$=RAFRDF
M[!0!:QX#_'K,$EJ;**"NLCE,Z$90[UF3:P[DI]1U1>*ZE*DYL]R:8U4[."O/
MIG,D+)P5E6]5_R!XC8%()X,N(5M;W$6223"JR<7YQQTEF=`)J94>E%R\"U(C
MZBZIE`Y((:%<\CUVJ$1LIC(HK215B$WDW268O@*QD&6HG]+#AU.-[:*KFI&:
M_`>IM$V":2#7N241=896:GS<K0I4&NP+?+I6RI-6M"!WJ!:%F+39-#)QN_.5
M&G1SKA++.D,H#4"N2GHAUE-T]A+%:1Z1NS^N(7=24"AA+08KAE:%79M?#SZ\
M<DR"LR^%$%A#2P-+E\65E\*`Q-;>Z;%S"@,-NP2XA`4M:1=)(8:HX4B5,41-
ME5.J[ER8=)=`/Z017&E@K"YB-W3)@VL&(???#TX:!2@^(K@7<8,&'V`,$R\B
MI1N";1C3"[7)D=-B&9-T5:MEM3"L61<:M6'5*LY0R@QGFV6%%BNIT=#K:>V:
MD(@Y3#.,LRSOB/=F&YA*#Z7K-*RM7F;0J^5++3XX;\PQ\ALAID1)PXKC0>`S
M/<>.EB]@\A#Z\*,7>QO(2B>GTF)Y,F&KH5TEX$9X5R@Y.*V,X+49M9=B)M&Q
MCM=)YJ#]S_%66_H#?A>$1K2)EK6YR+P+U7RD5QF</-UPZE@D-:Q3\`.=NURQ
MK^<)6L,TI9G;@JVZ7,QNN7,QR&:)\Z;,X(32`!,<(Z_$CK*!/PX_RC)5F/NU
M=$*UV:W1L<D<(_AU&BD5G.&4"4IYP3%:(W^?U-GSBB?&NI];1?.P7L?::F<*
MOUKK=`J#DZ@+2F,2"1:\GOA$DYQ*][6H:RT!:TP1`JMHT?C6C2PT*:[VJ%,9
MT'/(8`HSDM)[`=<H@33I=Y+!K7"$I:+6QEH#MAIUB9Q#XZ]&V&8"E@9$'#!Y
M0!4`U7##7IFB&.T@<2/%&Q8U+>^344<D#?1LVBW&W:C;+EJEP9>>KDC;]#LB
MW22ST#5F=;B)QX_^/?YA>LC@@Q>V0P]J46NSD`9L-0M)Y`:G@P&X-@,*:0`+
M<?"2'.+X&FRPBALS$.9S`CUR*HO]_R2^]D)69&*VOHOO8;"!P;YHYB3&C*=W
M",OVWL]IT')VSC,[WDK@.;"UP6E]M"YPX5M*^12$,5CCEEBJ-;GL-^!KL(;.
M.<3)6YV2UQNFLQAO)'!G_8R>,YRMK^!*MC+KU:Q&\0P[T0CC:72<(:PA4+YJ
M)C8(48Q9N,KV-Q;UM$`3C.0'9_$"9EE47)5-T$E34+0JUA9L0_#5PJV1'YPX
M'4!RT5^L52[>)%FV4F7SV2H[6B**@D@S;'80&S0/T_L2MJ#F>EG@0AHG/KPM
MJ]1[3G<;G#RD(7?(^@ST0A8C8H[6&U0LR:?'+\9_++/U`4_X!#W;D)61=JEM
M(Q.W:W*J03<-2K'LX+PT!"A-A0BIM!LL:E@0"R_"_[=6WA*H4AC,KA,"EUIT
M#6EGV*2%*+7BPG2'4B\BDYA'%?IU^.(=_1S/E4@8".)E;+MX.7AMWVXEX)Y3
MMPU-ZLU=HX36>F'2/8WWA9>&/HDWA5&>P:#`*#D-;J1AC0MFT"MFJ,4'GR+,
M,;8)0Y5H[*]0`Q6%=C`!5-6-A>A7&&[N,<#1`TR\#2R+OA:P3<]6=F[%YI)U
M8!?KZUC')@9G[O-PM]E<M@**9@!KARQ\Q1'.HF#AS+6SF]5!P-GZTDOOKR/T
M17?D3JUBMX20'GRSF)!<WAE&&H#D:PN5ISD)X;`2H%K.G>W$4SQ!-T_00QC`
MX.+I+H7!))Z5`;R1CW>YK(:-)L9Z0$-6@ZX'=[01A>W<BC,D/A@Z%Z@8+7X&
MUS>S7Q?@^G;V$<SFX]O1<C+]`$:7R\DG>H.T,^3>EY.3/Y:ZC&5*\O!:;-L+
MN+$#44$3[4#<J<(W"OZ1,P],2J[J(>,31K#1CR4ZSES8ST_9K87>W\-J5D\_
M_N\X,^/VV#F^0GOU4^Q:J>+'0%R\@^13\K=/3!$RUJ#*T0%>]2OO>_(.[.$I
MCOPJ):UY`]10*R^`6,PJ]?"^9H52*/43*2$>>BKXSQ9]?^-:I6=CQ-QJBN)3
M^O9&G2/R_Q_R@IP;Z"/TY9DI0F[87;4,`B^"C.3[:)@J=*34LAT_,NA">V)2
MJ+A&5C.XPJC22Y*=*4GS<)6!Y=MBSKZ:QK#,XZ"K65>)N\^X-M0CIF.XR4-L
M]F,;/'N:XVYFI,PS/6UE^+QDRD.R4]TA%5'%FJYS5HG:7@C^..RDQR^PD4EL
M3/418*&D3=XIH-9))A!SQC<@QR:U^T.^/`K9O1<%4MP@$8VI79`#HO7[G&1A
M%8FPW=OL58";%]J+))TAE!*>\.8+P"I7U*_1<H-$_,ZI<H@55Q;JZ]D:-S#L
M(1I=Q]2;8YFV,Z3L#%FQXZWY*^FJ2:?!FKGW;-]E7^2]1#'MXBWT(3935Q$D
M5QL9/S&9^K#$57=*35NQKFO&7D?<G$,UA\S/OD$/,(GI5L7;P-A_<I6G\P22
MVUW+^Q7+0[O%W=G*1-]#&QN6PUTZK&:T24ON\[M#+_@"1U05[\U9&8FBA`C>
MZ(2N[&_X_E97CS(+VO@Y<7K#TEC2#35C6TKNDU,,6'HY;&U_1.H#NDK!D>^C
M/,[2N?=$UA-29-7WDQP_G+UA8_R(S!H;EJQ=.JQFL$E+KL1CC](+P0685!7L
MF"ZKM<NTW0L#";8"9%6I]@.'$%[1PL#;.EW7-/LZF;K+&SL-9GFQL4T"BZ#1
M*@HWU`_A"&?-4R:?G7/I:C*L)"W14-NYG,5NN#E7['@):/;KW6)\!293MU-?
M17V]+LVBY^9U*QMR@,H&'36@M*(59Z;B@Z'K\KJO)]/1]-)%<N.^^A`&Z35F
M`KD2D!2*GZUKE[E)'I6!GN7*QV;=:)5"5BLY0TQ3I-S9]T*6!$C9_7HG)'75
M/>I=HAC;_%F(;6]%B2.EQE!TDT"7$:TE[B3%Q!@%ER254B`F)=N/PBU)VG,=
M'OY[&Z8I2IYHI?A6A_3BUA*@#4!76=`*V<$Y8@A04*J=:C#G_:[286QQ;Q):
MW*,D6\)D:S@%M>2'FH"$L&733T-X<&*9(E0S*T)>7+EN+,P_%<(++_Y\0WY\
M%+.K+PK7D^[U,6A@D#G*N&/"64NK/3C=#H;,)Q)E16#FJ-P[_I1V"S$TFG<\
M6]_"B,0*YEZ2/1G.<&KUH28\DT[)YC^5[N#\/!`P?X+M@1C]Q>SX,D-?@X1I
M8J(F[OBQ&Q9%T<EKE%#WIV#/;?"PC%H9BK8=NBACKT$33I+8'+<XO2[-5ZF?
MA#OW'=KFO.W2@)M>P.=Y__X4#FUSHE8.[?GM[-/D:GP%+GYSV.\GZ2\[J'0$
MI[:R(0?H;-!1`UHK6G%F'CX8NLZI/9E^&B^<C-B4R\T2C?P_\C"!C=,EV,37
MG1#JTH!5<Z)SQQJ6A+&V:SE,G9%S#@,,ZMY+J2-\G2=QF.4)R_*`I:8;U"6O
M:M''@%A.].\T5!S]4&K8)*<!]#H;%>+.S)UZC-PD28X7>84*.:.6P`>88.)Y
M>U4WF&:^+CQ[87%UQ7_>2O^G,&#EN/4&[.K)X36>=I:6X6TG4"G>99F"[6E2
M#;P]2XJEW:*?%B<7FIY>WHY'BS%X>35F?WU-TH`(`P>JOT*Z(!L"6S51BL>]
MHT]RD7E)IGOH\@HG^$F>@(OQA\ET2E[@V368CV\GLRL7'^_;`1[O.%;:G`U<
MXH<[GEZ9/5:+1\^3C1>'_Z2IGY<H3E$4!O0?V$B>XV>%#5WZS]FZ<&UX455?
M5;?5/U+;5H^W'_-Q-`[$'Z-A9^S<8_:&NXNRUO8):+1.-V#U]LGVK/H%L/\)
M]VK]>F0#.5L7":^X4S*S3"!HU1B6`FT8O9R4,]240N/LU]'R[G9,YN,BE7@V
M?;:I*KN1@X1_E\A\!C76LG=KAW$7]O=X:%4&)TTWG.*H?H:$4U!/5+J+O3P(
M,U)JHIP882"`?HT2>I%1N&56]A(^9A<1GY][K$:M$?%H#Z#BZ;-;=(/&Q^I&
MF^5WT]'=U62)]_>7>(:<W4RN1N0?1:AJ=`,62_S!Q_%TN0#7LULPFN)]V1*;
MN!^=,G3+0T_D:A;X`"-$G;@:"U:G9'-E-NM`?956:PS.VDXPY6?8R*4Y>S7G
M+#])[TAQO`U](<O2%DN$W\<U2K9ETD,JF[./V[0#'#[H81@PO5.[KK\/AW2&
M>VO&B_'H]O)G,/IP.V9S=D]VRKZF9''=9WDL]0EWJZK&J[1*.C=AS08YL'.5
MQ=%1?W!F/@,T5R4"FP2?\&;KTQC\.KJ]'4V7X&8RNIC<3):_8=,!VQ6CR2WX
M-+JY&[LQ?Q>)O6E9'L"+=&XOI8;EZ+\.>BO<+Q,?G('F&+E(?J%!#852QSDK
MH5V+@BM$498"JGUT%:9^A-(\@:2899XD>&G0F0P]_([5NU'Z>DR-BU&._2/.
MO#U]]8R+=LRFG\:WR\G%S1A,9\OQ`LQ'OXWPOWHR-NA)C/)%5]H4,DEKIH,:
M:F4AB,4&)Y(>&U=Z>3::]CW\S=.%RO&7BMH\/Z4"6S\I)9)S@P)J<-P2?#O[
M.%DL9K>_T=G`C16W?C9FB<W9E%S%A&*=<:=7L[N?-NM$<Z^LUAF<81V!\IXA
M=G2)ZH&ZHG-6GZR'^S57[P+JT((+S%1TS82D`G7G^2K'S+MG;JAO?3ZZQ;OA
M)=X=+T@:W1$"D\?AZT6"/L,DI8XI+R)_J2=+A;Q-+FIAUYDG%7:&9SJ$W.7R
M3+[PE%,-YV9"4C@_+W-&:&HJ+5%^%P<P64"\[2BW)^-'G]8E)[5LL`6"Y6_A
M)H^HIFZR//:/6,T"[>4!-?+JCOH+SKPMO72+3^^;3Y8T%#J[_,6--VJ1[W;L
M1C`O*F].'T=&>7MFJE:O"NG0F<;%(09ZSC"U`UCNU'--=7_E/2BUW9ONB^[5
M<>_-)&W@TUS==J)^ETZUDYI-=)TA:T?`'&'OYO,;&H#$LV9U4!1,IM>SVX\T
M%X\&@Z:SZ2G]MG:N9'KE\#'IPL,:QILYBD+?X+YRA<(`GG4%<(&+7"#M#$&U
M$"4UO4G=^E+#O7F3V";L7E!LL9`\``P7Q@0KQ?QD8`(;-V#9O.W8L9;I:JCM
M##T[0Q;$6,A\.,;SX'A!9\7+V<>/D^51DCJ.98*N4OA'COLX?B`=91TS(ZJA
MKETCM$-WFE:H@:(SS.R"EE_6+Q;C_[S#%`3C3SUF%]$;]\HS^D4Z2KHD`2EE
M],=(S5HDJ$,GJJB0@<[@1.H(E.,0T02[L@##L>X1EC")%:4EN_T9K1:E)Y%.
MPQI_S*!7U%&+N\$:(XSBNL)$"3"MWE,:J\PW/5L,E`9(6]1T0)"H*-%P@S:F
M,/DKJ[C+RY]]1:`Y><S7K0[*0Y+)<`TSUG267)W6,Q')P&G?ZUIU\(?='8CW
M&+6<+CWC.JE;X]P!G:I8UT'7#=YU!]QFWOY8HOC:WIZH-XG3+,G)UK8>!==S
MSDS/&MFZ=*-BF8F2&_3J@)0KQ5*I@JRFV]=>+]]NO>2)7E^R\^*GE)9X99:>
MR9ZOB[J]O5_W3NWW@.:Z;E"M.V`^OD5;(.4>LGL(BG:^2D%*R_VBXQ3ZU1&0
MG*'-TWTW[FBM+!ATYV+'ENS3\J"N\@SMU(QC9#T$NX:W*6V29W%>-&V+R-5[
M>*`;[:!V!IQ;#W&T'="(8P3NCMQ\VK7KHRMBS9.8''8MZPR1XRCXBWW!PC@0
M5-\V\.<=L75[OK^C/Y*]G_!H3;OQ/AR]/](ZUT.F+TA>G5$0T!*R]>2,65QT
MOMOV[."FK+T4S^QL]08<V(X;='\>>/YJF+(U$%3-D3+%,8I/28LV=H"CS2:A
M-;\_AG&XS;>C.,Z]J*KQK6=N)WU[=#V@6WN.=E!VA)C=$7-L+)L`6]8&\&@C
MH+SRJ"<"_HJ2SWA=*%*'K^":9`?%_I.HFW)9:\32P:U()!-T@S`:=&UR%.+`
M9_(@J!1Z8L4M9%7;E^BC]QE>PB3SPKCDLZA#&@5K_#`"7I%$*>T&4TP@\L<$
MBYK[&0);K`5\IM;W7'*9Y#Z,V/F#Y7V8CO"4!@57B^B$[6TU=(#W.P>9I!LL
MT<'C['HF#W*B@#?`80J\4J4G<LSR+,V\.,#SV(47D4OY&$WQOT4]4HI;(X@!
MZ(HB"EDW2*('R-4KWFN`%5,!2:G3ET6,.1C`H&)P4<E#:';)1.W9N6JP>Y-6
M+.<&+]3@.$.52>_G"^`Q^;YW2'-,.C_<>=%H2Y+9E78X)VM_YR.!R^]R6H*.
M<$*-3KY[V97RP*,*/?I-RULURX)9Y(Z7#.+'(+8W-!I6_9MZZ`V?I5S<#;88
M811>#[4K;R\G^1O%1`+"0K%_2X0>--_BOV57E<MEA[!!A'!%!DA#T`V.:-"I
M3`_"C:!2Z"U;>KM%,0W?[[-N;\D,"!,:9A(27Z]D,6?:L`.UM&F-AAO,,87)
M)T\3O2*/PM]G4B=TG<+['AKJZ_->A`OH)>4L6``FKL&MJ)<:!;NW(>B`-R]"
MD$F[01\3B.+K#U98J5J,]K0ACMEM?[FM>$>>7D/A=%/_UF9F:@M2/?&T^,J-
MH>;P"-)&B<!78`W[>O&OX!HF"=R'7"]1*O:9RB0MYKFKH-:2VD5B;HRX$AN?
MKLZ$P;J4QLM"VE]HI4@=&3_"Q`]3F8DI%+,74)&#W,=2>!DW1E\.C(N@%)(`
M[D7[FL++>N&S=?FKPKE*)&9O4I>#W,_NO(P;PRX'QLWW6!(\$-$RT:OG?"[^
M1`VKP'0%5T*OA%I^P!-//&S%(:>]L!L$,4!H<)0I+"JK$]H$6+,WRJPRDL\B
M<VHVO[=("1Y6C0+[+UT9<@X1/\2KC*;Z].B7O(M34G@-!J22]"AX("$3X?0O
M$;1XUY@":.W^,(&4&P.N@L;=\U7*@@@+`Z^0[BV"10AVC9+KG-S7>`,W7K2`
MR4,HH8):WF(L2P^[%M"2"[O!#P.$?&B+J(`U2L":*H&(:(&T4.NMQCO<>6$P
M?MQ!S%.V3NU0&@I7`X6PQ3KO&L"U2N\223<XHH/'57MG\G@3P10*SS15Z;^*
MQSS!)"Q]GL*91"X[0.4.,5Q!S8ZFH!O,T*!3U.G8$?G>W<L,S21-<Y(:]C.*
M`IC,UL1M*>J-2MIN32`EY&8I(*&H&^S0XA,6_DE!2#5(6A[94]Q3O7)C&F-M
M*Y>(I/+\"8G@0!>(I)+,":&4&\100>,7DU*6CGW:;\*$$%G)X-EZC2>MA*Q_
M80+]6IO:SJF:&)8W^LZI&277=YAK6M"&+*Q-57C#A%AK+$D#;Z%9BSTQ]:,7
M>^PRT&LH-G/:$M9X)H96T:CYM1LL$6)JDV`O1`)C?5FRXLM?53MCG8;%8P4F
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MN2M&\/?"PXU]&["<`Z6DHUQHP3/@!#%96/I0;UGB\0.B%[DD16ZB?$*0RUK,
M#5?#K:6%BP7=8(8&'9\,'I\R>;`K%?J=-&0`57.'7F=PFDAG$IV"V[31S"L*
M^O0^OY1''N9>&$QB<N).U#&1E,5:Q#*(M<K#;1$W""'%Q5<5+LZ0T.R!,`:D
MO)0;%QE-8A]MX=)[)#P.V\?LI5(V+R>20*Q?0]02&9P>:EP\/8@4R(@8I4B?
M9](FL3S^VQ*P>^:L#:QYQJS\=O"AE4(2GR'#+SN)[O<:VR6_M$2LWJ/8R]66
ML#JR/+3&T.Z_=F=L.4RBP2V"HV$AV5O4S(?A`PRN44(9)8[EM&4L1L;$\&JQ
ML*:`&X,L0<7'NY@8S0GM.4N'9JA*#G[NO[,VL&TXU8"67[@QD"TT[0&D7VN#
MVCT:+^R&D\L<6_VQ^+[9NL#O;P9_JFI<G".52IV`0L[R0RX"4Z(CH.2M_E80
M89/*.O#HC2'*#K8*=`:EO9SO#CQM"2`QPP=ZC+7C:XHIA)=RZ/$JP'&3]5YT
MJ!FE1%V^4?7,A_$?>9@]B09`+NW00!B`E!Z8K^L`IC38P.QSE3)O`\?$M;)+
MPA2R*KJD>EV^S6G&P55.ZA2V-<0#^-Q6G1KHHW6&)\0^Y8M*@GWC)Z!H'M3:
M!^P'`*<X$'UH.(@EWJ?R]YF7<FAX%>"$25F%Z%?%>PM&69:$JSPC)1#(%G;N
M#3C/-L]GFXV.3L>AL3*&JE@*:4;"(',NM4>7*/.B\H0<9U`WOG7@P2M`M1]Q
M0VJ()SN%V0U*TPNX1@F<9?<PF61P*PBFBN5<>=HZ>)SK3"P_X`A<HV0.DQ#Q
M=7O;`HX]<QZ7Y&%7@@--\Q@&"W(0,*(YO2'@P%-6XQ(\95`$<5X2P:_=6&19
MBESPCSS-B.%U!7<)]$-Q/KI8S(&1,$''7^TC$A^(^Q^\,":DF,4++X*S-4F-
M9M$%[E(*0Q4'1J4KTO8($;WR7<%;2J),#L+2M/&:OC-#5A8',ARN2MSIH>)1
M&@]3I>K(",T3M(-)]C3'\#-B+._:UWATTW1XW#2`#8>P;`709D#5SD#CB5?/
M!'K$0\'^?Q)?HCA+/#]C(3BRCJ9XF16-J*FN0V/:&;(@980J@I=E$U^35(.R
M%5!KY@3@AIP9UJ*$2NE9+/9?)&&?[`3D88/#6G)ZR#MUP)``986:HC'J.Z#-
M@4'C&'SG*V_TO9=LQ,NJ5LGIT95A-1S(O>N=Z3LS<".?UL]+Y]X3F5[VUSW4
M7%9FHVG2DM-#W*D#AN->M@F*1ND;7#0+:NT.MY$O+OMX"`,87#S=I>2BCQFV
M);RL<;^P9)=OJ.W0N!\`6N0?H->=E(V`U1-X2=K!0_XUJ)H"^[;<&E_!_=$=
MQE>@[?[XJD!W'-^JJ>''M[J3%HU\>DED8S>!9S#EWLE<VZ'Q/0`T=_ZX:()X
M\HI&J@W4"=M!G51AFB&W41(N[Z^"/^3U%6@[-+P'@.[X^E9-#?_ZTIY21W[;
M&A&-IUS:H?$S`"FZ.0R_=E0)".RH(=SLSRO[,OQPF*`3IA=PXG^^($>`?&O/
M'O]63@!("Q@I,7(Q[.IH"?'I%65I`=9"FSC\)YV_:-JZSY+I2%E2\LYD]UZ&
MI=81],FB1AJ):*HZ2>\JZE&2FU'HW_CW0KH1H0X$@!X@2X5G__X*Y"E<YQ&(
MB#?X%7D=HSR`*2F+6Z$'9*A8Z?483Z1D*X.8S8OB]-40A"EO*[S&'RWN49(M
M8;*]\.+/I)HXR=6@IP**/1C'HT[:;M'K$.B"<BSLTD;2"*"M`-(,(.T`VA#`
M+0%V`JIH2S#*]8]N\%_XX_(C_#^DEA3^Y'\!4$L#!!0````(`'9]<T'<?!`K
MW1D``"]L`0`5`!P`='!I=BTR,#$R,#DS,%]P<F4N>&UL550)``,`FJI0`)JJ
M4'5X"P`!!"4.```$.0$``.U=6W?;.))^WW/V/W`]+ST/BF^=F4ZF>^?(MI36
M:5O22G*R_91#DY#,#46H"=*QY]<O`(H4)1(WBC!`3_=#)[$!$/5]5;@4"H6?
M__F\#ITG$*,`1K^<G+\[.W%`Y$$_B%:_G-S/>_WY]6ATXJ#$C7PWA!'XY22"
M)__\[__\#P?_]_-_]7K.,`"A_]&Y@5YO%"WA/YRQNP8?G4\@`K&;P/@?SF<W
M3,E/X#`(0>Q<P_4F!`G`O\@^_-&Y?'<)G%Y/HMG/(/)A?#\;%<T^)LGFX^GI
M]^_?WT7PR?T.XV_HG0?EFIO#-/9`T5;B;H+U.HW`U_.S/]X]+W'G;]P$_^+B
M[/SB]/S\]/S#XN+LX\6'C^]_E/Q`XB8I*CYP]GRV_2^K_G,81-\^DO\]N`@X
MF(T(?7Q&P2\G);&^7[Z#\>KTXNSL_/1_[V[GWB-8N[T@(JQXX"2O15JIJW?^
MX<.'4_K;O&BEY/-#'.;?N#S-NU.TC'\;<,J7>H*"CXAV[Q9Z;D*52O@9AUF"
M_*N7%^N1'_7.+WJ7Y^^>D7^2@T\1C&$(9F#ID#^Q<A1?+0C%&K$^);\]Q0RE
M:Q`E_<@?1$F0O!"ZXC7M+9:`-O<8@^4O)\DF>.H1YL\^7)Z1;_Y%IF[RLL%6
M@@*BY"?.:=-N7L,(P3#PL?KY5VY(\)T_`I`@41^%%75W<.K&&*)'D`2>&S;N
M;6TK&KI.#!003M%D.=F0(0MSJ00ROP7-7;YVT>,PA-\;][C20$L='N-Q+P8J
MF+)KM-2E^\A-_0#+7\9B&$18Z0(WW($RA/$H2D`<K*?X?]`7=?S8=EL2;P80
M<&/OL;^*0?9!4<?9-5KJT@V6\PES^02^N''L1LEMX#X$(1XX\0@Z=(.83HO"
M45>IE?8,#J^+DN`A!&.8`#P>O;@/H;"O@FHM=>X6NI%LC^K*MM2-:0S7`4(P
M?B&RBCI27[HUY0^)U>%9(WE98!U!KB<UZ(CJM:5-^$<)&0N@]TVH0C5E6^K&
M/-W@!HBENV$^\)>6,-B<QC#JD=^,L!JC!&\#B(EE0QG^.\;F*4@"((2U]0^U
M9]7D6WB/@]O&7\1[D7602`V6$E5;8^D!@3]2W/+@2:9GK/*O.H@OR/@B[&J3
MMO0.Z'+]EJJL8:R0[!VSAFWCAIP\FCZG?PR15B:Y!K0MQ6]`X@8A&A,;),:H
MOC1GM:!M+:O:9?D6](XOJOU6;$;#@E*UQS)UM2PX53LJ5UOS@E1=C]7:T3`)
M*:NP1%W;)J9>W\=;>%S%#6\"Y(40D0$ORFO7(/]JDUCSKMD&LJHB:?^PI@6[
MNIQR]7G=W<1XPL-`$6!N\0_VJH#G!$0^*#Q.I-?'^LCQCTDC9V=GYT[/R6N4
M_^I&OI-5=\KUM]W..QY";Z^O(3DY@+$(,_*3K[Q^]A]0$F.[R!L*W0<0TN:_
MDKIR54^;=':+*SW+0,![MX)/ISX(3NDA$OX+%:1W=KX]R?@+_M'7K`\SL`K(
MIZ.$G!XQ>EY?]+"G97WHQYX#8Q_$F*Z\4;PVVM."ZNG+ML3IAGKB>]YC$!8*
MM,13J2J66]R@2)(ROK@/KT["-98D=L,1-ICGW\`+EX5*64D:SBWD@2&W"2)R
M01:X68']9D4D8;^P"O8Z*4VBG9U*#"*?G'D+8#\H*XG_I97XU\IM@H@^[HU/
M>C0,W16#@(,RDL#_:!7PM7*:`/PZC8F,0[RL=L/?@1OSE9]=7)*&]U;1()+>
MW!3\!83A;Q'\'LV!BV`$_!%"*8BY4S&SCB0W?[.*&RD<S!'T&88IAC!^H2%=
MB$M,I:PD(7^WD!"&W`87JYD-S\`&QF3_F\6;\=>LC"J2M/QD(2U\%,RQ0[7D
M&@^I*QCS-Q(')26Y^&`A%[4RFZ-@FCZ$@3<,H<OR!-24D][%68A_C<`&AR>X
M7L.(>H+GCUAP-$D3&DR,C90_2'$KRO)CY39;`A*3N\!L.9CMB8;X9ZS)A%->
MEAX[M^-,`,RS0A;I\IR42LLR8N<&G2%\#1\_GU;$N\4_T.<I%T=;%V[R"Z?G
M%,&@^._7D_%\<CNZZ2\&-\Y5_[8_OAXX\U\'@\7<^:&(*?UK(W]Y6=66+GJ@
MK*6HMW+=3:9O($Q0_I-#Q=O^^&O1V\FR"&>=0A1(N-?EJAYM1LUEZR.$61)(
M<5C(I)-=A8P]9TNMH&V.9<>2L%V]2W%1*6O4X<[`MH(^0T([2"#GIRR'%_V5
M4><Z'T!XV%>;@/T$GT`<$9,E$5^DWS/@@>"I'(E]`#B_BE$ONS01,F+;0=`T
M!ALW\`?/&Q`A@%<GD^01Q)F@#(+X58QZXZ4)DA';#H)NP!)@<;8A'>`:H@2-
M8>1E,HX!\W!?7,^HQUZ:*FD`[.!K3RZ9>=RP=UZ:AUK!2ICC7F=$W6;",OM&
M.Y;`Q`UIR89LL<)A]K0EB%9;?4G`>RE#.:AAU$_?T$1JA6Y,%)[('B`"QU#5
MIF%Q+<JP`U_1E,S;4#O$Y/=7LDA^ZM5[A"'&&0W^2,FU%OZF1KZZT1.!IGM/
M573LF,5*O9;;FO(JF#U*4":@GCRK]Z]]SX-IE.17$+"<^"=QBL>1G0"LD5.J
MJMG3!@D:H*I$-M%'-Q]5(1F,,4N;/7-0(TD@LAV\[*YJBNV(4=;LJ8,:)UQQ
MCV6$N5X__.9+=OV+9$6:;`A,9!W[HS3JK.JR1.AQ3!Q+!!\4.ZR%<6V//YB)
M*LG2IL=)H4:;'`!VD%6^L<AGJ+:D+"UZ?!9JM'!$M8.+^2.,DP6(UU<PCN%W
MO']G33*U)66YT..D4.."(ZH=7-RD8`%+%TZ%JS%>!5EF]+@C%.<<H>!V$"2]
M3#YFA:S'A:`X;,DLCCOI,%)V$;7@%+K0XUQHZA7JBA^H%*DW3M</()XLLX@]
M/$30/#7YT=GN6K8HH.2X)F7IUN.(4/,>M0&>=6JPEVB.3>VVF"Q=>EP2K1!0
M3VA-OCW3).UR)$S=P!]%VQP4I4ZS7(`2%66)U./':)M(>:@TN3VRWN->;W.`
MH06\`O1FD\^:`WDU9-G1X]QHFQT)<.RPN/S<E:3S!A&B<&?3@N"LN:Z"+(=Z
M/!UM<RB&1GT5^R%;Q49@138IYM>Q-^`)A'!#EG]X';@"`Y+9=A,'"&#I`R](
M^IZ7KE.ZI;I)8[S9/:S!5)/C&Y95)ST>FO;5J2VHNZ]V)5$IA,3$8O"(K2QX
M`J/(@VMP"Q$:`[PI6;C/[',_M59D%4J/FZGU%4`S$.V8=ZK;$.F-LSR/>IQ2
MK:\5F%!TW4LBBEMH&$XCKP!ZG&!M*X`L3*VJ@SUWK.K?B"@N7%VJ7+C::^O/
M2U?:72D8[TE,.^Q3S9^"F)J"V+O"KMG%ZUD*D-@Q_U;N+_?3Y!'&P;^8NW=N
M#:/WMUH@C86!I61QW2S,TD9O@+5&DHU>E`8)$EI)C:#'5=D:57(Y$8RN1`3/
M/A6KD!]YJY#Y`O]Q-QCC%<ADZ$RF@UE_,<(%++D`GNT%B]X+EA_,TD;M"R5D
M;;R]["8^GV,5-[FV$-"P;TE\>36Y](EAI"%)O30$S"C1PT)&IWXA4)#=\5>$
MDHZ)Y/E#GT35?9!"ME+'Z/3='&B&['9,W#<`HXCGMW)*[(HGNUS$Z,2L0D*=
M9'9@GKTI&Y)+#?XZB&C6:!(HO)6*08.PEM%;VRK,2,JO:6"B;Q<"E!0I]L$U
M7JNM`.+%J(LJ&;V&K8*]G/1VV,D<Q$^!!^[<R%V!+!$#8MX>914V>C%;A1F^
MM)J,8?>UZDR%?L(]9TW5,A6-7KQ6@5X>!3L,8QK#)4"(!K]P%JK58D:O5JLP
MPI+0#OR+1[DBOW1$S9^^!76,WHM6849*=DVC5?VW=_:J!'VYFMG;S<?#7X5`
M$P,+<I"6]Y,!]T$9L]>.5;"M%<ZZ["ACD)"HABNPA#&@IZRC!*Q99#!+F[UH
MK$*+0."NQPB,800SOVNTRCQD>48KOH]/HI[9B\L*[CYI##0-:T.L6<$J&CQ[
MCVZTHE%#G]R`Y1!AEC9[/UD>1"@ABTWK+2Q-#%P2)YC].8J*-Y8GR_OH$?@K
MX.\N7(\B+&^Z]Z1UU<7?N$&SMYD;D7P\?G;H`=%,1%04H$F$5T*XEUY"(T4G
MRQOPP!HIQ=7,7H5NQ*DL%II&3/)Y\O5)-`=)$FY/2\F'>0Y^82VS]Z`;$R&!
MA$8>)GCX)EU.`_28?[TF"TA^$X/GYVS>G-E[THV9.P8[.P;%[,U8TO=,\-S#
MRYSZ6,7-7JQN.+'Q9;>#H;VA>NZ&^(\E-Q,BKX+9N]+'3U6U\FL:'+<[1[S&
MS9[!X.^12\7,WE!N!#)+5NO\%U<N"CSBO@K"-`'^MM^"N%E1);-WE!L1)H>#
M'2/8%[Q'?,2=[#]A*5<@#_K?=ETVXD^Y%;,7EANQVA`IFZ,"\R?K:X("W\L'
M!5[WY[\ZP]O)%UN"`DM!GH6$\A<3:JJ8]"&"A'1H&L.G`#-^]7*/@#^*)KGZ
M]CV\GLWNUPB<B@T:LN2Z`I/$@UFR(5!V#,2X_[N+C6P.RV6,AB<>@3=D2F1Z
M8=-6JH__2[.]"R))NSP8>4$(]D1=P':L6L^GC(9CMJ-8.CG0M*?9=5DB=)-5
MV.P+/#I!KR57$`K:T<<43'O#-3W_\TK:T<!_WM%<$UT\/=/T7M$KZ5:KYVT=
MU;K2L8@;@LRF=NY:GN>36\OL.TNO.#9)8/<6E22W"7D%*=4P^]*3,>6H8/;V
M%`-CAE%*7J:A&R4D*0@->Y34$59ELP]-&5(7/I+=UQP:($C>%L30\2.R:TL:
MC<-^+9W@8&2'FXOZR:](/',Y]R#+*\LH;#:H^[6XY$-E!YW5]7`AY#9KJ_A*
MOG0#9N/-S6TQ1)#:J@K5UY41^T5<^>IFX]L;T,,EEP]2]V?MJL3;UYWS'+0J
MCULW;<QXN'RK*J,"X%M4H")[<7:_65I7*O7,1O6WK18,6-ZB!ASQHF;3QLQ>
M#FA;5QJ^PMG1\Y0:],A(64#81&LX+9B]<]"VJ@BALF/Y*7]L?'2`C/'+#&V%
M7B@"UO6X#(;$VT2`Q\=2<1LR>XNBI6@J":CL&`UPQST`?#3$*)"LFB0=#A9=
M^-B.1#W#ERF:$P.5Q+25S=(SKIQ0"&X-PQ<M6F>0`8FF,*7RE_'?UP%",'ZA
M"74DR*C4,'PAHW4R&)#89TC%8Z^29G10WO"]C-9YJX7C%4QH]^:N&WVCCR'C
MS5CY@6H5:MAM&+YPH8\N$6SV&=X,;-R7[0V,TI.^+Y)VR*]N]JVY]GF6`<L^
MBJ?;/@]A3+?/-0#(S)4RK9A]F$[#_"D/G1V\RT-P]&[2]+MQ[;"M#M@;=3QD
M@7\M.!ZX#9E]&:XEQX,$5':,!OGPM8!][X\TB,%>5!;)BR8(<5-IP.QC<4=0
M!9O)^U8.M`AL6VE],N?1OV>/D#"T@EO#[)-Q[:B!!"1V&+B\N$>/X0JWN2QF
M5AVPKD_W5%R:JN/P-(UCW:P*LBJ@_?TQJ>E;+/I;()=#HSQAVM\BDR;L:&HV
ME''\Z3BQGJ"O%_(4:7^#3)HBTNM62!I$A^N?5\]&,G:3-`;\-\G^YO2<W1.S
M^!_C_N)^-MA_@\Q@BI%)O'*CX%^T^[OL*D1](G]:`JOTS-PN\8I@D]=2VR;7
M2$R&#]="-05-)AUIE=:]11!;YRW(#U1D[2DG"JJ1<`ACFH<O6!]D(BOL]N^'
M=GL_[M_?C$C2H+T,0L/1N#^^'O5OR[F$AI.9TQ\[H_%B,!O=.=C.1Y.;1D;.
MRAI'S@<64-TD92JV>4#4E)`%9OXJ9(<WM-"N2?.4YZ]L>ZV!:8.I%J]$K&(`
M]N\,%T;XTZ$1S@;S07]V_:O3_S0;9,9F<.ZL?^A"8(&B2M:]&=,G:67SYYZR
M*QX+B!5K">-U?K:!1/;:3M,F35:.;/$[*,W@M,%B=[>XMZF&\Q#:%_)26YX]
MHFK%'PZM^`;/AY_QRO?SP/G2G\WZXX5S.^I?C6Y'B]_QO(DGU?YHYGSNW]X/
M_BTG33F@12:GW$KW)L2&0-E@3*50M]I@C]QZSL\.K0<O/S\/9HO1U>W`&4\6
M@[DS[?_>Q_\R.!-N>X_RZQ=N*+(I;@V3*>\.[I-4+I/DM]-*/]K10RZLIS%1
M=I%U:OB.2?N54("]O&>Z4+;!M&D0%].>SP_M^7;2'Q]GPUV?[\J`"5>2K,+=
MF[WX8MN@R?LAP%5=OCC4Y>EL<C>:SR>SW^G4]&^IS?N@B=296;I[^BP0W`:%
M+@=>+O""$6%1:OWVYY=5U\,M=?A-^S.\2UG@7<N\?VW:>\^21^B#$%4SZH6H
M[]R.#;&S0:$%LSX%.?KVO0K*\-A@>=L;N_MWL@IK^[&RR>E/1POJ5)]<_V;0
MP*YB^`W$B+IPW)#\C6]9G/(F3Y+A>I/F!SXTC(62<8\)C.<`KZ7S-7?^QB*Y
M0!?0MZUG8)6&M*;(ZMK^B$G#%-*^=ZRM!5T;C':>;C;9:W%NF)_PCR+BJ<S/
M$O%6K$=^LPN"BGQ>_'-A\>\/+7Y^/YW>4I<^-OOB)0YG-!Y.9G?TF)RZ!L>3
M<8_^=C3^/)@O1N-/F<<P.X8C_\*3\N?18C0P.2_7`3<(I9:K<E4-AZ603I4[
MNF-2N'^3KV[TT0X%`@]#7%3`L<'*R3$$ME:`;98.4W1X2NJ/Y,XK\2S7DS&Q
MP@&VOL&<VN+UY.YNM#!].+=U,6'!IC`,/(D7*#@5S,[=.1N4FQ)7M)\O$O.R
M=`,F34Y,V,&DJPB+#:8V3Q\0^"/%[0V>ZNVK$G<RO[^:#_[G'EN3,_C\ITVU
M-#WOTY!IC)PY2=;MCB4I@6&#$4F>^E&W:M7`*C$E"J?1S@]9J\W>A.NZ8Y.F
M\9VF,=[$H!QZ1`$1VHQ,S>XY/!4`T91_(3M%)CO)R8;N(F78$%4R^QI;(R;D
M<-!$0O4U[A<I'B3JF7V_[,B8#`$:K\>&TEBE4-_H$V6ML6-DX"JZG27YQ1-W
MZ:1?BB>E%HP^%]:,J08(V;`X8\0UL59CE=A`9G33<6NOMQ/FQ#"HW0-=Y4,A
M*4N2J]JAZ"(5+*RPF=+9&,-0+JIA@.43,AN,P_11&6O7DJ[7;OQ"DT)NW.@%
M49BS9:+D[D6EA<Z<6C7`1=-:H.@)F1A3M.O1/3U4`GXCLA0;,[KI:49<([AT
M<UAH4W-G0:.FC.Z4CC2\H]P(W3T49DUUE0C9]H^&;9@O[3PC9CF:6$1[DCS+
M'@NW\8$N'QRW!["FD;[O^S294?E<>Q)M.ZJ\]VC<FM'YNBG)1V)GP^C/"19@
MC>>5*'%NR(`-0[/Y<TZ6\:U6,<W]=A=$P3I=]Z,(;X:+S'-2%J?41'>.,9M`
M8X-!51-JW(#$#4(T)BM!XJFM6E0E.+TNJ8SSP[8AIVC)I$V]U40S#$O]`N-O
MNX>*;L"2*'#DO3`D8!=_DUED1.C88)C5!!5BPZS$L=<DK+#,+NU)8L&PI!G(
MDFDNX)W[#5R#&(,7Y>,ZLW_<.EW+(R$!@*X`@SCU0)C%LB\>`U08`VL;QRYO
M=,6NCKI0<DV(3]($)6[DX^'QR@W)>T89__C?K-F/5\.H7TP==0GI=>UKUW1V
M*&C>WDEGK:)9I8W&!*CC+9#:AGF8<:(LGHPK5TPX9\M63<D6'S,7NZPI-DDO
MV+AA?TTV::+-9J5XAXZ313+KFGJS7-/T/9'=L[8TL1M`S/E74,GH)*R(NQP`
M^J=A.IJN\=\YCUBQBQN=@!41%PFM+8JU>*YQ%\@Y(P8'8GHXQE)V<3VCT[&J
MOLO"H(D&.KM>X05$;F+;;Q-/VII!@:".T;@[1?BEQ-<7#HF!0$/`4O5R`4E0
M];R3I0AJ53!M8;]9!O'B>.P:(J9[@%58$ED];U(I(LL76!/*>73"X!G$7H`X
M$V)M24E\]3S@I(@O1U1=@T!^=6FRS#_.&@WJ2DJ"J^<))=5A@2WJJUT+R,XO
M.6]5\JM(PJWGJ2+EL4(LO#;<'Q*R">=L$O>+2.]0[`"V*IT-/I-R:CFQHZ1R
MIW\O)6%KSA'>LK,+]Q_O(T2RN0"?H-OWGXAWDC5",\IV[XXC5V@;5'T_ZYQ8
MV2L7[`]R%OZI[H5#G(QJ0Q@/4Q*A<`M6^)L@?@K86L^OTCWEEX%`T[PYC<'&
M#?S!\P9@"\PFZPU$`?MA;6;Y#M[G%4JO_3[U-,8DYXX7EKZSBW?PXJY(=ETW
M!^A'1@BEY(3[5QAB8";+<K[9NF0"C`H=O)$KEE_;"%.>.!'W'(=1MH/7:KE2
MOR;2.>.3Y1);6TR&N"`&7JE-&0YXK1CU$[;(CA@I&]:AS+RLPA5IS2M'K%3#
MEAU4VY5^F&%]=V[D9N_M#`%S)C\LU+6LP/5":AK/ZL-,!'L#427#X6%-$C'+
MH*!KU41.":]<1-Z"6Y-%,L6)M6)B%#8<&Z8..5_J$M1J#\KB9>\#1."8%W]Y
MWL\4+&!)6O:#ZLS2AH/*U(D2R/TZZZSF:ZNCUE-Z5KM-6%#`0UM0)7WF9_(]
MB%8+F'^4ONZ3=87K2.+6,[JZ;<*&-!8VK&;+*4G$*]AJ%I_]Y"16+5HMS5-2
MBOX1^)PJY3J3<X0IH_[`LNQ[V&#W'JD48;LKWYW\($*AM86/14^0WM;,%U]<
M/687[TXJ#Y'(KXRT0+O%U8RN,UM!7D+7NYLPI<?,'T!KUWB=*E/U926/F(;D
M*CUGUU''WWT,1DZ$^TJ2'3A)J;/%`N'/="S2V?ZR$-6I&_BCB'R3T;6Z@IU,
MG<&6^-A!MAWU&478WL'"?29C4,"Z-E8I972N:\Y%K:QO:JP5;GHN7R5-E54[
MITX-D=3E,8JXQYH'9;J8-ZI63#LL<?]9";%!5?($59X^L<P>K$T31-]?A=D(
MQ_1Y'A;J3JJ?>O&T'79Y`.N9/X0QM37F\=9A,:/++#5`63)J@I3&T;'O.NU^
M;71UI`;AH4Q*0_#V-^1_#RX"^"?_#U!+`P04````"`!V?7-!%1.:)DL-``"T
M>0``$0`<`'1P:78M,C`Q,C`Y,S`N>'-D550)``,`FJI0`)JJ4'5X"P`!!"4.
M```$.0$``.U=6W?;-A)^WCUG_P/73]W3(\NRD[1VG>ZA=7&XE46M1#O-4P],
M0A(:"E``4K;[ZW?`FW@#=:E<ZJR<AX0"9L!O9G"9`3#,];^?YZZVQ%P01C^>
MM$[/3C1,;>80.OUX<C]NZ..V89QH__[Y'W_7X,_U/QL-K4>PZUQI'68W##IA
M/VD#-,=7VBVFF"./\9^T!^3ZLH3UB(NYUF;SA8L]#!7AFZZTB],+K#4:&S3[
M@*G#^/W(2)J=>=[BJME\>GHZI6R)GAC_*DYMMEES8^9S&R=M>6A!YG.?XM]:
M9]].GR<`OH,\J#@_:YTW6ZUFZ](Z/[LZO[QZ_V[#%WC(\T7R@K/GL^C/9NQW
M1-@)\_=HNGCZX7E$?IV:]$=?1W1V-T;?!N1QZ/WQ_O*/[[%[XW_^S^6G+^Z'
MYHO]^R\?7&_0_AW]<7%[:UO=0?C*:V'/\!QI8&HJ/IZDU/=T<<KXM'E^=M9J
M_GK7'P=T)R'AU;-+Z-<R\M;EY64SJ(U)"Y3/C]R-F[YHRNI')'#2,M22"GI"
MA8>HG:%WO(0A3?R^&59F2$DIZ8>0E,2D#L[1"6R?3MFR"15-:?[&6:MQT8K)
M?=&8(K1(6"9(/`9-1Q4E+)11ZL_+!74\WO1>%K@)1`V@PIS8"=]ZIBP#0)#%
MHA1<4%."SEN09<*0C`,82/.`^.SR0DX&+IYCZO48GW?P!/DNF.&;CUPR(=@Y
M@>'#I]B3/5<LD(W7-1?W?T0I@V$",T%4(LL6"P+C``K^=BT[S!5G+K8`NR8?
M8/PK&I>U31A%OL2I4Z=+/>*]R"'%Y\$K3C3B?#RII)`O!0C!:QT\(90$V&#0
MMK2&%K.F'Q%UM+`=+=70=3/?1*IA7V#'I#\'SPN.!303,/6A(&*,2!1,-G)M
MW]V.9P6EE"4JB%6]F_+;C`KF$@?F3><&N7+DCF<8>R+4O+I:K?9ST+6<2'&D
M][8Y&)M]HZ-;W8YVH_?U0;NKC3]UN]98^^Z>(M\AT/J_WO2?4?`0<1!RACT"
MT-<8(TNKMLS%-I;)-/IF'2=1G#`GYD)Z2_#JDF&BH%-;Y5V55<86_'/7'8!%
MS)YF#KLCW3*`X&WDJ'3>1F+6<]G3&M.LR-26>;^Y9=KZ^)/6ZYN?WRS3'(`3
MS7%QE)24JW7_0:[8X$^[3``3_!CHUOVHFQT%QZG?I'^E^W:/4%@0"')7G1P<
M/X-ZX&O.A_`7<T(K[,RMMM4/>5O=#_3[CB%'26;(](P!+#&&WD\/GIXYTO2!
M9@RL[LBXT\"VAMDY3L..0!;$[9D^Y3@T0FBRDG*U,7[,&V/4'7?U4?N3IM^.
MNJ'2CU.]'>C'2X"UQ)\1YXAZ?8(>B0MQ``06/41X$+E'(<=FM&HS7.;-T(&.
M_0#3UD-7^ZR/1OK`TOJ&?F/T#>L+#``8';HQTA[T_GWW.,T#\]$2<X\\NGC`
M/`Q>[0N"YV09+ZU4&J!UEC<`3$4/W9%EW/2[VL"TNF-MJ'_1X==QJKO/$,WJ
M.%.B5FPKK]B^J0^.7)E#SN9$",9?9.\,U9DK4ROT/*_0X<B\,\9C<_0EZ*C'
MJ=(1=J5G`F&H]V+!#"R0G?(EE;5J-5\4%\9^X)8,]1%,P19,R6.]?<1^91N*
M/.D",OMK-.NF2]2:?5>8:O6A805NGMG^Y3B5.?87BW#_%;EQK)G:;00O8L!H
M0]88L+()C]"I]"Q"/QR>H3LO`2*.^OO^FE.;\7W>C./[X;`?>(Q@RR3"!5<=
M?/:[(`(+')>!.6@$M08LL&/+&-R&_DSH[<M?,*H>#,OH'NO`8E0:!(,IL`"S
MM-E\3KR4@U]%H+97(40&#T=JOPM:!^]&VJ!MWMT9UA'[_&/_4>!O/LC37:[T
M72A5*[D0VX[O;\;=_]Z#2K7NP_$J=K,`R9*^I-@FI(HXU`8IQ+=;!%;:=V'S
M1[HQIPBBTD:J)E%;I1#N*J.M8[=!RJ7**+Y8KM3V>3&V33M<1Z[AO;E*:?/L
MNU&U;0OA]?Z]L"/O(!7>5FXJ7$.F-F(AI*]TS8[<'L5SH0[V$''%0/H)TF%0
MG1\5Z-06*43_9>=)VG=1BUK2Y)':I'CD4&Z3#>C4-BGL&Y0<5;R99(WW5FZ7
M38G5QBGL!E1X=&\F*NZIE]NEDD)MC$*HG]ES?S-`^3Y\N0G6T*B-4-@*R.W3
MOYEAW=Z]:@W9D%IMFI)#;]7>_IN5RD)1Q2I21:&V1G$S(!N>OAE@SY%J0W><
M`"MR5WHW:<Q=,JCV'-7N`$#9?2X*NQNO$`$WM!5BS5F]C%%-7NJW`;3FI5`G
MG?:MJ_ZYGE(^T;Q>\^IN]I=LM+Q-=>7G,*INL(9*;<W"CDOAG.;_VQCR+YFG
M-<(3+<CONI*Y0Q]/!)'Y>R=1V8SCR<<3F3W4B!-[?@/13I_G;DPBFZ[([PJL
MF==&].*X"<3M0BN%_#-HA"UDB(I%,P8?-^`13[(/4Z_1Y'M@V6KN0V07/6XK
M,K!@]Q5E[<OV]RHD]+YMA<QUV%<2M;UZRUX%AJ&SK<#9T?9*\G:2EZ3%C5+G
MFJO<N>AW/K_N&@1GW--H(5.O*OLRS!OM,SMHJH)%_FK$?`U9U&B=-RY:I\_"
M62'=!L1*#=N!B/EV`%&=,ZF`$4`H305M8M<325N-55N;XJG,2:V"D^>1#SN\
MOS+!=7=UR)(=T&R0/+M)3TES#D)&V54N95=I??B38'8#L@Y%E((;.#=RLOJM
M*I55?Q00<MC>28"Z.NUU18NB)W@!E[?7*7%=N;L8_PX2MJ\600Z'%<RDCL^C
MY-IP9@TIH!7PI`T/SR45*`)\,7BI+REO.?,7,2$!DDH1\01SCE?>>9L)3\B]
MMO>)9)4D:P4(9RLOBW_.*+AW_&4O$L0W59(K*N%^NOS^@;F0[4FL[U;B;$Q?
MNVSC&>+!<69T"4=8[`8;0O@R)3P4IYJD=@EDWI+ORA"PA^59;0BZ4+KC,'@U
MH,$FFES>'-D7+LMQ%XGJ%R/(`H.8.PFX<7LF/QT@,F-@+57]@MPABJ;A)Q$*
MJA8_`O#$*!M1UB]0<OA*G0Y>8I<M9/T*;BS.!G3U"V.!U^MVGQ>8BM6HSA?6
M#W.`O3X3X@;#4HQ-;X:Y;#0!K*ZN'WH/()$I[3[;,T2G6.*\183&T-75]4.7
M0"0@DXZQYX6UYJ2#'[W,9+J>[#!$,4'+<LKWB9C%&/,N!`24\?J;F6C_!'_]
MPD?#`[I:G)*<&3;I\OK!WB!!;#EG$M?W8/(/,0+`P$&*H:^EJE\0W?G=%\'-
MM0Y><&R3Z'6A`,K:+8"'=8_A1TF@`C^2UW,`AYS9&#NBQ]D\>YB?3,/5)/5;
M)(UO/(-`U<)\?H/HU^!^2'#<D<Z`+0JU"=.AVB^`:;&2;P[D(^!-*`\N_MWU
M`PL6?O9NW"#W+I1^'PUMK8SPNV=77MS&7L/IRL2/O/C;LQV"L.D+7J(@D[+V
M$*!G)\H"=G7U(8`/5MNA#U$.1#3)QD60NY(79#/20Q`JOXM4+L]:JD,0I62/
MK%R:30@/5*#J;K<-PR$(F*PTNA#8D_Y%*K0H%W$[ED,0TJ"P[@>[[.D[2N72
M;4A["&*-_?D<G#5S(C_?B^A+N(<53@^J67$KEH,2,OQL[PKY?7!'"#N;R;LM
M]T&)GAAKB^5O-]Y#$%MY-<S>,/&NN';NL\5#4)'R(J:=NX=9KH_=V0]"^.F4
MXRG$17>$DKD_U^$-R`5_>Y6U5Y1X.YY#$/,SXU_EH6EX.UM>+[$)IO9++%)%
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M.-F7-B<QPJ1+E%;5CKCTY#B8]1Y7-Q&K:0Y`AD=/QBOI=3175CO&>RJP#=&4
M(\\`=&<I?:JD;Z@J:T<=^AX]QGN^_/A&'SP3=XSYDJ3`KZ&IWUD<<KQ`Q(GO
M$04==\$$2?I*%4']\%>K-[B$=K)\IZ\^JNJWCU;WN\"'0,*[HQ;[Q%Q8%,U)
M^(W<]&53!<6N1[EAF_L^$1-91UU567^'*446J]B<3*"3\.#&"L>VQWBE0)5L
M]8N:O:E9?G_S((`J[F#FIM*U5/4+$@04-_+:J-P_AODR<YE(65L_\,`A\+'%
M4M^;(%AD_(72ZKHGT=RXW&(('^RP#><683Y!M&&Q&)I<>"/`6=^BFK!V)RD5
M:>=7YF+%X:&%GA[]SQ<*U"F"VC<,Z)+)$QGPV,*@-:OPBOK=]+XW5T*%+*_\
M#>AJMD&\#3,$C]F@<K,OGP.2J:E_L@FF0H-FO;=\8>W#,KA4Q<(CQ]6$7BBM
M'><(VY@LL0/Q7N;*;4EY[5B#4#2U*Y?Z_1=BNVZ&2:7P^#]02P$"'@,4````
M"`!V?7-!)Z&A>(-T``!#"@4`$0`8```````!````I($`````='!I=BTR,#$R
M,#DS,"YX;6Q55`4``P":JE!U>`L``00E#@``!#D!``!02P$"'@,4````"`!V
M?7-!/G9/'00*``!48@``%0`8```````!````I('.=```='!I=BTR,#$R,#DS
M,%]C86PN>&UL550%``,`FJI0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M=GUS04P(9C#E!@``GS<``!4`&````````0```*2!(7\``'1P:78M,C`Q,C`Y
M,S!?9&5F+GAM;%54!0`#`)JJ4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`'9]<T$#;R1+G"8``,?@`0`5`!@```````$```"D@56&``!T<&EV+3(P,3(P
M.3,P7VQA8BYX;6Q55`4``P":JE!U>`L``00E#@``!#D!``!02P$"'@,4````
M"`!V?7-!W'P0*]T9```O;`$`%0`8```````!````I(%`K0``='!I=BTR,#$R
M,#DS,%]P<F4N>&UL550%``,`FJI0=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`=GUS0143FB9+#0``M'D``!$`&````````0```*2!;,<``'1P:78M,C`Q
M,C`Y,S`N>'-D550%``,`FJI0=7@+``$$)0X```0Y`0``4$L%!@`````&``8`
*&@(```+5````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONTINGENCIES AND COMMITMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AggregateMinimumAnnualPaymentsTableTextBlock', window );">Aggregate minimum annual payments</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; R&#38;D</td>
    <td nowrap="nowrap" style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Administrative</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 65pt; font-weight: bold; text-align: center; text-indent: -7.9pt">Commitments</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; font-weight: bold">Commitments</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">2012</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-indent: -8.3pt">&#160;$ 1,052,500</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in">&#160;$&#160;&#160;&#160;&#160; 195,821</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">2013</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in">&#160;&#160;&#160;&#160;&#160; 37,500</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 308,313</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">2014</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 22,284</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,090,000</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-left: 1in">$&#160;&#160;&#160;&#160;&#160; 526,418</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AggregateMinimumAnnualPaymentsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_AggregateMinimumAnnualPaymentsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4MAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RESEARCH AGREEMENTS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008</div>
        </th>
        <th class="th">
          <div>Aug. 07, 2003</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_RequiredToMakeCertainPayments', window );">Required to make certain payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 450,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CrucellUnderThisAgreement', window );">Crucell under this agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">243,598<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_OutstandingBalanceRequiring', window );">Outstanding balance requiring</a></td>
        <td class="nump">17,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AmendedAgreementAccrued', window );">Amended agreement accrued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 365,970<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AmendedAgreementAccrued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_AmendedAgreementAccrued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CrucellUnderThisAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_CrucellUnderThisAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_OutstandingBalanceRequiring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_OutstandingBalanceRequiring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_RequiredToMakeCertainPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_RequiredToMakeCertainPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock', window );">UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><u>Note
2:&#9;UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD</u></font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
the opinion of management, the accompanying balance sheets and related statements of operations and cash flows include all adjustments,
consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally
accepted in the United States of America (&#147;U.S. GAAP&#148;). Preparing financial statements requires management to make estimates
and assumptions that affect the reported amounts of assets, liabilities, and expenses. Examples include: valuation of the derivative
liabilities and stock-based compensation. Actual results and outcomes may differ from management&#146;s estimates and assumptions.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Interim results are not necessarily indicative of
results for a full year. The information included in this quarterly report on Form 10-Q should be read in conjunction with information
included in the Company&#146;s annual report on Form 10-K filed on April 16, 2012, with the U.S. Securities and Exchange Commission.</font></p>



<p style="margin: 0pt; text-align: justify"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_UnauditedConsolidatedFinancialStatementsForInterimPeriodTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">73,861,754<span></span></td>
        <td class="nump">52,073,460<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">73,861,754<span></span></td>
        <td class="nump">52,073,460<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><font style="text-transform: uppercase"><u>Note 12:&#9;SUBSEQUENT
EVENTS</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 15, 2012, the Company entered into
an agreement to issue a note to an investor for $340,000. The Company received $300,000 for the note which carried $30,000 of original
issue discount and $10,000 in legal fees. The note is due on October 15, 2013 and carries an interest rate of 8%. There are seven
installment payments due on the note beginning on the seventh month after its issuance of the note and each month thereafter until
maturity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The lender has the right, at any time after
issuance, at its election, to convert all or part of the outstanding and unpaid principal sum and accrued interest into fully paid
and non-assessable shares of the Company&#146;s common stock at $0.12 per share. If the Company issues shares (or reduces the
conversion or exercise price for outstanding debt or warrants) for less than $0.12, then the conversion price for the note shall
be reduced to that new issuance price. If the holder of the note converts the full amount of the note (excluding any interest that
becomes due thereon), it shall receive 2,833,333 shares of the Company&#146;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Provided that there is sufficient volume in
the trading of the Company&#146;s common stock and other criteria are met, the Company may elect to make any payment due on an
installment date in shares of common stock. If the Company elects to make a payment in shares of common stock, the number of shares
that the Company issues will be equal to the amount to be converted divided by the lesser of the conversion price or 70% of the
average of the three lowest closing bid prices of the shares of common stock during the prior twenty consecutive trading days.
If the Company elects to pay the full amount of the note in common shares (excluding any interest that becomes due thereon), the
holder shall receive at a minimum 2,833,333 shares of the Company&#146;s common stock, but this amount could be substantially
higher. Unless otherwise agreed in writing by both parties, at no time will the holder convert any amount of the debenture into
common stock that would result in the holder owning more than 4.99% of the common stock outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the agreement, the Company also
issued 3,000,000 warrants to the note holder exercisable at $0.25/share expiring on October 31, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The warrants include price adjustment provisions whereby
the exercise price will be adjusted downwards based on future grants, which results in a share issuance at a per share amount
less than $0.25 per share, or repricing of any existing warrants to a lower price.</font></p>



<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Nov. 19, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">TAPIMMUNE INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001094038<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73,861,754<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EECAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_SharePurchaseWarrantsTableTextBlock', window );">Share purchase warrants</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">December 31, 2011</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">September 30, 2012</td></tr>
<tr>
    <td style="vertical-align: top; width: 26%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Share purchase warrants</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">1.09 to 4.80</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.12% to 0.83%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">199%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.33 to 4.03</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.10% to 0.62%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">199%</td></tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ConversionOptionTableTextBlock', window );">Conversion Option</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">At Initial Recognition</td>
    <td colspan="4" style="border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">September 30, 2012</td></tr>
<tr>
    <td style="vertical-align: top; width: 24%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Expected Life (Years)</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Risk free Rate</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Dividend yield</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: windowtext 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Volatility</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Conversion Option</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.25 to 1.04</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.11% to 0.20%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">138.31% to 141.43%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.11 to 1.00</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.06% to 0.17%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0.00%</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">138.31% to 141.21%</td></tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DerivativeLiabilityTableTextBlock', window );">Derivative liability</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&#160;</td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>As of September 30, 2012 </b></p></td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td colspan="5" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Fair Value Measurements</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Carrying Value</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 1</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 3</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Total</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Derivative liability - warrants</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Derivative liability &#150; conversion option</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">200,700</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">200,700</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">200,700</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Total</td>
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558</td>
    <td style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558</td></tr>
<tr>
    <td style="width: 36%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 13%">&#160;</td></tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DerivativeLiabilityWarrantsTableTextBlock', window );">Derivative liability - warrants</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of December 31, 2011</b></p></td>
    <td colspan="2" style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Fair Value Measurements Using</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Carrying Value</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 1</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 2</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Level 3</td>
    <td colspan="3" style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Total</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Derivative liability - warrants</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Total</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td>
    <td colspan="3" style="border-top: windowtext 1pt solid; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,317,834</td></tr>
<tr>
    <td style="width: 33%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 6%">&#160;</td></tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_FinancialAssetsAndLiabilitiesTableTextBlock', window );">Financial assets and liabilities</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td colspan="3" style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"><b>Fair Value Measurements Using Level 3 Inputs</b></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 4pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></td>
    <td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Derivative liability - warrants</td>
    <td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Derivative liability &#150; conversion option</td>
    <td style="border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">Total</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Balance,&#160; December 31, 2010</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,819,512<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 175,389<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,994,901<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Additions during the year</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,587,275<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,587,275<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Total unrealized (gains) or losses included in net loss</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(631,631)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(37,079)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(668,710)</td></tr>
<tr>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Debt settlement</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(1,457,322)</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(138,310)</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(1,595,632)</td></tr>
<tr>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">Transfers in and/or out of Level 3</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Balance, December 31, 2011</td>
    <td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,317,834<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="vertical-align: bottom; border-top: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,317,834<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Additions during the year</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">299,300&#160;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">299,300&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Total unrealized (gains) or losses included in net loss</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(445,976)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(98,600)</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(544,576)</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Debt settlement</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Transfers in and/or out of Level 3</td>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">-&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Balance, September 30, 2012</td>
    <td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="width: 19%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 871,858&#160;</td>
    <td style="width: 20%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 200,700<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="width: 13%; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160; 1,072,558&#160;</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ConversionOptionTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ConversionOptionTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DerivativeLiabilityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DerivativeLiabilityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DerivativeLiabilityWarrantsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_DerivativeLiabilityWarrantsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_FinancialAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_FinancialAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_SharePurchaseWarrantsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_SharePurchaseWarrantsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENGBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">158 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ConsultingFees', window );">Consulting fees</a></td>
        <td class="nump">$ 57,260<span></span></td>
        <td class="nump">$ 43,750<span></span></td>
        <td class="nump">$ 119,790<span></span></td>
        <td class="nump">$ 119,250<span></span></td>
        <td class="nump">$ 2,158,477<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ConsultingFeesStockbasedNote9', window );">Consulting fees &#x2013; stock-based (Note 9)</a></td>
        <td class="nump">109,728<span></span></td>
        <td class="nump">307,734<span></span></td>
        <td class="nump">2,283,561<span></span></td>
        <td class="nump">692,253<span></span></td>
        <td class="nump">8,005,914<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">213,227<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">268,286<span></span></td>
        <td class="nump">23,875<span></span></td>
        <td class="nump">880,353<span></span></td>
        <td class="nump">66,012<span></span></td>
        <td class="nump">3,797,589<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_InterestAndFinanceChargesNote4', window );">Interest and finance charges (Note 4)</a></td>
        <td class="nump">214,811<span></span></td>
        <td class="nump">103,740<span></span></td>
        <td class="nump">411,783<span></span></td>
        <td class="nump">558,577<span></span></td>
        <td class="nump">6,242,796<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServiceManagementCosts', window );">Management fees (Note 8)</a></td>
        <td class="nump">22,500<span></span></td>
        <td class="nump">62,100<span></span></td>
        <td class="nump">125,100<span></span></td>
        <td class="nump">186,300<span></span></td>
        <td class="nump">2,897,154<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ManagementFeesStockbasedNotes8And9', window );">Management fees &#x2013; stock-based (Notes 8 and 9)</a></td>
        <td class="nump">31,334<span></span></td>
        <td class="nump">29,563<span></span></td>
        <td class="nump">146,960<span></span></td>
        <td class="nump">360,260<span></span></td>
        <td class="nump">4,471,749<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
        <td class="nump">21,757<span></span></td>
        <td class="nump">36,173<span></span></td>
        <td class="nump">208,866<span></span></td>
        <td class="nump">317,130<span></span></td>
        <td class="nump">5,135,438<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (Note 8)</a></td>
        <td class="nump">71,061<span></span></td>
        <td class="nump">297,996<span></span></td>
        <td class="nump">432,289<span></span></td>
        <td class="nump">406,944<span></span></td>
        <td class="nump">6,343,454<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ResearchAndDevelopmentStockbased', window );">Research and development &#x2013; stock-based</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">612,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_TotalExpenses', window );">Total Expenses</a></td>
        <td class="nump">796,737<span></span></td>
        <td class="nump">904,931<span></span></td>
        <td class="nump">4,608,702<span></span></td>
        <td class="nump">2,706,726<span></span></td>
        <td class="nump">39,877,798<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NetLossBeforeOtherItems', window );">Net Loss Before Other Items</a></td>
        <td class="num">(796,737)<span></span></td>
        <td class="num">(904,931)<span></span></td>
        <td class="num">(4,608,702)<span></span></td>
        <td class="num">(2,706,726)<span></span></td>
        <td class="num">(39,877,798)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ForeignExchangeLossGain', window );">Foreign exchange (loss) gain</a></td>
        <td class="num">(7,193)<span></span></td>
        <td class="nump">14,654<span></span></td>
        <td class="nump">2,304<span></span></td>
        <td class="num">(293)<span></span></td>
        <td class="nump">55,894<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments', window );">Changes in fair value of derivative liabilities (Note 4)</a></td>
        <td class="nump">121,385<span></span></td>
        <td class="nump">46,000<span></span></td>
        <td class="nump">544,576<span></span></td>
        <td class="num">(277,118)<span></span></td>
        <td class="nump">4,619,716<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Loss on debt financing</a></td>
        <td class="num">(85,550)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(85,550)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,354,263)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_GainLossOnSettlementOfDebtNote9', window );">Gain (loss) on settlement of debt (Note 9)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">28,688<span></span></td>
        <td class="num">(482,474)<span></span></td>
        <td class="num">(11,602,894)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4', window );">Gain on extinguishment of derivative liabilities - warrants (Note 4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,088,575<span></span></td>
        <td class="nump">290,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">33,344<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Loss on disposal of assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(5,399)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NetLossForPeriod', window );">Net Loss for the Period</a></td>
        <td class="num">(768,095)<span></span></td>
        <td class="num">(844,277)<span></span></td>
        <td class="num">(4,118,684)<span></span></td>
        <td class="num">(2,378,036)<span></span></td>
        <td class="num">(47,840,900)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_BasicAndDilutedNetLossPerShare', window );">Basic and Diluted Net Loss per Share</a></td>
        <td class="num">$ (0.01)<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="num">$ (0.07)<span></span></td>
        <td class="num">$ (0.05)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Common Shares Outstanding</a></td>
        <td class="nump">73,128,058<span></span></td>
        <td class="nump">47,213,710<span></span></td>
        <td class="nump">62,560,295<span></span></td>
        <td class="nump">44,845,195<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_BasicAndDilutedNetLossPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_BasicAndDilutedNetLossPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ConsultingFeesStockbasedNote9">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ConsultingFeesStockbasedNote9</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ForeignExchangeLossGain">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ForeignExchangeLossGain</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_GainLossOnSettlementOfDebtNote9">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_GainLossOnSettlementOfDebtNote9</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_GainOnExtinguishmentOfDerivativeLiabilitiesWarrantsNote4</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_InterestAndFinanceChargesNote4">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_InterestAndFinanceChargesNote4</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ManagementFeesStockbasedNotes8And9">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ManagementFeesStockbasedNotes8And9</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NetLossBeforeOtherItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NetLossBeforeOtherItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NetLossForPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NetLossForPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ResearchAndDevelopmentStockbased">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ResearchAndDevelopmentStockbased</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_TotalExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_TotalExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 15<br><br> -Paragraph 25<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnRestructuringOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net gain (loss) resulting from the sale, transfer, termination, or other disposition of assets during the period, excluding transactions involving capital leases, assets-held- or available-for-lease, and other real estate owned which, to the extent appropriate, are included in gains (losses) on the disposition of assets in nonoperating income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnSalesOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period, which was recognized in earnings, in the unrealized gains or losses on derivative instruments that are not or are no longer designated as hedging instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 20<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6439004&amp;loc=d3e65527-113976<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 18<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 3<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfessionalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServiceManagementCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs related to delivering management services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ServiceManagementCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROMISSORY NOTE<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_PromissoryNoteTextBlock', window );">PROMISSORY NOTE</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><u>Note
7:&#9;Promissory note</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">During the year ended December 31, 2011, the Company issued a note in the amount of $100,000 towards future
legal services, which matured July 24, 2011. As of September 30, 2012, the Company had received legal services in the amount of
$100,000 against the note. The note bears interest at 10% per annum and may be converted into shares at equal to lower of $0.09
or 65% of the arithmetic average of the lowest closing bid prices of the Company&#146;s shares during the consecutive twenty day
trading period prior to notice of conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended, the Company issued 500,000 shares to the holder of the note in exchange for the note holder&#146;s agreement
to forbear from pursuing collections actions on the outstanding note (Note 9). As of September 30, 2012, the Company is negotiating
terms for repayment and settlement of the note.</font></p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2012, the
Company issued additional promissory notes in the amount of $67,942, of which $38,000 of promissory notes were issued to an officer
and a director of the Company (Note 8). The promissory notes had no interest charges and no fixed repayment terms.</font></p>



<p style="margin: 0pt; text-align: justify"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_PromissoryNoteTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_PromissoryNoteTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LOANS PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_LoansPayablesTextBlock', window );">LOANS PAYABLE</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><u>Note
6:&#9;Loans payable</u></font></p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As at September 30, 2012, there were unsecured loan
advances from third parties in the amount of $28,000 (December 31, 2011 - $7,000), which are due on demand. The loans are accruing
interest between 10-19% per annum.</font></p>



<p style="margin: 0pt; text-align: justify"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_LoansPayablesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_LoansPayablesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_WorkingCapitalDeficiency', window );">Working capital deficiency</a></td>
        <td class="nump">$ 3,315,751<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_WorkingCapitalDeficiency">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_WorkingCapitalDeficiency</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_InstrumentTransactionsTableTextBlock', window );">Instrument transactions</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&#160;</td>
    <td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Face Value</b></p></td>
    <td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Principal Repayment</b></p></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unamortized</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Note</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Discount</b></p></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance at</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2012</b></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">February 2011 Secured Convertible Notes</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Senior Secured Notes, due February 24, 2014</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,184,694<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160; 225,800&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 958,894<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">April 2011 Secured Convertible Notes</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Senior Secured Notes, due April 4, 2014</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">215,000<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">51,786&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">163,214<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">June 2011 Secured Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Senior Secured Notes, due June 6, 2014</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">30,000<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,650&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">25,350<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">August 8, 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Note due August 8, 2013</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">111,430<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">95,250&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,180<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">August 12, 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Note due November 12, 2012</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">27,500<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,658&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">15,842<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">August 20, 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Note due August 20, 2013</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">20,000<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">17,757&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,245<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">September 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Note due October 1, 2013</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">82,500<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">79,874&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,626<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Total</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,671,124<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160; 486,773&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,184,351<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_InstrumentTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_InstrumentTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><font style="text-transform: uppercase"><u>Note 10:&#9;Supplemental
Cash Flow Information AND NON-CASH INVESTING AND FINANCING ACTIVITIES </u></font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td colspan="5" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nine Months Ended</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2012</p></td>
    <td style="border-bottom: windowtext 0.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Shares/warrants</td>
    <td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Amount</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Shares issued pursuant to debt settlement agreements</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,126,447</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">$326,937</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Common shares issued pursuant to consulting service arrangements</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">14,535,179</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$1,998,000</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td colspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nine Months Ended</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2011</p></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Shares/warrants</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Amount</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Accounts payable settled by issuing common shares</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,214,766</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 815,527</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Common shares issued pursuant to consulting service arrangements</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,327,059</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$500,527</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td style="width: 47%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 4%">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">Pursuant to the 2010 Note settlement and
warrant extinguishment agreements entered during the nine months ended September 30, 2011, the Company issued February 2011 Notes
in the amount of $240,000 (Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">See Notes 5 and 9 for additional disclosure
on non-cash transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td rowspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">Nine Months Ended September 30,</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2012</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2011</td></tr>
<tr>
    <td style="vertical-align: top; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Interest paid in cash</td>
    <td style="vertical-align: bottom; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right">$&#160; -</td>
    <td style="vertical-align: bottom; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right">$&#160; -</td></tr>
<tr>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Income taxes paid</td>
    <td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right">$&#160; -</td>
    <td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right">$&#160; -</td></tr>
</table>


<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowSupplementalDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowElementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><font style="text-transform: uppercase"><u>Note 8:&#9;Related
Party Transactions</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">During
the nine months</font> ended September 30, 2012<font style="letter-spacing: -0.1pt">, the Company entered into transactions with
certain officers and directors of the Company as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0 0.75in; text-align: justify; text-indent: -0.5in"><font style="letter-spacing: -0.1pt">(a)<font style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font>incurred $173,500 (September 30, 2011 - $187,200) in management fees and $67,500 (September 30, 2011 - $67,500) in research
and development services paid to officers and directors during the period;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in"><font style="letter-spacing: -0.1pt">(b)<font style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font>recorded $31,333 (September 30, 2011 - $360,260) in stock based compensation for the fair value of options granted to management
that were granted and or vested during the period;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in"><font style="letter-spacing: -0.1pt">(c)<font style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font>converted $25,000 (September 30, 2011 - $100,000) of debt due to related parties during the period, which were settled with
shares; </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in"><font style="letter-spacing: -0.1pt">(d)<font style="font: 7pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font>issued $38,000 (September 30, 2011 - $nil) in promissory notes to an officer and director of the Company (Note 7).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">All
related party transactions (other than stock based consideration) involving provision of services were recorded at the exchange
amount, which is the amount established and agreed to by the related parties as representing fair value. The Company accounted
for the debt settlement transactions with related parties at management&#146;s estimate of fair value, using amounts similar to
arm&#146;s length settlements for debt settled.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At September 30, 2012, the Company had amounts owing
to directors and officers of $281,475 (December 31, 2011 - $322,905). Amounts due to related parties are unsecured, non-interest
bearing and have no specific terms of repayment.</font></p>



<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CAPITAL STOCK<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BrokersAndDealersAbstract', window );"><strong>Brokers and Dealers [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock', window );">CAPITAL STOCK</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><font style="text-transform: uppercase"><u>Note 9:&#9;Capital
Stock</u></font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Share Capital</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">The
authorized capital of the Company consisted of 150,000,000 common shares with $0.001 par value and 5,000,000 non-voting preferred
shares with $0.001 par value. </font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>2012 Share Transactions</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 15, 2012, the Company issued 333,334 shares of its restricted common stock to related parties, pursuant to debt settlement
agreements to settle $50,000 of outstanding trade payable. </font>At the time of issuance the fair value of the shares was determined
to be $50,000 based on the quoted market price of $0.15 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 15, 2012, the Company issued </font>400,000 shares of its restricted common stock pursuant to a debt settlement and a consulting
agreement. At the time of issuance the fair value of the shares was determined to be $71,200 based on the quoted market price of
$0.15 per share. The Company recorded $9,930 as gain on settlement of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 15, 2012, the Company issued </font>789,778 shares of its restricted common stock in settlement of accrued interest on the
outstanding 2011 Notes. At the time of issuance the fair value of the shares was determined to be $118,467 based on the quoted
market price of $0.15 per share. No gain or loss was recorded on settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In March 2012, the Company received subscription
proceeds of $85,000. The subscribers purchased 733,334 share units at $0.15 per unit. Each unit consists of 1 share of Company&#146;s
common stock and half a warrant exercisable at $0.40, which expires in two years. The fair value of these warrants was determined
to be $5,133.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In April 2012, the Company received subscription
proceeds of $345,000. The subscribers purchased 2,300,000 share units at $0.15 per unit. Each unit consists of 1 share of Company&#146;s
common stock and half a warrant exercisable at $0.40, which expires in two years. The fair value of these warrants was determined
to be $123,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.1pt">In April, 2012, the Company
issued 1</font>00,000 shares of its restricted common stock pursuant to a debt settlement and a consulting agreement. At the time
of issuance the fair value of the shares was determined to be $18,500 based on the quoted market price of $0.185 per share. The
Company recorded $18,758 as gain on settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">In April 2012, the Company issued 933,333 restricted common
shares, at $0.15 per share, for proceeds of $140,000 received in October 2011, in a private placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In April 2012, the Company issued 1,000,000
common shares to a consultant pursuant to a consulting agreement effective October 1, 2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">In
April, 2012, the Company issued </font>163,334 shares of its restricted common stock in settlement of accrued interest on the outstanding
2011 Notes. At the time of issuance the fair value of the shares was determined to be $24,500 based on the quoted market price
of $0.15 per share. No gain or loss was recorded on settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In May 2012, the Company issued 14,000,000
common shares to consultants pursuant to a consulting agreement (Note 11). At the time of issuance the fair value of the shares
was determined to be $1,918,000 based on the quoted market price of $0.137 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">In
June 2012, the Company issued </font>35,179 shares of its restricted common stock pursuant to a consulting agreement. The fair
value of the shares was determined to be $6,000 based on the quoted market price of $0.17 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">In
August 2012, the Company issued </font>500,000 shares of its restricted common stock pursuant to a consulting agreement. The fair
value of the shares was determined to be $74,000 based on the quoted market price of $0.148 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In September 2012, the Company issued <font style="font: 10pt Times New Roman, Times, Serif">500,000 shares
of its restricted common stock to the holder of a promissory note in exchange for the note holder&#146;s agreement to forebear
from pursuing collection action on that note (Note 7). The fair value of the shares was determined to be $72,750 based on the quoted
market price of $0.146 per share.</font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>&#160;</u></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>2011 Share Transactions</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 21, 2011, the Company issued </font>641,023 shares of its restricted common stock pursuant to debt settlement and warrant
extinguishment agreement to settle $83,333 of the 2010 Notes and partial extinguishment of the Series A, Series B and Series C
Warrants. At the time of issuance, the fair value of the shares was determined to be $115,384, based on the quoted market price
of $0.18 per share, which has been recorded against the carrying value of the debt. The Company recognized a loss of $87,734 on
partial settlement of 2010 Notes and partial extinguishment of the Series A, Series B and Series C Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 23, 2011, the Company issued </font>1,180,000 shares of its restricted common stock pursuant to various consulting agreements.
At the time of issuance the fair value of the shares was determined to be $227,432 based on the quoted market price of $0.18 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 23, 2011, the Company issued 885,295 shares of its restricted common stock pursuant to debt settlement agreements to settle
$150,500 of outstanding trade payables. </font>At the time of issuance the fair value of the shares was determined to be $172,633
based on the quoted market price of $0.195 per share. The Company recorded $22,133 as loss on settlement of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 23, 2011, the Company issued 441,177 shares of its restricted common stock to related parties, pursuant to debt settlement
agreements to settle $75,000 of its outstanding trade payables. At the time of issuance the fair value of the shares was determined
to be $86,030 based on the quoted market price of $0.195 per share. The Company recorded the calculated loss on settlement of $11,030
to the statement of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
March 30, 2011, the Company issued </font>2,048,578 shares of its restricted common stock pursuant to an exchange agreement to
settle $233,333 of the 2010 Notes. At the time of issuance the fair value of the shares was determined to be $450,687 based on
the quoted market price of $0.22 per share. The discounted carrying amount of the 2010 Note as of March 30, 2011 was $77,421. The
Company recorded the difference between the fair value and accreted amount of $373,266 as loss on settlement of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 5, 2011, the Company issued </font>500,000 shares of its restricted common stock pursuant to a consulting agreement. At the
time of issuance the fair value of the shares was determined to be $125,000 based on the quoted market price of $0.25 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 25, 2011, the Company issued </font>350,000 shares of its restricted common stock pursuant to a consulting agreement. At
the time of issuance the fair value of the shares was determined to be $87,500 based on the quoted market price of $0.25 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 25, 2011, the Company issued 366,783 shares of its restricted common stock pursuant to debt settlement agreements to settle
$84,315 of outstanding trade payables. </font>At the time of issuance the fair value of the shares was determined to be $91,696
based on the quoted market price of $0.25 per share. The Company recorded $7,381 as loss on settlement of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 25, 2011, the Company issued 20,000 shares of its restricted common stock pursuant to a debt settlement agreement to settle
$4,575 of outstanding trade payables. </font>At the time of agreement the fair value of the shares was determined to be $6,800
based on the quoted market price of $0.34 per share. The Company recorded $2,225 as loss on settlement of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 25, 2011, the Company issued 108,696 shares of its restricted common stock to related parties, pursuant to a debt settlement
agreement to settle $25,000 of its outstanding accounts payables. At the time of issuance the fair value of the shares was determined
to be $27,174 based on the quoted market price of $0.25 per share. The Company recorded the calculated loss on settlement of $2,174
to the statement of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In April 2011, the Company received subscription
proceeds of $90,000 and issued 600,001 shares of common stock in a private placement. The subscribers to the subscription proceeds
have agreed to purchase one unit for each $3.00 of subscription proceeds. Each unit consists of 20 share of Company&#146;s common
stock and 6 warrants each exercisable at $0.25, which expire in two years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
June 1, 2011, </font>586,858 shares of <font style="letter-spacing: -0.1pt">the Company&#146;s </font>restricted common stock
was returned to treasury due to an adjustment to the final settlement of the $233,333 2010 Notes. The return of the shares resulted
in a $134,977 reduction to the previously calculated loss on debt settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On July 7, 2011, the Company received
subscription proceeds of $65,000 and issued 325,000 shares of common stock in a private placement. The subscribers purchased one
unit for each $2.00 of subscription proceeds. Each unit consists of 10 shares of Company&#146;s common stock and 6 warrants each
exercisable at $0.25, which expire in two years. The fair value of these warrants was determined to be $33,600.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On August 19, 2011, the Company received
subscription proceeds of $45,000 and issued 225,000 shares of common stock in a private placement. The subscribers purchased one
unit for each $2.00 of subscription proceeds. Each unit consists of 10 shares of Company&#146;s common stock and 6 warrants each
exercisable at $0.25, which expire in two years. The fair value of these warrants was determined to be $23,400.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Stock Compensation Plan</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On October 14, 2009, the Company adopted
the 2009 Stock Incentive Plan (the &#147;2009 Plan&#148;) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows
for the issuance of up to 10,000,000 common shares. <font style="letter-spacing: -0.1pt">Options granted under the Plan shall be
at prices and for terms as determined by the Board of Directors.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 30, 2012, the Company granted 250,000 stock options to management at an exercise price of $0.18 per share, vesting monthly
over a thirty six month period. The aggregate fair value of the new grant was estimated at $45,000, or $0.18 per option, using
the Black-Scholes option pricing model with weighted average assumptions as follows: a risk free interest rate of 1.95%, a dividend
yield of 0%, an expected volatility of 199%, and an expected life of 10 years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
May 8, 2012, the Company granted 250,000 stock options to a consultant at an exercise price of $0.17 per share, vesting monthly
over a twelve month period. The aggregate fair value of the new grant was estimated at $40,000, or $0.16 per option, using the
Black-Scholes option pricing model with weighted average assumptions as follows: a risk free interest rate of 1.71%, a dividend
yield of 0%, an expected volatility of 199%, and an expected life of 10 years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">The
expensed portion of the value of the vesting options during the nine months ended September 30, 2012 was $205,516 (September 30,
2011 - $369,116) which was recorded as stock based consulting and management fees. During the periods, stock-based consulting and
management fees also includes share and warrant based compensation.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt"><b>&#160;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt"><b>Share
purchase options</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><font style="letter-spacing: -0.1pt">A
summary of the Company&#146;s stock options as of September 30, 2012 and changes during the period is presented below:</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 17%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Options</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Exercise Price</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Remaining Life</p></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, December 31, 2011</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">6,278,000&#160;</td>
    <td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">6.85</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Issued</td>
    <td style="padding-right: 6.15pt; padding-left: 5.4pt; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 500,000</td>
    <td style="padding-right: 19.9pt; padding-left: 5.4pt; text-align: right">0.18</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160; Cancelled</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, September 30, 2012&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">6,778,000&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">6.61</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><font style="letter-spacing: -0.1pt">At
September 30, 2012, the intrinsic value of the vested options was equal to $nil (September 30, 2011 - $nil).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><font style="letter-spacing: -0.1pt">A
summary of the status of the Company&#146;s unvested options as of September 30, 2012 is presented below:</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Shares</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Grant-Date</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Fair Value</p></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Unvested, December 31, 2011</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">1,037,709&#160;</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Granted</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">500,000&#160;</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">0.17</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Vested</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">(843,676)</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">0.18</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160; Cancelled</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">-<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Unvested, September 30, 2012</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">694,033&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td></tr>
</table>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="background-color: yellow"><u>&#160;</u></font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Share Purchase Warrants</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify; text-indent: 0.5in"><font style="letter-spacing: -0.1pt">On
February 24, 2011, the Company issued 2,369,388 share purchase warrants to acquire an equivalent number of common shares of the
Company, at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants
were issued pursuant to a securities purchase agreement (Note 5). The fair value of these warrants of $483,355 was recognized under
derivative liabilities, using the Binomial option pricing model with an expected life of 5 years, a risk free interest rate of
2.06%, a dividend yield of 0%, and an expected volatility of 199%.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">In
March 21, 2011, the Company issued 250,000 share purchase warrants to acquire an equivalent number of common shares of the Company,
at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued
pursuant to a debt settlement agreement (Note 5). The fair value of these warrants of $43,750 was recognized under derivative liabilities,
using the Binomial option pricing model with an expected life of 5 years, a risk free interest rate of 0.77%, a dividend yield
of 0%, and an expected volatility of 199%.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 4, 2011, the Company issued 1,000,000 share purchase warrants to acquire an equivalent number of common shares of the Company,
at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued
pursuant to a debt settlement agreement (Note 5). The fair value of these warrants was determined to be $349,000, using the Black-Scholes
option pricing model with an expected life of 5 years, a risk free interest rate of 2.20%, a dividend yield of 0%, and an expected
volatility of 252%.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
April 25, 2011, the Company issued 180,000 share purchase warrants to acquire an equivalent number of common shares of the Company,
at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued
pursuant to the private placement of $90,000.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">On
June 6, 2011, the Company issued 60,000 share purchase warrants to acquire an equivalent number of common shares of the Company,
at an exercise price of $0.25 per share for an exercise period of up to five years from the issuance date. The warrants were issued
pursuant to a securities purchase agreement (Note 5). The fair value of these warrants was determined to be $10,146, using the
Black-Scholes option pricing model with an expected life of 5 years, a risk free interest rate of 1.60%, a dividend yield of 0%,
and an expected volatility of 254%.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">In
March, 2012, the Company issued 366,668 share purchase warrants to acquire an equivalent number of common shares of the Company,
at an exercise price of $0.40 per share for an exercise period of up to two years from the issuance date. The warrants were issued
pursuant to the private placement of $110,000 and included within equity. The fair value of these warrants was determined to be
$5,133, using the Black-Scholes option pricing model with an expected life of 2 years, a risk free interest rate of 0.37%, a dividend
yield of 0%, and an expected volatility of 63%.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">In
April, 2012, the Company issued 1,150,000 share purchase warrants to acquire an equivalent number of common shares of the Company,
at an exercise price of $0.40 per share for an exercise period of up to two years from the issuance date. The warrants were issued
pursuant to a private placement and included within equity. The fair value of these warrants was determined to be $123,000, using
the Black-Scholes option pricing model with an expected life of 2 years, a risk free interest rate of 0.27%, a dividend yield of
0%, and an expected volatility of 146.6%.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><font style="letter-spacing: -0.1pt">A
summary of the Company&#146;s share purchase warrants as of September 30, 2012 and changes during the period is presented below:</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Warrants</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Exercise Price</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Remaining Life</p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, December 31, 2011</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">12,106,355&#160;</td>
    <td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">$&#160; 0.56</td>
    <td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">2.81</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Issued</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,516,668&#160;</td>
    <td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">0.40</td>
    <td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">1.80</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160; Extinguished or expired</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(714,400)</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">2.33</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, September 30, 2012</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">12,908,623&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">$&#160; 0.43</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">1.86</td></tr>
</table>


<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BrokersAndDealersAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BrokersAndDealersAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of computation of net capital under the SEC Regulations which may include a reconciliation (including appropriate explanations) if material differences exist between the computations made by the independent auditor based on the audited financial statements and the broker-dealer's original unaudited Part II or IIA filing, a statement that a reconciliation is not necessary if no material differences exist between the computations made by the independent auditor based on the audited financial statements and the broker-dealer's unaudited Part II or IIA filing, when different, total assets and total liabilities, as reported in the statement of financial condition, are reconciled to the total current assets and total liabilities, respectively, as reported in the statement of computation of minimum net capital.  Disclosure may also include stockholder's equity, stockholders' equity not allowable for net capital, stockholders' equity qualified for net capital, subordinated borrowings allowable in computation of net capital, other deductions or allowable credits and total capital and allowable subordinated borrowings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-8<br><br> -IssueDate 2006-05-01<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Rule 15c3<br><br> -Number 240<br><br> -Section 1<br><br> -Paragraph 1<br><br> -Article 15c3<br><br> -Subsection a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComputationOfNetCapitalUnderSecuritiesAndExchangeCommissionRegulationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONTINGENCIES AND COMMITMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">CONTINGENCIES AND COMMITMENTS</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><font style="text-transform: uppercase"><u>Note 11:&#9;ContingencIES
AND COMMITMENTs</u></font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Contingencies</u></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Tax Filings</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">The
Company has not filed income tax returns for several years in certain operating jurisdictions, and may be subject to possible compliance
penalties and interest. Management is currently not able to make a reliably measurable provision for possible liability for penalties
and interest, if any, at this time, and the Company may be liable for such amounts upon assessment. Penalties and interest, if
assessed in the future, will be recorded in the period such amounts are determinable.</font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Commitments</u></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Combined Research and
Operating Obligations</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">Effective
May 25, 2010, the Company entered into a research and license Option Agreement with the Mayo Clinic for the development and possible
commercial use of a cancer vaccine. Subject to the approval and guidance of the United States Food and Drug Administration (&#147;FDA&#148;)
the Mayo Clinic plans to conduct a Phase I human clinical trial (&#147;Phase I Trial&#148;) to test and develop the Company&#146;s
technology. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><font style="letter-spacing: -0.1pt">The
Company has agreed that, during the period of the option and upon approval of FDA to conduct Phase I Trials, will pay all the costs
incurred by the Mayo Clinic, not to exceed a total of $841,000. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On April 13, 2012, the Company entered
into a Patent &#38; Know-How agreement with the Mayo Foundation for Education and Research (&#147;Mayo&#148;) to license a proprietary
MHC Class I HER2/neu antigen technology. Under the terms of the agreement, the Company acquired from Mayo (i) an exclusive worldwide
license to use the patent rights related to patent application numbered 61600480 (titled &#147;Methods and materials for generating
CD8+ T-cells having the ability to recognize cancer cells expressing a Her2/neu polypeptide&#148;) to make products in the prophylactic
and therapeutic field (the &#147;Licensed Products&#148;) and (ii) a non-exclusive license to use certain of Mayo&#146;s know-how
to make the Licensed Products. The Company may sublicense the technology with the approval of Mayo, which approval may not unreasonably
withheld.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In connection with the grant of the licenses,
the Company is to (i) make an upfront license payment of $100,000 to Mayo followed by an additional $150,000 in license payments
over a 12 month period, (ii) reimburse Mayo for documented patent expenses incurred to date by Mayo in connection with the license,
(iii) pay an annual license fees, (iv) make milestone payments and (iv) pay royalties of gross annual sales. In addition, the Company
is required to pay Mayo a fee if it fails to initiate a Phase I clinical trial of a Licensed Product within five years and if it
fails to initiate a Phase II clinical trial of a Licensed Product within eight years.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Management Services Agreement</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">In February
2011, the Company approved an employment agreement with Dr. Wilson with an initial term of 2 years, which may be automatically
extended for successive one-year terms. This employment agreement provides for annual compensation of $180,000 and the grant of
an option to acquire 2,000,000 shares of the Company&#146;s common stock at $0.19 per share, 50% of which vested on March 16,
2011, while the remainder will vest monthly over a period of two years (41,667 per month). The options shall be exercisable for
at least five years.</font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>&#160;</u></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Consultant Agreements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">In April
2012, the Company entered into an investors&#146; relation consulting agreement for a one year term, with a one-time right to
terminate the agreement at its six month anniversary. The consulting agreement provides for the Company to issue 620,690 shares
to the consultant and a monthly payment of $7,500.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">In April
2012, the Company entered into financial consulting service agreements, which included compensation of 14,000,000 shares of common
stock, whereby the Company agreed to issue additional shares to the consultants to restore their holdings to 24.8% of fully diluted
capitalization of the Company if the Company completes a re-organization, re-capitalization or a liquidity event during the eighteen
months commencing with the signing of these agreements.</font></p>

<p style="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><b>&#160;</b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><u>Rental Lease Agreement</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">In December
2011, the Company entered into a lease agreement, which started in January 2012 for a two year period. The Company will pay a monthly
basic rent of $7,152 and additional rent for operating costs of 2.20% of total operating expenses of the property.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">The Company
has obligations under various agreements through December 31, 2014. The aggregate minimum annual payments for the years ending
December 31 are as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.1pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; R&#38;D</td>
    <td nowrap="nowrap" style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" style="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Administrative</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 65pt; font-weight: bold; text-align: center; text-indent: -7.9pt">Commitments</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; font-weight: bold">Commitments</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">2012</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-indent: -8.3pt; text-align: right">&#160;$ 1,052,500</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right">&#160;$&#160;&#160;&#160;&#160; 195,821</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">2013</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right">&#160;&#160;&#160;&#160;&#160; 37,500</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 308,313</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">2014</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-top: 6pt; padding-left: 1in; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 22,284</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,090,000</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 1pt solid; padding-top: 6pt; padding-left: 1in; text-align: right">$&#160;&#160;&#160;&#160;&#160; 526,418</td></tr>
</table>


<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Technical Bulletin (FTB)<br><br> -Number 90-1<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Technical Bulletin (FTB)<br><br> -Number 90-1<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 45<br><br> -Paragraph 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 450<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 45<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-HCO<br><br> -Paragraph 12, 13<br><br> -IssueDate 2006-05-01<br><br> -Chapter 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 45<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 45<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 450<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 45<br><br> -Paragraph 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 45<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155897<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Technical Bulletin (FTB)<br><br> -Number 90-1<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 45<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock', window );">CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td colspan="5" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nine Months Ended</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2012</p></td>
    <td style="border-bottom: windowtext 0.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Shares/warrants</td>
    <td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Amount</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Shares issued pursuant to debt settlement agreements</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,126,447</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">$326,937</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Common shares issued pursuant to consulting service arrangements</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">14,535,179</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$1,998,000</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td colspan="4" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nine Months Ended</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2011</p></td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Shares/warrants</td>
    <td nowrap="nowrap" colspan="2" style="border-top: windowtext 0.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Amount</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Accounts payable settled by issuing common shares</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,214,766</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 815,527</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Common shares issued pursuant to consulting service arrangements</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,327,059</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$500,527</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr>
    <td style="width: 47%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 4%">&#160;</td></tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock', window );">Additional disclosure on non-cash transactions</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td rowspan="2" style="border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td colspan="2" style="border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">Nine Months Ended September 30,</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2012</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2011</td></tr>
<tr>
    <td style="vertical-align: top; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">Interest paid in cash</td>
    <td style="vertical-align: bottom; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right">$&#160; -</td>
    <td style="vertical-align: bottom; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right">$&#160; -</td></tr>
<tr>
    <td style="vertical-align: top; border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Income taxes paid</td>
    <td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 12.4pt; padding-left: 5.4pt; text-align: right">$&#160; -</td>
    <td style="vertical-align: bottom; border-bottom: windowtext 1.5pt solid; padding-right: 15.9pt; padding-left: 5.4pt; text-align: right">$&#160; -</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_AdditionalDisclosureOnNoncashTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_CashFlowInformationAndNoncashInvestingAndFinancingActivitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowElementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4G">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>LOANS PAYABLE (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_UnsecuredLoanAdvances', window );">Unsecured loan advances</a></td>
        <td class="nump">$ 28,000<span></span></td>
        <td class="nump">$ 7,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_UnsecuredLoanAdvances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_UnsecuredLoanAdvances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECCBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">158 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (4,118,684)<span></span></td>
        <td class="num">$ (2,378,036)<span></span></td>
        <td class="num">$ (47,840,900)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AdjustmentDepreciation', window );">Depreciation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">213,228<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Non-cash loss on debt financing</a></td>
        <td class="nump">85,550<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,354,263<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments', window );">Changes in fair value of derivative liabilities</a></td>
        <td class="num">(544,576)<span></span></td>
        <td class="nump">277,118<span></span></td>
        <td class="num">(4,619,716)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDebtInvestments', window );">Loss (gain) on settlement of debt</a></td>
        <td class="num">(28,688)<span></span></td>
        <td class="nump">482,474<span></span></td>
        <td class="nump">11,602,894<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Gain on extinguishment of derivative liabilities - warrants</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,088,575)<span></span></td>
        <td class="num">(290,500)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">5,399<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest and financing charges</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">558,577<span></span></td>
        <td class="nump">5,468,499<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump">2,430,521<span></span></td>
        <td class="nump">1,052,513<span></span></td>
        <td class="nump">13,105,913<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractReceivablesNet', window );">Due from government agency</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,077)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and deposits</a></td>
        <td class="nump">34,123<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(46,504)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred financing costs</a></td>
        <td class="num">(1,118)<span></span></td>
        <td class="nump">54,974<span></span></td>
        <td class="num">(8,160)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">919,884<span></span></td>
        <td class="nump">85,019<span></span></td>
        <td class="nump">4,501,360<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Research agreement obligations</a></td>
        <td class="nump">106,218<span></span></td>
        <td class="nump">79,207<span></span></td>
        <td class="nump">584,101<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
        <td class="num">(1,116,770)<span></span></td>
        <td class="num">(876,729)<span></span></td>
        <td class="num">(15,971,200)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of shares, net</a></td>
        <td class="nump">455,000<span></span></td>
        <td class="nump">194,750<span></span></td>
        <td class="nump">10,760,575<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Convertible notes, net</a></td>
        <td class="nump">206,000<span></span></td>
        <td class="nump">724,535<span></span></td>
        <td class="nump">1,727,906<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ProceedsFromPromissoryNotes', window );">Proceeds from promissory notes</a></td>
        <td class="nump">67,942<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">67,942<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from loans payable</a></td>
        <td class="nump">21,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">446,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ProceedsFromShortTermBankLoansAndNotesPayable', window );">Notes and loans payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">919,845<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Advances from (to) related parties</a></td>
        <td class="nump">120,321<span></span></td>
        <td class="num">(31,300)<span></span></td>
        <td class="nump">1,707,912<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Stock subscriptions</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">140,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
        <td class="nump">870,263<span></span></td>
        <td class="nump">887,985<span></span></td>
        <td class="nump">15,770,180<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of furniture and equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(218,626)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired on reverse acquisition</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">423,373<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH PROVIDED by INVESTING ACTIVITIES</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">204,747<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">INCREASE (DECREASE) IN CASH</a></td>
        <td class="num">(246,507)<span></span></td>
        <td class="nump">11,256<span></span></td>
        <td class="nump">3,727<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">CASH, BEGINNING OF PERIOD</a></td>
        <td class="nump">250,234<span></span></td>
        <td class="nump">23,516<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">CASH, END OF PERIOD</a></td>
        <td class="nump">$ 3,727<span></span></td>
        <td class="nump">$ 34,772<span></span></td>
        <td class="nump">$ 3,727<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AdjustmentDepreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes depreciation from discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_AdjustmentDepreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ProceedsFromPromissoryNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ProceedsFromPromissoryNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ProceedsFromShortTermBankLoansAndNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Short Term Bank Loans And Notes Payable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ProceedsFromShortTermBankLoansAndNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDebtInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the carrying value and the sale price of debt securities, not separately or otherwise categorized as trading, available-for-sale, or held-to-maturity. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.3(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.13(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfDebtInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.13(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 15<br><br> -Paragraph 25<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnRestructuringOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractReceivablesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in receivables arising from the contracting of goods and services, net for uncollectible accounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInContractReceivablesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period, which was recognized in earnings, in the unrealized gains or losses on derivative instruments that are not or are no longer designated as hedging instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 20<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6439004&amp;loc=d3e65527-113976<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 18<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3095-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from the proceeds and repayments made on the long-term borrowing from related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and such forth. Alternate caption: Proceeds from (Payments for) Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromShortTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock', window );">CONVERTIBLE NOTES PAYABLE</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><font style="text-transform: uppercase"><u>Note 5:&#9;CONVERTIBLE
NOTES PAYABLE</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><font style="letter-spacing: -0.1pt">The
following is a summary of debt instrument transactions that are relevant to the current period:</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&#160;</td>
    <td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Face Value</b></p></td>
    <td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Principal Repayment</b></p></td>
    <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unamortized</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Note</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Discount</b></p></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance at</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2012</b></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-top: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">February 2011 Secured Convertible Notes</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Senior Secured Notes, due February 24, 2014</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,184,694<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160; 225,800&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 958,894<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">April 2011 Secured Convertible Notes</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Senior Secured Notes, due April 4, 2014</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">215,000<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">51,786&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">163,214<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">June 2011 Secured Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Senior Secured Notes, due June 6, 2014</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">30,000<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">4,650&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">25,350<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">August 8, 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Note due August 8, 2013</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">111,430<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">95,250&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">16,180<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">August 12, 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Note due November 12, 2012</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">27,500<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11,658&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">15,842<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">August 20, 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Note due August 20, 2013</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">20,000<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">17,757&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,245<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">September 2012 Convertible Note</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Note due October 1, 2013</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">82,500<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">79,874&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2,626<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Total</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,671,124<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$&#160;&#160;&#160; 486,773&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$ 1,184,351<font style="letter-spacing: -0.1pt">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>February 2011 Secured Convertible Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On February 24, 2011, the Company entered
into a securities purchase agreement with accredited investors to place Senior Secured Convertible Notes (the &#147;February 2011
Notes&#148;) with a maturity date of three years after the issuance thereof in the aggregate principal amount of $1,184,694. Consideration
under the notes consisted of $944,694 in cash proceeds, including accrued interest, and $240,000 was subscribed for by two of the
holders of outstanding and demandable 2010 secured convertible notes (the &#147;2010 Notes&#148;). The holders of the 2010 Notes
returned their Series A, Series B and Series C warrants to the Company for cancellation. In connection with the issuance of the
February 2011 Notes, the Company entered into a 2011 Security Agreement with the note holders securing the February 2011 Notes
with all of the Company&#146;s assets. One year after the issuance of the February 2011 Notes, the note holders have the option
to convert a portion or all of the outstanding balance of the February 2011 Notes including any accrued interest into shares of
the Company&#146;s common stock at a conversion rate of $0.15 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The February 2011 Notes bear interest
at the rate of 10% per annum except in case of default, in which case they bear interest at the rate of 20% per annum. The interest
is due on the February 2011 Notes at the end of each three month period, starting three months from their issuance. One year after
the issuance of the February 2011 Notes, the Company may elect to prepay a portion of the principal. If the Company makes such
an election, the holders may elect to receive such prepayment in cash or in shares of the Company&#146;s common stock, at a conversion
rate of $0.15 per share, or in a combination thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The Company paid a finders&#146; fee
of $41,500. The finder&#146;s fee was accounted for as deferred financing costs, and is being amortized over the term of the notes.
At September 30, 2012, $18,495 of the $20,768 in deferred financing costs relates to the February 2011 Notes which remains unamortized,
and is presented in long-term assets on the Company&#146;s Balance Sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In connection with the issuance of the
February 2011 Notes, the Company issued 2,369,388 warrants, exercisable into common stock at $0.25 with five year terms. The Company
may force the exercise of the warrants at any time that the average volume weighted average price of the Company&#146;s common
stock over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&#146;s common stock
sold over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of
the shares underlying the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">After reviewing a Fundamental Transaction
clause contained in the warrants, the Company allocated the net proceeds to the warrants based on the calculated fair value at
the date of issuance. The fair value of the warrants was recorded at $483,355 and recognized as derivative liabilities and the
debt was recorded at $701,339. The fair value of the warrants was calculated using the Binomial option pricing model under the
following assumptions: estimated life of five years, risk free rate of 2.06%, dividend yield of 0% and volatility of 199%. The
debt discount is being accreted over the three year term of the February 2011 Notes using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">For the nine months ended September 30,
2012, accretion of the debt discount of $120,839 was recorded for the February 2011 Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><b>April 2011 Secured Convertible Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On April 4, 2011, the Company entered
into a securities purchase agreement with accredited investors to place Senior Secured Convertible Notes (the &#147;April 2011
Notes&#148;) with a maturity date of three years after the issuance thereof in the aggregate principal amount of $215,000. Consideration
under the notes consisted of $190,000 in cash proceeds, and $25,000 was subscribed for by a holder of 2010 Notes in exchange for
the extinguishment of the Series A, Series B and Series C warrants related to the 2010 Notes. In connection with the issuance of
the April 2011 Notes, the Company entered into a 2011 Security Agreement with the note holders securing the April 2011 Notes with
a secondary security interest in all of the Company&#146;s assets. One year after the issuance of the April 2011 Notes, the note
holders have the option to convert a portion or all of the outstanding balance of the April 2011 Notes including any accrued interest
into shares of the Company&#146;s common stock at a conversion rate of $0.15 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The April 2011 Notes bear interest at
the rate of 10% per annum except in case of default, in which case they bear interest at the rate of 20% per annum. The interest
is due on the April 2011 Notes at the end of each three month period, starting three months from their issuance. One year after
the issuance of the April 2011 Notes, the Company may elect to prepay a portion of the principal. If the Company makes such an
election, the holders may elect to receive such prepayment in cash or in shares of the Company&#146;s common stock, at a conversion
rate of $0.15 per share, or in a combination thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The Company paid a finders&#146; fee
of $4,550. The finder&#146;s fee was accounted for as deferred financing costs, and is being amortized over the term of the notes.
At September 30, 2012, $2,273 of the $20,768 in deferred financing costs relates to the April 2011 Notes which remains unamortized,
and is presented in long-term assets on the Company&#146;s Balance Sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In connection with the issuance of the
April 2011 Notes, the Company issued 430,000 warrants, exercisable into common stock at $0.25 with 2 year terms. The Company may
force the exercise of the warrants at any time that the average volume weighted average price of the Company&#146;s common stock
over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&#146;s common stock sold
over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of the
shares underlying the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">The Company has allocated the net proceeds
to the warrants based on the calculated fair value. The fair value of the warrants was recorded at $130,720 and recognized as derivative
liabilities and the debt was recorded at $84,280. The fair value of the warrants was calculated using the Binomial option pricing
model under the following assumptions: estimated life of two years, risk free rate of 0.77%, dividend yield of 0% and volatility
of 199%. The debt discount is being accreted over the three year term of the April 2011 Notes using the effective interest rate
method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">For the nine months ended September 30,
2012, accretion of the debt discount of $25,752 was recorded for the April 2011 Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><b>June 2011 Secured Convertible Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On June 6, 2011, the Company entered
into a securities purchase agreement with accredited investors to place Senior Secured Convertible Note (the &#147;June 2011 Note&#148;)
with a maturity date of three years after the issuance thereof in the aggregate principal amount of $30,000. In connection with
the issuance of the June 2011 Note, the Company entered into a 2011 Security Agreement with the note holder securing the June 2011
Note with a secondary security interest in all of the Company&#146;s assets. One year after the issuance of the June 2011 Note,
the note holder has the option to convert a portion or all of the outstanding balance of the June 2011 Note including any accrued
interest into shares of the Company&#146;s common stock at a conversion rate of $0.15 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The June 2011 Note bears interest at
the rate of 10% per annum except in case of default, in which case it bears interest at the rate of 20% per annum. The interest
is due on the June 2011 Note at the end of each three month period, starting three months from its issuance. One year after the
issuance of the June 2011 Note, the Company may elect to prepay a portion of the principal. If the Company makes such an election,
the holders may elect to receive such prepayment in cash or in shares of the Company&#146;s common stock, at a conversion rate
of $0.15 per share, or in a combination thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">In connection with the issuance of the
June 2011 Note, the Company issued 60,000 warrants, exercisable into common stock at $0.25 with two year terms. The Company may
force the exercise of the warrants at any time that the average volume weighted average price of the Company&#146;s common stock
over the prior ten trading days is greater than $0.50, the average daily dollar volume of the Company&#146;s common stock sold
over those ten trading days is greater than $25,000 and there is an effective registration statement covering the resale of the
shares underlying the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">The Company has allocated the net proceeds
to the warrants based on the calculated fair value. The fair value of the warrants was recorded at $8,280 and recognized as derivative
liabilities and the debt was recorded at $21,720. The fair value of the warrants was calculated using the Binomial option pricing
model under the following assumptions: estimated life of two years, risk free rate of 0.43%, dividend yield of 0% and volatility
of 199%. The debt discount is being accreted over the three year term of the June 2011 Note using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">For the nine months ended September 30,
2012, accretion of the debt discount of $2,075 was recorded for the June 2011 Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><b>August 8, 2012 Convertible Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On August 8, 2012, the Company entered
into a securities purchase agreement with accredited investors to place a Convertible Note (the &#147;August 8, 2012 Note&#148;)
with a maturity date of one year after the issuance thereof in the aggregate principal amount of $111,430. Consideration under
the notes consisted of $92,000 in cash proceeds after $8,000 payment of finders&#146; fee and an original issue discount of $11,430.
The note holder has the option to convert a portion or all of the outstanding balance of the August 8, 2012 Note including any
accrued interest into shares of the Company&#146;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded
price in the 25 trading days prior to conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The August 8, 2012 Note carries no interest
if the Company repays the note within 90 days from issuance. If the Company does not repay the note within 90 days, a one-time
interest of 5% shall apply to the principal sum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The finder&#146;s fee of $8,000 was
accounted for as deferred financing costs, and is being amortized over the term of the note. At September 30, 2012, $6,838 of the
$12,641 in deferred financing costs relates to the August 8, 2012 Note which remains unamortized, and is presented in current assets
on the Company&#146;s Balance Sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">The Company has allocated the net proceeds
to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $1155,700
and recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt
financing of $55,700. The fair value of the conversion option was calculated using the Binomial option pricing model under the
following assumptions: estimated life of one year, risk free rate of 0.19%, dividend yield of 0% and volatility of 139.77%. The
debt discount is being accreted over the one year term of the August 8, 2012 Note using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">For the nine months ended September 30,
2012, accretion of the debt discount of $16,180 was recorded for the August 8, 2012 Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><b>August 12, 2012 Convertible Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On August 12, 2012, the Company entered
into a securities purchase agreement with accredited investors to place a Convertible Note (the &#147;August 12, 2012 Note&#148;)
with a maturity date of three months after the issuance thereof in the aggregate principal amount of $27,500. Consideration under
the notes consisted of $25,000 in cash proceeds after an original issue discount of $2,500. The note holder has the option to convert
a portion or all of the outstanding balance of the August 8, 2012 Note including any accrued interest into shares of the Company&#146;s
common stock at a conversion rate of $0.09 per share or on similar terms as of any future financings with more favorable terms.
The agreement provides for the Company to issue 50,000 shares to the note holder as risk premium. The 50,000 shares were valued
at $6,250 and recorded as loss on debt financing and obligation to issue shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The August 12, 2012 Note bears interest
at the rate of 10% per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">The Company has allocated the net proceeds
to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $31,100 and
recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt
financing of 6,100. The fair value of the conversion option was calculated using the Binomial option pricing model under the following
assumptions: estimated life of three months, risk free rate of 0.11%, dividend yield of 0% and volatility of 138.31%. The debt
discount is being accreted over the three month term of the August 12, 2012 Note using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">For the nine months ended September 30,
2012, accretion of the debt discount of $15,842 was recorded for the August 12, 2012 Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><b>August 20, 2012 Convertible Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On August 20, 2012, the Company entered
into a securities purchase agreement with accredited investors to place a Convertible Note (the &#147;August 20, 2012 Note&#148;)
with a maturity date of one year after the issuance thereof in the aggregate principal amount of $20,000. The note holder has the
option to convert a portion or all of the outstanding balance of the August 8, 2012 Note including any accrued interest into shares
of the Company&#146;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded price in the 25 trading
days prior to conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The August 20, 2012 Note bears interest
at the rate of 8% per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">The Company has allocated the net proceeds
to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $36,100 and
recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt
financing of $16,100. The fair value of the conversion option was calculated using the Binomial option pricing model under the
following assumptions: estimated life of one year, risk free rate of 0.19%, dividend yield of 0% and volatility of 140.11%. The
debt discount is being accreted over the one year term of the August 20, 2012 Note using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">For the nine months ended September 30,
2012, accretion of the debt discount of $2,247 was recorded for the August 20, 2012 Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><b>September 18, 2012 Convertible Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">On September 18, 2012, the Company entered
into a securities purchase agreement with accredited investors to place a Convertible Note (the &#147;September 18, 2012 Note&#148;)
with a maturity date of one year after the issuance thereof in the aggregate principal amount of $82,500. Consideration under the
notes consisted of $69,000 in cash proceeds after $6,000 payment of finders&#146; fee and an original issue discount of $7,500.
The note holder has the option to convert a portion or all of the outstanding balance of the September, 2012 Note including any
accrued interest into shares of the Company&#146;s common stock at a conversion rate of $0.09 per share or 70% of the lowest traded
price in the 20 trading days prior to conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The September, 2012 Note carries no interest
other than the original issue discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">The finder&#146;s fee of $6,000 was
accounted for as deferred financing costs, and is being amortized over the term of the note. At September 30, 2012, $5,803 of the
$12,641 in deferred financing costs relates to the September, 2012 Note which remains unamortized, and is presented in current
assets on the Company&#146;s Balance Sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">The Company has allocated the net proceeds
to the conversion option based on the calculated fair value. The fair value of the conversion option was recorded at $76,400 and
recognized as a derivative liability and the debt was recorded at $nil. The transaction resulted in an accounting loss on debt
financing of $1,400. The fair value of the conversion option was calculated using the Binomial option pricing model under the following
assumptions: estimated life of one year, risk free rate of 0.20%, dividend yield of 0% and volatility of 141.43%. The debt discount
is being accreted over the one year term of the September, 2012 Note using the effective interest rate method.</p>

<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For the nine months ended September 30, 2012, accretion
of the debt discount of $2,626 was recorded for the September, 2012 Note.</font></p>



<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2JAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROMISSORY NOTE (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AmountForFutureLegalServices', window );">Amount for future legal services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_PrepaidExpensesAndDeposit', window );">Prepaid expenses and deposits</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,703<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ConversionPricePerShares', window );">Conversion price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.23<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_SharesIssuedToHolderOfNote', window );">Shares issued to the holder of the note</a></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_PromissoryNotesAmount', window );">Promissory notes amount</a></td>
        <td class="nump">67,942<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector', window );">Promissory notes amount issued to an officer and a director</a></td>
        <td class="nump">$ 38,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AmountForFutureLegalServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_AmountForFutureLegalServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ConversionPricePerShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_ConversionPricePerShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NotesToFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_NotesToFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_PrepaidExpensesAndDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_PrepaidExpensesAndDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_PromissoryNotesAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_PromissoryNotesAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_PromissoryNotesAmountIssuedToOfficerAndDirector</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_SharesIssuedToHolderOfNote">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_SharesIssuedToHolderOfNote</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>23</ContextCount>
  <ElementCount>151</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/UnauditedConsolidatedFinancialStatementsForInterimPeriod</Role>
      <ShortName>UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR AN INTERIM PERIOD</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - RESEARCH AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ResearchAgreements</Role>
      <ShortName>RESEARCH AGREEMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValue</Role>
      <ShortName>DERIVATIVE WARRANT LIABILITY AND FAIR VALUE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - CONVERTIBLE NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tapimmune.com/role/ConvertibleNotesPayable</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - LOANS PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/LoansPayable</Role>
      <ShortName>LOANS PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - PROMISSORY NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/PromissoryNote</Role>
      <ShortName>PROMISSORY NOTE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - CAPITAL STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/CapitalStock</Role>
      <ShortName>CAPITAL STOCK</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - CONTINGENCIES AND COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ContingenciesAndCommitments</Role>
      <ShortName>CONTINGENCIES AND COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/DerivativeWarrantLiabilityAndFairValueTables</Role>
      <ShortName>DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tapimmune.com/role/ConvertibleNotesPayableTables</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - CAPITAL STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/CapitalStockTables</Role>
      <ShortName>CAPITAL STOCK (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesTables</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - CONTINGENCIES AND COMMITMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ContingenciesAndCommitmentsTables</Role>
      <ShortName>CONTINGENCIES AND COMMITMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/NatureOfOperationsDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - RESEARCH AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/ResearchAgreementsDetailsNarrative</Role>
      <ShortName>RESEARCH AGREEMENTS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tapimmune.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - LOANS PAYABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/LoansPayableDetailsNarrative</Role>
      <ShortName>LOANS PAYABLE (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - PROMISSORY NOTE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/PromissoryNoteDetailsNarrative</Role>
      <ShortName>PROMISSORY NOTE (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - CAPITAL STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>CAPITAL STOCK (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES - Additional disclosure on non-cash transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivities-AdditionalDisclosureOnNon-CashTransactionsDetails</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES - Additional disclosure on non-cash transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/SupplementalCashFlowInformationAndNon-CashInvestingAndFinancingActivitiesDetailsNarrative</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tapimmune.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jul. 26, 1999'</Log>
    <Log type="Info">Process Flow-Through: 0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>tpiv-20120930.xml</File>
    <File>tpiv-20120930.xsd</File>
    <File>tpiv-20120930_cal.xml</File>
    <File>tpiv-20120930_def.xml</File>
    <File>tpiv-20120930_lab.xml</File>
    <File>tpiv-20120930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CAPITAL STOCK (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BrokersAndDealersAbstract', window );"><strong>Brokers and Dealers [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_SummaryOfCompanysStockOptionsTableTextBlock', window );">Summary of the Company's stock options</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 47%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 17%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Options</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Exercise Price</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Remaining Life</p></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, December 31, 2011</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">6,278,000&#160;</td>
    <td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">6.85</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Issued</td>
    <td style="padding-right: 6.15pt; padding-left: 5.4pt; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 500,000</td>
    <td style="padding-right: 19.9pt; padding-left: 5.4pt; text-align: right">0.18</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160; Cancelled</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, September 30, 2012&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">6,778,000&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">6.61</td></tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock', window );">Summary of the status of the Company's unvested options</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" align="center" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Shares</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Grant-Date</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Fair Value</p></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Unvested, December 31, 2011</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">1,037,709&#160;</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Granted</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">500,000&#160;</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">0.17</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Vested</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">(843,676)</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">0.18</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160; Cancelled</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">-<font style="letter-spacing: -0.1pt">&#160;</font></td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Unvested, September 30, 2012</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right">&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right">694,033&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right">$&#160; 0.18</td></tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock', window );">Summary of the Company's share purchase warrants</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="width: 47%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 17%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Number of</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Warrants</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Exercise Price</p></td>
    <td style="width: 18%; border-top: windowtext 1.5pt solid; border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Remaining Life</p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, December 31, 2011</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">12,106,355&#160;</td>
    <td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">$&#160; 0.56</td>
    <td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">2.81</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160; Issued</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1,516,668&#160;</td>
    <td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">0.40</td>
    <td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">1.80</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#160; Extinguished or expired</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">(714,400)</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">2.33</td>
    <td style="border-bottom: windowtext 0.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">-</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold">Balance, September 30, 2012</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">12,908,623&#160;</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right">$&#160; 0.43</td>
    <td style="border-bottom: windowtext 1.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right">1.86</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_SummaryOfCompanysSharePurchaseWarrantsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_SummaryOfCompanysStockOptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_SummaryOfCompanysStockOptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tpiv_SummaryOfStatusOfCompanysUnvestedOptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tpiv_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BrokersAndDealersAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BrokersAndDealersAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
